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The endocannabinoid (eCB) system consists of cannabinoid receptors 1 and 2 (CB1 and CB2) 
that are activated by two well characterised lipid ligands, namely 2-arachidonoylglycerol (2-
AG) and N-arachidonyl ethanolamine (AEA). 2-AG is synthesised by the diacylglycerol lipases 
(DAGLα and β), however these enzymes also synthesise other related lipids including 2-
linoleoylglycerol (2-LG). The synthetic pathway for AEA synthesis is less clear. N-
acylphosphatidylethanolamine-specific phospholipase D (NAPEPLD) is the most studied 
enzyme that can make AEA, however genetic knockout of NAPEPLD from animal models has 
little impact on AEA levels. More recently, a calcium activated N-acyl transferase (CaNAT) 
called PLA2G4E has been identified as a key regulatory enzyme in the AEA pathway.  
In this thesis, three key questions have been addressed. Firstly, a detailed study using a CB1 
reporter cell assay was undertaken to test whether 2-LG can signal via the CB1 receptor 
and/or modulate the activity of eCBs. The results clearly showed that 2-LG is a novel CB1 
receptor partial agonist capable of signalling on its own, and also capable of modulating eCB 
signalling. Using the same human osteosarcoma reporter cell assay, the hypothesis that a 
nine amino acid peptide Hemopressin is an antagonist for the CB1 receptor was tested. 
Hemopressin failed to inhibit CB1 activation stimulated by a synthetic CB1 agonist, or the 
response stimulated by 2-AG and AEA. Finally, the CB1 reporter cell assay was utilised to 
measure activation of the receptor in response to stimulation by calcium or by direct 
activation of PKA or PKC, presumably as a consequence of the regulated synthesis of one or 
more eCBs. The CRISPR/Cas9 system was then used to systematically knockout the DAGLs 
that are involved in the generation of 2-AG. The results from this section confirmed that the 
DAGLs are responsible for over 90% of 2-AG synthesis in the cells and that in some 
circumstances they can contribute to eCB signalling. However robust eCB signalling is still 
found in their absence, possibly mediated by AEA. Interestingly, genetic deletion of NAPEPLD 
had no impact on AEA levels or eCB signalling. The cells do not express detectable levels of 
PLA2G4E suggesting that an as yet to be discovered enzyme is responsible for AEA synthesis 
in the cells. I identified PLA2G4B as a possible candidate, however genetic deletion of this 
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 PIP2 Phosphatidylinositol 4,5-Bisphosphate 
 PKA Protein Kinase A 
 PKC Protein Kinase C 
 PLA2 Phospholipase A2 
 PLA2G4 Cytosolic Phospholipase group IV 
 PLA2G4E or cPLA2 Phospholipase A2 group IVE 
 PLAAT Phospholipase A/Acyltransferase 
 PLC Phospholipase C 
 PLD Phospholipase D 
 PMA Phorbol 12-Myristate 13-Acetate  
 PNPB 4-Nitrophenyl Butyrate  
 pNAPE N-acylethanolamine plasmalogen 
 PPAR Peroxisome Proliferators Activated Receptor  
 PTPN22 Protein tyrosine phosphatase, non-receptor type 22 
   
Q qPCR Quantitative PCR 
   
R RER Receptor-Driven Endocannabinoid Release 
 RMS Rostral Migratory Stream 
 RNA Ribonucleic Acid 
 rpm Revolutions Per Minute 
 RT-PCR Reverse Transcription Polymerase Chain Reaction 
   
S SCP Sterol carrier protein  
 SDS Sodium Dodecyl Sulfate 
 SDS-PAGE SDS-Polyacrylamide Gel Electrophoresis 
 SEA Stearoyl Ethanolamine 
 SEM Standard Error of the Mean 
 sgRNA Single Guide RNA 
 SHSY5Y Bone marrow Neuroblastoma 
 SVZ Sub-Ventricular Zone 
 STD Short Term Depression  
   
T TALENs Transcription Activator-Like Effector Nucleases 
 TAE  TRIS-Acetate-EDTA buffer 
 TBI Traumatic Brain Injury 
 Δ9-THC Δ9-Tetrahydrocannabiniol 
 THL Tetrahydrolipstatin 
 tracrRNA Trans-activating crRNA 
 TRPV1 Transient Receptor Potential Vanilloid Type-1  
 TXB2 Thromboxane B2 
   
U U2OS Human Osteosarcoma Cell Line 
 URB579 FAAH Inhibitor 
 UTR Untranslated Region 
   
W WT Wild Type 
   
Z ZFNs Zinc Finger Nucleases 
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Chapter 1. Introduction 
 
1.1 History of cannabinoid research 
 
1.1.1 Origins of cannabinoid research 
Indigenous to central and South Asia, the cannabis plant Cannabis sativa has been used for 
cultural and religious purposes by numerous civilisations, with the earliest discovery of its 
cultural use dating back to around 2700 BC when it was found in a grave of a Chinese shaman 
(Russo et al., 2008). The earliest reference to its medicinal properties was described in a 
compendium dedicated to the Emperor of China Shen Nung (Li, 1974), but the therapeutic 
use of cannabis was introduced into western medicine by British physician William 
O'Shaughnessy (O'Shaughnessy, 1843). His observations of the analgesic, antiemetic and 
anticonvulsant properties of a local preparation of cannabis on rheumatism, tetanus and 
rabies led to the expansion of the therapeutic use of cannabis. Since then, medicinal cannabis 
has been used for the treatment of many ailments such as pain, asthma, and dysmenorrhea 
(Mikuriya, 1969; Baker et al., 2003).  
The biological effects of cannabis are well known: cannabis induces a psychoactive effect 
with altered perception, euphoria and impairment of short-term memory. In some limited 
cases of chronic use, it can also induce anxiety, panic, and paranoia. Cannabis can also cause 
physiological effects such as an increase in heart rate, a lowering of blood pressure due to 
vasodilatation, appetite stimulation, dry mouth, and dizziness (Kumar et al., 2001). The 
psychoactive side-effects however limited the therapeutic potential of its use until the 
constituents of the plant were known. 
 
1.1.2 Isolation of active phytocannabinoids 
The effort to identify the active constituents of cannabis began in the late 20th century and 
the Cannabis sativa plant itself contains many different active compounds. Cannabis is a 
source of over 70 compounds now known as phytocannabinoids (ElSohly and Slade, 2005), 
but the major psychoactive ingredient 9-tetrahydrocannabinol (9-THC) was first isolated 
by Gaoni and Mechoulam in 1964 in its pure form, and its structure was elucidated (Gaoni 
16 
 
and Mechoulam, 1964). Cannabidiol is one of the main non-psychoactive component of 
cannabis which may have therapeutic potential itself in the treatment of epilepsy and other 
neuropsychiatric disorders (Devinsky et al., 2014). Strains of cannabis plant with higher levels 
of 9-THC and lower levels of cannabidiol tend to exert more negatively associated 
psychotropic effects when consumed (Watson et al., 2000), and through years of 
investigation the psychotropic effects of cannabis could indeed be attributed essentially just 
to 9-THC (Hollister, 1974). 9-THC also exerts effects on other biological systems other than 
the nervous system, such as the suppression of immune responses and causing 
vasodilatation in the cardiovascular system (Dewey, 1986). However, the mechanism of 
these actions of 9-THC remained elusive for several years after its discovery due to the 
highly lipophilic properties of cannabinoids delaying experimental procedures. 
 
1.1.3 Identification of cannabinoid receptors 
The highly lipophilic properties of cannabinoids and 9-THC were originally thought to be 
responsible for the effects of cannabis by interfering with membrane fluidity. However, the 
presence of a specific binding site for 9-THC as the mechanism of action was proposed by 
several investigators in the 1970s. This was derived from the varying potencies of several 
structurally related cannabinoids and stereoisomers of 9-THC, which are indicative of a 
specific and selective site-mediated response (Mechoulam et al., 1998). By the 1990’s, novel 
potent and selective synthetic analogues of radiolabelled 9-THC such as HU-210 
(Mechoulam et al., 1990) and CP-55,940 (Pfizer in 1974) were developed. Radiolabelled CP-
55,940 was found to bind in a highly specific and selective manner to cortical membrane 
preparations from rat brain (Devane et al., 1988), with dense binding of [3H] CP-55,940 in the 
striatum of the basal ganglia, substantia nigra pars reticulata and globus pallidus, the 
cerebellum, the dentate gyrus of the hippocampus, as well as the cerebral cortex 
(Herkenham et al., 1990). This discovery was shortly followed by the cloning of the 
cannabinoid receptor 1 (CB1) from rat brain cDNA library (Matsuda et al., 1990) and from a 
human cDNA library (Gerard et al., 1991) and the cannabinoid receptor 2 (CB2) from a human 
leukemic cell line (Munro et al., 1993).  
The cannabinoid receptors are seven transmembrane G-protein coupled receptors (GPCRs) 
and share approximately ~48% homology (68% identity for the TM domains) (Howlett, 2002). 
The downstream effects of cannabinoid receptor activation are mediated through the 
pertussis toxin-sensitive Gi/o proteins. The Gi alpha subunit inhibits the production of cyclic 
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adenosine monophosphate (cAMP) by the inhibition of adenylate cyclase, which in turn 
causes increased mitogen-activated protein kinase (MAPK) activity, and this is the 
fundamental downstream signalling cascade of the cannabinoid receptors (Howlett et al., 
1986). The second messenger cAMP also interacts in many other signalling proteins such as 
protein kinase A (PKA), protein kinase C (PKC), c-Jun N-terminal kinases (JNKs), as well as 
regulating calcium and potassium ion channels (Pagotto et al., 2006), linking the cannabinoid 
receptors to a wide range of cellular processes in many different cell types (Pertwee, 1997; 
Bosier et al., 2010). 
The biological effects of certain cannabinoids are not fully mediated by classical CB1 or CB2 
receptors, suggesting the presence of non-classical CB receptors (Di Marzo, 2018). These 
non-classical CB receptors are responsive to cannabinoids but do not necessarily share 
sequence homology to CB1 and CB2 receptors. Orphan GPCRs have been put forward as 
potential cannabinoid receptors: G-protein coupled receptor 18, 55 and 119 (GPR18, GPR55 
and GPR119) (Morales and Reggio, 2017). GPR18 (McHugh et al., 2012), GRP55 (Baker et al., 
2006; Ryberg et al., 2007) and GPR119 (Overton et al., 2006) are responsive to cannabinoid 
ligands, including 9-THC, despite having low sequence homology to CB1 and CB2 receptors, 
however their physiological function requires further clarification. Other non-classical CB 
receptors include transient receptor potential of vanilloid type-1 (TRPV1) (Zygmunt et al., 
1999; Smart et al., 2000) and the peroxisome proliferators activated receptors (PPAR) 





1.2 Physiological functions of the CB receptors and 
eCB system 
 
1.2.1 Cannabinoid receptor expression 
The identification of the two cannabinoid receptors enabled further studies into the 
mechanisms behind the physiological effects of cannabinoids. The CB1 receptors from rat, 
mice and human species share 97-99% homology and is highly expressed in the mammalian 
central nervous system (CNS) (Herkenham et al., 1990; Howlett et al., 2002). In 1999, 
transgenic mice bearing genetic deletion of the CB1 receptor were generated (Ledent et al., 
1999; Zimmer et al., 1999). The mice lacked responsiveness to cannabinoid drugs and the 
CB1 receptor was demonstrated to be a mediator of analgesia, hypotension and 
hypothermia as well as having an involvement in feeding behaviour and the motivational 
aspects of opiates. 
CB1 is the most abundant GPCR in the mammalian brain. An immunohistochemical study 
using an antibody targeting the intracellular C-terminal tail of the receptor confirmed the 
expression of CB1 receptor in the cerebellum, hippocampus, basal ganglia, olfactory bulb and 
the neocortex in rat brain, which are mainly localised in nerve fibre systems and axon 
terminals (Egertova and Elphick, 2000). The expression of CB1 receptors in the brain 
correlate well with the well-known psychological effects of cannabis on motor coordination 
and short-term memory processing (Howlett et al., 2002). CB1 receptors are also expressed 
in non-neuronal CNS tissues in the periphery, including the neuromuscular junction and 
dorsal root ganglion cells where it may mediate pain sensation (Hohmann and Herkenham, 
1999; Howlett, 2002) and also on peripheral organs such as the liver, small intestine and 
reproductive organs (Matias and Di Marzo, 2007).  
The creation of a CB2 knockout (KO) mice revealed the CB2 receptor is predominantly 
expressed in tissues with immunological function such as in the spleen, tonsil and lymph 
nodes (Buckley et al., 2000). The CB2 receptor is abundantly expressed in B cells, monocytes, 
neutrophils and T cells where it may have a role in the regulation of immune responses 
and/or inflammatory reactions such as cytokine release (Munro et al., 1993; Galiegue et al., 
1995; Howlett, 2002). It was originally thought that CB2 receptors have no functional role in 
the CNS, however lower levels of CB2 receptors are found in restricted areas in the CNS, for 
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example in microglial cells (Howlett et al., 2002; Pertwee, 2005) and also in neurons (Van 
Sickle et al., 2005; Gong et al., 2006; Li and Kim, 2015).  
 
1.2.2 Discovery of the endocannabinoids 
The identification and characterisation of the cannabinoid receptors implied the presence of 
endogenous cannabinoid ligands that could activate these receptors, leading to the search 
for endocannabinoids (eCBs). The lipophilic nature of the phytocannabinoids provided 
insight into the possible lipid nature of the eCBs and through studies using the lipid-soluble 
fractions of the brain, the first eCB was identified. Devane et al. (1992) found porcine brain 
fractions could compete with the binding of radiolabelled cannabinoid probe [3H] HU-243 on 
rat synaptosomal membranes and subsequent chromatography of the brain fractions 
allowed them to isolate and identify the first putative eCB. This was the lipid N-arachidonyl 
ethanolamine (AEA), also known as anandamide from the Sanskrit word ananda meaning 
‘bliss’ (Devane et al., 1992).  
AEA belongs to a family of N-acyl ethanolamines (NAEs) which has been extensively studied 
and reviewed (Schmid and Berdyshev, 2002; Ueda et al., 2013). AEA bound to CB1 receptors 
potently (Ki = 52nM) and shared the ability with synthetic CB1 agonists to inhibit electrically 
evoked contractions of the mouse isolated vas deferens twitch assay. It was also 
demonstrated that AEA administrations reduces spontaneous motor activities, and results in 
immobility, hypothermia and analgesia in mice, very similarly to the effects of the 
phytocannabinoid 9-THC (Devane et al., 1992). To date, many studies have shown AEA to 
exhibit a variety of effects via the CB1 receptor in vitro and in vivo (reviewed in Mechoulam 
et al., 1998; Sugiura et al., 2002). 
However, there are some unresolved issues about the physiological role of AEA as an eCB to 
the CB receptors. For example, whilst AEA binds potently to the CB receptors, it acts as a 
partial agonist to the CB receptors in some studies which is unusual for an endogenous 
agonist (Mackie et al., 1993; Burkey et al., 1997; Sugiura et al., 2002). Indeed, AEA was later 
revealed to also act as a full agonist at TRPV1 receptors (Zygmunt et al., 1999; Smart et al., 
2000). Furthermore, AEA did not fully recapitulate the behavioural effects of Δ9-THC, being 
up to 18 times less potent than that of Δ9-THC in behavioural assays (Smith et al., 1994). The 
endogenous levels of AEA are relatively low in fresh brain (in the order of pmol/g tissue) in 
comparison to the abundance of CB1 receptors in the brain, although it is possible that AEA 
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is localised to certain areas of the brain (Felder et al., 1996; Sugiura et al., 2002). There are 
multiple synthesis pathways of AEA (described further below) with no efficient or selective 
preference for synthesis (Liu et al., 2008) and stimulation of these pathways generate 
relatively low levels of AEA as there are low levels of the precursor to AEA (Sugiura et al., 
1996). Thus, AEA may have a separate primary signalling role in addition to the activities at 
the CB receptors and the presence of other eCB(s) were postulated.  
Shortly after the discovery of AEA, 2-arachidonoylglycerol (2-AG) was identified from canine 
gut and was demonstrated to bind to cell membranes overexpressing CB1 and CB2 receptors 
(Mechoulam et al., 1995). 2-AG is a monoacylglycerol and was originally thought to be part 
of the synthesis pathway for arachidonic acid (AA) (Prescott and Majerus, 1983). 
Phospholipase C (PLC) activity on inositol phospholipids generates 1,2-diacylglycerols (DAG) 
which is cleaved by diacylglycerol lipase (DAGL) to release 2-AG. 2-AG was reported to 
displace the radioactive cannabinoid probe [3H]CP-55,940 from cannabinoid receptors in rat 
brain synaptosomes (Sugiura et al., 1995) and caused very similar responses to Δ9-THC such 
as antinociception, immobility and reduction of spontaneous activity when administered in 
vivo in mice (Mechoulam et al., 1995; Di Marzo, 1998). 2-AG had the same effect as CB1 
synthetic agonists in the hippocampus, whereby 2-AG inhibited long-term potentiation (LTP), 
an effect that could be blocked by CB1 antagonists (Stella et al., 1997). Despite the weaker 
binding affinity of 2-AG for the CB1 receptor (Ki = 472nM) in comparison to AEA, 2-AG has 
been argued to be the true endogenous ligand for CB receptors as the levels of 2-AG are 
considerably (>200x) higher than AEA in the brain and functions as a full agonist to the CB 
receptors (Sugiura et al., 1999). In peripheral organs such as the pancreas and spleen, 2-AG 
is accompanied by other monoacylglycerols such as 2-linoleoylglycerol (2-LG) and 2-
palmitoylglycerol (2-PG) which have been reported to potentiate the activity of 2-AG (Ben-
Shabat et al., 1998), suggesting a possible endogenous mechanism for the modulation of the 
activity of eCBs.  
The umbrella term – the eCB system is generally used to collectively describe the two most 
well studied eCBs (AEA and 2-AG), their main target receptors (CB1 and CB2), as well as the 
enzymes involved in their synthesis and degradation which will be discussed further below. 
The discovery of the two major eCBs, along with several pharmacological tools, to the CB 
receptors have pioneered the characterisation of important functional roles of CB receptors 




1.2.3 CB receptor functions in the CNS  
The psychoactive properties of Δ9-THC and the eCBs gave insight into certain neuropathways 
that are possibly modulated by the CB receptors. Expression of the CB1 receptor is detected 
both in the neonatal and postnatal brain with distinctively separate roles in brain 
development and function (Berrendero et al., 1998; Marsicano and Lutz, 1999; Wang et al., 
2003; Begbie et al., 2004). Expression of CB2 receptors have been reported in restricted areas 
of the CNS in relatively much lower levels than CB1, such as rat dorsal root ganglia neurons 
and neuronal progenitors (Ross et al., 2001; Palazuelos et al., 2006) as well as in in brainstem, 
cerebellar and hippocampal pyramidal neurons of adult mammals (Van Sickle et al., 2005; 
Gong et al., 2006). However, the role of the CB2 receptor in CNS functions is not fully 
elucidated as the focus has mainly been placed on CB1 as the mediator of CNS functions. 
Development axonal growth and guidance 
The damaging effects of pre-natal exposure of cannabis on the neural development of 
offspring has been well documented (Keimpema et al., 2013). Exceptionally high levels of Δ9-
THC doses (>100 mg/kg) may induce in utero death (Harbison and Mantilla-Plata, 1972) and 
consumption of cannabis during pregnancy can cause growth impedance, damage to brain 
development, and adverse neurodevelopmental outcomes (Hurd et al., 2005; Spano et al., 
2007; El Marroun et al., 2009; Psychoyos et al., 2012). It was therefore no surprise that the 
eCB system and the CB1 receptor is involved in the formation of the CNS. Both the eCB 
system and the CB1 receptor has been implicated in the development of the brain, through 
a variety of different processes including neural progenitor cell differentiation (Aguado et al., 
2005; Compagnucci et al., 2013), cell migration (Song and Zhong, 2000; Zhou et al., 2014), 
synapse formation (Kim and Thayer, 2001) and axonal growth and guidance (Williams et al., 
2003; Oudin et al., 2011b).  
One significant role of the eCB system is in axonal growth and guidance, which is the process 
whereby neurons send out their axons to innervate their correct targets. 
Immunohistochemical studies have shown the expression of CB1 receptors are highly 
localised to the axons and growth cones of developing neurones, and are highly correlated 
with the expression of the DAGLs – the synthesising enzymes for 2-AG (Buckley et al., 2000; 
Bisogno et al., 2003; Berghuis et al., 2007) implying a possible autocrine signalling role in 
axonal development. Pharmacological and/or genetic disruption of the CB1 receptor has 
been shown to impair various axonal processes in vivo and in vitro. For example, the Harkany 
lab established that specific deletion of CB1 receptor from cortical GABAergic interneurons 
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results in impaired target selection in vivo (Berghuis et al., 2007). In other studies, both 
genetic and pharmacological ablation of the CB1 receptor led to abnormal axon growth of 
pyramidal neurons in embryonic and early postnatal mice (Mulder et al., 2008), and in 
corticothalamic and thalamocortical projections (Wu et al., 2010). Furthermore, both 
pharmacological studies in chick and morpholino knock down in zebrafish embryos show CB1 
function is required for normal axonal growth and fasciculation in the early nervous system 
(Watson et al., 2008). These studies taken together support the role of the CB1 receptor as 
a modulator of axonal growth and guidance during brain development.  
The CB1 receptors are localised primarily at the site of axonal growth, alongside the enzymes 
responsible for the generation of 2-AG, which is likely to be the eCB involved in the autocrine 
activation of CB1 receptors in this role (Watson et al., 2008). Although AEA is also present in 
the developing brain, levels of 2-AG are magnitudes higher and therefore it is postulated that 
2-AG is the prime eCB in the developing brain (Harkany et al., 2008). Thus, the 2-AG 
synthesising enzymes – the DAGLs, are likely to be the connection between the eCB system 
and other signalling cues to regulate axonal growth and guidance (Bouquet and Nothias, 
2007). 
Pharmacological studies suggested that DAGL activity is required for axonal growth and 
guidance in a signalling cascade following activation of the fibroblast growth factor receptor 
(FGFR) (Williams et al., 1994a; Brittis et al., 1996). Activation of FGFR by certain cell adhesion 
molecules (CAMs) such as neural CAM (NCAM), N-cadherin (NCAD) and L1, or by direct 
activation by fibroblast growth factor 2 (FGF2) lead to downstream signalling cascades that 
culminate to calcium influx into the growth cone, promoting axonal growth and guidance 
(Figure 1.2.1) (Williams et al., 1994c; Walsh and Doherty, 1997; Williams et al., 2003). The 
DAGL inhibitor RHC-80267 inhibited FGFR mediated neurite outgrowth from cultured 
neurons, suggesting DAGL activity is present downstream of FGFR, but upstream of calcium 
influx (Williams et al., 1994b; Brittis et al., 1996). Further studies revealed that FGFR 
stimulates neurite outgrowth through the eCB system as this can be inhibited by CB1 
antagonists, DAGL inhibitors RHC-80267 and tetrahydrolipstatin (THL), as well as a PLCγ 
inhibitor (Bisogno et al., 2003; Williams et al., 2003). In support of these findings is the 
observation that the expression of the 2-AG degrading enzyme monoacylglycerol lipase 
(MAGL) is excluded from the growth cone and is restricted to further back along the axon, 
thereby allowing 2-AG to be available to activate the CB1 receptor for neurite outgrowth 




Figure 1.2.1. The role of the eCB system for axonal growth and guidance 
A simplified schematic of the FGFR signalling cascade within the growth cone. Activation of 
FGFR by CAMs and/or FGF2 stimulates PLCγ to synthesise DAG, which in turn is hydrolysed 
by DAGL to generate 2-AG. This then acts on the CB1 receptor on the same growth cone 
leading to calcium influx via N- and L-type voltage gated calcium channels into the cell to 
promote motility and axonal growth. 
Adapted from Zhou et al. (2014). 
 
 
The role of the CB1 receptor in axonal growth and guidance has been the primary focus with 
the role of the CB2 receptor in the CNS in dispute. The CB2 receptor may be involved in neural 
stem cell proliferation in cell culture as well as in the adult mouse (Palazuelos et al., 2006; 
Molina-Holgado et al., 2007; Goncalves et al., 2008). It has also been recently reported that 
CB2 receptors may also have a modulatory role in axon guidance in retinal ganglion cells 
(Duff et al., 2013). Duff et al. (2013) reported CB2 receptor expression in the developing 
neurovisual system of mice, primarily located in the growth cones, filopodia and neurites of 
retinal ganglion cells. Unlike CB1 receptors, agonism of CB2 receptors caused a retraction of 
growth cone surface, reduced axonal growth and reduced filopodia, while antagonism of CB2 
caused the converse, suggesting a contrasting modulatory effect to regulate axonal growth 
and guidance.  
Taking together the pharmacological, genetic, and anatomical studies described above 
demonstrates the importance of eCB signalling and the CB receptors in axonal growth and 
guidance in the developing brain. After the establishment of synapses, expression of the eCB 
system shifts from an autocrine signalling system in axons and the growth cone to a 




Synaptic plasticity and retrograde signalling  
In the adult brain, both excitatory and inhibitory synapses can undergo changes and alter 
connection strengths between neurons. It is widely accepted that synapses strengthen or 
weaken over time in response to increases or decreases in their activity, and it is thought to 
be the underlying mechanism for learning and memory (Eccles and McIntyre, 1951; Holtmaat 
and Svoboda, 2009). Generally, synaptic plasticity can be divided into two forms: short-term 
synaptic plasticity which lasts from milliseconds to at most a few minutes, and long-term 
synaptic plasticity which can last from minutes to hours, or substantially longer (Citri and 
Malenka, 2008). Thus, there are numerous short-term and long-term changes to a synapse 
which can alter its connection, including the quantity of neurotransmitter released and the 
responsiveness of the postsynaptic site to the neurotransmitters. In the 1990s, retrograde 
signalling at synapses became a well-accepted phenomenon. This referred to the release of 
a signalling molecule from the depolarised postsynaptic site which then acts on the 
presynaptic terminal to suppress further neurotransmitter release (e.g. the inhibitory 
gamma-aminobutyric acid (GABA) and the excitatory glutamate). Retrograde signalling thus 
regulates release of neurotransmitters and thereby affects synaptic strength and plasticity 
(Regehr et al., 2009). 
The development of CB1 antibodies and the generation of CB1 KO mice revealed the 
restricted expression of CB1 receptors to presynaptic terminals throughout the adult brain 
and spinal cord (Katona et al., 2006; Kawamura et al., 2006). Presynaptic expression of CB1 
occurs at both excitatory and inhibitory synapses (Egertova and Elphick, 2000) which 
suggests the role of the CB1 receptor and eCB signalling in the regulation of synaptic function 
(Castillo et al., 2012; Kano, 2014).  
Pharmacological studies have shown that activation of CB1 receptors can inhibit the release 
of various neurotransmitters (e.g. GABA, glutamate, acetylcholine) in cultured neurons as 
well as from slices from various parts of the brain including the hippocampus, cerebellum 
and the cerebral cortex (reviewed in Schlicker and Kathmann, 2001). For example, the 
cannabinoid agonist WIN55,212-2 was shown to suppress glutamatergic excitatory 
postsynaptic currents (EPSCs) which was sensitive to the CB1 antagonist SR141716A, 
confirming the involvement of CB1 receptors (Shen et al., 1996). Similarly, the inhibitory 
effects of cannabinoids on GABA release were first reported in neurons in the striatum 
(Szabo et al., 1998). In these neurons, WIN55,212-2 suppressed GABAergic inhibitory 
postsynaptic currents (IPSCs), but did not affect the postsynaptic response to exogenously 
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applied GABA, indicating a presynaptic site of action. The suppression of IPSCs were sensitive 
to the antagonist SR141716A which confirmed the involvement of CB1 receptors (Szabo et 
al., 1998). 
Studies have shown that AEA and 2-AG can be released from postsynaptic neurons to act as 
retrograde messengers in distinct regions of the brain (Figure 1.2.2A) (Wilson and Nicoll, 
2001; Alger, 2002). However, 2-AG is likely to be the primary eCB retrograde messenger for 
the CB1 receptor. The reasons for this are that the relative abundance of 2-AG is much higher 
in comparison to AEA, and the highly restricted positioning of the 2-AG synthesising enzymes 
in the postsynaptic density in close proximity to the CB1 receptors on the presynaptic density 
suggests 2-AG is well positioned to act as a retrograde messenger (Bisogno et al., 2003; 
Yoshida et al., 2006; Oudin et al., 2011a). Furthermore, inhibition of MAGL, the enzyme 
responsible for 2-AG degradation, but not AEA hydrolyzing enzyme fatty acid amide 
hydrolase (FAAH), can generally prolong the inhibition of neurotransmitter release 
(Hashimotodani et al., 2007).  
Various stimuli can induce eCB production from the postsynaptic neuron. In 2001, several 
groups reported that depolarisation of the postsynaptic neuron results in suppression of the 
pre-synaptic release of inhibitory or excitatory neurotransmitters – termed depolarisation-
induced suppression of inhibition/excitation (DSI and DSE) (Kreitzer and Regehr, 2001; Ohno-
Shosaku et al., 2001; Wilson and Nicoll, 2001). This eCB mediated short-term depression 
(eCB-STD) was mediated by calcium influx in the depolarised postsynaptic cell which leads to 
the release of an eCB retrograde messenger through a yet unclarified mechanism and termed 
calcium-driven eCB release (CaER) (Figure 1.2.2A). CB1 antagonist AM251 blocked DSI/DSE 
whereas the CB1 agonist WIN55212-2 occluded DSI/DSE (Kreitzer and Regehr, 2001; Ohno-
Shosaku et al., 2001; Wilson and Nicoll, 2001; Kano, 2014). In the same year, depolarisation-
independent short-term depression of neurotransmitter release was also reported in the 
cerebellum (Maejima et al., 2001) and hippocampus (Varma et al., 2001). This was mediated 
by the activation of postsynaptic group 1 metabotropic glutamate receptors (mGluR1) which 
drives the generation of 2-AG and causes reduced neurotransmitter release in a CB1-
dependent manner. This mechanism is termed receptor-driven eCB release (RER) and does 
not rely on a calcium influx to generate 2-AG, but activation of mGluR1 does enhance 
DSI/DSE (calcium-assisted RER) which can be blocked by CB1 and mGluR1 antagonists (Figure 
1.2.2A) (Varma et al., 2001; Kano, 2014). 
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The mechanisms governing short term DSI/DSE (i.e. CaER, RER and calcium-assisted ER) also 
mediate long-term depression of synaptic transmission. Endocannabinoid mediated long-
term depression (eCB-LTD) has been found in several areas of the brain at both excitatory 
and inhibitory synapses, causing long-lasting reduction in the efficiency of synapses (Heifets 
and Castillo, 2009). Repeated neuronal stimulation for lengthy periods (5-10 mins) causes 
prolonged eCB release and CB1 activation alongside additional presynaptic mechanism(s) 
such as presynaptic calcium influx to cause LTD (Figure 1.2.2B) (Collingridge et al., 2010; 
Kano, 2014). The presynaptic mechanisms of eCB-LTD have not been fully elucidated but 
inhibition of the downstream cAMP/PKA pathway seems to be crucial (Castillo et al., 2012; 
Ohno-Shosaku et al., 2012). For example, the presynaptic elevation of calcium can activate a 
phosphatase calcineurin which dephosphorylates target proteins (Figure 1.2.2B). In tandem, 
the activation of CB1 receptors causes a decrease in cAMP levels and PKA activity, leading to 
a reduction in phosphorylated target proteins. The resulting decrease in phosphorylation of 
target proteins causes suppression of transmitter release selectively from presynaptic 
terminals that have been active during CB1 activation (Heifets et al., 2008; Ohno-Shosaku et 










Figure 1.2.2. Molecular mechanisms of eCB-STD and eCB-LTD 
Schematic of the molecular mechanism of eCB-STD is shown in (A). Calcium-driven eCB 
release (a, CaER) occurs when a large calcium elevation is caused by activation of voltage-
gated calcium channels or NMDAR and 2-AG is generated by DAGL-dependent manner. The 
method by which elevated calcium levels lead to 2-AG synthesis via DAGL remains unclear. 
Receptor-driven eCB release (b, RER) occurs through activation of Gq/11-coupled receptors. 
Upon receptor activation, PLC is stimulated to generate DAG, which is then converted to 2-
AG by DAGL. Through the combination of subthreshold activation of Gq/11-coupled receptors 
and small calcium elevation, 2-AG is produced through the PLC-dependent pathway 
because the receptor-driven PLC stimulation is calcium dependent (c, Ca-assisted RER). 2-
AG is released from postsynaptic neurons, activates presynaptic CB1 receptors, and induces 
transient suppression of transmitter release.  
Schematic of the molecular mechanism of eCB-LTD is shown in (B). Stimulation of the post 
synaptic Gq/11-coupled receptors drives the generation of 2-AG synthesis through the PLC-
DAGL pathway which can be enhanced by concomitant calcium elevation, but is not always 
necessary for eCB-LTD induction at some synapses. Activation of the presynaptic CB1 
receptor by 2-AG inhibits adenylyl cyclase (AC), which decreases cAMP levels and reduces 
PKA activity. Presynaptic activity causes calcium elevation, which activates a phosphatase, 
calcineurin (CaN). In concert with reduced PKA activity, calcineurin dephosphorylates of 
target proteins (X), and induces persistent suppression of transmitter release, through yet 
unclarified mechanisms. 






It is possible that CB2 receptors may be present in distinct neuronal populations and play a 
similar but complementary role to CB1 receptor in modulating neurotransmitter release and 
hence, network activity. When CB2 receptors were expressed in cultured CB1 KO mice 
autaptic hippocampal neurones, DSE was restored indicating that CB2 receptors can also 
possess similar functions to CB1 receptors (Atwood et al., 2012). In support of this, CB2 
receptors have been suggested to function in conjunction to CB1 receptors in the medial 
entorhinal area of rat brain in mediating DSI (Morgan et al., 2009). Genetic deletion of CB2 
receptor in mice also revealed decreases in excitatory synaptic transmission and long-term 
potentiation in the hippocampus, which could suggest that CB2 might also have distinctly 
different synaptic functions to CB1 (Li and Kim, 2016). The precise location of endogenous 
CB2 receptors are reported to be present on postsynaptic densities in the hippocampus 
rather than presynaptic densities where CB1 receptors are primarily located (Brusco et al., 
2008). However, due to the low level of expression of CB2 receptors in the CNS overall, the 
physiological contribution of CB2 to synaptic function is not fully elucidated.  
Adult Neurogenesis 
Neurogenesis is the generation of new functional neurons from neural stem cells and neural 
progenitors in the brain and are added to existing circuitry throughout life. This process is 
most active during prenatal CNS development, but declines rapidly after birth and is 
restricted to certain niches in the post-mitotic adult brain (Sanai et al., 2011). Adult 
neurogenesis was first described in the 1960s by Joseph Altman, who reported new neurons 
were generated in adult rat hippocampus (Altman and Das, 1965) and also subsequently 
reported neurogenesis in the adult olfactory bulb (Altman, 1969). After a contentious 
beginning, neurogenesis is now known to constitute a form of cellular plasticity in the 
developed brain that impacts on memory, depression and neurodegenerative diseases and 
thus, has wide therapeutic applications (Arvidsson et al., 2002; Zhao et al., 2008).  
Neurogenesis occurs in mainly in two areas of the mammalian adult brain: in the sub-
granular zone in the dentate gyrus of the hippocampus and in the sub-ventricular zone (SVZ) 
of the lateral ventricle (Alvarez-Buylla and Garcia-Verdugo, 2002; Vadodaria and Jessberger, 
2014). In the adult hippocampus, the neural stem cells form dentate granule cells that 
integrate into the local circuitry associated with the formation of new memories and in the 
SVZ, stem cells produce migratory neurons which traverse through the rostral migratory 
stream (RMS) to the olfactory bulb where they integrate. In humans, adult neurogenesis has 
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been described in the hippocampus (Eriksson et al., 1998; Ihunwo et al., 2016), the lateral 
ventricles (Sanai et al., 2004) and more recently in the striatum (Ernst et al., 2014).  
Several lines of study have implicated the eCB system to be involved in adult neurogenesis 
(reviewed in Prenderville et al., 2015). The expression of the CB receptors and the DAGLs are 
detected in the rat dentate gyrus and the SVZ (Morales and Backman, 2002; Goncalves et al., 
2008; Xapelli et al., 2013). Neural progenitor cells and neural stem cells also express both 
CB1 and CB2 receptors (Aguado et al., 2005; Jiang et al., 2005; Molina-Holgado et al., 2007; 
Compagnucci et al., 2013; Xapelli et al., 2013) and both CB1 and CB2 agonists have been 
found to promote proliferation/neurogenesis in neural progenitor cells and neural stem cells 
in vivo and in vitro. For example, chronic administration of CB1/CB2 agonist HU-210 (Jiang et 
al., 2005) or CB2 selective agonist HU-308 (Palazuelos et al., 2012) enhances both 
proliferation and survival of cells in the rat dentate gyrus. This effect is reversed by CB1 and 
CB2 antagonists (Palazuelos et al., 2006; Molina-Holgado et al., 2007; Rubio-Araiz et al., 
2008). The pharmacological inhibition of the 2-AG synthesising enzymes in adult mice over 7 
days resulted in a significant decrease (~50%) in new neurons formed in the olfactory bulb 
post drug administration (Goncalves et al., 2008), indicating the effects of neurogenesis in 
the SVZ is mediated by the activity of the eCBs on the CB receptors.  
Furthermore, a number of genetic studies have targeted enzymes involved in the 
biosynthesis and degradation of eCBs (Aguado et al., 2005; Gao et al., 2010), in addition to 
CB1 receptor (Jin et al., 2004) and CB2 receptors (Palazuelos et al., 2006), and have placed 
the eCB system as a key player in the processes underlying adult neurogenesis. The genetic 
knockdown of the enzyme responsible for AEA degradation increases cell proliferation 
(Aguado et al., 2005), whilst the KO of the 2-AG synthesising enzymes in adult mice reduced 
cell proliferation (~20-30%) in the hippocampus (Gao et al., 2010). A 50% reduction in adult 
neurogenesis was also observed in the dentate gyrus and SVZ of adult CB1 KO mice (Jin et 
al., 2004) whilst in CB2 KO mice showed ~50% decrease in proliferation rate (Palazuelos et 
al., 2006), indicating both CB receptors and eCBs are involved in mediating neurogenesis in 
the hippocampus and SVZ. 
After the generation of new neuroblasts in the SVZ, these cells must migrate through the 
rostral migratory stream to the olfactory bulb and differentiate into mature neurons. 
Recently, the eCB system has also been shown to play a prominent role in neuroblast 
migration in the RMS of young adult mammals (Oudin et al., 2011b). Administration of CB1 
and CB2 antagonists to cultured neuroblasts dramatically changed the morphology of the 
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migratory cells to a non-migratory phenotype. As well as this, DAGL inhibition caused 
shortening and branching of the leading process from the neuroblasts and decreased cell 
migration rates (Goncalves et al., 2008; Oudin et al., 2011b). Based on both pharmacological 
and KO studies, it has been demonstrated that the eCB system plays a fundamental role in 
adult neurogenesis in both the SVZ and hippocampus and neuronal migration in the SVZ 
which impacts on the number of proliferating neuronal stem cells in the adult brain. 
Adult neurogenesis declines in the hippocampus (Marchalant et al., 2009) and in the SVZ 
with age in both the mouse (Goncalves et al., 2008) and the adult brain (Knoth et al., 2010), 
which may be due to an overall decline in eCB signalling that may account for age-related 
deterioration in neurogenesis. In support of this, 20-month-old mice – which have negligibly 
detectable levels of cell proliferation, were treated with CB1 agonist WIN55,212-2. The 
effects of WIN55,212-2 stimulated a ~6-fold increase in cell proliferation, returning 
proliferation levels to the levels of a 6-month old mouse (Goncalves et al., 2008). 
Furthermore, administration of WIN55,212-2 for 3 weeks partially restored neurogenesis in 
the hippocampus of aged rats (Marchalant et al., 2009). These experiments reveal the 
dependence of the eCB system in neurogenesis especially in old age and may be subject to 
influence from lifestyle circumstances such as diet. Therefore, targeting the eCB system is of 
therapeutic interest in the potential treatment of neurodegeneration.  
 
1.2.4 Pathological and therapeutic perspective of the eCB system 
The eCB system is involved in many roles throughout life, both within the CNS as previously 
described and in many peripheral physiological roles such as GI motility, modulation of the 
immune system and in the regulation of bone turnover (reviewed in Maccarrone et al., 2015). 
Therefore, abnormal regulation of the eCB system often results in disease phenotypes such 
as anxiety and depression, pain, fatty liver disease, obesity and osteoporosis (Di Marzo, 
2008b; Sophocleous et al., 2017a; Capasso et al., 2018; Martin et al., 2018). Indeed, rare 
genetic variants of the CB1 receptor and the 2-AG synthesising enzyme DAGL are associated 
with various neurological phenotypes in humans such as pain sensitivity (especially 
migraine), sleep and memory disorders and prevalence of seizures (Smith et al., 2017). 
Hence, it is not surprising that the eCB system provides a promising target for therapeutics 
in various disease states. 
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Brain injury and therapeutic potential 
The eCB system has been reported to provide neuroprotective effects in cases of brain 
damage such as in ischemia or Alzheimer’s disease (Fowler et al., 2010; Paloczi et al., 2017). 
Levels of AEA and 2-AG have been reported to be elevated after brain injury and damage 
(Natarajan et al., 1986; Hansen et al., 2001b; Panikashvili et al., 2001) which may reflect a 
self-neuroprotective response.  
Exogenously applied CB receptor agonists have been shown to exert neuroprotection in 
various in vitro and in vivo models of neuronal injury (reviewed in Sarne and Mechoulam, 
2005; van der Stelt and Di Marzo, 2005b). For example, 2-AG levels were elevated in the 
brains of mice following closed head injury and when synthetic 2-AG was administered, 
significant reductions in brain oedema and hippocampal cell death was observed with 
noticeable improved clinical recovery. These effects were dose dependent and could be 
antagonised by CB1 receptor antagonist SR1417161, indicating a protective role of the eCB 
system in damage and repair (Panikashvili et al., 2001). As well as this, application of AEA 
was found to reduce the infarct volume in an in vivo model of acute neuronal injury caused 
by ouabain-induced excitotoxicity (van der Stelt et al., 2001). AEA was also shown to be 
neuroprotective following inflammation-induced neuronal damage by engaging CB receptors 
on microglial cells which prevents their activation (Eljaschewitsch et al., 2006). Thus, levels 
of both eCBs are elevated in response to different brain injuries and may play a role in brain 
function homeostasis.  
The neuroprotective effects of the eCBs can be attributed to the activity of the CB receptors. 
In CB1 receptor KO mice, more severe symptoms were present after cerebral ischemia, such 
as larger infarct size and a higher mortality rate (Parmentier-Batteur et al., 2002) and 
recovery from closed head injury was slower in CB1 receptor KO mice compared to wild type 
(WT) mice (Panikashvili et al., 2001). In experimental models of Alzheimer’s disease, 
stimulation of CB1 and CB2 prevented microglial activation and microglia-mediated 
neurotoxicity and neurodegeneration (Ramirez et al., 2005). The activation of CB receptors 
have also been shown to be beneficial in other neurodegenerative diseases such as in 
Parkinson’s disease, multiple sclerosis, and HIV-associated dementia (Centonze et al., 2007). 
CB1 receptor mediated neuroprotective activity likely occurs via the prevention of 
excitotoxicity by the inhibition of glutamate release from neurones. However, other forms 
of eCB mediated neuroprotection that are independent of the CB1 receptor also exists. For 
example, 2-AG has antioxidant effects which suppresses the formation of reactive oxygen 
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species (McCarron et al., 2003). As mentioned previously, eCBs may activate CB receptors on 
microglial cells and prevent their activation; thus, supressing the inflammatory response and 
preventing further pathological cascades (Ramirez et al., 2005).  
However, in some cases the eCB mediated mechanisms and the activation of CB1 receptors 
can have a neurotoxic effect as well. For example, activation of the CB1 receptors also exert 
detrimental effects on dopamine cell survival by potentiating the toxic effects of the TRPV1 
agonist capsaicin (Kim et al., 2005). It is therefore conceivable that activation of both TRPV1 
and CB1 receptors by AEA might contribute to Parkinson’s disease pathophysiology by 
favouring apoptosis of dopamine neurons. As well as this, elevation of intracellular calcium 
levels is suggested to be one of the main causes for neuronal cell death, and cannabinoids 
can either stimulate or inhibit calcium entry into the cell, depending on their concentration. 
Low doses of cannabinoids will induce cell death, while high doses of cannabinoids will 
protect from neuronal loss, leading to a dual aspect of cannabinoid pharmacology (Sarne and 
Keren, 2004; Sarne and Mechoulam, 2005). Therefore, further research is needed to 
determine the subtle details of which aspects of eCB signalling are neuroprotective. 
As well as neuroprotective effects of the eCB system in brain injury, the eCB system is 
involved in adult neurogenesis and can promote neuroblast migration, which may be of 
therapeutic interest as some studies have suggested that the progenitor cells produced by 
the SVZ can migrate out of the RMS to the site of brain injury (Arvidsson et al., 2002; Goings 
et al., 2004; Romanko et al., 2004; Sundholm-Peters et al., 2005). Overall, the eCB system is 
not only an attractive therapeutic target for early neuroprotection by reducing excitotoxicity 
and preventing microglial activation after injury, but also for replacing damaged neurones 
after injury or in neurodegenerative diseases.  
TBI and osteoporosis  
As mentioned above, levels of 2-AG and AEA are increased following neuronal injury which 
may have neuroprotective roles. Traumatic brain injury (TBI) is the disruption of brain activity 
due to an external force or violent blow to the head which can lead to a series of physical, 
cognitive, social, emotional, and behavioural impairments depending on the severity which 
is based on the length of time of lost consciousness (Yu et al., 2014). One interesting 
discovery from the studies of TBI in addition to neurological impairment is the dysregulation 
of peripheral bone turnover, which suggests the central involvement of the eCB system in 
bone maintenance. In fact, TBI is the beginning of an ongoing, and possibly lifelong, process 
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that impacts multiple organ systems including bone that can be distal to the site of injury 
(Bajwa et al., 2018).  
Bone maintenance relies on the balanced action of osteoblasts – cells that form bone, and 
osteoclasts – cells that absorb bone (Manolagas, 2000). This balance is orchestrated through 
central control, mainly through the sympathetic nervous system which is partially regulated 
by the endocannabinoid system (Ishac et al., 1996; Idris and Ralston, 2012). CB2 receptors 
are present in osteoblasts and osteoclasts, stimulating bone formation and inhibiting bone 
resorption respectively in the cells when activated (Idris et al., 2008). CB1 expression is 
extremely low in bone cells but is expressed in bone sympathetic nerve fibres which 
innervate the cancellous bone (Tam et al., 2006). CB2 KO mice have a low bone mass 
phenotype, indicating the role of the CB2 receptor in bone formation (Ofek et al., 2006). The 
results from CB1 KO mice are more contentious: mice from a C57BL/6J background have low 
bone density, in part because of a substantial decrease in their bone formation (Tam et al., 
2006) whilst mice from a CD1 background have a high bone density phenotype which is 
gender specific (Idris et al., 2005). The discrepancy could result from genetic differences 
between the background strains which can provide insight into a genetic basis of 
osteoporosis. Nonetheless, the results from the generation of KO mice revealed the 
involvement of CB receptors in the balance of bone remodelling.  
In mice from a C57BL/6J background, there is mounting evidence linking the association 
between TBI and enhanced osteogenesis which leads to heterotopic ossification (the growth 
of bone tissue outside of the skeleton) and enhanced fracture healing and bone density 
(Melamed et al., 2002; Locher et al., 2015; Bajwa et al., 2018). The mechanisms underlying 
osteogenesis following TBI is not fully understood, but the involvement of the eCB system 
has been reported (Tam et al., 2008). Following TBI, the levels of eCBs 2-AG and AEA in 
cancellous bone increases, which may be from two sources: local production by bone cells 
which can produce comparable levels of 2-AG as in the brain, or from the release of eCBs 
from sympathetic nerve terminals following TBI damage. The release of eCBs from the 
sympathetic nerve cells could result from brain injury; hence, the mechanisms underlying 
the increase in both brain and bone eCBs levels after neuronal injury may be similar (Tam et 
al., 2008). The increase in eCB levels activate the CB1 receptors expressed on sympathetic 
nerve endings which inhibit the release of noradrenaline (Ishac et al., 1996). Noradrenaline 
released from sympathetic fibres inhibits bone formation and stimulates bone resorption 
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(Takeda et al., 2002). Therefore, activation of CB1 alleviates tonic inhibition of bone 
formation by the sympathetic nervous system leading to osteogenesis (Tam et al., 2008).  
The discovery of the involvement of centrally and locally released eCBs following TBI in 
osteogenesis gives therapeutic potential to skeletal disorders such as osteoporosis. Whilst 
the evidence from animal studies are contentious depending on which model is used, 
observations in humans have shown that heavy use of recreational cannabis, which can 
activate both CB1 and CB2 receptors, is associated with low bone mineral density and 
increased bone turnover (Sophocleous et al., 2017b). As well as this, the loss of both CB1 and 
CB2 receptors in mice reduced age-related bone loss when compared with WT mice due to 
a reduction in osteoclast number (Sophocleous et al., 2017a). Further elucidation of the 
involvement of the eCB system in bone remodelling could provide interesting therapeutic 
targets, both centrally and locally, in the treatment of injury induced osteogenesis and age-
related osteoporosis. 
Given the importance of the roles of the eCB system in many physiological roles in the body 
and its therapeutic potential, a complete comprehension of the signalling pathway is needed 
to fully understand underlying mechanisms in disease phenotypes and for drug discovery 
efforts. Previous drug discovery efforts targeting the CB receptors are hindered by unwanted 
neurological side effects, for example the small molecule CB1 antagonist Rimonabant was 
approved for the treatment of obesity; however, it was later withdrawn due to depression 
and suicidal ideation (Moreira and Crippa, 2009). Thus, alternative targets which can 
modulate CB receptor activity, particularly of CB1 as it is involved in many neuronal roles, is 
particularly attractive but requires full understanding of the mechanisms of action. The work 
in this thesis will be focused on clarifying the involvement of natural ligands to the CB1 






1.3 Endogenous ligands to the CB receptors – 
Endocannabinoids 
 
Much of what is known about the functions of the CB receptors and the roles of the eCB 
system has been through the discovery of the eCBs 2-AG and AEA. Unlike other 
neurotransmitters that are water-soluble and stored in vesicles prior to release, the eCBs are 
lipid based and synthesised and released “on demand” in response to cellular changes 
(Marsicano et al., 2003). 2-AG and AEA are the two main eCBs most extensively studied but 
both are members of wider families of structurally related molecules that may also have 
physiological roles and/or contribute to eCB signalling (Figure 1.3.4) (Schmid et al., 1990; 
Ben-Shabat et al., 1998). The processes that underlie the biosynthesis of eCBs have been 
extensively studied for 2-AG and AEA and will be described here. 
  
1.3.1 Anandamide Synthesis 
After the identification of AEA as the first eCB, speculation arose into the synthesis pathway 
of AEA. Two synthesis methods were reported for the generation of AEA. First, through the 
combination of ethanolamine and free arachidonate which may be energy-independent or 
catalysed by the backwards reaction of AEA hydrolysis (Devane and Axelrod, 1994; Ueda et 
al., 2000). Levels of ethanolamine and free arachidonate are low in neurones and many 
enzymatic steps are needed to generate the free molecules, which suggest that it is not likely 
to be the primary method of synthesis (Di Marzo et al., 1994). However as local levels may 
reach high enough concentrations, this pathway cannot be rigorously ruled out (Ueda et al., 
2000). The second and most accepted pathway of AEA biosynthesis occurs by release from 
membrane phospholipid precursors (Di Marzo et al., 1994; Cadas et al., 1996). Di Marzo et 
al. (1994) used [3H] ethanolamine labelled cultured neurons to demonstrate that the calcium 
ionophore ionomycin could stimulate the synthesis of AEA. This calcium stimulated AEA 
synthesis begins with the transfer of a fatty acyl chain from the sn-1 position of membrane 
phospholipids such as phosphatidylcholine (PC) to phosphatidylethanolamine (PE) by a 
calcium-sensitive N-acyltransferase enzyme (CaNAT). The activity of CaNAT leads to the 
formation of N-acyl phosphatidylethanolamine (N-acylPE), including arachidonoyl-
containing N-arachidonyl phosphatidylethanolamine (NAPE) which is the precursor to AEA 
(Figure 1.3.1) (Cadas et al., 1997).  
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The calcium dependent formation of N-acylPEs was first noticed from dog tissues by Schmid’s 
group (Natarajan et al., 1981; Natarajan et al., 1983; Reddy et al., 1983), but was later 
partially characterised by Piomelli’s group with rat tissues (Cadas et al., 1997). Using 
neurones labelled with [3H] ethanolamine or various [3H] free fatty acids, ionomycin was able 
to induce the formation of various [3H] N-acylPEs and the process was sensitive to the 
presence of EDTA (Cadas et al., 1996). Furthermore, activation of PKA to generate cAMP has 
also been shown to potentiate the activity of CaNAT, leading to the increased synthesis of 
AEA (Cadas et al., 1996; Cadas et al., 1997). However, the full identification of the CaNAT 
enzyme was proving problematic to elucidate due to purification difficulties and the lack of 
genetic advances. The identity of the CaNAT remained elusive for many years, until it was 
recently proposed to be PLA2G4E (also known as cPLA2) which is part of the cytosolic PLA2 
group (PLA2G4) of enzymes. PLA2G4E was identified as possessing N-acyl transferase activity 
through the aid of activity-based protein profiling, as well as being calcium sensitive and 
could interact with PC and PE to generate NAPE when expressed in HEK293T cells (Ogura et 
al., 2016).  
In the search to identify the elusive CaNAT, other enzymes with N-acyl transferase activity 
but lacking calcium sensitivity were also identified through the efforts of Ueda’s group and 
termed calcium insensitive NAT (iNAT) (Jin et al., 2007; Jin et al., 2009). The search began 
with lecithin retinol acyltransferase (LRAT) which catalyses the transfer of the sn-1 acyl group 
from PC to vitamin A leading to the formation of retinyl ester, which is used in visual 
processes (Rando, 2002). This N-acyl transferase activity is similar to the N-acyl transferase 
activity of the partially characterised CaNAT, thus LRAT was the basis of a bioinformatics 
search for homologous enzymes that may have similar activity. This identified enzymes of 
the HRAS-like suppressor (HRASLS) subfamily (also known as phospholipase 
A/acyltransferase (PLAAT) 1–5) which are a family of class II tumour suppressors (Jahng et 
al., 2003; Golczak et al., 2012). In particular, HRASLS5 was cloned from rat cDNA library and 
expressed in COS7 cells where it showed ability to bind to PC and PE and catalysed a transfer 
of an acyl group to form NAPE. However, HRASLS5 showed little sensitivity to calcium and 
different expression profiles to CaNAT, but might be distinctive N-acyl transferases that could 












Figure 1.3.1. Multiple pathways of AEA biosynthesis and degradation 
The major pathway of AEA synthesis begins with the combination of phospholipids PC and 
PE by CaNAT or iNAT to generate NAPE. NAPE can release AEA from different pathways: (1) 
through one step hydrolysis by NAPEPLD, (2) through PLC to generate p-AEA which can be 
dephosphorylated by PTPN22, (3) through the action of ABHD4 or PLA2 to generate lysoNAPE 
which can either be cleaved by lysoPLD to release AEA or undergo the combined action of 
ABHD4 and GDE1 to release AEA. AEA synthesis has also been described by cleavage of N-
acylethanolamine plasmalogen (pNAPE) in NAPEPLD-dependent and independent manners. 
AEA is hydrolysed primarily by FAAH into AA and ethanolamine. AEA can also be oxygenated 
by: (1) COX-2 into prostaglandin ethanolamides (PG-EA), (2) LOXs into hydroxy-
ethanolamines (HETE-EAs) and (3) P450s into epoxytrienoic acid ethanolamides (EET-EAs). 















N-acylPE can then be hydrolysed to NAEs, by a calcium sensitive phospholipase D (PLD) 
activity (Di Marzo et al., 1994; Schmid, 2000). The NAPE-specific PLD (NAPEPLD) thought to 
be involved in the hydrolysis of N-acylPEs was then cloned (Okamoto et al., 2004) and was 
shown to be expressed ubiquitously, with high expression in the brain and is highly conserved 
between mammalians. Unlike other PLDs, NAPEPLD is part of the metallo-lactamase family 
of enzymes, show calcium sensitivity (Ueda et al., 2001) and when overexpressed in COS7 
cells can hydrolyse N-acylPEs in NAEs, including NAPE into AEA. NAPEPLD was soon 
positioned as the likely primary enzyme in the generation of AEA despite no studies at the 
time demonstrating the direct involvement of NAPEPLD in AEA synthesis in vivo (Ligresti et 
al., 2005). 
 
1.3.2 Generation of NAPEPLD KO mice 
After the cloning of NAPEPLD, a NAPEPLD KO mice was generated to further characterise the 
activity of NAPEPLD in vivo (Leung et al., 2006). Levels of saturated and mono-unsaturated 
NAEs had decreased, with significant decreases in N-palmitoyl ethanolamine (PEA), N-
stearoyl ethanolamine (SEA), and N-oleoyl ethanolamine (OEA). Surprisingly, there were no 
observable differences in the levels of AEA in the brains of WT and NAPEPLD KO mice. Brain 
homogenates did have reduced NAPE hydrolysis activity but a NAPEPLD-independent 
synthesis of AEA was still present at similar enzymatic rates as in WT mice. This suggested 
that NAPEPLD may have some preference for N-acylPEs and the generation of NAEs in vivo, 
with more preference for very long chain saturated NAEs. The results also suggested that 
there are other calcium-insensitive synthesis pathways of AEA involving other enzymes with 
potential to compensate for NAPEPLD.  
Two other NAPEPLD KO mice were generated with comparable results. Tsuboi et al. (2011) 
reported the whole brain levels of AEA were lower in KO mice than in wild type mice but was 
not completely abolished. The levels of saturated and mono-unsaturated NAEs were more 
varied, as levels of PEA and OEA were significantly lower, as also observed by Leung et al. 
(2006), but levels of SEA remained unchanged. A third NAPEPLD KO mice was generated and 
had levels of NAEs and other structurally related lipid moieties measured from various brain 
regions (Leishman et al., 2016). In this comprehensive lipidomics profiling, levels of all NAEs 
were lower in the NAPEPLD KO mice in comparison to WT, including AEA, with surprisingly 
greater reductions in polyunsaturated NAEs in comparison to saturated and mono-
unsaturated NAEs. The largest changes in AEA levels were observed in the striatum and 
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hippocampus of the KO mouse with ~3x reduction, but the levels were not completely 
abolished from other brain regions, suggesting perhaps a brain-region specific involvement 
of NAPEPLD in AEA synthesis.  
At least two other synthesis pathways for AEA have been reported following the results from 
the studies with NAPEPLD KO mice (Figure 1.3.1). The remaining NAPEPLD independent 
generation of AEA was reported to be blocked by a broad serine hydrolase inhibitor methoxy 
arachidonyl fluorophosphonate (MAFP) (Simon and Cravatt, 2006). It was suggested that AEA 
synthesis can be mediated through the activity of a serine hydrolase catalysed double 
deacylation of NAPE to form lysoNAPE and subsequently generate glycerol-phospho-AEA 
(GP-AEA), followed by the phosphodiesterase-mediated cleavage of GP-AEA to release AEA. 
The serine hydrolase α/β-hydrolase domain containing 4 (ABHD4) which can selectively 
deacylate both NAPEs and lysoNAPEs prior to the generation of GP-AEA, was subsequently 
identified (Simon and Cravatt, 2006). The EDTA-sensitive conversion of GP-AEA to AEA was 
attributed to the metal-dependent glycerophosphodiester phosphodiesterase 1 (GDE1) 
(Simon and Cravatt, 2008). Both ABHD4 and GDE1 are expressed in various tissues including 
the brain, however the generation of GDE1 KO mice or double GDE1/NAPEPLD KO mice did 
not show significant decreases in AEA levels in the KO brain compared to WT (Simon and 
Cravatt, 2010). Furthermore, rat brain tissues have been shown to contain lysoPLD activity 
that can generate AEA from the intermediate lysoNAPE (Sun et al., 2004). 
Another pathway was described in macrophages which produce AEA in response to 
stimulation by lipopolysaccharide (LPS). This pathway involves the actions of an unidentified 
PLC to generate phosphor-AEA (pAEA) and subsequent dephosphorylation by phosphatases 
such as phosphatase 22 (PTPN22) to release AEA (Figure 1.3.1). The LPS-induced synthesis of 
AEA in macrophages is mediated exclusively by this PLC/phosphatase pathway, which is up-
regulated by LPS. Conversely, NAPEPLD is down-regulated by LPS and functions as a salvage 
pathway of AEA synthesis when the PLC/phosphatase pathway is compromised (Liu et al., 
2006). In addition, a novel route was reported for AEA formation from N-acylethanolamine 
plasmalogen (pNAPE), one of the major classes of glycerophospholipids in mouse brain 
(Tsuboi et al., 2011). 
Although it is accepted that NAPE is the precursor to AEA, the precise enzymatic steps leading 
to the generation of AEA remains unclear. The synthesis of AEA can also be elicited through 
the activities of PKA and PKA directly. Activation of PKA and PKC in HEK-293 cells and DRG 
neurones can increase the levels of AEA which is unaffected by the presence of a calcium 
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chelator (van der Stelt and Di Marzo, 2005a; Vellani et al., 2008). However, CaNAT is not 
directly responsive to kinase activation and requires calcium to function (Cadas et al., 1996) 
thus which of the pathways that might be affected by kinase activity has not been 
investigated. It is also unknown particularly how these pathways can selectively release AEA 
over other NAEs. KO studies so far have failed to identify a specific and selective pathway for 
the majority of AEA synthesis suggesting that different pathways can work in a co-operative 
and compensatory manner to maintain AEA levels in tissues. The global deletion of a widely 
expressed enzyme such as NAPEPLD may cause secondary pathways which may not normally 
be active to compensate. Pharmacological tools could be beneficial in determining the 
contribution of NAPEPLD by defining shorter end points in experiments, however currently 
no pharmacological tools have been developed for the inhibition of AEA synthesis. This may 
also help elucidate the contribution of the various pathways in basal AEA synthesis and “on-
demand” stimulated AEA synthesis by calcium and LPS.  
 
1.3.3 Anandamide Degradation  
AEA signalling is terminated by its cellular uptake and subsequent catabolism into AA and 
ethanolamine. The primary enzyme responsible for the degradation of AEA in brain and 
peripheral tissues was cloned by Cravatt et al. (1996) from rat liver membranes and 
demonstrated its ability to hydrolyse AEA in vitro. FAAH is expressed in a wide range of 
tissues, especially in the brain and liver and is conserved in humans (Cravatt et al., 1996; 
Giang and Cravatt, 1997). The generation of a FAAH KO mouse showed barely any AEA 
hydrolysis activity and 15-fold higher brain levels of AEA compared to WT control. FAAH KO 
mice also displayed cannabimimetic behavioural effects that could be antagonised by the 
CB1 receptor antagonist SR141716A (Cravatt et al., 2001). Other genetic and 
pharmacological studies showed disruption of FAAH activity elevates brain levels of AEA and 
also displays CB1 dependent analgesia in multiple pain assays (Cravatt et al., 2001; Lichtman 
et al., 2004b; Lichtman et al., 2004a; Jhaveri et al., 2008; Ahn et al., 2009). In high 
concentrations of AA and ethanolamine, it has been shown that FAAH can catalyse the 
backwards reaction to generate AEA, but whether this function occurs physiologically is 
unclear (Ueda et al., 2000).  
The intracellular endoplasmic reticulum location of FAAH suggested that transporters which 
uptake AEA into the cell and transport across the cytosol for degradation might exist (Di 
Marzo et al., 1994; Cravatt et al., 1996). Whilst AEA is lipid soluble and can freely diffuse 
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through membranes, evidence for transport-mediated uptake of AEA was described by Di 
Marzo et al. (1994) using exogenously applied [3H] AEA to characterise the cellular uptake of 
AEA. The uptake of [3H] AEA in neuronal cultures was rapid, temperature dependent, 
saturable at 37oC but perturbed by the addition of non-radioactive AEA and finally selective 
as [3H] PEA did not compete with the uptake of [3H] AEA.  
The identification of the transporters gained interest as a potential therapeutic target as it 
has been suggested that the cellular uptake of AEA is the rate limiting step to the termination 
of AEA signalling (Hillard and Jarrahian, 2000; Maccarrone et al., 2000b; Maccarrone et al., 
2010). To date, several proteins capable of binding AEA have been identified which may have 
a role in the intracellular transport of AEA. For example, trafficking of AEA from the plasma 
membrane can be mediated by cytosolic carriers found in different cell types, including fatty 
acid binding proteins (FABPs) (Kaczocha et al., 2009), heat shock protein 70 (HSP70) and 
albumin (Oddi et al., 2009), FAAH-1-like AEA transporter (FLAT-1) (Fu et al., 2011), and 
potentially by sterol carrier protein 2 (SCP-2) (Liedhegner et al., 2014). These proteins may 
transport AEA via a non-vesicular mechanism or may interact with liposomes which have 
been shown to accumulate AEA (Oddi et al., 2008; Maccarrone et al., 2010). However, the 
roles of these proteins were elucidated through overexpression in recombinant systems and 
their functions have not been clarified in vivo. Thus, there still remains open questions about 
the specificity of these proteins in orchestrating AEA uptake and transport, and roles of AEA 
accumulation in different cell types (Maccarrone, 2017).  
In addition to hydrolysis by FAAH, AEA can undergo oxygenation by cyclooxygenase-2 (COX-
2) (Kozak et al., 2002; Rouzer and Marnett, 2011), 5-, 12- and 15-lipoxygenase (5-/12-/15-
LOX) (Hampson et al., 1995; van der Stelt et al., 2002) as well as by several cytochrome P450 
monooxygenases (P450) (Snider et al., 2010; Urquhart et al., 2015). Oxygenation by COX-2 
turns AEA into prostaglandin ethanolamides (PG-EA), while LOXs convert AEA into hydroxy-
ethanolamines (HETE-EAs), and P450s convert AEA into epoxytrienoic acid ethanolamides 
(EET-EAs) (Figure 1.3.1) (Urquhart et al., 2015). The oxygenated derivatives of AEA may have 
a biological activity of their own in mediating the inflammatory response, but their impact 




1.3.4 2-AG Synthesis  
2-AG is formed “on-demand” from AA-containing phospholipids in response to cellular 
responses. Phosphatidylinositol (PI) serves as the most preferred phospholipid substrate for 
2-AG formation in the brain (Sugiura et al., 2006) with the main synthesis pathway of 2-AG 
release from PI through combined actions of PLC and the DAGLs. Following cellular 
stimulation such as receptor activation, the activity of PLC cleaves PI containing AA into 
inositol 1,4,5-trisphosphate (IP3), and AA-containing DAG which is then subsequently 
hydrolysed by DAGL into 2-AG (Figure 1.3.2). PI containing other fatty acids in the sn-2 
position are precursors to other 2-acylglycerols such as 2-LG, 2-PG and 2-oleoylglycerol (2-
OG), which may also have physiological roles (Ben-Shabat et al., 1998). A secondary pathway 
was also described to occur through the activity of PLA1 cleaving PI to release lysoPI, and the 
subsequent cleavage by lysoPI-specific PLC to release 2-AG (Figure 1.3.2) (Ueda et al., 1993).  
DAG is an important second messenger in mammalian cells and is synthesised in response to 
cellular activation such as through the activation of various GPCRs (Brose et al., 2004). DAG 
can activate various downstream effectors, with the most prominent target being the PKC 
family of serine/threonine kinases which can subsequently activate various other effectors. 
The termination of DAG signalling generally occurs by the action of DAG kinase (Merida et 
al., 2008), so the activity of the DAGL was originally studied as an intermediate pathway to 
the release of AA (Prescott and Majerus, 1983). However, it was not until the discovery of 2-
AG as an important signalling molecule in its own to the CB receptors (Mechoulam et al., 
1995) that focus was placed on the synthesis steps of 2-AG as a signalling molecule by DAGLs.  
After the discovery of 2-AG as an important eCB signalling molecule, many studies reported 
the abundance of 2-AG in many different tissues, including the highest levels in brain 
(Bisogno et al., 1997; Stella et al., 1997; Kondo et al., 1998). This places importance on 
elucidating the synthesis enzyme for the most abundant eCB in the brain. The DAGL activity 
was partially characterised in the context of AA synthesis pathway and found that the 
enzyme has an optimal pH of 7.0, and its action at the sn-1 position can lead to the 
downstream release of AA (Chau and Tai, 1981; Okazaki et al., 1981; Prescott and Majerus, 
1983). The enzyme(s) responsible for the synthesis remained elusive until bioinformatics 













Figure 1.3.2. Pathways of 2-AG biosynthesis and degradation 
2-AG synthesis begins with activation of PLC following cell stimulation, which hydrolyses 
phospholipid PI to release DAG. DAG is further hydrolysed to 2-AG by DAGL. 2-AG can also 
be generated by a secondary pathway through the actions of PLA1 to generate LysoPI and 
subsequent hydrolysis by PLC. 2-AG is degraded into glycerol and AA, the precursor to 
prostaglandin synthesis primarily by MAGL but ABHD6 and ABHD12 can also catalyse this 
process. 2-AG can also be oxygenated by: (1) COX-2 into prostaglandin glyceryl esters (PG-
Gs), (2) LOXs into hydroxyeicosatetraenoic acid glyceryl esters (HETE-Gs), and (3) P450s into 
epoxytrienoic glyceryl esters (EET-Gs) (not depicted).  










The gene encoding a known mono- and diacylglyceride hydrolysing enzyme in Penicillium 
camembertii fungus (Yamaguchi et al., 1991) was queried against mammalian genomes and 
clear homologues were identified. The two human homologues of DAGLs, diacylglycerol  
(DAGL) and diacylglycerol  (DAGL), were subsequently identified and cloned (Bisogno et 
al., 2003). These enzymes were highly specific and selective for the sn-1 position of DAG to 
release 2-acylglycerols, including 2-AG, in response to calcium influx, and could be inhibited 
by established DAGL inhibitors THL and RHC80267. Overexpression of these enzymes in COS7 
cells also showed 3-fold greater lipase ability against 1-stearoyl-2-arachidonoy-sn-glycerol 
compared to untransfected cells (Bisogno et al., 2003). Furthermore, overexpression of 
DAGLα in Neuro-2A cells resulted in an increase in 2-AG and stearic acid and a decrease in 1-
stearoyl-2-arachidonoyl-sn-glycerol (Jung et al., 2007).  
Whilst on-demand 2-AG synthesis and release can be stimulated by calcium, the DAGLs do 
not seem to be directly activated by calcium (Farooqui et al., 1984; Moriyama et al., 1999; 
Rosenberger et al., 2007). The synthesis of 2-AG by the DAGLs therefore likely involves 
additional steps from calcium elevation that leads to the activation of DAGL (Reisenberg et 
al., 2012; Kano, 2014). DAGL from bovine brain microsomes can be directly activated by PKA 
(Rosenberger et al., 2007) and activation of PKA and PKC can both increase 2-AG synthesis in 
DRG neurons and HEK-293 cells (Vellani et al., 2008). Both PKA and PKC can also be activated 
by calcium (Steinberg, 2008; Dunn et al., 2009), thus it has been hypothesised that the 
activation of kinases may lead to the phosphorylation of DAGLs causing its activation as a 
way of regulating DAGL activity (Reisenberg et al., 2012). 
Immunohistochemical studies showed that whilst DAGL and DAGLwere coexpressed in 
embryonic mice neurons correlating with the role in axonal growth and guidance, a 
developmental switch in expression led to the DAGL isoform expression to be enriched in 
adult mouse brain and spinal cord. This suggested that DAGL is the main isoform for the 
generation of 2-AG in the adult brain and that DAGL is downregulated during development. 
Expression of DAGL is found in the high levels in the dendritic spines in adult neurones, also 
correlating well with eCB signalling in retrograde synaptic transmission (Bisogno et al., 2003). 
DAGL is expressed at lower levels in the CNS but at particularly high levels in macrophages 
and microglia which correlates well with its recently established role in inflammation 
(Bisogno et al., 2003; Hsu et al., 2012). These results demonstrated that the DAGLs were able 
to hydrolyse DAG to generate 2-AG in vitro and are positioned at the right place at the right 
time to mediate the well-established eCB signalling roles in the CNS and in the periphery.  
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1.3.5 Generation of DAGL KO mice 
The generation of DAGL and DAGL KO mice further supported the contribution of the 
DAGLs to the generation of 2-AG and clarified specific role differences between the two 
DAGLs. The role of DAGLα in retrograde eCB signalling in the CNS was also revealed by 
independent KO mice studies (Gao et al., 2010; Tanimura et al., 2010; Shonesy et al., 2014). 
In the brain and spinal cord of adult DAGLα KO mice, an astonishing 80% reduction of 2-AG 
levels was observed, establishing this enzyme as the major 2-AG synthesising enzyme in the 
CNS (Figure 1.3.3) (Gao et al., 2010). In a separate study, DAGLα KO mice also displayed an 
80% reduction in 2-AG in the cerebellum, hippocampus and striatum, with little change to 
these brain regions in DAGLβ KO mice (Tanimura et al., 2010). Furthermore, DAGL KO mice 
lost stimulus-induced increases in 2-AG in the brain and DSE and DSI in hippocampus, 
cerebellum and striatum were also lost, which is also observed in CB1 KO mice (Ohno-
Shosaku et al., 2002; Tanimura et al., 2010). This loss of DSE and DSI was not observed in 
DAGLβ KO mice, indicating that DAGL is principally involved in the generation of the 
retrograde messenger 2-AG for short term synaptic plasticity (Gao et al., 2010; Tanimura et 
al., 2010; Yoshino et al., 2011).  
DAGL KO mice displayed similar neurological phenotypes to mice with genetic deletion of 
the CB1 receptor. DAGL KO mice showed increased emotional and stress-related 
behaviours such as anxiety and depressive-like behaviour in open-field tests (Shonesy et al., 
2014; Jenniches et al., 2016) which was also observed in CB1 KO mice (Marsicano et al., 2002; 
Valverde and Torrens, 2012). In a separate study, DAGL and CB1 KO mice showed similar 
anxiety behaviours in the hot plate, forced swim, tail suspension test and others, which were 
both statistically significantly different to WT mice (Powell et al., 2015). As well as this, CB1 
KO mice display hypophagia and have a lean phenotype, which was also seen in DAGL KO 
mice but not seen in DAGL or NAPEPLD KO mice (Powell et al., 2015). Finally, as mentioned 
previously, genetic mutations of CB1 and DAGL are associated with similar neurological 
phenotypes in humans (Smith et al., 2017). Collectively, these results show the close 
behavioural phenotypes of DAGL and CB1 KO mice, supporting the role of DAGL as the 
predominant synthesising enzyme for the bulk of 2-AG required for eCB signalling at the CB1 






Figure 1.3.3. Comparison of 2-AG and AA levels in wild type and DAGL KO mice 
2-AG and AA levels were measured in tissues of DAGLα KO (α-/-) and DAGLβ KO (β-/-) mice 
and compared to wild type (+/+) mice control. An 80% reduction of 2-AG levels was observed 
in the brains and spinal cord of adult DAGLα KO mice. A 50% reduction in 2-AG levels was 
observed in the brains of adult DAGLβ KO mice with no significant reduction in the spinal 
cord detected. In the adipose tissue, there was a 50% reduction in 2-AG in DAGL KO mice 
while no significant reduction was observed in DAGLβ KO mice. In the liver, there was a 50% 
reduction in 2-AG in DAGLα KO mice, compared to a 90% reduction in the liver of DAGLβ KO 
mice. Reduction in AA levels changed in parallel with the reductions in 2-AG in the brain, 
spinal cord and liver, most notably was 80% reduction in AA levels in brain and spinal cord of 
DAGLα KO mice and a 90% reduction in AA in the liver of DAGLβ KO mice. 




Interestingly, AEA levels were also affected in DAGL KO animals. Levels of AEA were 
comparable to WT in DAGL KO mice brains but were reduced in the cerebellum and 
hippocampus of DAGL KO mice (Tanimura et al., 2010). Furthermore, AEA levels were ~25-
75% lower in the cortex, hippocampus and amygdala but not in the striatum of DAGL KO 
mice (Jenniches et al., 2016). A separate report suggested a slight (~10%) reduction in AEA 
levels in the hippocampus of DAGL KO mice but this was more pronounced in DAGL KO 
mice (~60%) (Yoshino et al., 2011). This crosstalk between 2-AG and AEA has been suggested 
to be a result of phospholipid remodelling in KO mice, which could affect the fatty acid 
composition of brain precursors for NAPE (Di Marzo, 2011) which can make it difficult to 
dissect the two synthesis pathways. Moreover, the relatively long-term loss of function in 
one pathway can lead to alterations in other pathways, thus genetic results should be 
interpreted with caution. 
In adult DAGLβ KO mice, a 50% reduction in 2-AG levels was observed in the brains with no 
significant reduction in the spinal cord detected. However, a 90% reduction in 2-AG levels 
was observed in the liver of the DAGLβ KO mice, compared to a 60% reduction in the DAGLα 
KO mice (Figure 1.3.3). Interestingly, whilst DAGL is attributed to most of generation of 2-
AG in the brain, the KO of both DAGL and DAGL collectively (DAGL KO) in mice have 
even lower levels of 2-AG than in DAGL KO alone across several areas of the brain (Yoshida 
et al., 2006). The loss of DAGL showed no impact on DSE/DSI whilst these were impaired in 
the loss of DAGL, and had little impact in adult neurogenesis in the SVZ, but did show a ~30-
40% reduction in the hippocampus (Gao et al., 2010; Tanimura et al., 2010). DAGL KO 
mouse peritoneal macrophages also show reductions in 2-AG, as well as AA and eicosanoids 
levels, and a reduction in LPS-induced TNF-, supporting the role of DAGL in inflammation 
and as a key mediator in lipid metabolism (Hsu et al., 2012). These studies show that the 
individual contributions of the DAGLs to maintaining steady-state levels of 2-AG are different 
in different tissues, with the production of 2-AG in brain attributed to the activity of DAGL. 
Furthermore, the DAGLs appear to maintain tissue 2-AG levels in a cooperative and 
compensatory manner.  
The genetic deletion of the DAGLs revealed the interesting observation of a reduction in AA 
levels alongside reductions in 2-AG levels. 2-AG is the precursor to AA after hydrolysis by 
MAGL, however PLA2 was generally believed to be the primary enzyme involved in AA 
synthesis (Balsinde et al., 2002). DAGL KO studies showed AA was reduced by ~80% in the 
brain and spinal cord in DAGLα KO mice, as well as ~90% reduction in the liver of DAGLβ KO 
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mice which is in parallel to the reduction in 2-AG (Gao et al., 2010). This was also observed 
in DAGL KO mouse peritoneal macrophages (Hsu et al., 2012). Thus 2-AG appears to be the 
main precursor for AA and points to a role for DAGL activity in the regulation of AA synthesis.  
 
1.3.6 2-AG Degradation 
2-AG is degraded in vivo primarily by monoacylglycerol lipase (MAGL) which hydrolyses 2-
acylglycerols to release a fatty acid and glycerol (Figure 1.3.2). MAGL was cloned from rat 
brain cDNA library and is widely expressed in the brain (Dinh et al., 2002). The overexpression 
of MAGL in HeLa cells showed markedly increased 2-AG hydrolysis (but not AEA hydrolysis) 
and resulted in reduced accumulation of 2-AG following stimulation of rat primary cortical 
neurons (Dinh et al., 2002). The inhibition of MAGL in vivo raises brain 2-AG concentrations 
by 8-10 fold (without altering AEA) and MAGL-inhibited mice exhibited much of the 
pharmacological behavioural responses typically seen with CB1 agonists (Long et al., 2009b; 
Schlosburg et al., 2010). Genetic deletion of MAGL in mice also exhibit elevated levels of 2-
AG, but do not fully recapitulate the pharmacological behavioural responses seen with 
pharmacological blockade, possibly due to the desensitisation of the CB receptors (Taschler 
et al., 2011; Imperatore et al., 2015).   
MAGL is considered to be responsible for ~85% of the 2-AG hydrolysing activity in the brain, 
with the remaining 15% of 2-AG hydrolysis being attributed to other serine hydrolases such 
as ABHD6, ABHD12 and FAAH (Figure 1.3.2) (Blankman et al., 2007). MAGL co-localises with 
CB1 in presynaptic terminals which positions MAGL as the main terminator of 2-AG-CB1 
signalling (Kano et al., 2009). In a study by Marrs et al. (2010), the acute inhibition of ABHD6 
in neuronal cultures led to activity-dependent accumulation of 2-AG. They described the 
post-synaptic location of ABHD6 which is well positioned to act as a guard to the intracellular 
pool of 2-AG, perhaps to control the seepage of 2-AG from the intended synaptic cleft. 
Furthermore, the inhibition of ABHD6 in cortical slices facilitated the induction of eCB-LTD 
with sub-threshold stimulation, placing ABHD6 as an important mediator of synaptic eCB 
signalling. The role of ABHD12 in eCB signalling is currently unclear, its 2-AG hydrolysing 
ability was discovered through activity-based protein profiling (ABPP) (Blankman et al., 2007) 
and is found to be expressed in microglia where it may have a role in mediating immune 
function in the CNS (Savinainen et al., 2012). FAAH can hydrolyse both AEA and 2-AG in vitro; 
however, the in vivo role of FAAH in 2-AG degradation is very minor in the brain and is much 
more involved in the hydrolysis of AEA in vivo (Blankman et al., 2007; Ueda et al., 2011). 
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Other pharmacological studies have since shown that MAGL is the key hydrolysing enzyme 
limiting 2-AG and CB1 signalling (Hashimotodani et al., 2007; Long et al., 2009b; Pan et al., 
2009; Savinainen et al., 2012; Keimpema et al., 2013) making it a key regulator of eCB 
signalling.  
In addition to hydrolysis by serine hydrolases, 2-AG can be oxygenated by many of the same 
enzymes described in AEA oxygenation (Kozak et al., 2002; Urquhart et al., 2015). 
Oxygenation by COX-2 turns 2-AG into prostaglandin glyceryl esters (PG-Gs), while LOXs 
convert 2-AG into hydroxyeicosatetraenoic acid glyceryl esters (HETE-Gs), and P450s convert 
2-AG into epoxytrienoic glyceryl esters (EET-Gs) (Figure 1.3.2) (Urquhart et al., 2015). The 
oxygenation of the eCBs by these enzymes show the complexity of the eCB system and how 
it may influence the generation of potentially biologically active inflammatory mediators, 
some of which may be implicated in a range of neuroinflammatory diseases (reviewed in 
Turcotte et al., 2015). 
 
1.3.7 Other putative eCBs and endogenous ligands to the CB 
receptors 
Other structural analogues of AEA and 2-AG exist and may function as potential eCBs based 
on their structures (Figure 1.3.4). 2-AG ether (noladin) (Hanus et al., 2001; Fezza et al., 2002), 
AEA derivative O-arachidonoyl ethanolamine (virodhamine) (Porter et al., 2002) and N-
arachidonoyldopamine (NADA) (Hu et al., 2009) have been reported to act as eCBs from 
various studies. Noladin was isolated from porcine brain and was shown to bind selectively 
to CB1 and CB2 receptors in mice causing sedation, hypothermia, intestinal immobility, and 
mild antinociception in mice (Hanus et al., 2001; Fezza et al., 2002). However, role of noladin 
as an eCB is disputed as some studies report the presence of noladin in the brain whilst 
others suggest endogenous levels of noladin in various mammalian species is not significant 
(Oka et al., 2003; Richardson et al., 2007). Porter et al. (2002) reported virodhamine is 
present in the human hippocampus at levels similar to AEA levels and in rat brain. It has been 
reported that virodhamine is an antagonist of CB1 but is an agonist of CB2 (Porter et al., 
2002). NADA is detected in the brains of rats with especially high concentrations in the 
hippocampus, cerebellum and striatum (Huang et al., 2002). NADA has been shown to be an 
agonist to CB1 receptors inducing analgesia upon systemic administration and hyperalgesia 
when intradermally injected, but is also an agonist to the transient receptor potential of 
vanilloid type-1 (TRPV1) receptor (Bisogno et al., 1997; Huang et al., 2002). These putative 
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eCBs show activity towards the CB receptors in various studies but their full mechanism of 
action, the synthesis and degradation pathways and whether they are true eCBs in 





Figure 1.3.4. Structure of the Endocannabinoids 
Structures of the two most well studied eCBs: 2-AG and AEA, three putative eCBs: 




2-LG is structurally similar to 2-AG with a substitution of a linoleoyl group in place of 
arachidonoyl group (Figure 1.3.4) and could be generated by DAGL (Bisogno et al., 2003). 2-
LG was profiled as the most abundant 2-acylglycerol in Drosophila melanogaster and may 
have a role in eCB signalling in invertebrates lacking arachidonic acid (Tortoriello et al., 2013). 
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2-LG is also detected in mammalian brain homogenate at around 10x lower concentrations 
than 2-AG (Richardson et al., 2007; Williams et al., 2007) and is in mouse spleen tissue (Ben-
Shabat et al., 1998) and canine gut tissue (Mechoulam et al., 1995) in relatively high amounts 
compared to 2-AG. However, the physiological role of 2-LG is currently unclear. It was 
previously reported that whilst 2-LG is unable to directly activate mammalian CB receptors, 
it can potentiate the role of other eCBs, including 2-AG activation of CB1 receptors (Ben-
Shabat et al., 1998). The mechanism for this potentiation is unknown, it has been suggested 
2-LG may inhibit 2-AG breakdown by binding to MAGL (Ghafouri et al., 2004). However, a 
recent publication by Murataeva et al. (2016) showed 2-LG did not have an entourage effect 
but rather displayed antagonistic activity against 2-AG in a model of DSE, which would 
suggest that 2-LG can have direct ligand interaction with the CB1 receptor in order to 
antagonise 2-AG activity. Unlike the other putative eCBs, the synthesis and degradation 
pathways of 2-LG are known as they are likely to be the same pathways as 2-AG, and the 
levels of 2-LG are high enough to be physiologically relevant. Thus, 2-LG may have an active 
role in the eCB system which has not been fully elucidated and could be a novel eCB. 
As well as novel agonists of the CB receptors, novel endogenous antagonists have also been 
described. The novel peptide hemopressin (Hp) is a 9-residue peptide derived from the 1 
chain of haemoglobin which was extracted from rat brain homogenate and was found to be 
biologically active when injected in vivo (Rioli et al., 2003). Hp was shown to have 
hypotensive and antinociceptive effects when administered in vivo (Blais et al., 2005; Dale et 
al., 2005b) but the mechanism of its effects was unclear until Heimann et al. (2007) reported 
Hp as a selective antagonist to the CB1 receptor. Thus far, the ligands of the CB receptors 
have been lipid based, but the discovery of Hp garnered interest as a novel endogenous 
peptide cannabinoid ligand which would expand the repertoire of CB ligands and could be 
novel therapeutic targets. However, although some of its effects in vivo are reported to be 
mediated by CB1 receptor blockade (Dodd et al., 2010; Dodd et al., 2013; Zhang et al., 
2016b), some studies have shown contentious findings that Hp does not exert its effects 
through the CB1 receptor (Lippton et al., 2006; Straiker et al., 2015; Dvoracsko et al., 2016). 
As well as this, evidence that Hp directly binds to CB1 has not been confirmed so far in 
laboratories other than the one that first described this activity (Heimann et al., 2007; Gomes 
et al., 2009). Finally, very little is known about the biosynthesis and inactivation of Hp, which 
makes any interpretation of its biological importance as an endogenous ligand to the CB1 
receptor difficult.  
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1.4 Additional activities of the eCB system 
 
DAGL and NAPEPLD have been studied extensively in the context of the generation of eCBs 
for eCB signalling. However, it is often overlooked that these enzymes are central to the 
generation of a range of other signalling moieties which could also have physiologically 
important roles, thus placing the synthesis enzymes as key modulators of many signalling 
systems.  
 
1.4.1 Non-CB functions of 2-acylglycerols  
The DAGLs are highly conserved between mammals and many species express some form of 
DAGL (Yuan et al., 2016). In some species such as Drosophila, a DAGL homologue is expressed 
in the absence of a homologue to the vertebrate CB receptors (Elphick and Egertova, 2001). 
This might suggest the DAGL homologue is relevant in non-eCB signalling contexts, for 
example it has been shown to be vital for visual processes in Drosophila (Leung et al., 2008). 
As well as this, Drosophila lacks an arachidonic acid pool but has a relatively abundant 
linoleoyl fatty acid pool. Therefore, the major 2-acylglycerol generated is 2-LG, which could 
have important physiological functions that are not mediated through CB receptors 
(Tortoriello et al., 2013).  
Aside from the generation of 2-AG as the major eCB, the DAGLs can generate other 2-
acylglycerols in mammals which have been suggested to function as entourage molecules of 
2-AG (Ben-Shabat et al., 1998), or as ligands to other receptors, for example 2-OG is a 
proposed ligand for GPR119 which may have implications in diet and satiety (Hansen et al., 
2011; Syed et al., 2012). Levels of 2-LG and 2-PG are in physiologically relevant levels in 
certain mammalian organs (Ben-Shabat et al., 1998), suggesting the DAGLs can generate 
steady state levels of these 2-acylglycerols, but their physiological function is not yet fully 
elucidated.  
Furthermore, it has been reported that AA – which has no intrinsic activity at CB receptors, 
can modulate neuronal function by directly affecting voltage-dependent potassium channels 
(Figure 1.4.1) (Oliver et al., 2004; Meves, 2008; Carta et al., 2014). As 2-AG and AEA contain 
AA, they can also modulate the gating of ion channels in a CB-independent manner by 
entering the phospholipid bilayer directly (Oz, 2006; Gantz and Bean, 2017). 2-AG and AA has 
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been shown to accelerate firing of isolated midbrain dopamine neurones where expression 
of CB receptors is negligible (Herkenham et al., 1990). This occurs by the inhibition of Kv4.3 
channels by interacting with the voltage sensing region of the channel which faces the lipid 
bilayer (Swartz, 2008). This in turn reduces the inactivating A-type potassium current (IA) 
which leads to more rapid neuronal firing. The latter effect can be weakly enhanced by 
calcium influx from cell depolarisation but is more enhanced by activation of Gq/11 GCPRs 
(Gantz and Bean, 2017). In this context, 2-AG is able to modulate neuronal signalling through 






Figure 1.4.1. Schematic of the working model for the inhibition of A-type potassium current 
by 2-AG 
Calcium entry during high-frequency action potential firing or activation of Gq/11 GPCRs 
mobilises 2-AG synthesis. 2-AG is generated through the activity of PLC to generate DAG, and 
conversion of DAG to 2-AG by DAGL. 2-AG may also be degraded by MAGL to release AA. 2-
AG and AA inhibits IA by lipid interaction with Kv4.3 channels. Inhibition of IA enhances the 
excitability of dopamine neurons in an autocrine signalling manner. 





1.4.2 Eicosanoid signalling  
The substantial reduction of AA in DAGL KO mice provides strong evidence for the 
DAGL/MAGL pathway as the major pathway for the release of AA (Gao et al., 2010). In this 
context, the role of DAGL would be to generate 2-AG as a substrate for MAGL rather than for 
eCB signalling. The role of MAGL therefore would be to hydrolyse 2-AG to maintain levels of 
AA for generation of eicosanoids instead of terminating the signalling action of 2-AG. This 
pathway would serve to maintain steady-state levels of AA and serve as a response pathway 
to generate signalling pools of AA in inflammatory states.  
In support of this DAGL/MAGL mediated generation of AA, MAGL inhibition in vivo resulted 
in an increase in 2-AG levels coupled with a complimentary decrease in AA levels in mouse 
brain, spinal cord, liver, spleen, and lung (Nomura et al., 2008). In the brain, inhibition of 
MAGL with specific inhibitor JZL184 is associated with substantial decreases of AA (Long et 
al., 2009b). Furthermore, in animal models of cerebral artery occlusion stroke, 
administration of JZL184 reduced brain levels of AA levels and inflammatory cytokine TNF- 
but increased brain levels of anti-inflammatory cytokine IL-10 (Rahmani et al., 2018). 
Similarly, in a separate study of ischemic stroke, JZL184 suppressed the inflammatory 
response, decreased the number of degenerating neurons as well as reducing brain oedema 
and improving behavioural functions which resulted in neuroprotective effects (Choi et al., 
2018). These neuroprotective effects of MAGL inhibition were not fully antagonised by 
antagonists of CB receptors, indicating that the anti-inflammatory effects are likely caused 
by inhibition of eicosanoid production rather than by CB receptor activation. 
In the brains of MAGL KO animals, a 5-fold decrease in AA was observed but also a decrease 
in levels of eicosanoids like prostaglandin E2 (PGE2), prostaglandin D2 (PGD2) and 
thromboxane B2 (TXB2) (Nomura et al., 2011). MAGL inhibition also reduced LPS-stimulated 
inflammatory cytokine levels by ~4-8 fold in a CB1/2 independent manner, as well as 
supressing microglial activation (Nomura et al., 2011). In support of the hypothesis that 
MAGL makes a much more substantial contribution to the generation of AA than the 
classically described pathway of release by PLA2, basal levels of AA and eicosanoids remain 
unaltered in PLA2G4A (cPLA2) KO mice, which is in contrast a 5 to 10-fold reduction in MAGL 
KO mice or following MAGL inhibition. Furthermore, only a 20% reduction in LPS-induced 
prostaglandins production was detected in brains of PLA2G4A KO mice which is modest when 
compared to a >3-fold reduction in MAGL KO mice. In addition to this, a clear partitioning of 
function between MAGL and PLA2G4A was uncovered: MAGL was mainly responsible for 
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regulating basal and LPS-stimulated levels of AA and prostaglandins in the liver and lung, 
whereas PLA2G4A regulated these lipids more in the gut and spleen (Nomura et al., 2011).  
These studies, alongside DAGL KO studies reveal the large contribution of DAGL/MAGL 
signalling to the production of AA and downstream eicosanoids. The KO of MAGL in the liver 
reduced AA levels by around 50% (Nomura et al., 2011), whereas the KO of DAGL revealed 
a 90% reduction of AA in the liver (Gao et al., 2010), suggesting that the bottleneck of AA 
synthesis is likely to be the DAGL step in certain areas of the body. The reduction of 
downstream eicosanoids implicate a role of DAGL/MAGL as mediators of inflammation. In 
support of this, DAGL is expressed primarily in immune cells where a substantial reduction 
in 2-AG, AA and eicosanoids were observed in DAGLβ deficient macrophages (Hsu et al., 
2012). The reduction of eicosanoids associated with decreases in AA following disruption of 
DAGL or MAGL further confirms that the release of AA is not simply a by-product of 2-AG 
hydrolysis, but may have implications in the regulation of inflammatory responses.  
 
1.4.3 Synthesis and Functions of NAEs  
N-acylPEs containing various fatty acid side chains can be generated by the transferase 
activity of CaNAT and the hydrolysis of N-acylPEs generate NAEs (Ueda et al., 2010). It is 
generally accepted that N-acylPEs and NAEs occur in low levels ubiquitously in many 
organisms and have a variety of functions (Schmid and Berdyshev, 2002).  
Various NAEs have been functionally characterised, with AEA being the best characterised as 
an agonist to the CB receptors and the TRPV1 receptor (Devane et al., 1992; Smart et al., 
2000). PEA has been reported to exhibit pharmacological activities such as anti-
inflammatory, analgesic, and neuroprotective actions through agonistic activity toward the 
PPAR receptor (Hansen, 2010; Petrosino et al., 2010). OEA is known to exert an anorexic 
action, which appears to be mediated largely by its binding to GPR119, but could also act 
through PPAR and TRPV1 receptors (Fu et al., 2003; Piomelli, 2003; Movahed et al., 2005; 
Overton et al., 2006). SEA has been reported to have pro-apoptotic activity through CB and 
TRPV receptor independent mechanisms (Terrazzino et al., 2004) also possesses anti-
inflammatory and anorexic properties (Astarita and Piomelli, 2009). The activity of these 
NAEs are mediated through non-CB receptors but the physiological roles of these NAEs have 
not yet been fully characterised.  
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Whilst endogenous levels of NAEs are generally at a low level, NAEs have been of interest as 
they are shown to be more highly detected following tissue injury in different organs, 
including the brain (Hansen et al., 2001a; Hansen, 2010). Different species of NAEs have 
shown protective properties, for example through the activation of CB receptors by AEA to 
prevent excitotoxicity (Eljaschewitsch et al., 2006) or through non-CB related mechanisms 
by the other NAEs. NAEs can also protect cells in different ways, for example through the 
antioxidative properties of saturated NAEs, by monounsaturated NAEs preventing calcium 
leakage from mitochondria, and by inhibiting release of mediators that promote necrosis and 
inflammation (Hansen et al., 2000; Esposito et al., 2014). The accumulation and protective 
properties of NAEs following injury are of interest as potential future therapeutics for brain 
injury and neurogenerative diseases.    
These NAEs have been shown to be generated by NAPEPLD in vitro showing that NAPEPLD is 
not selective for the fatty acyl chain (Okamoto et al., 2004). However, the KO of NAPEPLD in 
mice show the largest changes in saturated and monounsaturated NAEs over 
polyunsaturated NAEs (Leung et al., 2006). The partiality of NAPEPLD in vivo for the 
generation of saturated and monounsaturated NAEs over polyunsaturated NAEs such as AEA 




1.5 Aims and Objectives 
 
After 25 years since the identification of the two major endocannabinoids, many studies have 
established the importance of the role of the eCBs and the CB receptors in eCB signalling for 
many brain processes in neonatal neuronal development, in postnatal synaptic retrograde 
signalling and neurogenesis. The eCB system also plays important roles in maintaining the 
physiological functions of peripheral systems such as GI mobility and bone maintenance. As 
well as this, the eCB synthesis enzymes might also have distinct roles outside of eCB 
signalling. Given these important roles of the eCB system, a full understanding of the 
synthesis and signalling pathways of endogenous ligands to the CB receptors is needed. 
However, there are still many unanswered questions about the endogenous ligands of the 
CB receptors.  
Aside from the two major eCBs, little is known if there are any other endogenous eCBs or 
molecules that may modulate eCB signalling. The unclear role of 2-LG as an entourage for 2-
AG or as a CB1 antagonist warrants further investigation as 2-LG can be detected at 
physiologically relevant levels and the synthesis and degradation pathways are already 
elucidated. Hp, the first proposed endogenous peptide antagonist of the CB1 receptor could 
be a promising pharmacological tool or for potential therapeutics. However, conflicting 
reports of its activity at the CB1 receptor and disputed presence of its synthesis and 
degradation pathways would require further clarification prior to further drug discovery 
efforts.  
There also remains questions regarding the generation of the major eCBs 2-AG and AEA 
through the actions of DAGL/DAGL and NAPEPLD, respectively. The contribution of the 
DAGLs in retrograde eCB signalling in the brain has been very well characterised. However, 
the DAGLs have also been shown to be involved in autocrine signalling and non-CB signalling 
roles. Unlike neurons, 2-AG synthesis in these roles may not be stimulus-induced and the 
contributions of DAGL and 2-AG to eCB signalling in these instances are less well 
characterised. A full understanding of AEA synthesis is still elusive given the redundancy of 
AEA synthesis pathways. Despite this, the two main enzymes currently accepted to be the 
main enzymes synthesising AEA are NAPEPLD and CaNAT. Therefore, it is of interest to 
elucidate the contribution of NAPEPLD and the recently discovered CaNAT enzyme PLA2G4E 
have in AEA synthesis and eCB signalling.  
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The CB1-Tango assay is an industry standard cell-based reporter assay system that gives 
quantitative activation of the CB1 receptor (van der Lee et al., 2009) and was adopted as the 
model system for the study of novel CB ligands and eCB signalling.  
The CB1-Tango assay was used to address the following questions: 
o Does 2-LG have direct activity on the CB1 receptor or is it an entourage for 2-AG?  
o Is the Hp peptide a CB1 receptor antagonist and can it modulate eCB signalling? 
o Can the CB1-Tango assay be adapted to measure eCB signalling? 
o Does DAGL generate 2-AG for eCB signalling in the CB1-Tango cells? 
o To what extent is NAPEPLD required for AEA synthesis and eCB signalling? 
o Is the recently described PLA2G4E enzyme the elusive CaNAT and are there other 











2.1.1 Cell Culture  
Phosphate Buffered Saline (PBS)  
Ten Dulbecco 'A' tablets from Oxoid (Cat No: BR0014) dissolved in 1 litre of distilled water 
and autoclaved. 1 litre of PBS contains sodium chloride (8.0g/l), potassium chloride (0.2g/l), 
disodium hydrogen phosphate (1.15g/l) and potassium dihydrogen phosphate (0.2g/l) 
PBS-EDTA 
PBS with 0.5mM Ethylenediaminetetraacetic acid (EDTA) at pH 8.0 
Trypsin  
2.5% Trypsin in PBS-EDTA from Gibco (Cat No: 15090046) diluted with PBS-EDTA to desired 
concentration 
Cell culture plastics from Thermofisher Scientific 
Polystyrene Nunclon™ Delta Surface 10 cm cell culture dishes (Cat No: 150350) 
Nunc Polystyrene T75 cell culture flask (Cat No: 156499) 
Transfection Reagent 
FuGene HD Transfection Reagent from Promega (Cat No: E2311) 
Puromycin selection 
Puromycin (hydrochloride) from Cayman Chemicals (Cat No: 13884-25mg-CAY) diluted in 






2.1.2 CB1-TANGO Assay 
CB1-TANGO Cells 
TANGOTM CNR1-bla U2OS cell line from Invitrogen, Life Technologies (Cat No: K1513) 
CB1-TANGO Growth Media  
McCoy’s 5A Medium (Cat No: 26600-023) with 10% dialysed FBS (Cat No: 26400-036), 0.1M 
NEAA (Cat No: 11140-050), 25mM HEPES (pH 7.3) (Cat No: 15630-080), 1mM Sodium 
Pyruvate (Cat No: 11360-070), 100µg/ml Penicillin/Streptomycin (Cat No: 15140-122), 
200µg/ml Zeocin™ (Cat No: R250-01), 50g/ml Hygromycin (Cat No: 10687-010) and 
100g/ml Geneticin (Cat No: 10131-027), all from Invitrogen, Life Technologies 
0.5% FBS McCoy’s Assay Medium 
McCoy’s 5A Medium supplemented with 0.5% FBS, 0.1M NEAA, 25mM HEPES (pH 7.3), 1mM 
Sodium Pyruvate, 100µg/mL Penicillin/Streptomycin, all from Invitrogen, Life Technologies 
Freestyle Assay media 
Freestyle 293 expression media Invitrogen, Life Technologies (Cat No: 12338-018) 
No Starve Freestyle Assay media 
Freestyle 293 expression media supplemented with 2mM sterile CaCl2 from Sigma (Cat No: 
21114-1L) and 100nM JZL195.  
Tango Assay Plates 
Costar 96-well black clear bottom polystyrene plates, from Fisher Scientific (Cat No: 
10530753) 
Detection reagent 
LiveBLAzer™-FRET B / G Loading Kit, from Life Technologies (Cat No: K1096 and K1156) 
Fluorescent Reader 












CB1 receptor agonist Sigma (Cat No: A9719-
25MG) 
AM251 CB1 receptor inverse 
agonist 
Sigma (Cat No: A6226-
10MG) 
IONOMYCIN Ca2+ ionophore Cambridge Biosciences (Cat 
No: 10004974-10 mg-CAY) 
TETRAHYDROLIPASTATIN 
(THL) 
Serine lipase inhibitor Tocris (Cat No: 3540), Sigma 
(Cat No: O4139 SIGMA) 
KT109 DAGL inhibitor Cravatt compounds, Sigma 
(Cat No: SML1364) 
KT172 DAGL and DAGL 
inhibitor 
Cravatt compounds, Sigma 
(Cat No: SML1688) 
JZL195 Dual MAGL and FAAH 
inhibitor 
Sigma (Cat No: SML0257-
5MG) 
FORSKOLIN (FSK) Adenylyl Cyclase activator Sigma (Cat No: F6886) 
PHORBOL 12-MYRISTATE 
13-ACETATE (PMA) 
PKC activator Sigma (Cat No: P1585-1MG) 
2-LINOLEOYL GLYCEROL (2-
LG) 
Lipid containing linoleoyl 
glycerol 
Cambridge Biosciences (Cat 




CB1 receptor agonist Cambridge Biosciences (Cat 
No:  62160-1 mg-CAY) 
ANANDAMIDE (AEA) CB1 receptor agonist Cambridge Biosciences (Cat 
No: 90050-5 mg-CAY) 
HEMOPRESSIN (HP) Putative CB1 receptor 
antagonist 
(1) Tocris (Cat No: 
3791/1) 
(2) Cambridge 
Biosciences (Cat No: 
10011038-1 mg-CAY) 
(3) Sigma (Cat No: 
H3042-1MG) 
Table 2.1.1. Drug compounds used in Tango assay characterisation 
 
2.1.3 Multiplex Assay 
Multiplex bead and probe set 
Quantigene Multiplex set from Affymetrix (Cat No: QP1013 and QGP-113) 
Multiplex Analysis System 
MAGPIX® multiplex system from Luminex  
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Total RNA Samples 
Total human RNA of cerebellum and hippocampus from Takara Bio Europe (Cat No: 636535 
and 636593) and skin from AMS Biotechnology Ltd (Cat No: R1234218-50) were purchased 
and diluted to desired concentration using nuclease free water and used in the Magpix beads 
assay. 
2.1.4 Molecular Biology for CRISPR 
Plasmids and Oligomers 
pSpCas9(BB)-2A-Puro (PX459) was a gift from Feng Zhang (Addgene plasmid #48139)  
Primers and oligomers were ordered from Sigma Aldrich and diluted in deionised water. 
DAGL CRISPR gRNA oligomers: 
DAGL Exon 14 gRNA 1 5’– CGGAACCAAACACTACGGCC –3’ 
DAGL PCR reaction primers: 
DAGL Exon 14 Intron FWD 5’– AGCAAGGTTTGGAAGCGTAA –3’ 
DAGLExon 14 Intron REV 5’– CAGACCTCCATGTGACCAGA –3’ 
DAGL CRISPR gRNA oligomers: 
Exon 9 gRNA 1 5’– GTCAGCGGAGAGTGAGGTGC –3’ 
Exon 9 gRNA 2 5’– GGTGCTGGACGTGGAGTGTG –3’ 
Exon 9 gRNA 3 5’– GTGTGAGGTGCAGGACCGCC –3’  
Exon 9 gRNA 4 5’– GCACCTCACTCTCCGCTGAC –3’  
Exon 10 gRNA 1 5’– GATACGTTTACCAACGACTC –3’  
Exon 11 gRNA 1 5’– GAGCCGCCTACCCGCAGGTC –3’  
Exon 11 gRNA 2 5’– GGGCGGGGCGGCCGCCCTGC –3’  
Exon 11 gRNA 3 5’– GTAGCACCTGACCTGCGGGT –3’ 
Exon 11 gRNA 4 5’– GTCATAGTGGGCCACAGCCT –3’  
CelI assay PCR primers (in introns):  
DAGL Ex9 intron FWD 5’–CGCTGGGTTTCCCTCTTTAG –3’ 
DAGL Ex9 intron REV 5’–GTCAGCATTCACAGGCAAGA –3’ 
DAGL Ex10 intron FWD 5’–GCAGTCTCAGATCCCAGGAG –3’ 
DAGL Ex10 intron REV 5’–CAGCTCCAAAGAGGACAAGG –3’ 
DAGL Ex11 intron FWD 5’–CCTTGTCCTCTTTGGAGCTG –3’ 
DAGL Ex11 intron REV 5’–AGCAGGAAAACAAAGGCTCA –3’ 
DAGL PCR reaction primers:  
DAGL Exon 9 Intron FWD 5’– CGCTGGGTTTCCCTCTTTAG –3’ 
DAGL Exon 9 Intron REV 5’– GTCAGCATTCACAGGCAAGA –3’ 
NAPEPLD CRISPR gRNA oligomers:  
Exon 3 gRNA 1 5’– GATAAGGACCGCATCTATTGG –3’ 
Exon 3 gRNA 2 5’– GCTTCACCATCGCAGTACAT –3’ 
Exon 3 gRNA 3 5’– GAAGTGACCTTATCATGTCCG –3’ 
Exon 3 gRNA 4 5’– GGGGAACGACGAAATCGCTT –3’ 
NAPEPLD PCR reaction primers:  
NAPEPLD Exon 2 FWD 5’– TTCCGGAGCAAGTGATTCTT –3’ 
NAPEPLD Exon 4 REV 5’– CCACCTCGGTTCATAAGCTC –3’ 
PLA2G4B CRISPR gRNA oligomers:   
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PLA2G4B Exon 13 gRNA 1 5’– GCTATTATGGCCACTGGTGGT –3’ 
PLA2G4B Exon 13 gRNA 2 5’– GCTATTATGGCCACTGGTGG –3’ 
PLA2G4B Exon 19 gRNA 3 5’– GCAGGCACAGGTGGGGCTCCG –3’ 
PLA2G4B Exon 19 gRNA 4 5’– GCACCTGTGCCTGCTGGATGT –3’ 
PLA2G4B PCR reaction primers:  
PLA2G4B Exon 13 Intron FWD 5’– CTGGTCCCAAGACCTGTGAT –3’ 
PLA2G4B Exon 19 Intron REV 5’– AGGGGACCCAGCTACAAGAT –3’ 
Table 2.1.2. Table of oligomers and primers 
 
Enzyme Kits 
T4 DNA Ligase kit (Cat No: M0202S), T4 Polynucleotide Kinase (Cat No: M0201S), BbsI 
Restriction Enzyme kit (Cat No: R0539S) and Calf Intestinal Phosphatase (CIP) kit (Cat No: 
M0290S) were ordered from New England Biolabs and used following manufacturer’s 
instructions. 
DNA Processing and Purification Kits 
QIAprep Spin Mini Prep Kit (Cat No: 27104), QIAamp DNA Mini Kit (Cat No: 51304) and 
QIAquick Gel Extraction Kit (Cat No: 28704) were from Qiagen  
Qiashredder (Cat No: 79654), RNeasy Mini Kit (Cat No: 74104) and RNase-free DNase Kit (Cat 
No: 79254) for RNA extraction were from Qiagen 
High-Capacity RNA to cDNA Kit (Cat No: 4387406) from Thermo Fisher Scientific 
Competent cells for transformation 
NEB 10-beta Competent E. coli (High Efficiency) (Cat No: C3019I) from New England Biolabs 
 
2.1.5 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction 
Phusion Green Hot Start II High-Fidelity DNA Polymerase (Cat No: F-537S) from Thermo 
Scientific 
1% Agarose 
Agarose from Eurogentec (Cat No: EP-0010-05) dissolved in 1X TAE buffer – 40mM Tris, 




Quick-Load 1 kb DNA Ladder (Cat No: N0468S) and Quick-Load 100bp DNA Ladder (Cat No: 
N0467S) from New England Biolabs  
Visualiser 
Molecular Imager® Gel Doc™ XR+ System and Quantitiy One software v4.6.5, from Bio-Rad 
Spectrophotometer 
Nanodrop ND-1000 from Thermo Scientific 
2.1.6 Protein Assays 
Membrane Preparation Lysis Buffer  
20mM HEPES pH 7.0 (Cat No: H3375), 2mM DTT (Cat No: 443853B), 0.25M Sucrose (Cat No: 
S0389), 10mM NaF (Cat No: S7920), 1mM Na3VO4 (Cat No: S6508) with Complete Protease 
Inhibitor (Roche) (Cat No: 04693116001) made up in deionised water. Sucrose free lysis 
buffer is used for the final resuspension. 
Cell Lysate Buffer 
RIPA Lysis Buffer (Millipore) (Cat No: 20-188) diluted to 1x concentration and supplemented 
with Complete Protease Inhibitor (Roche). 
Homogeniser 
POLYTRON PT 1200 E handheld homogeniser from Kinematica 
Protein Quantification Assays 
Pierce BCA Protein Assay Kit (Cat No: 23227) from Thermo Scientific 
Pierce Coomassie® Plus Protein Assay (Cat No: 23200) from Thermo Scientific 
Absorbance Reader 
SpectraMax Plus384 Absorbance Microplate Reader, from Molecular Devices 
2.1.7 Western Blot 
Gels and membranes 




AmershamTM Hybond ECL Nitrocellulose Blotting Membrane (0.45m) (Cat No: RPN78D) 
from GE Healthcare 
 
Antibodies 
ANTIBODY WESTERN BLOT 
DILUTION 
SPECIES SUPPLIER 
ACTIN 1:10,000 Mouse Millipore (Cat 
No: MAB1501) 
DAG LIPASE Β (D4P7C)  1:2500 Rabbit Cell Signaling 
(Cat No: 12574S) 
ALEXA FLUOR 700 ANTI-MOUSE 
(SECONDARY) 
1:5000 Goat Invitrogen (Cat 
No: A21036) 
IRDYE 800CW ANTI-RABBIT 
(SECONDARY) 
1:5000 Goat  Licor (Cat No: 
925-32211) 
PEROXIDASE ANTI-RABBIT IGG 
(H+L) (SECONDARY) 
1:3000 Goat Vector 
Laboratories (Cat 
No: PI-1000) 
Table 2.1.3. Antibodies used in western blot analysis 
ECL Reagent 
Pierce® ECL Western Blotting Substrate (Cat No: 32209) from Thermo Scientific 
Imaging Systems 
Odyssey Infrared Imaging System V3.0.25 from LI-COR 






2.2.1 Passage of Cell Cultures 
When cells were around 90% confluent, they were passaged using aseptic techniques. Cell 
culture medium was removed by aspiration and cells were washed with PBS-EDTA to remove 
residual serum before treatment with 0.05% trypsin in PBS-EDTA for 3-5 minutes in the 
incubator. Equal volume of media containing 10% serum was then added to inactivate the 
trypsin, and the cells were centrifuged at 1000rpm for 3 minutes. The cell pellet was 
resuspended in media and the density of cells were determined before seeding into 
appropriate dishes. Plated cells were incubated at 37oC in a humid atmosphere with 5% CO2 
content. 
 
2.2.2 CB1-Tango Assay 
CB1-Tango cells were seeded in a 96 well black assay plate at a density of 30,000 cells per 
well in 100l of 0.5% FBS McCoy’s media or Freestyle media and incubated in 37oC, 5% CO2 
incubator for 24 hours. Drug compounds were made up in plating media in 6x 
concentrations, and 50l of total drug volume was added to appropriate wells (25l of 
agonist plus 25l of media, or 25l of agonist and 25l antagonist) and returned to the 
incubator for 4 hours. 6x concentration of LiveBLAzer™-FRET B/G (CCF4-AM) TANGO 
substrate (Invitrogen) was prepared according to manufacturer’s instructions and 30l was 
added to each well. The plate was left in the dark for 90 minutes at room temperature and 
then read on the Flexstation microplate reader (Molecular Devices). CB1 activation is 
measured as the fluorescence ratio between fluorescent blue channel (excitation 409nM, 
emission 460nM) from the cleaved substrate and FRET signal in green channel (excitation 
409, emission 530nM) from the intact substrate using SoftMax Plus software). Ratios were 
normalised to control wells (set as 100%) where no agonists or antagonists were added; to 
wells with antagonist AM251; or by subtracting control wells from treatment wells and 




2.2.3 Multiplex Assay 
QuantiGene Multiplex assay system is a high-throughput profiling technology that enables 
gene expression quantitation of up to 50 different genes simultaneously. Sample cells were 
trypsinised and centrifuged to remove all media for RNA extraction. RNA was extracted from 
the cell lines using the Qiashredder (Qiagen) and RNeasy Mini Kit (Qiagen) according to 
manufacturer’s instructions with additional β-mercaptoethanol added during cell lysis, plus 
digestion of genomic DNA with RNase-free DNase (Qiagen). Other RNA from tissues were 
purchased (Takara Bio Europe and AMS Biotechnology Ltd) and diluted with nuclease free 
water. A fixed concentration of RNA was processed with the Quantigene Plex Assay kit 
according to manufacturer’s instructions. In brief, probe sets are generated against specific 
gene transcripts of interest which are coupled to magnetic beads with unique identification 
ratios of red and far-red light emissions. These are incubated with RNA samples overnight 
shaking at 600rpm at 54oC in a 96 well plate. The next day the hybridised samples and beads 
were washed and amplifier solutions were added to amplify the signal from the beads. The 
beads were then washed and read on the MAGPIX® multiplex system (Luminex) immediately. 
The median fluorescent intensity (MFI) was collected from each well for each bead type and 
the background was subtracted to get the Net MFI value. When comparing across cell lines, 
Net MFIs were normalised to the GEO means of two housekeeping genes (HKGs) HLCS and 
FOXJ2 and averaged. Analysis was carried out in Excel.  
 
2.2.4 Molecular Biology for CRISPR 
Designing gRNA Oligomers 
pSpCas9(BB)-2A-Puro (PX459) Version 2 plasmid (Ran et al., 2013) is a cloning backbone 
plasmid for single guide RNA (sgRNA) and encodes Cas9 endonuclease from S. Pyogenes with 
Puromycin resistance (Figure 2.2.1). Guide RNA (gRNA) targeting specific DNA sequences can 
be cloned into the plasmid between two BbsI restriction sites located subsequent to the U6 
promoter. The plasmid can then be transfected into mammalian cell lines for targeted gene 
editing. Oligomers targeting the catalytic domain of DAGL, NAPEPLD and PLA2G4B (listed 








Figure 2.2.1. Vector map of pSpCas9(BB)-2A-Puro (PX459) Version 2 plasmid 
Vector map of PX459 Version 2 plasmid (a gift from Feng Zhang (Ran et al., 2013)) with gene 
features was created on SnapGene Viewer. The restriction enzyme sites that are digested by 













Oligomers were diluted to 100M in sterile deionised water. The pairs of oligomers were 
then phosphorylated and annealed in one reaction. 
COMPONENT VOLUME (L) 
Forward Oligomer (100M) 1 
Reverse Oligomer (100M) 1 
10X T4 Ligation Buffer 1 




The reaction was carried out in a thermocycler using the following parameters: 
STEP TEMPERATURE (OC) TIME 
1 37 30 min 
2 95 5 min 
3 95 to 25 Ramp down at 5oC/min 
 
After annealing, the oligomers were diluted 1:200 with deionised water to give a 
concentration of 50nM. 
BbsI digest and dephosphorylation of PX459 plasmid 
Digestion of the plasmid was carried out using the following reaction mix:  
COMPONENT VOLUME 
PX459 Vector 1g 
BbsI enzyme 1l 
10x BbsI buffer 5l 
H2O Quantity Sufficient 
TOTAL 50L 
 
The reaction mix was incubated at 37oC for 30 minutes. After incubation, 1 unit of CIP was 
added and the reaction was incubated again at 37oC for 60 minutes. The digested PX459 was 
then loaded with 6X loading dye and run on 1% TAE agarose gel and purified using QIAquick 
Gel Extraction Kit using a microcentrifuge (Qiagen) following manufacturer’s instructions.  
 
Ligation of oligomers and PX459 plasmid 
Oligomers and PX459 plasmid were incubated together at 16oC for 2 hours using the 






10X T4 Ligase Buffer 2l 
Digested PX459 Vector 50ng 
Annealed Oligomer pair 1l 
T4 Ligase 1l 
H2O Quantity Sufficient 
TOTAL 20L 
 
The mix was then heat inactivated at 65oC for 10 minutes, and then chilled for 
transformation. 
Transformation into E.coli DH5 
25l of competent E.coli cells (New England Biolabs) were thawed on ice for 10 minutes 
before adding 4l of ligated CRISPR vector and incubated on ice for 30 minutes. The cells 
were then heat-shocked at 42oC for 1 minute and replaced immediately on ice. 250l of S.O.C 
medium was added to the cells and incubated at 37oC, shaking at 250rpm for 1 hour. Cells 
were then plated on 100µg/ml ampicillin selective LB agar plates and incubated at 37oC 
overnight.  
Individual colonies grown on LB agar plates were selected with a sterile loop and placed into 
5ml LB broth containing 100µg/ml ampicillin in a culture tube. The tube was incubated in a 
250rpm shaker at 37oC overnight. The plasmid was then extracted from the E.coli cells with 
QIAprep Spin Miniprep Kit (Qiagen) according to manufacturer’s instructions.  
Transfection  
Cells were plated in 6-well plates at a density of around 80% confluency and were transfected 
the following day with plasmid DNA using FuGene HD Transfection Reagent (Promega) 
according to manufacturer’s instructions. In brief, plasmid DNA was diluted in sterile water 
to the concentration of 0.02g/l and 12l of FuGENE reagent was added and incubated for 
15 minutes at room temperature. The complex was then added to cells and the cells were 
returned to the 37oC incubator for 24 hours. Cells were either trypsinised for the SURVEYOR 
Nuclease assay or the media was changed with puromycin antibiotic selection for 24 hours 
for clonal expansion.  
SURVEYOR Nuclease Assay 
Surviving transfected cells were trypsinised and pelleted by centrifuging and the remaining 
medium was removed. Genomic DNA was extracted from the cells using Puregene Core Kit 





Surveyor nuclease assay verifies the presence of indel mutations by hybridising indel 
mutated DNA with wild type DNA and cleaving mismatched hetero-duplexes. The CRISPR site 
is amplified by PCR from the pooled genomic DNA and half is run on 1% agarose gel to check 
for successful PCR reaction. The remaining PCR reaction mix is heated and cooled to allow 
annealing to form heteroduplexes: 95°C for 10 min; ramping down at a rate of -0.3°C s-1 to 
85oC and holding for 1 min; continuing ramping down -10oC at a time and holding for 1 min 
until 25°C; and 25°C hold for 1 min and finally hold at 4°C. After re-annealing, 10μl of PCR 
products were treated with 1μl of Surveyor nuclease and 1μl of enhancer (supplied with the 
kit) and incubated at 42oC for 40 minutes. Finally the PCR mix is run on 2% agarose gel to 
visualise any smaller cleaved bands. 
Clonal isolation and expansion  
Surviving cells that were transfected with CRISPR vector after puromycin treatment were 
trypsinised – ensuring cells are fully dissociated from each other, and split into a large 
150mm cell culture dish with varying densities of cells to ensure cells are isolated for clonal 
expansion. Cells are left to grow for 2-3 weeks in a 37oC incubator. Individual colonies of cells 
were selected with cloning discs (Sigma Aldrich) and placed into separate wells in 24 well 
plates for expansion. The discs were removed after 24 hours and the cells were left to grow 
until around 50% confluent and then transferred to larger vessels.  
 
2.2.5 PCR and RT-PCR 
For mutation analysis in CRISPR treated cells, both genomic PCR and RT-PCR were carried out 
on the cell lines. Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen) 
according to manufacturer’s instructions. RNA were extracted from sample cell lines using 
RNeasy Mini Kit (Qiagen). Conversion of RNA to cDNA was carried out using High Capacity 
RNA-to-cDNA Kit (Thermo Fisher Scientific) according to manufacturer’s instructions. PCR 
reactions of CRISPR sites were carried out with primers (Sigma Aldrich) located before and 
after the CRISPR mutation site.  









Genomic DNA or cDNA 1g 
100µM Primer FWD 1l 
100µM Primer REV 1µl 
5X HF Buffer 4µl 
50mM dNTPs 0.08µl 
Phusion Polymerase 0.2µl 
H2O Quantity Sufficient 
TOTAL 20µL 
 
STEP TEMPERATURE (OC) TIME (SECONDS) 
1 98 30 
2 98 5 
3 63 10 
4 72 30 
5 Go to step 2 for 30 cycles 
6 72 60 
7 12 Hold 
 
The samples were run on 1% or 2% agarose gel at 90V for 45 minutes. The PCR product was 
purified from the gel using QIAquick Gel Extraction Kit using a microcentrifuge (Qiagen) 
following manufacturer’s instructions and then sent for Sangar sequencing (Source 
Biosciences). 
 
2.2.6 Protein Assays 
Cell Membrane Preparations 
Cells were grown in 10cm dishes until confluent. The media was removed and cells were 
washed in cold PBS before adding 600µl of lysis buffer to each dish and left to stand for 1 
minute. The cells were harvested using a cell scraper and collected into an eppendorf tube 
on ice. Cells were then homogenised in 7 second bursts at 10 second intervals, repeated 3 
times using the POLYTRON PT 1200 homogeniser (Kinematica). The homogenate was then 
centrifuged at 53,000rpm for 30 minutes at 4oC to pellet the membranes. The supernatant 
was removed and pellet resuspended in 200µl of sucrose-free lysis buffer, and homogenised 
again in 7 second bursts at 10 second intervals, repeated 3 times. Protein concentration was 
determined using Bradford Coomassie assay (Thermo Fisher Scientific). Remaining aliquots 





Whole Cell Lysates 
Media was removed from cells and washed in cold PBS before 600µl of RIPA buffer containing 
protease inhibitors were added to the plate. The cells were harvested using a cell scraper 
and collected into an eppendorf tube and placed on a rocker at 4oC for 30 minutes. The lysed 
cells were then spun at 3000rpm for 5 minutes at 4oC and the supernatant was collected. 
Protein concentration was determined using Bradford BCA assay (Thermo Fisher Scientific). 
Remaining aliquots of cell lysates were stored at -20oC. 
Crude brain lysate 
Mice brains were kindly provided by Karen Steel’s group. Wild type C57BL/6 male mice were 
culled at P50 and the whole brain plus cerebellum were collected and lysed in lysis buffer 
containing 0.2% SDS, 0.01M EDTA pH8.0 and 1x Protease inhibitor cocktail (Roche). Cells 
were then homogenised in 7 second bursts at 10 second intervals, repeated 3 times using 
the POLYTRON PT 1200 homogeniser (Kinematica). The homogenate was then centrifuged 
at 13,000g for 15 minutes at 4oC and the supernatant was collected. Protein concentration 
was determined using Bradford BCA assay. Remaining aliquots were stored at -20oC. 
Western Blot 
Cell membrane preps and whole cell lysate samples containing 1µg/µl of protein were 
prepared by adding 5x protein loading buffer, boiled for 5 minutes at 100oC and then loaded 
into precast gels. The gel was run for 1 hour at 100V. The gel was then transferred onto 
nitrocellulose membrane at 100V for 1 hour. The membrane was then blocked with 5% milk 
in PBS and then washed in PBS-T before incubating with primary antibody in 2% milk in PBS-
T overnight in 4oC. The primary antibody was then removed with PBS-T wash and the 
membrane was then incubated with fluorescent secondary antibody in 2% milk in PBS-T for 
1 hour in the dark. The blot was then visualised using Odyssey Infrared Imaging System 
V3.0.25 (LI-COR).  
For enhanced chemiluminescence (ECL) detection of horse radish peroxidase (HRP), the blot 
was treated as above with the exception of peroxidase conjugated antibody as the secondary 
antibody. The substrate was then mixed according to manufacturer’s instructions and 
applied to the blot. The blot was then visualised using UVP™ BioSpectrum 810 Imaging 






2.2.7 Data Analysis 
Data collected was analysed using Graph Pad Prism 5.0 or Microsoft Excel.  
CB1-Tango Assays 
Ratios obtained from CB1-Tango assays were averaged across technical repeats and 
normalised to average control ratios set as 100% stated in each experiment (control 
determined as either in the absence of any pharmacological drugs or in the presence of 
AM251 only). Normalised data were then averaged across independent experiments and 
plotted on Graph Pad Prism. Log EC50 values were obtained from non-linear regression curve 
fitted to the data points generated by Graph Pad Prism and averaged across experiments.  
QuantiGene Multiplex Assays 
The Median Fluorescent Intensity (MFI) was collected for each gene which is proportional to 
the abundance of the RNA for that gene and averaged across technical repeats. The MFI from 
the background wells were subtracted from the sample data to give the Net MFI. The Net 
MFIs of each gene were plotted in Graph Pad Prism when comparing within a cell type. When 
comparing across cell types, the Net MFIs of each gene were normalised to the GEO mean of 
two housekeeping genes: HLCS and FOXJ2. The relative expression of the genes to the 
housekeeping genes are then graphed in Graph Pad Prism.  
Student’s two-tailed T-test and One Way or Two Way ANOVA followed by Dunnett’s multiple 
comparison test or Bonferroni’s multiple comparison test used for all statistical analysis. 













The two human DAGLs, DAGL and DAGL, were first discovered using a bioinformatics 
approach. The gene encoding a known mono- and diacylglyceride hydrolysing enzyme in 
Penicillium camembertii fungus (Yamaguchi et al., 1991) was queried against mammalian 
genomes and clear homologues were defined. The human homologues were subsequently 
identified and cloned (Bisogno et al., 2003). The DAGLs have a high degree of conservation 
in mammals and are expressed in a wide range of species including fungi, invertebrates and 
vertebrates (Yuan et al., 2016). The DAGLs are sn-1 specific and can produce 2-acylglycerols 
with varying lengths of fatty acids in the sn-2 position, including linoleic, oleic, arachidonic 
and stearic acid (Bisogno et al., 2003). 2-AG is synthesised primarily by DAGL and has an 
important role as the major endocannabinoid in activating CB1 and CB2 receptors 
(Mechoulam et al., 1995; Sugiura et al., 1995). However, other structurally related lipids such 
as 2-LG, 2-OG and 2-PG generated by DAGL are less well studied. Knockout experiments in 
mice have shown that the DAGLs are required for all of the well-established eCB functions 
and for the synthesis of nearly all of the 2-AG in tissues (Gao et al., 2010; Tanimura et al., 
2010; Shonesy et al., 2014; Jenniches et al., 2016); this supports the hypothesis that 2-AG is 
the major eCB in the body, but it leaves speculation for other DAGL derived lipids playing 
minor roles. 
 
Despite Drosophila melanogaster lacking the expression of functional CB receptors (Elphick 
and Egertova, 2001; McPartland et al., 2001; McPartland, 2004), DAGL homologue 
Inactivation No After-potential E (INAE) is expressed and presumably has a non-cannabinoid 
signalling role. INAE activity is required to couple photo-excitation of rhodopsin to the 
opening of TRP/TRPL channels in photoreceptors (Leung et al., 2008) and is able to generate 
2-acylglycerols primarily containing linoleic acid, as Drosophila lacks an arachidonic acid pool 
(Shen et al., 2010). 2-LG is in relatively high abundance in Drosophila, and has been 
postulated as an active signalling ligand for the activation of photoreceptors via the action 
of INAE (Tortoriello et al., 2013). However, these findings have been challenged, (Hardie and 






In recent collaborative experiments, the Doherty and Harkany labs have seen up to 50% 
reductions in 2-LG in Drosophila that have had INAE/DAGL knocked out (unpublished 
observation). Homologues of CB1 receptors have been described in various species including 
Hydra vulgaris (De Petrocellis et al., 1999), the mollusc Mytilus edulis (Stefano et al., 1996), 
and in some Crustaceans (McPartland et al., 2006). Insects likely emerged from a Crustacean-
like ancestor expressing a CB1 homologue (Abzhanov and Kaufman, 2000; Regier et al., 2010) 
so the reason for their unique lack of expression of CB receptors is open for conjecture. A 
pragmatic explanation of a “secondary loss” of CB receptors could be due to various 
evolutionary pressures, for example, the toxicity of phytocannabinoids (McPartland, 2004). 
This raises an interesting, albeit speculative, concept that 2-LG could be an ancestral eCB. 
 
2-LG is present in mammalian brain homogenate (Richardson et al., 2007; Williams et al., 
2007) and mouse hippocampal neurones (Murataeva et al., 2016) at around 10x lower 
concentration than 2-AG. 2-LG is also found in mouse spleen tissue (Ben-Shabat et al., 1998) 
and canine gut tissue (Mechoulam et al., 1995) in relatively high amounts compared to 2-AG. 
Despite the physiologically detectable levels of 2-LG, its physiological role is undetermined. 
It has been previously reported that 2-LG is unable to directly activate mammalian CB 
receptors but instead can potentiate 2-AG activation of CB1 receptors in behavioural assays 
(Ben-Shabat et al., 1998; Gallily et al., 2000). The mechanism for this potentiation is not clear. 
It has been suggested that 2-LG may limit 2-AG breakdown by occupying MAGL with similar 
affinities (Ghafouri et al., 2004), thus prolonging 2-AG signalling leading to an ‘entourage 
effect’. Conversely, experiments in autaptic mouse hippocampal neurons show that 2-LG 
does not have an entourage effect on the action of 2-AG on CB1 dependent DSE, but instead 
2-LG displays an antagonistic effect in this study (Murataeva et al., 2016). One explanation 
for the antagonistic effect seen by Murataeva et al could be due to 2-LG acting as a partial 
agonist which can behave as an antagonist in the presence of a full agonist (Calvey and 
Williams, 2008). Therefore, 2-LG might have a wider role in eCB signalling. With the above 
studies in mind, we decided to directly test the hypothesis that 2-LG is a partial CB1 receptor 
agonist by using a sensitive industry standard cell-based CB1 receptor reporter assay.  
 
The CB1-Tango assay is a recombinant cell-based assay that utilises the commercially 
available Tango™ CNR1-bla U2OS cell line from Invitrogen. The assay allows us to study CB1 
signalling via a -lactamase reporter gene in a human osteosarcoma cell line (Barnea et al., 





linked at the C terminus to a TEV protease site and a Gal4-VP16 transcription factor. This 
parental cell line also stably expresses the -arrestin protein fused to a TEV protease, and a 
-lactamase reporter gene under the control of a UAS response element (Figure 3.1.1). Upon 
activation of the CB1 receptor, -arrestin is recruited to the CB1 receptor C terminus where 
it cleaves the transcription factor. The transcription factor is then transported to the nucleus 
and activates the -lactamase reporter gene which is non-native to a human cell line and 
therefore provides a level of specificity. Levels of -lactamase enzyme can be detected by 
application of the ester CCF4-AM FRET substrate (“LiveBLAzer”) which emits fluorescence at 
530nM when intact. Once cleaved by -lactamase, FRET transfer is not able to occur, 
resulting in a different emission at 460nM. Therefore, the ratio of green (530nM) to blue 
fluorescence (460nM) will directly correlate to the activation of CB1.  
 
In this chapter, I will report on the successful utilisation of the CB1-Tango assay to assess the 
activity of a small molecule CB1 agonist (ACEA) and antagonist (AM251) on the CB1 receptor 
and to directly compare the activity of 2-LG with that of 2-AG and AEA on the CB1 receptor. 
I will also derive some insights into the activity of 2-LG as a potential eCB and its relevance 








Figure 3.1.1. Schematic overview of the Tango Assay system 
The CB1 receptor is extended at the C-terminus with a non-native transcription factor by a 
linker that contains a protease cleavage site. β-Arrestin-2 is fused to a TEV protease. Upon 
CB1 activation by agonist(s), β-arrestin-2 is recruited to the receptor. Close proximity of the 
protease and the cleavage site allows the transcription factor to be released, which activates 
transcription of β-lactamase reporter gene in the nucleus. Activity of the β-lactamase 
enzyme is detected with the fluorogenic membrane-permeable substrate ester CCF4/AM, 
which is cleaved by the β-lactamase enzyme resulting in blue fluorescence. The ratio of green 









The use of ACEA as a control agonist and AM251 as a control antagonist in the 
CB1 reporter assay 
In order to establish baseline positive controls, we tested the response of the CB1-Tango 
cells to the potent and selective CB1 agonist arachidonyl-2'-chloroethylamide (ACEA) (Ki = 
1.4nM) (Hillard et al., 1999) as well as the potent and selective CB1 antagonist AM251 (Ki = 
7.49 nM) (Lan et al., 1999). CB1-Tango cells were plated in Freestyle Media as described in 
Methods. The cells were incubated in 37oC incubator overnight and starved (Freestyle media 
is serum free) to reduce the background signal in the assay. The cells were then treated with 
a serial dilution of ACEA (0.04 – 25M, 1:5 dilution) in the presence and absence of 10M 
AM251 to ensure a molar excess over the highest concentration of ACEA (all concentrations 
in this and all other experiments relate to the final concentration during the assay period). 
The assay was carried out as described in Methods. The fluorescence ratio between blue and 
green excitation wavelengths was calculated and the data was normalised to control wells 
which have not been treated with any drugs.  
 
The results from a representative experiment are shown in Figure 3.2.1. A robust CB1 
response can be readily detected at all tested concentrations of ACEA with relatively low 
SEMs (SEMs were below 2.5% of control) which is statistically significantly different to the 
control values from 0.04M ACEA (185.5% ± 1.8% of control, p<0.001) indicating the 
sensitivity of the assay. This response is concentration dependent, as CB1 response increases 
with increasing concentrations of ACEA, until the maximal response of 259.2% ± 2.5% of 
control levels at around 5M is reached. Thus, this confirms the cells’ ability to respond to 
CB1 activation by a synthetic CB1 agonist. Importantly, no significant response to ACEA was 
seen when AM251 was present (p>0.05), which indicated that AM251 successfully 
antagonised the CB1 responses. In further studies AM251 was seen to fully inhibit the 5M 
ACEA response when used at 2.5M. These concentrations were then generally used in 
subsequent experiments throughout as positive controls (unless otherwise stated).  It is 
important to note that on its own AM251 did not have any effect in the assay; this shows 
that under the normal assay conditions there is no basal CB1 dependent signalling (Figure 
3.2.1). The EC50 obtained from a series of concentration response experiments carried out 







Figure 3.2.1. Small molecule agonist ACEA elicits CB1-dependent responses in CB1-Tango 
cells in a concentration dependent manner 
CB1-Tango cells were seeded at 30,000 cells per well in Freestyle expression media for 24 
hours in clear bottom black plates. CB1 response was established by adding ACEA (final top 
concentration 25M, 1:5 serial dilutions) in the absence and presence of AM251 (final 
concentration 10M). Drug compounds were left for 4 hours for the accumulation of -
lactamase enzyme before, 6x concentration of -lactamase substrate was added to the wells 
for 90 minutes. Green and blue fluorescence detection of the cleavage of the -lactamase 
substrate was measured. Fluorescence ratio between green and blue channels were 
calculated and values were normalised to the control wells (set as 100) as % of control. Graph 
shows means of 8 replicates from a single representative assay. In this experiment, SEMs of 
the data points were relatively narrow (<2.5%) and for this reason are not evident on the 
graph. Statistical significance of ACEA responses compared to the control in the absence of 
ACEA, and ACEA responses in the presence of AM251 compared to AM251 only control, were 
established with One Way ANOVA. 





Characterisation of 2-AG and AEA responses in the CB1-reporter assay 
We next wanted to determine the cellular response to the two major established eCBs: 2-AG 
(Ki = 472nM) (Mechoulam et al., 1995) and AEA (Ki = 52nM) (Devane et al., 1992), and to 
confirm that AM251 is able to antagonise the responses to the native ligands. Cells were 
treated with a range of concentrations of 2-AG (0.04 – 25M, 1:5 dilution) in the absence or 
presence of AM251 (FAC 2.5M). The result from a representative experiment is shown in 
Figure 3.2.2. Detectable CB1 responses are observed at all tested concentrations of 2-AG, 
with a statistically significant responses detected from 0.04M (140.6% ± 2.0% of control, 
p<0.001). With increasing concentrations of 2-AG the CB1 response increased, reaching a 
maximal activation between 5M (318.4% ± 9.0% of control response) and 25M (325.5% ± 
9.2% of control response). Quite notably, 2.5M AM251 is able to fully inhibit the response 
to all tested concentrations of 2-AG confirming that the response is indeed CB1 dependent. 
 
Similarly, the second major eCB AEA was also tested on the CB1-Tango cells for its ability to 
activate the CB1 receptor (Figure 3.2.3). A range of AEA concentrations (0.0025 – 5M) was 
used to treat the CB1-Tango cells. AEA was observed to elicit a normal concentration 
response curve with significant responses apparent at as little as 0.025M (119.4% ± 2.4% of 
control, p<0.001), reaching the maximal response at around 2.5 - 5M (242.0% ± 3.0% of 
control). Importantly, there were no statistically significant AEA responses observed when 
2.5M AM251 was present across all concentrations (p>0.05). This confirms that the 
response to AEA is CB1 dependent. The assay is sensitive to the response of the agonists as 
it is able to detect responses from low concentrations of drugs (40nM ACEA and 2-AG; 25nM 
AEA).  
 
Based on a series of independent concentration response curves, the EC50 for 2-AG was 
1.17M (Log EC50 = -5.930 ± 0.42 SEM, n = 4) as compared with 0.057M for AEA (Log EC50 = 








Figure 3.2.2. The eCB 2-AG stimulates CB1-dependent responses in CB1-Tango cells in a 
concentration dependent manner 
30,000 CB1-Tango cells were seeded per well in Freestyle media in clear bottom black plates 
for 24 hours. Serial dilutions of 2-AG (final top concentration 25M, 1:5 dilution) in the 
presence and absence of AM251 (final concentration 2.5M) were made up in Freestyle 
media. Drug compounds were left for 4 hours for the accumulation of -lactamase enzyme 
before 6x concentration of -lactamase substrate was added to the wells for 90 minutes. 
Green and blue fluorescence detection of the cleavage of the -lactamase substrate was 
measured. Fluorescence ratio between green and blue channels were calculated and values 
were normalised to the control wells (set as 100) as % of control. Graph shows means and 
bars represent SEMs of 8 replicates from a single representative assay. Statistical significance 
of 2-AG responses compared to the control in the absence of 2-AG, and 2-AG responses in 
the presence of AM251 compared to AM251 only control were established with One Way 
ANOVA. 






Figure 3.2.3. The eCB AEA stimulates CB1-dependent responses in CB1-Tango cells in a 
concentration dependent manner 
30,000 CB1-Tango cells were seeded per well in Freestyle media in clear bottom black plates 
for 24 hours. A varying range of concentrations of AEA (final top concentration 5M, 1:2 and 
1:10 dilutions) in the presence and absence of AM251 (final concentration 2.5M) were 
made up in Freestyle media. Drug compounds were left for 4 hours for the accumulation of 
-lactamase enzyme before 6x concentration of -lactamase substrate was added to the 
wells for 90 minutes. Green and blue fluorescence detection of the cleavage of the -
lactamase substrate was measured. Fluorescence ratio between green and blue channels 
were calculated and values were normalised to the control wells (set as 100) as % of control. 
Graph shows means of 8 replicates from a single representative assay. SEMs of the data 
points were relatively narrow (<3.4%) and are not evident on the graph. Statistical 
significance of AEA responses compared to the control in the absence of AEA, and AEA 
responses in the presence of AM251 compared to AM251 only control were established with 
One Way ANOVA. 





2-LG exhibits an eCB like activity in the reporter assay, but only in the presence 
of a hydrolase inhibitor 
The CB1-Tango cells are viable and are able to detect CB1 activation by synthetic and natural 
ligands. Furthermore, signalling can be blocked by a robust synthetic CB1 antagonist. Since 
2-LG is structurally similar to 2-AG and for reasons discussed above, we have postulated that 
it might serve as a partial agonist at the CB1 receptor. We have utilised the CB1-Tango assay 
to test this hypothesis.  
To test whether 2-LG has agonist-like activity at the CB1 receptor, CB1-Tango cells were 
plated as previously described and treated with varying concentrations of 2-LG on its own 
over a 1 - 50M range for 4 hours. Initial experiments indicated 2-LG could induce a modest 
concentration dependent CB1 response on the cells across all concentrations, but the 
response was limited and relatively variable across a large number of independent 
experiments, even at higher concentrations of 2-LG (Figure 3.2.4). In brief, the results 
"tended" towards a concentration dependent response, but even at 25M, whilst 
statistically significant to the control (134.3% ± 4.18% of control, p<0.001), the response was 
at best only 34% higher than control and only around 10-15% of the response seen with 
maximally active concentrations of 2-AG or AEA (Figure 3.2.2 and Figure 3.2.3).   
 
Initially, the above results do not support the hypothesis that 2-LG is a partial agonist of the 
CB1 receptor, but if 2-LG is unstable we have perhaps not actually tested the hypothesis 
critically. We reasoned that the CB1-Tango cells are likely to express eCB degrading enzymes 
MAGL, FAAH and ABHD6 which may contribute to the early and rapid termination of any 2-
LG elicited signalling or other eCB signalling that 2-LG may be potentiating. Thus, 2-LG 
concentrations were again tested on CB1-Tango cells but in the presence of 100nM of JZL195 
– a MAGL, FAAH and ADBH6 inhibitor (Long et al., 2009a) (Figure 3.2.4).  
 
The first important observation that we need to consider is that when added at 100nM, 
JZL195 on its own stimulated a small response to 112.3% ± 3.65% of control.  Experiments to 
be discussed later suggest that this reflects a small but significant increase in a basal eCB 
tone in the cells as it is not seen in the presence of AM251. However, in the presence of 
100nM JZL195, 2-LG elicited a very clear concentration dependent response with a maximal 
effect between 25M (169.4% ± 7.13% of control) and 50M (175.4% ± 8.30% of control) 
(Figure 3.2.4). When JZL195 is present, a significant response is reached at 12.5M (145.0% 





and 50M 2-LG are much higher when compared to the equivalent concentration in the 
absence of JZL195. This suggests that one or more eCB degrading enzymes (MAGL, FAAH and 
ABHD6) might limit the action of 2-LG in the assay. In other experiments, a MAGL specific 
inhibitor JZL184 (Long et al., 2009b) and a FAAH specific inhibitor URB597 (Mor et al., 2004) 
did not significantly enhance 2-LG signalling when added alone or in combination, suggesting 
the involvement of all three eCB degrading enzymes (data not shown).  Nonetheless the 
above results support the hypothesis that 2-LG is a partial agonist at the CB1 receptor, but 
firm conclusions on this point are tempered by the fact that JZL195 has to be present to fully 









Figure 3.2.4. 2-LG mediated response is detectable but full response requires JZL195 
30,000 CB1-Tango cells were plated into black 96 well plates in Freestyle media as described 
previously. The cells were treated with varying concentrations of 2-LG (50M – 0M) in the 
presence and absence of JZL195 (100nM) for 4 hours. Responses were measured as 
described previously and normalised to the control wells in the absence of JZL195 and 2-LG 
(set to 100) as % of control. Graph shows means and bars represent SEMs of pooled 
independent experiments (n indicated on the graph) with 8 replicates in each experiment. 
Statistical significance of 2-LG responses in the absence of JZL195 compared to its control, 
and 2-LG responses in the presence of JZL195 compared to JZL195 only control were 
established with One Way ANOVA. 









The 2-LG effects are fully inhibited by AM251 
The experiments in Figure 3.2.4 show the effects of 2-LG and JZL195 relative to the control 
that has neither agent present. Most of the experiments had also in parallel, the same 
conditions in the presence of AM251 to determine if the response was dependent on CB1 
receptor function. In this section, all of the data has been plotted as a percentage of the 
control value obtained in the presence of JZL195 (the JZL195 control). When plotted in this 
way, 2-LG still demonstrated a concentration dependent response with statistically 
significant responses to the JZL195 control apparent at 12.5M (129.1% ± 12.9% of control) 
(Figure 3.2.5). 2-LG was maximally active at concentrations between 25M (150.9 ± 6.4% of 
control) and 50M (156.3% ± 7.4% of control). The EC50 for 2-LG calculated from these series 
of experiments was 16.56M (Log EC50 = -4.781 ± 0.19 SEM) (Figure 3.2.7). When plotted in 
this manner, AM251 on its own reduces the control value to 87.7% ± 3.4%, a small yet highly 
significant (p=0.002, Students’ unpaired T-Test) response that presumably reflects inhibition 
of a low level of eCB tone consequential to JZL195 treatment. Importantly, 2-LG failed to 
stimulate any response when AM251 is present (p>0.05), confirming that the response seen 
in the presence of JZL195 is CB1 dependent. Thus, when plotted against the JZL195 control, 
the data still support the hypothesis that 2-LG has concentration dependent agonist-like 







Figure 3.2.5. 2-LG activates a CB1-dependent response in a concentration dependent 
manner 
30,000 CB1-Tango cells were seeded overnight in Freestyle media into black 96 well plates. 
The cells were treated with varying concentrations of 2-LG (50M – 0M) in the absence or 
presence of CB1 antagonist AM251 (2.5M) in Freestyle media with 100nM JZL195 present 
to prevent the hydrolysis of 2-LG. The compounds were incubated for 4 hours before 
detecting β-lactamase expression by addition of a FRET-enabled substrate, as per 
manufacturer’s protocol. The data has been normalised to control wells (set to 100) as % of 
control. Graph shows means and bars represent SEMs of pooled independent experiments 
(n indicated on the graph) with 8 replicates in each experiment. Statistical significance of 2-
LG responses in the absence of AM251 compared to its control, and 2-LG responses in the 
presence of AM251 compared to AM251 only control were established with One Way 
ANOVA. 







2-LG shows submaximal CB1 receptor activation  
The maximum response of 2-LG was compared to the maximal response of ACEA, 2-AG and 
AEA over a large number of independent experiments. These agonists were used at their 
maximally active concentrations (2LG – 25M, ACEA – 5M, 2-AG – 25M, AEA – 5M) to 
treat the CB1-Tango cells as previously described and JZL195 was included in all 2-LG 
experiments to prevent the breakdown of 2-LG. 2-LG shows submaximal activation of the 
CB1 receptor, giving rise to around 163.1% ± 4.5% of control response whilst the full agonists 
give around 300% of the control response (ACEA = 320.0% ± 12.5%; 2-AG = 300.2% ± 14.2%; 
AEA = 299.5% ± 26.4%) (Figure 3.2.6). The full agonists each have a significant difference in 
their responses when compared to 2-LG (p<0.001), but are not statistically different in 
comparison to each other, suggesting their maximal responses are all similar in the full 
occupation and activation of CB1 receptors (One Way ANOVA, Bonferroni Multiple 
Comparison post-test). AM251 in control conditions did not significantly inhibit baseline 
levels. However, in the presence of JZL195, AM251 on its own reduced the baseline to around 
90% of control values across the experiments (data not shown), as demonstrated in previous 
experiments (Figure 3.2.5). All CB1 responses elicited were antagonised in the presence of 
2.5M AM251 to near control levels (2-LG = 91.7%, ACEA = 92.2%, 2-AG = 106.7%, AEA = 
107.0% of control), demonstrating the ability of AM251 to robustly antagonise activation of 
the CB1 receptor by all tested agonists.  
 
The log concentration response curves for all 4 tested agonists pooled across experiments 
are displayed in Figure 3.2.7. Comparing the previously mentioned EC50 values for ACEA, 2-
AG and AEA from Figure 3.2.7, ACEA and AEA have similar values of under 0.1M, while 2-
AG has a slightly higher EC50 value at just above 1M. 2-LG has an EC50 value of around 
18.03M in the absence of JZL195 (not displayed) and has an EC50 value of 16.56M in the 
presence of JZL195 (Figure 3.2.7) from our experiments, suggesting that 2-LG is a much less 









Figure 3.2.6. 2-LG is a partial agonist in comparison to full CB1 agonists 
30,000 CB1-Tango cells were plated in 100l Freestyle media for 24 hours overnight as 
described previously. Drugs were diluted in Freestyle media (final assay concentrations of 
2LG – 25M, ACEA – 5M, 2-AG – 25M, AEA – 5M) in the presence and absence of 2.5M 
FAC AM251. 100nM JZL195 was included in all 2-LG wells and experiments. Drugs were 
added to the cells for 4 hours before responses were measured as described previously. For 
each agonist experiment group, responses were normalised to the control wells in the 
absence of agonist or antagonist drug (set to 100) as % of control. Graph shows means and 
bars represent SEMs of pooled independent experiments (n indicated on the graph) with 8 
replicates in each experiment. Significance between groups was established with One Way 
ANOVA. 






Figure 3.2.7. Log concentration response curves of eCBs, CB1 agonists and 2-LG 
Log concentration response curves for CB1-Tango cells treated with CB1 agonists ACEA, 2-
AG, AEA and 2-LG (2-LG in the presence of 100nM JZL195), generated according to Methods. 
Data was pooled across several independent experiments: ACEA n = 5, 2-AG n = 4, AEA n = 6, 
2-LG n = 2 to 17 independent experiments. Points represent the means and bars represent 
SEMs of pooled data. Non-linear regression curve was fitted to the data points and log EC50 







The 2-LG response remains in the presence of DAGL inhibitors 
As mentioned before, the presence of JZL195 will likely prevent the hydrolysis of other eCBs 
present in the system, causing those eCBs to also activate CB1 as a basal tone. This is evident 
in Figure 3.2.4 and Figure 3.2.5, where JZL195 has been included in the CB1-Tango assay. 
Thus, a component of the 2-LG effect might reflect potentiation of this eCB tone by 2-LG 
rather than a direct action on the CB1 receptor, akin to a positive allosteric modulator. 
 
In order to investigate this, we sought to determine the effects of 2-LG in the presence of 
DAGL inhibitors, as 2-AG is perhaps the most likely "entourage" candidate (Ben-Shabat et al., 
1998). CB1-Tango cells were treated with 25M 2-LG in the presence of DAGL specific 
inhibitors KT109 and KT172 (Hsu et al., 2012) and broad serine lipase inhibitor THL (Bisogno 
et al., 2006) to inhibit the synthesis of 2-AG (Figure 3.2.8). 100nM JZL195 was again included 
in the wells and the data has been normalised to this JZL195 control. An AM251 control was 
also included and reduced the tone to 92.2% ± 0.22% of the control response (data not 
shown), consistent with data obtained from previous experiments. The two DAGL specific 
inhibitors on their own do not inhibit the basal response to below control levels as AM251 
does (KT109 = 104.9% ± 4.4% of control; KT172 = 98.7% ± 4.8% of control) suggesting the 
basal eCB activity is not due to DAGL contribution (Figure 3.2.8). THL however, does have a 
significant effect on the control levels and inhibits the value to 90.2% ± 2.3%, this could be 
due to THL reducing the control eCB tone via an unknown or a non-specific mechanism. 
 
Importantly there is still a significant response caused by 2-LG activation in the presence of 
DAGL inhibitors. For example, although the 2-LG response in the presence of KT109 (154.0% 
± 10.5% of control) and KT172 (147.9% ± 7.3% of control) were slightly lower than control 2-
LG responses (171.7% ± 9.4% of control) these differences were not statistically different to 
the control 2-LG response, but are significantly different to responses with KT109 and KT172 
alone.  
 
The results in the presence of THL are more difficult to interpret, as THL reduces the control 
value to 90.2% ± 2.3%. However, 2-LG in the presence of THL is still eliciting a statistically 
significant response to 131.7% ± 2.8% of the control. Furthermore, if the 2-LG response is 
normalised to the THL control, the response increases to almost 150%, which is essentially 
the same as that seen in the presence of the KT compounds. Thus, we can conclude that the 






Figure 3.2.8. 2-LG signalling is still present in the presence of DAGL inhibitors  
30,000 CB1-Tango cells were plated into black 96 well plates in Freestyle media as described 
previously. The cells were treated with DAGL inhibitors KT109 (FAC 1M), KT172 (FAC 1M) 
and THL (FAC 20M) in the presence and absence of 25M 2-LG for 4 hours. 100nM JZL195 
was included in all wells. CB1 responses were measured as described previously and 
normalised to the control wells in the absence of inhibitors and 2-LG (set to 100) as % of 
control. Graph shows means and bars represent SEMs of 3 independent experiments, 8 
replicates in each experiment. Significance of responses over respective control wells was 
established with Student’s T-test. 






Fixed concentrations of 2-LG show antagonist activity against eCBs 2-AG and AEA 
A CB1 receptor dependent response is still elicited by 2-LG in the presence of DAGL inhibitors, 
indicating 2-LG alone can induce a CB1 signal when production of 2-AG is suppressed. 
However, this does not clarify if 2-LG could still function as a positive allosteric modulator or 
“entourage” molecule for the potentiation of 2-AG or other eCBs, as the presence of JZL195 
would occlude any potentiation by 2-LG. To directly test the effects that 2-LG has on the eCBs 
2-AG and AEA, concentration response curves of 2-AG and AEA were determined in the 
presence of a fixed concentration of 2-LG in the absence of JZL195.  
CB1-Tango cells were treated with a range of concentrations of 2-AG (FAC 0.2 – 50M) in the 
absence and presence of 2-LG (FAC 20M) for 4 hours. The control wells were subtracted 
and data was normalised to the maximum 2-AG response obtained and the results are shown 
in Figure 3.2.9. In the absence of 2-LG, detectable CB1 responses are seen at all tested 
concentrations of 2-AG similarly to previous results and a normal concentration response 
curve is obtained. 2-LG on its own gave a CB1 activation 31.7% ± 1.5% of the maximal 2-AG 
response, similar to previous results. The 2-LG responses occlude the increases in CB1 
activation as the concentration of 2-AG increases, suggesting little “additive” effect of 2-AG 
and 2-LG together. At 5M of 2-AG and above, the responses of 2-AG in the presence of 2-
LG are lower than that in the absence of 2-LG; this is not characteristic of the activity of a 
positive allosteric modulator or an entourage molecule, which should potentiate the 2-AG 
response at the same concentration. Finally, at the highest concentrations of 2-AG, rather 
than potentiating the 2-AG response, the presence of 2-LG instead inhibits the maximal 2-
AG response and causes a lower maximal plateau which is statistically significant (p<0.01).  
Similarly, the second major eCB AEA was also tested on the CB1-Tango cells in the absence 
or presence of 2-LG (Figure 3.2.10). A range of AEA concentrations (FAC 0.0025 – 5M) was 
used to treat the CB1-Tango cells in the absence or presence of 2-LG (FAC 20M). In the 
absence of 2-LG, AEA was able to elicit a normal concentration response curve, reaching the 
maximal response at around 2.5M, similarly to previous results. 2-LG on its own again 
elicited a CB1 dependent response that is ~30% of the maximal response of AEA, but 
occluded the responses of increasing concentrations of AEA, as with 2-AG. At 0.025M of 
AEA, there is no additive response of AEA and 2-LG and no potentiation effect, but rather the 
AEA response is lower in the presence of 2-LG. At the higher concentrations of AEA, 2-LG 










Figure 3.2.9. Effect of 2-LG on 2-AG concentration response curve 
30,000 CB1-Tango cells were seeded per well in Freestyle media in clear bottom black plates 
for 24 hours. Serial dilutions of 2-AG (final top concentration 50M, 1:2 and 1:5 dilutions) in 
the presence and absence of 2-LG (FAC 20M) were made up in Freestyle media. Drugs were 
added to the cells for 4 hours before CB1 responses were measured as described previously. 
The background was subtracted and data were normalised to the maximal 2-AG response 
(set to 100) as % maximal 2-AG response. Graph shows means and bars represent SEMs of 2 
independent experiments, 6 replicates from each experiment. Significance between the 
responses at the highest concentrations was established with Student’s T-test. 







Figure 3.2.10. Effect of 2-LG on AEA concentration response curve 
30,000 CB1-Tango cells were seeded per well in Freestyle media in clear bottom black plates 
for 24 hours. Serial dilutions of AEA (final top concentration 5M, 1:2 and 1:10 dilutions) in 
the presence and absence of 2-LG (FAC 20M) were made up in Freestyle media. Drugs were 
added to the cells for 4 hours before CB1 responses were measured as described previously. 
The background was subtracted and data were normalised to the maximal AEA response (set 
to 100) as % maximal AEA response. Graph shows means and bars represent SEMs of 2 
independent experiments, 6 replicates from each experiment. Significance between the 
responses at the highest concentrations was established with Student’s T-test. 








The DAGLs are able to generate the main eCB 2-AG, but also a wide range of 2-acylglycerols, 
some of which may have a role in the larger eCB signalling pool. The presence of 2-LG in 
mammalian tissue has raised interest in its biological importance to eCB signalling. The aim 
of this chapter was to evaluate the activity of 2-LG on the CB1 receptor as a potential eCB, 
as conflicting reports of the entourage effect of 2-LG have emerged (Ben-Shabat et al., 1998; 
Murataeva et al., 2016).  
There are many functional assays that have been used to test for activity of ligands at the 
CB1 receptor. For example, the inhibition of the vas deferens twitch response was used to 
identify the two major eCBs (Devane et al., 1992; Mechoulam et al., 1995; Zhang and Xie, 
2012). However, these methods are usually low throughput, expensive and are subject non-
specificity and other limitations. We have opted for a 96-well microtiter cell-based assay 
system to study the direct effect of 2-LG on the CB1 receptor, which has been extensively 
characterised in previous studies with other CB1 pharmacological tools (van der Lee et al., 
2009). The main advantage of this cell-based assay system is that the measured response is 
mediated only through the constructed CB1 receptor linked to a non-mammalian -
lactamase reporter system and thereby removing any interference from activation of other 
endogenous receptors (Barnea et al., 2008).  
We first confirmed the CB1-Tango cells were sensitive to an established CB1 agonist and 
antagonist. We obtained CB1-dependent concentration response curves to ACEA, 2-AG and 
AEA and the EC50 values were compared to published EC50 values obtained from [35S]GTPS 
binding assays (Hillard et al., 1999; Ryberg et al., 2007; Pertwee, 2015). Values vary across 
preparations, species and methods used. However, the EC50 values obtained from the CB1-
Tango assay were all within the published range and towards the lower side (Pertwee, 2015). 
Our EC50 values obtained were lower than those published by Hillard et al (1999) for ACEA 
(51 ± 6nM). The values for AEA were comparable to EC50 values (31 ± 6nM) published by 
Ryberg et al (2007), who published the lowest EC50 values for 2-AG and AEA as reviewed by 
Pertwee (2015). This indicates the sensitivity of the assay as the pathway is not affected by 
other metabolic processes that may be active within the cell. The EC50 value of 2-AG obtained 
in this set of experiments is noticeably higher than reported by Ryberg (2007) (519 ± 48nM). 





AG which is inactive at the CB1 receptor (van der Stelt et al., 2002), thus decreasing the 
effective concentrations of 2-AG. This spontaneous isomerisation is difficult to prevent due 
to the long incubation time at 37oC. However, our values still lie within the range of published 
EC50 values (Pertwee, 2015).  
In Figure 3.2.1, Figure 3.2.2 and Figure 3.2.3, there are no noticeable differences in the 
responses produced by the AM251 treated cells and control cells, suggesting that in control 
conditions there is no eCB signalling at the CB1 receptor. This may be due to the lack of 
substrate available under the growth conditions, as the CB1-Tango assay requires the cells 
to be starved in Freestyle expression media to reduce background noise. The manufacturer 
has confirmed that the media is serum free and calcium free but do not reveal the 
composition of the media, suggesting the cells may not have necessary components to drive 
eCB signalling. The absence of basal activity could also be possibly due to the function of eCB 
degrading enzymes acting in a “gatekeeper” role to prevent eCB from activating the CB1 
receptor. The gatekeeping role has been previously described in developing neurones where 
MAGL is not expressed in the growth cone but has increased expression on axons, thus 
restricting eCBs to only accumulate locally on the growth cone to promote CB1 activation, 
but terminates any signalling along the axon (Keimpema et al., 2013). When MAGL, FAAH 
and ABHD6 activity was inhibited by JZL195, there was around 10% increase of the basal 
response and this can be antagonised by AM251, indicating some tonal eCB is signalling at 
the CB1 receptor when JZL195 is present. This suggests that small amounts of eCBs are 
produced under control conditions but are not signalling through the CB1 receptor due to 
the actions of the eCB hydrolysing enzymes. From previous results in our lab, it has been 
shown that inhibition of MAGL alone with MAGL specific inhibitor JZL184 alone does not 
reveal an eCB tone, but inhibition of both MAGL and FAAH with JZL195 can reveal the 
presence of a low, but statistically significant eCB tone (thesis of Rachel Lane Markwick, 
2015). This is possibly due to compensation of both hydrolysis enzymes or there is more than 
one component to the eCB tone, namely the presence of both 2-AG and AEA. In further 
chapters, the nature of this eCB tone will be explored.  
2-LG was also tested in the assay and has demonstrated CB1 activation ability in our 
experiments but only at around half of the maximal activation elicited by the other 
established agonists. This ability is only revealed at high concentrations of 2-LG or when 
JZL195 is included to mitigate against 2-LG hydrolysis (Figure 3.2.6). However as mentioned 





contribute to the activation of the CB1 receptor, casting uncertainty on whether the 
observed effect of 2-LG is direct on the CB1 receptor, in combination with the eCBs or 
through positive allosteric modulation to potentiate the activity of the eCBs produced. Since 
2-AG is the likely molecule for the entourage effect of 2-LG and pharmacological tools are 
available to target DAGL, 2-AG synthesis was inhibited with DAGL inhibitors to discern 
whether the effect of 2-LG is direct (Figure 3.2.8).  
The DAGL inhibitors KT109 and KT172 alone did not inhibit the basal eCB tone to below 
control levels suggesting the basal eCB activity is not due to DAGL. THL was able to elicit a 
very small response in the assay, reducing the control value by around 10%. THL has 
previously been shown to have inhibitory effects against several serine lipases, some with 
greater affinity than DAGL (Hoover et al., 2008). Therefore, the small inhibition of the control 
value may not be due to the blockade of DAGL alone. If the controls were redefined as the 
wells in the presence of DAGL inhibitors and the data was normalised to these controls, the 
2-LG response is consistent in the presence of all three inhibitors at around 150%, suggesting 
the activity of 2-LG is not affected by the presence of the DAGL inhibitors. In the presence of 
the DAGL inhibitors, the total 2-LG response is around 20% lower for all three inhibitors than 
the 2-LG control response, suggesting that part of the total response might be due to the 
activity of 2-AG, but the remaining response is likely to be attributed to the activity of 2-LG 
or other eCBs on the CB1 receptor.  
Unfortunately there are currently no effective pharmacological inhibitors of AEA synthesis 
due to redundancy of possible pathways that can generate AEA (Liu et al., 2008; Ueda et al., 
2013; Maccarrone, 2017). It is not known whether 2-LG can potentiate AEA, but it can be 
reasoned that since AEA is also broken down by a crossover of MAGL and FAAH (Cravatt et 
al., 1996), and is also structurally similar to 2-AG and 2-LG, it is conceivable that 2-LG could 
also potentiate AEA by the same manner proposed for 2-AG. Ben-Shabat et al (1998) have 
shown that 2-LG is the 2-acylglycerol that primarily slows the hydrolysis of 2-AG, likely by 
preventing the breakdown of 2-AG by occupying and blocking access to the active site on 
degrading enzymes and therefore increasing the presence of 2-AG to activate the CB1 
receptor. The potentiation of AEA was not tested by the group but our experiments show 
that blocking eCB degradation with JZL195 has no effect on the activity of 2-LG, thus ruling 
out the AEA potentiation hypothesis.  
It has also been suggested that 2-LG may work via different mechanisms to potentiate the 





2-LG could have activity on other GPCRs such as GPR119, in the same way that 2-OG and 2-
PG may be endogenous ligands for GPR119 (Hansen et al., 2011; Syed et al., 2012). 2-LG was 
not shown to enhance direct 2-AG binding to CB1, but 2-PG did potentiate the direct binding 
of 2-AG to receptors. This binding potentiation occurs through currently unknown 
mechanisms; perhaps through allosteric modulation or through inhibition of 2-AG binding to 
plasma proteins. Nonetheless, full potentiation effect is achieved by a mix of the two 2-
acylglycerols (Ben-Shabat et al., 1998). Whilst 2-LG being an active ligand to other receptors 
is not refuted by our results, the coupling of the protease-fused arrestin to the non-native 
transcription factor ensures specificity of the CB1-Tango assay and is therefore unaffected 
by activation of other GPCRs (Barnea et al., 2008). The results we obtained in this set of 
experiments therefore only show the activity of 2-LG at the CB1 receptor, but perhaps 2-LG 
can also have effects at other GPCRs.  
Antagonistic properties of 2-LG were observed by Murataeva et al (2016) in DSE experiments 
with pre-incubation of 5M 2-LG for 5 minutes, crucially without JZL195. In experiments 
described here, 5M of 2-LG without JZL195 in a 4 hour assay gave rise to a CB1 response 
around 15% above control levels (Figure 3.2.4), which was not statistically significant. In the 
presence of JZL195, this rises to around 25% above control levels (Figure 3.2.5) but is also 
not statistically significant, suggesting 2-LG is indeed occupying CB1 receptors but has low 
intrinsic activity. In the presence of endogenously released 2-AG from the stimulation of 
autaptic hippocampal neurones, 2-LG may compete with the full agonist, but with low 
efficacy for the receptor and therefore acting as an antagonist with small non-significant 
activation of the receptor (Ariuens and Simonis, 1964; Calvey and Williams, 2008).  
Submaximal concentrations of 2-LG (20M) was included in the concentration response 
curves for both 2-AG and AEA and showed notable partial agonism effects as described by 
Calvey and Williams (2008). In the absence of the full agonist, 2-LG elicits a small response 
on its own. In small concentrations of full agonist, there is little additive effect observed as 
the effect of the agonist is occluded by the response from 2-LG. When the response to 2-AG 
or AEA equals the maximal response of 2-LG, there is no additive or inhibitory effect and 2-
LG does not seem to have any effect on the response that occurs around 5M for 2-AG and 
0.025M for AEA. Finally, at higher concentrations of 2-AG and AEA, 2-LG acts as a antagonist 
and reduces the response to the full agonist. This indicates that 2-LG can bind to the same 
binding site as 2-AG and AEA on the CB1 receptor, causing an inhibition of the CB1 response 





not likely to cause saturation of MAGL/ABHD6 in the absence of JZL195, as JZL195 can 
enhance the 2-LG response as observed in Figure 3.2.4. This submaximal concentration of 2-
LG caused sufficient inhibition of the eCB responses, indicating that lower concentrations of 
2-LG is able to modulate the responses to the eCBs and that 2-LG is not saturating the active 
sites of MAGL/ABHD6 to cause an entourage effect. Lastly, the antagonist effect of 2-LG to 
high concentrations of eCBs is evidence against 2-LG acting as a positive allosteric modulator 
and could explain the antagonistic effect observed by Murataeva et al. (2016), and the partial 
agonism effect could also explain the additive entourage effect observed by Ben-Shabat et 
al. (1998). 
Physiologically, 2-LG is present in mammalian the brain at levels much lower than 2-AG, 
suggesting that it is not likely to function as an agonist in retrograde eCB signalling 
(Murataeva et al., 2016). In our results, significance was reached at only the higher 
concentrations of 2-LG without JZL195 present, supporting the notion that 2-LG may not be 
physiologically relevant in the brain for the entourage of 2-AG. It could be more likely that 
the role of 2-LG is subtler in the brain and rather than behaving as a partial agonist, may act 
as an endogenous antagonist to modulate eCB signalling. However, further clarifications of 
its role will need to be explored. Importantly, in the experiments conducted by Ben-Shabat 
et al (1998) and Gallily et al (2000), it was noted that the potentiation effect of 2-LG, in 
conjunction with 2-PG, on 2-AG was maximal in ratios close to what is found physiologically 
in the spleen, where levels of 2-LG are around 12x higher than levels of 2-AG. This ratio of 2-
LG to 2-AG was shown to have the most profound entourage effect and thus may be 
physiologically relevant to the biological activity of 2-LG in areas of the body where 2-LG is 
in relatively high abundance (Mechoulam et al., 1995; Ben-Shabat et al., 1998).  
In conclusion, this chapter has shown that through our CB1-Tango assay system, 2-LG has 
partial agonist activity at the CB1 receptor, which is independent of the entourage of 2-AG, 
but whether this is physiologically relevant in the mammalian brain remains to be elucidated. 
This signalling activity is limited by the function of eCB hydrolysing enzymes, which can also 
conceivably hydrolyse 2-LG. The inhibition of these eCB hydrolysing enzymes thus enhances 
2-LG signalling, but in turn also reveals a basal eCB tone. From this, we postulate that the 
eCB tone consists of 2-AG and AEA and go on to explore this in further chapters. We have 
successfully utilised the CB1-Tango assay to elucidate the activity of a potential CB1 agonist 
and will go on to use this assay system to next look at the effects of a putative endogenous 










The eCB system has been studied extensively in many disease states, including in the fields 
of pain, cardiovascular disease and neurodegenerative disease (Di Marzo and Petrosino, 
2007; Fine and Rosenfeld, 2013; Sierra et al., 2017). The CB1 receptor is able to modulate 
pain nociception and appetite (Salamone et al., 2007; Pernia-Andrade et al., 2009) and novel 
antagonists targeting CB1 for the treatment of pain or obesity have been under investigation. 
However, drugs targeting CB1 receptors, such as Rimonabant, often display side effects due 
to the expression of CB1 in the CNS associated with mood and cognition (e.g. limbic system 
and prefrontal cortex) (Zarate et al., 2008; Heng et al., 2011). In 2009 Rimonabant was 
withdrawn as an appetite suppressant to treat obesity following reports of unwarranted side 
effects such as severe depression and suicide ideation (Christensen et al., 2007; Moreira and 
Crippa, 2009). These side effects limit the therapeutic targeting of the CB1 receptor to 
modulate the eCB system (Herkenham et al., 1990; Svendsen et al., 2004), warranting the 
need to identify drug targets without such severe side effects.  
 
Canonically, CB1 ligands are lipid based, with the two major eCBs being derived from 
membrane phospholipids. CB1 drugs are also often hydrophobic, which can cause difficulties 
with drug delivery and may cross the BBB. A lot of interest was therefore raised when a 
publication by Heimann et al. (2007) claimed an endogenous peptide could serve as a CB1 
ligand; this not only suggested a whole new field of study on the physiological function of 
the peptide in the eCB system, it also raised hopes of developing a completely new drug class 
to target the eCB system. Hemopressin (Hp) is a 9-residue peptide derived from the 1 chain 
of haemoglobin (Table 4.1.1), first discovered from crude rat brain extracts using a substrate-
capture assay of catalytically dead endopeptidases (Rioli et al., 2003). A homology search 
showed that Hp is part of the 1 chain of haemoglobin and highly conserved across species, 
except for one amino acid substitution found in the rat orthologue, suggesting a potentially 
important biological function (Table 4.1.1) (Dale et al., 2005a). Mass spectrometry of 





to detect levels of Hp and two N-terminally extended forms of Hp (VD-Hp and RVD-Hp), 
which have also been reported to have activity on the CB1 receptor, giving rise to a 






RAT -AHKLRVD PVNFKFLSH SLLVTLA-  
HUMAN -AHKLRVD PVNFKLLSH SLLVTLA- 
MOUSE -AHKLRVD PVNFKLLSH SLLVTLA- 
PIG -AHKLRVD PVNFKLLSH SLLVTLA- 
Table 4.1.1. Amino acid sequences of hemopressin in different mammalian species 
The sequence of Hp within the a1 haemoglobin sequence is displayed from various species. 
Hp sequence is underlined and residues in red represent the singular amino acid 




One of the key assays suggesting Hp could to bind to CB1 receptors was an ELISA on dried 
SK-N-SH cells with conformation-sensitive antibodies generated to the extracellular N-
terminal portion of CB1 receptors (Gupta et al., 2007). The presence of CB1 agonist Hu-210 
enhanced antibody binding and CB1 antagonist SR141716 (Rimonabant) reduced antibody 
binding. Hp reduced CB1 antibody binding to the same level as SR141716 and did not display 
the same effect to similarly generated antibodies against other related receptors including 
CB2 (Heimann et al., 2007). Hp was also tested in [35S]GTPS binding and adenylyl cyclase 
assays for any biological activity. On HEK cells expressing CB1 receptors, Hp showed 
antagonist activity against Hu-210 and inverse agonist activity in the absence of any agonist 
akin to SR141716. This effect was not seen in HEK cells expressing CB2 receptors, suggesting 
that Hp shows specificity to CB1 receptors (Heimann et al., 2007). Hp also demonstrated 
marked analgesic effects when administered to animal models of inflammatory pain, on a 
comparable level to the CB1 antagonist AM251 and was active independently of 
administration route (oral, local or intrathecal) (Heimann et al., 2007). This analgesic effect 





al., 2005b). However, there was no direct evidence that the peptides worked via a CB1-
dependent mechanism in these pain models. 
 
Nonetheless, additional studies have supported the hypothesis that the antagonist activity 
of Hp might be attributable to binding to CB1 receptors. For example, in silico molecular 
docking assays have predicted that Hp has the potential to bind to the same pocket as the 
classic CB1 agonist SR141716 and moreover, the first 6 amino acids of Hp are necessary for 
this in silico binding. This is in keeping with the indication that Hp fragments are also 
biologically active (Scrima et al., 2010). Hp was also able to block CB1 receptor internalisation 
induced by WIN55,212-2 similarly to AM251 in CB1-transfected cells, and reduce animal 
feeding in WT but not in CB1-/- KO mice (Dodd et al., 2010). Mice models of memory also 
showed Hp acts very similarly to AM251 in preventing CB1 induced memory loss (Zhang et 
al., 2016b). In experiments measuring c-Fos expression as an indicator for neuronal firing, Hp 
and AM251 both increased c-Fos expression in WT but not CB1-/- KO mice suggesting activity 
as a CB1 antagonist, albeit in distinctly different areas of the brain (Dodd et al., 2013). These 
studies support the hypothesis that Hp is a CB1 antagonist but importantly they are based 
on in silico models and/or indirect assays. 
 
Indeed, other studies have utilised Hp as a CB1 antagonist without actually directly testing if 
Hp directly and/or solely acts at CB1 receptors. These have uncovered various physiological 
effects of Hp, for instance its analgesic effects in certain animal models of pain (Dale et al., 
2005b; Hama and Sagen, 2011b; Petrovszki et al., 2012; Toniolo et al., 2014); its ability to 
promote the differentiation of oligodendrocytes and the maturation of sub ventricular zone 
progenitor cells (Xapelli et al., 2014) and its ability to slow GI transit (Li et al., 2016). Again, 
although these effects might reflect activity at the CB1 receptor, they might conceivably be 
attributable to other indirect mechanisms. One prominent paper has used the failure of Hp 
to mimic AM251 in blocking a biological response to argue that the response must be 
mediated by intracellular CB1 receptors on mitochondria that can be accessed by AM251 – 
which is hydrophobic, but not by Hp (Ma et al., 2015). Other studies have also implicated 
mitochondrial CB1 function in the thalamic paraventricular nucleus neurons based on the 
use of Hp as a specific and selective CB1 receptor antagonist, again with little regard for the 






Several other studies have shown that Hp has pronounced activities that are independent of 
the CB1 receptor or activities that do not mimic the effects of established CB1 antagonists. 
For example, Hp displays hypotensive effects that do not seem to be mediated through CB1 
receptors, as established CB1 antagonists or genetic KO of CB1 receptors from mice models 
have little effect on blood pressure (Jarai et al., 1999; Ledent et al., 1999; Lippton et al., 
2006). Hp also did not antagonise the analgesic effect of the CB1 agonist WIN55,212-2 in a 
spinal cord injury model, in contrast to SR141716 which did antagonise the WIN55,212-2 
response (Hama and Sagen, 2011a). Likewise, Hp has not shown CB1 antagonist-like activity 
in other models of chronic pain (Petrovszki et al., 2012; Toniolo et al., 2014). The effects of 
Hp on autaptic mouse hippocampal neurons on CB1-dependent DSE have also been 
reported; these studies also failed to show Hp antagonism against 2-AG activity on CB1 
receptors (Straiker et al., 2015). In support Dvorácskó et al (2016) have reported Hp binding 
to as-yet-to-be identified targets in CB1-/- KO mice brain homogenate. Many of these studies 
indicate Hp having no activity at the CB1 receptor and/or acting at sites other than the CB1 
receptor. 
 
The contradictory results of the activity of Hp need to be clarified if Hp is to be of interest 
therapeutically in the wider eCB drug discovery effort, or for it to be seriously considered as 
an endogenous and selective CB1 receptor antagonist. A recent Pubmed search (accessed 
2nd February 2018) identified 58 publications that mention Hp with no less than 38 of these 
also mentioning the CB1 receptor. Many of the publications draw conclusions based on the 
premise that Hp is a selective CB1 antagonist, yet this conclusion is largely based on a number 
of indirect experiments published in a single paper. Given the increasing volume of the 
literature that used Hp as a tool compound, it is very important to determine if it is or is not 
an effective and selective CB1 antagonist. 
 
In this chapter I have directly tested if three independently sourced preparations of Hp 
display antagonistic activity towards the CB1 receptor. In this context, in the previous 
chapter I have shown that the recombinant cell line CB1-Tango can be used to quantify 
responses from the synthetic CB1 agonist ACEA and from the two best characterised eCBs 2-
AG and AEA. Furthermore, this reporter cell line approach has provided the first direct 
evidence for 2-LG acting as a partial CB1 receptor agonist. In this chapter I have utilised the 
CB1-Tango assay to directly test if Hp, sourced from three independent companies, can 







Hemopressin does not exhibit antagonist activity against CB1 agonist ACEA 
Most of the published literature has reported on the effects of the rodent Hp (rHp) peptide 
in assays against the rodent CB1 receptors, with contradicting reports of Hp antagonism. As 
of yet, there are no publications based on the activity of human Hp (hHp) on human CB1 
(hCB1) receptors. To determine if hHp acts as an antagonist of the hCB1 receptor, we have 
tested it on agonist responses in the CB1-Tango assay. This hHp peptide was purchased from 
Cayman Chemicals and is designated as Hp1.  
 
The activity of Hp1 was initially tested in the CB1-Tango assay by determining if it could 
inhibit the activity of CB1 agonist ACEA. The CB1-Tango cells were plated in Freestyle media 
as described in methods and after 24 hours, ACEA was added at a range of concentrations 
(FAC 0.0025 – 25M) for 4 hours in the presence and absence of 10M of the Hp1. Control 
experiments established that Hp1 on its own did not exhibit any effect on the basal activity 
of the assay over a concentration range of 0.4M – 20M (data not shown). A robust 
concentration-dependent ACEA response was obtained with a maximal response detected 
at 2.5M (457.4% ± 16.6% of control) (Figure 4.2.1) similarly to previous experiments with 
an EC50 value of 0.045M (log EC50 = -7.34 ± 0.07 SEM). 10M Hp1 was unable to significantly 
affect ACEA responses across the full range of ACEA concentrations tested. The EC50 value 
for the ACEA response curve in the presence of Hp1 was 0.051M (log EC50 = -7.29 ± 0.07 
SEM) which was not significantly different to ACEA response curve on its own (p>0.05, 
Student’s unpaired T-Test). Multiple experiments were carried out and the log EC50 values 
were pooled across experiments. Statistical analysis comparing the effect of Hp1 has shown 












Figure 4.2.1. Human hemopressin 1 (Hp1) does not antagonise a range of ACEA 
concentrations 
CB1-Tango cells were seeded at a density of 30,000 cells per well in Freestyle media 
overnight as described in methods. The following day, varying concentrations of ACEA were 
added to the cells (FAC of 25M, 1:10 dilution) in the presence and absence of 10M human 
hemopressin (Hp1) for 4 hours. Assay substrate was added for 90 minutes and read on the 
Flexstation. Data was normalised to control wells without any drugs (set to 100) as % of 







Preparations of rodent Hp do not antagonise CB1 responses  
Initially human Hp peptide was tested for its ability to antagonise the ACEA response, 
however, most publications have used the rat form of Hp which has a one amino acid 
difference (Table 4.1.1) to the human form (Dale et al., 2005a). The one amino acid 
substitution of Hp itself does not seem to make much difference in activity when tested in 
rabbits, rats and mice (Blais et al., 2005) but may have an effect on the activity of Hp on the 
hCB1 receptor. Rodent versions of Hp (rHp) were purchased from separate companies and 
designated as Hp2 from Cayman Chemicals and Hp3 from Sigma Aldrich. Both preparations 
were tested against the maximal ACEA response to determine if they could antagonise 
responses at the hCB1 receptor.  
 
The ability of all three preparations of Hp to antagonise the maximal ACEA response was 
compared to the inhibition seen with the established CB1 antagonist AM251 (Figure 4.2.2). 
The CB1-Tango cells were treated with 5M ACEA in the absence and presence of 20M of 
either Hp1, Hp2, Hp3 or 10M AM251. The maximal ACEA response obtained across 
experiments was 416.0% ± 18.6% of control (data not shown) which is of similar magnitude 
to results reported in the previous chapter. To best present the inhibitory effects of the 
antagonists, the background well levels were subtracted and all data was normalised to the 
maximal ACEA response (set to 100) as % of ACEA response.  
 
All three preparations of Hp and AM251 did not exhibit any significant effects on the baseline 
when added by themselves to cultures for the standard 4 hour assay period (Hp1 = 100.4%; 
Hp2 = 97.7%; Hp3 = 101.0%, AM251 = 105.1% of the control, data not shown). AM251 
(10M) essentially fully inhibited the ACEA (5M) response (Figure 4.2.2), similarly to 
experiments reported in the previous chapter. In marked contrast when added at 20M; 
Hp1, Hp2 and Hp3 did not significantly antagonise the ACEA response and there were no 










Figure 4.2.2. Comparison of the inhibition of ACEA between Hp from different sources and 
AM251 
CB1-Tango cells were seeded at a density of 30,000 cells per well in Freestyle media 
overnight as described in methods. FAC of 5M ACEA were added to the cells in the absence 
or presence of 10M AM251, 20M Hp1 (Tocris), Hp2 (Cayman Chemical) or Hp3 (Sigma) for 
4 hours. Assay substrate was added for 90 minutes and read on the Flexstation. To show the 
full ACEA elicited CB1 response, control well ratios were subtracted from the sample well 
ratios and the data was then normalised to the maximal ACEA response (set to 100) and 
displayed as % of ACEA response. Graph shows means and bars represent SEMs of pooled 
independent experiments, with 8 replicates in each experiment. Significance of the 
responses was compared to ACEA control using One Way ANOVA. 






Hemopressin does not exhibit antagonism against eCBs 
AM251 has been shown to be a robust CB1 receptor antagonist against the synthetic agonist 
ACEA and the major eCBs in the previous chapter. However, AM251 is synthetic and cell 
permeable and so might differ in its mode of action from Hp, which is not cell permeable 
(Rozenfeld and Devi, 2008; Benard et al., 2012). It has also been proposed previously that 
the effects of Hp may not be as effective against synthetic agonists such as WIN55,212-2 
versus endogenous agonists such as 2-AG and this could explain some differences in Hp 
activity reported in the literature (Petrovszki et al., 2012). It was therefore important to test 
whether Hp can antagonise the activation of the CB1 receptor stimulated by the natural 
ligands 2-AG and AEA. 
 
In a series of experiments, a range of concentrations of the eCBs 2-AG (FAC 0.04 – 25M) 
and AEA (FAC 0.0025 – 25M) were tested for their ability to activate the CB1 receptor in the 
absence and presence of Hp1 with the results summarised in Figure 4.2.3 and Figure 4.2.4. 
2-AG-elicited a concentration-dependent response reaching a maximal stimulation to 
216.3% ± 14.8% of control at 25M (Figure 4.2.3) with an EC50 value of 1.84M (log EC50 = -
5.74 ± 0.19 SEM, n = 3) (Table 4.2.1). In the presence of 10M Hp1, the 2-AG responses 
remain unchanged at all tested concentrations. The pooled EC50 value for 2-AG in the 
presence of Hp1 was 2.30M (log EC50 = -5.64 ± 0.13 SEM, n = 3) and this was not significantly 
different from that seen in the absence of Hp1.  
 
Likewise, AEA elicited a concentration-dependent response with a maximum stimulation 
seen at 2.5M (288.1% ± 25.8% of control) but at the highest tested concentration of 25M, 
the response was slightly (but not significantly) reduced (260.1% ± 37.1% of control). When 
added at 10M, Hp1 does not significantly antagonise AEA at all concentrations tested. The 
EC50 value of AEA alone was 0.11M (log EC50 = -6.97 ± 0.34 SEM, n = 3), which is similar to 
the EC50 values obtained in the previous chapter. In comparison, the EC50 value of AEA in the 
presence of Hp1 was 0.092M (log EC50 = -7.04 ± 0.31 SEM, n = 3) and this is not statistically 









Figure 4.2.3. Hp1 does not antagonise a range of 2-AG concentrations 
30,000 CB1-Tango cells were seeded per well in black 96 well plates in Freestyle media 
overnight. Varying concentrations of 2-AG (final top concentration 25M, 1:5 dilution) were 
diluted in Freestyle media and added to the cells in the presence and absence of 10M Hp1 
for 4 hours incubating at 37oC. FRET substrate was added for 90 minutes after incubation and 
read on the Flexstation. Data was normalised to control wells (set to 100) as % of control. 
Graph shows means and bars represent SEMs of 3 independent experiments, 8 replicates in 










Figure 4.2.4. A range of AEA concentrations is not inhibited by Hp1 
30,000 CB1-Tango cells were seeded per well in Freestyle media overnight. The following 
day, varying concentrations of AEA were added to the cells (final top concentration of 25M, 
1:10 dilution) in the presence and absence of 10M Hp1 for 4 hours incubating at 37oC. Assay 
substrate was added for 90 minutes and read on the Flexstation. Data was normalised to 
control wells (set to 100) as % of control. Graph shows means and bars represent SEMs of 3 






Rodent hemopressin does not antagonise eCBs 
In the above experiments we have established that when used at 10M, human Hp1 did not 
significantly inhibit the activity of 2-AG or AEA at any of the tested concentrations of the 
eCBs. As mentioned previously, the amino acid substitution in the rat orthologue could be 
the key residue that is responsible for the activity of Hp at the CB1 receptor. We therefore 
again tested the two independently sourced preparations of the rat variant of Hp alongside 
the human Hp and AM251 against the responses elicited by 5M 2-AG and AEA to determine 
if rHp has antagonist effect against these eCBs.  
 
The 2-AG response was averaged at 250.6% ± 15.3% of control and this has been normalised 
as the maximal 2-AG response (set at 100%) as described previously. Similarly to the 
experiments with ACEA, AM251 inhibited the 2-AG response by approximately 90% across 
this series of experiments (Figure 4.2.5). In contrast 10M Hp1, Hp2 and Hp3 had no 
significant effect on the 2-AG response. There is perhaps a trend towards a very minor 
inhibition with Hp2 inhibiting the 2-AG response by 12.1%, nonetheless this is a marginal 
response and it was not a significant inhibition.    
 
Next, AEA similarly averaged a response at 383.1% ± 20.8% of control and is displayed as 
100% of AEA response as described previously. AM251 inhibited the AEA responses by ~93% 
across this series of experiments (Figure 4.2.6). Again none of the Hp preparations used at 
the same concentration had a significant effect on the AEA response but there was again 
perhaps a trend towards a very small, but not significant effect with Hp2 reducing the 







Figure 4.2.5. Comparison of the inhibition of 2-AG between Hp from different sources and 
AM251 
CB1-Tango cells were seeded in black 96 well plates in Freestyle media overnight. Final assay 
concentration of 5M 2-AG was added to the cells in the absence or presence of 10M 
AM251, 10M Hp1 (Tocris), Hp2 (Cayman Chemical) or Hp3 (Sigma) for 4 hours. Assay 
substrate was added for 90 minutes and read on the Flexstation. To show the full 2-AG 
elicited CB1 response, control well ratios were subtracted from the sample well ratios and 
the data was then normalised to the maximal 2-AG response (set to 100) and displayed as % 
of 2-AG response. Graph shows means and bars represent SEMs from pooled independent 
experiments, 8 replicates in each experiment. Significance of responses were compared to 
2-AG control using One Way ANOVA. 







Figure 4.2.6. Comparison of the inhibition of AEA between Hp from different sources and 
AM251 
CB1-Tango cells were seeded in black 96 well plates in Freestyle media overnight. Final assay 
concentration of 5M AEA was added to the cells in the absence or presence of 10M 
AM251, 10M Hp1 (Tocris), Hp2 (Cayman Chemical) or Hp3 (Sigma) for 4 hours. Assay 
substrate was added for 90 minutes and read on the Flexstation. To show the full AEA elicited 
CB1 response, control well ratios were subtracted from the sample well ratios and the data 
was then normalised to the maximal AEA response (set to 100) and displayed as % of AEA 
response. Graph shows means and bars represent SEMs from pooled independent 
experiments, 8 replicates in each experiment. Significance of the responses was compared 
to AEA control using One Way ANOVA. 







2-LG response remains in the presence of hemopressin  
In contrast to AM251, three independent preparations of Hp (one human and two rat) failed 
to significantly inhibit the response to ACEA, 2-AG and AEA tested over a wide-range of 
concentration of the three agonists. In the previous chapter we have provided the first clear 
evidence that 2-LG can function as a partial agonist at the CB1 receptor, identifying it as a 
putative novel endogenous ligand for the CB1 receptor. For this reason, we decided to test 
the effects of Hp on the 2-LG response. 
 
The maximal response to 2-LG is revealed when JZL195 is included to mitigate against the 
hydrolysis of 2-LG, and it was again added in this series of experiments. As before, 2-LG (FAC 
6.25 – 50M) elicited a concentration-dependent and saturable CB1-dependent response 
(Figure 4.2.7), reaching a maximum at 25M (160.4% ± 4.8% of control). AM251 was shown 
to reveal an eCB tone when JZL195 was present previously, however, Hp1 on its own did not 
have any effect on baseline value (data not shown). The 2-LG response is not inhibited by the 
presence of 10M Hp1 at all tested concentrations of 2-LG. The EC50 values for 2-LG 
concentration response curve was 2.28M (log EC50 = -5.64 ± 1.74 SEM, n = 2) and 3.70M 
(log EC50 = -5.43 ± 1.89 SEM, n = 2) in the absence and presence of 10M Hp1 respectively. 
When comparing the log EC50 values, the difference is not statistically significant (Table 
4.2.1).  
 
We next compared the activity of the independent preparations of Hp with AM251 on the 
maximal 2-LG response. The average 2-LG response across this series of experiments was a 
stimulation to 179.3% ± 10.6% relative to control, in line with the results from the previous 
chapter. The 2-LG response was expressed as 100% by subtracting the background ratios and 
normalising the data to the maximal 2-LG response. As before, AM251 revealed a small eCB 
tone induced by the presence of JZL195 throughout the assay period and this explains why 
AM251 reduces the signal to a value below the control in Figure 4.2.8.  
 
The three independently sourced preparations of Hp alone did not have an effect on the 
baseline value seen in the presence of JZL195 (Hp1 = 100.3% ± 1.6%, Hp2 = 98.5% ± 1.1%, 
Hp3 = 99.4% ± 1.6% of control) unlike AM251 which consistently and significantly reduces 
the baseline value by ~10%. This reinforces the observation that the Hp preparations do not 
display AM251-like CB1 antagonism, in this case against a small but significant tone induced 





around 10% of the full response (Hp1 = 88.5%, Hp2 = 87.6%, Hp3 = 87.1% of 2-LG response) 
but this was not significantly different to the control maximal 2-LG response nor significantly 
different from each other (p>0.05, Bonferroni’s multiple comparison test). As expected, 
AM251 fully inhibited the 2-LG response, taking the basal value down to the same level seen 
in the absence of 2-LG which is ~90% of the basal control as a consequence of the presence 




Figure 4.2.7. 2-LG concentration response curve is not inhibited by Hp1 
30,000 CB1-Tango cells were plated in Freestyle media overnight. Drugs were diluted in 
Freestyle media and the cells were treated with a range of concentrations of 2-LG (final top 
concentration 50M, 1:2 serial dilutions) in the presence and absence of 10M Hp1 for 4 
hours in a 37oC incubator. 100nM JZL195 was also present in all wells. Assay substrate was 
added for 90 minutes and read on the Flexstation. Data was normalised to control wells (set 
to 100) as % of control. Graph shows means and bars represent SEMs for 2 independent 







Figure 4.2.8. Comparison of the inhibition of 2-LG between Hp from different sources and 
AM251 
CB1-Tango cells were seeded in black 96 well plates in Freestyle media overnight. Final assay 
concentration of 25M 2-LG was added to the cells in the absence or presence of 10M 
AM251, 10M Hp1 (Tocris), Hp2 (Cayman Chemical) or Hp3 (Sigma) for 4 hours. 100nM 
JZL195 was included in all wells in all experiments. Assay substrate was added for 90 minutes 
and read on the Flexstation. To show the full 2-LG elicited CB1 response, control well ratios 
were subtracted from the sample well ratios and the data was then normalised to the 
maximal 2-LG response (set to 100) and displayed as % of 2-LG response.  Graph shows 
means and bars represent SEMs of pooled independent experiments, 8 replicates in each 
experiment. Significance of the responses was compared to 2-LG control using One Way 
ANOVA. 









AGONIST CONTROL LOG EC50 + HP1 LOG EC50 P VALUE SIGNIFICANCE 
ACEA -7.74 ± 0.37 -7.67 ± 0.22 0.8664 ns 
2-AG -5.74 ± 0.19 -5.64 ± 0.13 0.7235 ns 
AEA -6.97 ± 0.34 -7.04 ± 0.31 0.8912 ns 
2-LG -5.64 ± 1.74 -5.43 ± 1.89 0.9513 ns 
Table 4.2.1. Comparison of log EC50 values obtained of CB1 agonists in the absence and 
presence of Hp1 
Log EC50 values of agonist alone and agonist with Hp1 concentration response curves were 
obtained from each experiment and were pooled together. Statistical analysis was carried 
out to determine if the log EC50 values were significantly different to each other. Unpaired 








The CB1 receptor is an attractive target for therapeutics as it mediates many physiological 
processes including pain and appetite (Salamone et al., 2007; Davis, 2014). According to the 
World Health Organisation, obesity is becoming a major epidemic with increasing prevalence 
in a number of obesity-related diseases in many countries worldwide (Segula, 2014). 
Evidence in the literature supports the appetite reducing effects of CB1 antagonists (Rinaldi-
Carmona et al., 1994; Colombo et al., 1998) and Rimonabant, a CB1 specific antagonist, was 
approved for medical use as an anti-obesity drug receptor (Pi-Sunyer et al., 2006). 
Rimonabant, however, was promptly removed from the market as its ability to cross the 
blood brain barrier caused an increased risk of centrally mediated side effects such as 
depression and suicide ideation. This lead to a fall in interest in the development of other 
CB1 antagonists (Moreira and Crippa, 2009). However, blockade of peripherally located CB1 
receptors has demonstrated similar, albeit smaller, weight loss (Pavon et al., 2008) and 
analgesic effects (Agarwal et al., 2007) with reduced central activity. Therefore, peripherally 
restricted CB1 antagonists are being pursued as potential therapeutics (Kunos et al., 2009). 
In this context, the claim that the 9 amino acid peptide Hp functions as a CB1 antagonist was 
of considerable interest (Heimann et al., 2007) as it might be, or might be modified to be, 
peripherally restricted. 
 
Many companies currently sell Hp as a CB1 antagonist based upon these studies utilising Hp 
as a CB1 antagonist. However with contradictory reports emerging negating the claim that 
Hp is a true CB1 receptor antagonist (Hama and Sagen, 2011a; Straiker et al., 2015; Dvoracsko 
et al., 2016), it is important to resolve the direct effects of Hp on the CB1 receptor. In this 
chapter the direct antagonistic activity of three independently sourced preparations of Hp, 
one human and two rat, was tested using the CB1-Tango assay against three full CB1 agonists 
ACEA, 2-AG and AEA and one novel partial agonist, 2-LG. 
 
Hp1 was tested over the range of 0.4M – 20M and failed to inhibit the response to CB1 
agonists (data not shown). The agonists produced a CB1-dependent response with EC50 
values similar to those reported in the previous chapter, indicating reproducibility of the 
assay. When tested at a fixed concentration (10M), Hp1 failed to inhibit the activity of any 
of the CB1 agonists over their full concentration-response range (Figure 4.2.1, Figure 4.2.3 





literature and used in vitro assays (1M) (Heimann et al., 2007). There is no statistically 
significant difference between the log EC50 values (Table 4.2.1); and no difference in the 
maximal responses of the concentration response curves of all tested agonists in the absence 
and presence of Hp1, indicating no antagonism or allosteric modulation of the agonists.  
 
Hp was reported to be able to antagonise synthetic CB1 receptor ligand Hu-210 and acted 
similarly to CB1 antagonist SR141716 in displaying both antagonist and inverse agonist 
activity (Heimann et al., 2007). Here, Hp was hypothesised to bind to the same pocket as 
SR141716 on the CB1 receptor, thus explaining the similar activity profiles of Hp and 
SR141716 (Scrima et al., 2010). AM251 is structurally closely related to SR141716 (Lan et al., 
1999), which we utilised in our experiments to compare to the activity of Hp. 1M of Hp was 
shown to be sufficient to demonstrate antagonism of the CB1 receptor at similar activity 
levels to 1M of SR141716 (Heimann et al., 2007). In our results from the previous chapter, 
molar excess of AM251 was able to antagonise all CB1 ligands and natural eCBs fully whilst 
molar excess of Hp was unable to show any antagonism. We also utilised AM251 at its 
maximally active concentration of 2.5M in the previous chapter whilst Hp showed no 
discernible antagonism at 2.5M against the tested CB1 agonists (data not shown). The 
activity of Hp was therefore significantly different to AM251 in our assay system.  
 
The effects of Hp have largely been demonstrated with the rat orthologue and Hp was 
originally tested in rodent models (Heimann et al., 2007). The one amino acid difference 
between rat and human Hp might conceivably have an effect on the antagonist activity of 
the peptide against CB1 receptors from different species. For this reason, we tested different 
sources of Hp (one human Hp and two rat Hp) and found there was no significant difference 
between the three independently sourced batches of Hp and no difference between the 
actions of human Hp and rodent Hp against four CB1 agonists; including 2 eCBs. Our inability 
to detect any significant inhibition in the CB1-Tango assay is not in keeping with the proposed 
function of Hp as a CB1 antagonist.  
 
Our results are in agreement with the results reported by Straiker et al (2015) who tested 
2M Hp against endogenously produced 2-AG in autaptic hippocampal neurones and did not 
see any antagonism by Hp when applied both extracellularly and intracellularly. Likewise 
other scientific groups have failed to find any evidence for Hp acting as a CB1 antagonist in 





against the antinociceptive effect of centrally administered WIN55,212-2 by Hp was also 
reported by Hama and Sagen (2011a). Finally, Dvorácskó et al (2016) have shown truncated 
[3H]Hp(1-7) displaying saturable binding to an as-yet-to-be identified target in CB1-/- KO mice 
which cannot be displaced by conventional CB1 ligands SR141716, AM251 or JWH-018 but 
can be displaced by full length Hp. Thus it is reasonable to conclude that Hp may not have 
CB1 antagonist activity and can bind to and perhaps signal via a non-CB1 receptor.  
 
These findings are in contrast to the original study by Heimann et al (2007) who first reported 
the activity of Hp on the CB1 receptor. The conformation-sensitive antibodies generated to 
the N-terminus of the CB1 receptor used in the ELISA assay are reported to only bind to the 
activated CB1 receptor (Gupta et al., 2007). The antibodies were produced in-house by the 
same group and the anti-CB1 antibody have as yet not been validated by other groups. 
Interestingly the antibody is reported to bind to an epitope in the N-terminal region of the 
CB1 receptor that is not actually involved in CB1 receptor activation; in fact deletion of up to 
89 amino acids of the N-terminal region (including the epitope used for antibody recognition) 
showed no difference to activation by CB1 agonist CP-55,940 (Andersson et al., 2003). In the 
preliminary verification of the antibodies by Gupta et al (2007), receptor internalisation was 
intentionally compromised in the whole cell and membrane assays, which could have led to 
false positive antibody binding due to the overexpression of the target receptor and other 
receptors. As well as this, the antibodies in the presence of 1M SR141716 did not originally 
reduce antibody binding to CB1 receptor, in contrary to the study by Heimann et al (2007) 
which did show a reduction in antibody binding in the presence of 1M SR141716 despite 
using the same assay set up. This suggests that the antibody might not be indicative of 
changes in CB1 conformation.  
 
Furthermore, the [35S]GTPS binding assay and adenylyl cyclase assays are also indirect 
measures of ligand activity to transfected CB1 receptors and these assays can be subject to 
false positives through influence from other receptors that are expressed. In fact, in the 
[35S]GTPγS binding assay, Heimann et al (2007) originally saw a decrease in binding in the 
presence of 1M Hp in the same manner as SR141716. However, in separate studies, Szlavicz 
et al (2015) and Dvorácskó et al (2016) saw a slight increase in [35S]GTPγS binding in the 
presence of 1M Hp and did not exhibit the same activity as SR141716 in their binding assays. 
In contrast to assays which measure secondary effectors as an indirect measurement of 





influenced by the expression or activation of other GPCRs. The response is also not altered 
or terminated by endogenous cellular metabolism during incubation time, thus allowing 
direct measurement of CB1 receptor activation and antagonist modulation (Barnea et al., 
2008). Other receptors could form heterodimers with the CB1 receptor to modulate 
signalling (Birdsall, 2010) but it is unknown whether this occurs in the CB1-Tango assay. Since 
there is little change in the concentration response curves of 4 different CB1 agonists and 
little difference between the log EC50 values of these agonists in the presence of Hp, it is not 
very likely that there is modulation of CB1 receptors through heterodimer formation.  
 
Hp has in fact displayed opposing differences in mechanism of action both in vitro (as 
mentioned above) and in vivo. In some animal studies, Hp has no discernible difference to 
other CB1 agonists. Hp has shown antinociceptive effects similarly to CB1 agonists 
(WIN55,212-2 and VD-Hp) and animal models show cross-tolerance to the three treatments 
(Pan et al., 2014). Hp has also shown ability to slow gut motility which can be blocked by 
AM251 in a similar fashion to WIN55,212-2 and VD-Hp (Li et al., 2016).  
 
Variability between results might conceivably be related to peptide solubility, in vitro 
systems such as the CB1-Tango assay or autaptic hippocampal neuron cultures rely on cell 
culture media, which may affect the ability of Hp to stay in monomeric form. In fact, Bomar 
et al (2012) has shown that Hp aggregates in physiologically relevant conditions at high 
concentrations (>1mM) and that hHp tend to aggregate more than rHp (Song et al., 2015), 
this could account for the variability of activity across experiments. At physiological levels, 
Hp is able to bind to metal ions which could have an effect on its mechanism of action in vivo 
(Remelli et al., 2016) or perhaps protein chaperones or local release of low concentrations 
of Hp can prevent aggregations in vivo (Gomes et al., 2010). However, physiological 
implications of the self-assembly remain unclear and even in some in vivo studies, Hp showed 
opposing effects or has been unable to antagonise CB1 receptors (Hama and Sagen, 2011a; 
Petrovszki et al., 2012). In our studies Hp was readily soluble in all media and there was no 
indication of Hp aggregates or precipitation in the media.  
 
Further studies have indicated Hp exerts non-CB1 mediated effects. Administration of Hp to 
anesthetised rats causes dose-dependent hypotension caused by reduction in systemic 
vascular resistance (Lippton et al., 2006). This hypotensive effect was also seen across 





unclear but was thought to be through the release of nitric oxide (Lippton et al., 2006). Hp 
has also recently been shown to be able to stimulate -opioid receptor and is antagonised 
by broad opioid antagonist naloxone (Szlavicz et al., 2015) despite previous studies indicating 
that Hp does not induce opioid-mediated analgesia (Dale et al., 2005b; Heimann et al., 2007). 
Hp has also been linked to activity on the TRPV1 receptor; rats treated with Hp displayed 
anxiogenic behaviour which was prevented by TRPV1 antagonists but not by CB1 antagonists 
(Fogaca et al., 2015; Leone et al., 2017). 
 
Studies which have utilised Hp as a CB1 antagonist but did not see CB1 antagonism when 
applied extracellularly have accredited this result to intracellularly located CB1 receptors on 
the mitochondria (mtCB1) (Zhang et al., 2015, 2016a). Zhang et al. reported no CB1 
antagonism when Hp was applied extracellularly whilst conventional CB1 antagonists, such 
as AM251 and SR141716, show typical CB1 antagonism. This result was hypothesised to be 
due to conventional CB1 antagonists being cell permeable whilst Hp cannot cross the plasma 
membrane (Rozenfeld and Devi, 2008). This led to the conclusion that the effect seen by 
conventional CB1 antagonists must be due to intracellular mtCB1 receptors. Applying Hp 
intracellularly through the recording pipette solution showed more noticeable effects, 
supporting this claim of modulation by mtCB1. However, when Straiker et al (2015) applied 
2M Hp intracellularly in autaptic mouse hippocampal neurons in DSE experiments, they 
observed no CB1 antagonism. In comparison to the studies by Straiker et al. (2015), Zhang et 
al. (2015, 2016a) applied higher intracellular concentrations of Hp (10-20M). As mentioned 
previously, high concentrations of Hp may form aggregates. However, when applied 
intracellularly, the presence of proteases and other metabolic enzymes may degrade Hp 
aggregates and cause non-specific effects in the cell. This may have been interpreted as a 
response mediated by mtCB1. The use of Hp as a CB1 antagonist therefore has posed a 
problem in literature where mistaken conclusions might have been drawn if, as this and 
other studies suggest, Hp is not actually a CB1 antagonist. 
 
The physiological relevance of Hp as a biological signalling molecule has also been 
questioned. Although it could be extracted from tissues and, on this basis, was postulated to 
be an endogenous signalling molecule, it is not known exactly where and how it is produced. 
Mass spectrometry originally suggested that Hp is detected in the brain thus is endogenously 
produced, but speculation arose that Hp could be an artefact of hot acid extraction which 





2013). More recent studies using mass spectrometry without hot acid extraction method in 
mice brains failed to detect fragments of Hp shorter than RVD-Hp (Gomes et al., 2009; 
Gelman et al., 2013). This was further supported by Bauer et al (2012), who only detected 
RVD-Hp from mice brain homogenate using antibodies raised against the C terminus of Hp, 
suggesting that only RVD-Hp is produced endogenously but not Hp. These publications 
suggest Hp does not exist as an endogenous free peptide in the body, plus research shown 
through the CB1-Tango assays and other studies indicate that even as a free peptide, Hp does 
not function as an endogenous ligand for the CB1 receptor. 
 
Interestingly, N-terminally extended peptides containing the Hp sequence of up to 23 amino 
acids long can be extracted from tissues (Bauer et al., 2012), with the best characterised of 
these being RVD-Hp and VD-Hp (Gomes et al., 2009). Of the related peptides, VD-Hp has 
been proposed to be a CB1 receptor agonist (Han et al., 2014), while RVD-Hp was initially 
suggested to act as a CB1 agonist (Gomes et al., 2009) but later studies then showed RVD-
Hp exhibited negative allosteric modulation at CB1 receptors (Bauer et al., 2012) and positive 
allosteric modulation at CB2 receptors (Petrucci et al., 2017). It has been suggested that RVD-
Hp and VD-Hp interact with the CB1 receptor in a distinctively different manner to the lipid 
eCBs (Gomes et al., 2009), perhaps due to binding to an allosteric site (Bauer et al., 2012). In 
these models one would assume that Hp is likely to bind to the same pocket as its related 
longer peptides suggesting it could be a better antagonist for Hp related peptides and not 
endogenous eCBs. To this end the activity of RVD-Hp and VD-Hp has not been tested in the 
CB1-Tango assay system, so no comment can be made on whether they truly have activity at 
the CB1 receptor.  
 
Taking together many of the studies highlighting the non-CB1 mediated activity of Hp and 
that Hp can bind to potential unidentified targets in CB1-/- KO mice brain homogenate, it is 
possible that Hp is biologically active in vivo through different receptor(s). On that basis, even 
if Hp was a CB1 antagonist, any results obtained need to be interpreted with caution given 
that Hp clearly has the potential to have major "off-target" effects relative to any CB1 
activity. Based on these observations together with the research conducted in this thesis and 
in literature mentioned earlier in support of these findings, Hp is clearly not a specific CB1 
antagonist. This puts into question whether publications that have used Hp on the basis it is 
a CB1 antagonist also considered these factors as this causes a serious risk of reaching false 





sciences (see Begley and Ellis, 2012; Baker, 2016). This is likely, or at least partly, due to some 
compounds such as Hp being marketed as having selective activities, which upon closer 
inspection, they do not possess. Unfortunately, the consequence of this is we end up in a 
vicious cycle where the more often the compound is used as a "selective antagonist", the 
more it is adopted by others for the same purpose. 
 
In summary, the CB1-Tango assay system was utilised to test if three independently sourced 
preparation of Hp can inhibit the ability of a wide range of agonists to activate the CB1 
receptor. The results show no marked antagonism by Hp of any CB1 ligands used at a range 
of concentrations. This is supported by several other publications and is contradictory to the 
conclusions reached in the original publication. The question as to why others have 
concluded that Hp is a true CB1 antagonist might be related to Hp having actions at other 
receptors that in turn can modulate CB1 function via indirect mechanisms. Furthermore, it 
would now appear that Hp does not exist as a free endogenous peptide but is actually an 
artefact of hot acid extraction. Taking together the direct in vitro assay results and the 
published literature data, it can be concluded that Hp is not an endogenous CB1 antagonist. 
Moreover, the fact that Hp appears to have significant activity at targets other than the CB1 
receptor questions its value in any assay, as based on these observations there is no basis for 















Chapter 5. Results 3 – Development of a cell-




The two established eCB ligands are 2-AG and AEA (Devane et al., 1992; Mechoulam et al., 
1995) and both have been extensively studied since their discovery (Iannotti et al., 2016). In 
the context of retrograde synaptic signalling, the ligands are thought to be synthesised “on-
demand” from membrane lipids in response to cellular signalling rather than being premade 
and stored in vesicles like other neurotransmitters (Marsicano et al., 2003; Piomelli, 2003). 
The process underlying the generation of 2-AG and AEA for retrograde synaptic signalling 
have been comprehensively studied and several stimuli, such as membrane depolarization, 
increases in intracellular calcium levels and specific receptor stimulation can increase the 
cellular release of 2-AG and AEA for eCB signalling (Williams et al., 2003; Di Marzo, 2008a, b; 
Wang and Ueda, 2009). However, in non-synaptic forms of eCB signalling, such as autocrine 
signalling that is believed to be important for adult neurogenesis and axonal growth and 
guidance (Gao et al., 2010; Oudin et al., 2011b; Oudin et al., 2011a; Maccarrone et al., 2014), 
there is no simple consensus on how these two eCB signalling pathways are regulated.  
Several stimuli like ionomycin can increase 2-AG and AEA levels in cells and tissues, but it is 
not always clear as to whether the measured eCBs are from a signalling pool that can 
contribute to eCB signalling or a general metabolic pool as they are usually quantified from 
homogenates of cells and/or tissues (Devane et al., 1992; Bisogno et al., 1997; Stella et al., 
1997). Besides monitoring physiological responses like DSI/DSE for 2-AG signalling, studying 
eCB activity relies heavily on mass spectrometry quantification, which requires an elaborate 
laboratory setup, specialised equipment and tends to be low throughput (Balgoma et al., 
2013). Thus, it is often difficult to study stimuli-induced eCB signalling, especially for AEA.  
As hinted at above, it is unclear if the 2-AG and AEA measured in many studies is reflective 
of a signalling pool of the lipid, as opposed to a general metabolic pool. A bottle neck in our 
understanding of the synthesis of eCBs is the lack of simple cellular models that report 





the CB1-Tango cells for addressing the question as to whether Hp might be a novel 
endogenous CB1 antagonist, and whether 2-LG might be a novel eCB. CB1-Tango cells are 
genetic variants of the U2OS human osteosarcoma cell line (Ponten and Saksela, 1967) where 
eCB signalling is important for bone development and maintenance (Tam et al., 2008; Idris 
and Ralston, 2012) and thus the CB1-Tango cells could potentially produce eCBs for eCB 
signalling.  
5.1.1 Aims 
We reasoned that this human osteosarcoma cell line might provide an opportunity to 
address some fundamentally important questions that relate to eCB signalling. However, to 
be of value to eCB signalling, the cells would need to express the key enzymes thought to be 
involved in the synthesis and breakdown of 2-AG and AEA, and moreover pathways that are 
established to activate eCB signalling would need to be functional and report via CB1 
receptor activation in the CB1-Tango cell line. It follows that if the osteosarcoma cell line 
expresses the key enzymes and the pathways are active and can be detected by the CB1-
Tango assay, pharmacological and genetic tools (e.g. CRISPR) can be employed to critically 
test the requirement of individual components for both 2-AG and AEA synthesis, as well as 
eCB signalling. With this in mind the aims of this chapter are to: 
- Profile the level of transcript expression of the major known enzymes implicated in 
eCB signalling in the CB1-Tango cells and compare the individual transcript levels in 
the CB1-Tango cells to the levels found in a variety of tissues to see if each is within 
a range expected for a role in eCB signalling 
- Adapt the CB1-Tango assay to produce and detect an eCB tone using different 








5.2 Results 3A. Are the CB1-Tango cells a suitable 
model to study eCB signalling? 
 
5.2.1 Results 3A. Introduction 
In previous chapters, the CB1-Tango cells have been shown to be able to generate a 
measurable and reliable CB1-dependent response to exogenously applied CB1 agonists and 
have reduced responses in the presence of CB1 antagonists. The use of the FAAH and MAGL 
inhibitor JZL195 in the previous chapters reveals an eCB tone which can be antagonised by 
AM251. In the absence of JZL195, there is no eCB tone revealed by AM251, suggesting that 
the eCB degrading enzymes are acting as gate keepers to prevent a relatively low level of 
signalling at the CB1 receptor under the manufacturer’s recommended conditions. CB1-
Tango cells therefore are able to synthesise and hydrolyse eCBs, albeit the eCB tone revealed 
by JZL195 is very modest relative to the response elicited by a maximally active concentration 
of ACEA, or by exogenously applied 2-AG or AEA.  
 
To fully understand the nature of the eCB system in the CB1-Tango cells, it was prudent to 
profile the cells to determine specifically which of the eCB synthesis and degrading enzymes 
were expressed and whether these were expressed to physiologically relevant levels as 
cancer cell lines may have irregularly upregulated or downregulated genes. In the context of 
the DAGL and 2-AG pathway, western blotting analysis was carried out by previous members 
of the lab and detected the presence of both the DAGLs and MAGL proteins in the CB1-Tango 
cells, but was unable to detect FAAH (thesis of Praveen K Singh, 2013). As well as this, in 
previous qPCR experiments carried out in the lab, endogenous expression of DAGL and 
DAGL transcripts were detected; DAGL RNA transcripts were around 2.5x higher than 
DAGL (thesis of Rachel Lane Markwick, 2015). At the time, the AEA pathway was not 
characterised in the CB1-Tango cells, however focus has been placed on the AEA pathway as 
an important signalling molecule in peripheral systems such as cardiovascular system, 
gastrointestinal tract and bone maintenance (reviewed in Maccarrone et al., 2015). 






Figure 5.2.1. Workflow of the QuantiGene Multiplex assay system 
Image from QuantiGene Multiplex assay user manual, Thermofisher Scientific. 
The amount of RNA bound to each bead is quantified using branched DNA technology, where 
the pre-amplifier DNA molecules bind to each bound RNA sample. Signal amplification is 
based on the DNA branch structures capturing multiple labels rather than RNA being 
amplified as in standard microarray platforms, which may lead to bias (Boelens et al., 2007). 
Finally, an R-Phycoerythrin conjugate is added to give a detectable fluorescence emission 
and the intensity of the emission is collected. The Median Fluorescent Intensity (MFI) is 
collected for each gene which is proportional to the abundance of the RNA for that gene. The 









To quantitatively determine the expression of the necessary synthesis and degrading 
enzymes required for both the 2-AG and AEA pathway, we have utilised a more robust 
multiplex assay system to detect the RNA transcripts of major eCB components and their 
relative transcript expression. The QuantiGene Multiplex assay system can quantitatively 
measure gene transcripts of up to 50 different genes simultaneously (Figure 5.2.1). Several 
bespoke capture extender probes are designed to unique sequence areas of RNA on a given 
target gene to improve specificity of binding. Other probes (label extenders and blocking 
probes) are also designed in the probe set alongside the capture probes to further reduce 
off target binding. The probes are coupled to magnetic beads labelled with unique 
identification ratios of red and far-red light emissions and each probe set per gene is coupled 
to only one colour bead to identify specifically which gene is being detected.  
In this section, I will report on the selection and bespoke design of the probes for a panel of 
eCB genes, the optimisation of the QuantiGene Mulitplex assay system and utilisation of the 
assay to quantify the expression of the eCB panel of genes in the CB1-Tango cell line and for 
comparison to other cell lines and total RNA from human tissues. This is an important basis 
to determine whether the CB1-Tango assay can be adapted to address some fundamental 
question relating to eCB signalling in general, and more specifically eCB signalling in a human 






5.2.2 Results 3A. Results 
Design of the eCB panel of genes 
For the eCB panel, we designed probes to the gene transcripts of two established CB 
receptors, the major eCB synthesis enzymes and the major eCB degrading enzymes listed 
(Table 5.2.1). In brief we wanted to profile the cells for the transcript level of the CB1 and 
CB2 receptors, the enzymes implicated in 2-AG synthesis (DAGL, DAGL), the enzymes 
postulated to regulate AEA levels (NAPEPLD and PLA2G4E) and the main enzymes that 
degrade 2-AG and/or AEA (MAGL, FAAH and ABHD6). In addition, we also decided to profile 
PLA2G4B as although it has not been implicated in AEA synthesis, it is structurally very closely 
related to PLA2G4E and its expression matches more closely with CaNAT and on that basis 
worthy of some investigation. 
The probes for each transcript are generated in tandem on a single stretch of sequence 
(Figure 5.2.2). There are several capture extender probes generated along the region and the 
redundancy of the probes increase the specificity of binding to the RNA samples. The 
blocking probes and label extenders are generated around the capture extender probes in 
order to form a steric complex that amplifies only the specific signal of the bound RNA, again 
to increase specificity of the signal produced and reduce off target binding.   
The probes were largely generated to stretches of unique sequences that share little 
homology to other genes in order to reduce off-target binding (Table 5.2.1). For some genes 
however, the probes were designed to catalytic regions of interest, for instance in the case 
of DAGL and DAGL, the probes were designed to the exons of the catalytic regions of each 
gene (Reisenberg et al., 2012). The NAPEPLD probes were also designed to exon 3, which is 
the largest exon, and harbours the catalytic motif (Daiyasu et al., 2001; Tsuboi et al., 2011) 
and PLA2G4E and PLA2G4B probes were designed to their respective catalytic regions (Song 
et al., 1999; Ogura et al., 2016). The design of the probes to the catalytic region serves two 
purposes. Firstly, there are different splice variants of these genes, and though it is common 
practice to generate probes to areas that span all splice variants, not all splice variants are 
enzymatically active and consequently such probes are not necessarily reflective of 
enzymatically active protein expression. It is therefore more reflective of functional protein 







Figure 5.2.2. Example of the design of probe sets against the panel of eCB genes 
Schematic of the probe set interacting with the sample RNA and forming a bead complex. 
Probe sets were designed to each gene in the panel. Example shown in the figure of DAGL 
gene on the right, red sequence corresponds to capture extender probes, green sequence 
corresponds to label extenders and purple corresponds to blocking probes which are 
schematically displayed on the left.  
 
 
GENE ROLE IN eCB SIGNALLING REGION OF GENE TARGETED 
CNR1 Cannabinoid Receptor 1 Exon 2 – UTR (532bp) 
CNR2 Cannabinoid Receptor 2 Exon 2 (368bp) 
DAGL Key 2-AG synthesising enzyme Exon 13 – Exon 17 (347bp) 
DAGL Key 2-AG synthesising enzyme Exon 7 – Exon 11 (400bp) 
NAPEPLD Key AEA synthesising enzyme Exon 3 (486bp) 
ABHD6 eCB hydrolysing enzyme Exon 5 – Exon 9 (511bp) 
MGLL eCB hydrolysing enzyme Exon 7 – UTR (563bp) 
FAAH eCB hydrolysing enzyme Exon 5 – Exon 10 (463bp) 
PLA2G4E Putative CaNAT enzyme Exon 13 – Exon 16 (430bp) 
PLA2G4B Candidate CaNAT enzyme Exon 16 – Exon 18 (413bp) 
HLCS Housekeeping gene Exon 5 (572bp)   
FOXJ2 Housekeeping gene Exon 2 – Exon 6 (425bp)  
 








Secondly, we wanted to design probes that would not only report on transcript levels in 
parental cell, but could also be used in screening assays where strategies have been adopted 
to delete the catalytic sites from each of the key genes. This would allow us to use the 
multiplex system as a fast and convenient validation tool to characterise the KO of genes, if 
the deleted region of the gene is the region where the probes are targeting, then there will 
be no signal from the beads assay. As a result, we have specifically designed the probes to 
catalytic regions that could be targeted with gene editing tool CRISPR in the future. In later 
experiments, we use CRISPR to genetically KO genes for the characterisation of the 2-AG and 
AEA pathway and to KO candidate genes for validation of the putative CaNAT enzymes.  
Probes to two housekeeping genes HLCS and FOXJ2 were also generated, these 
housekeeping genes were selected based on data analysed across published microarray 
studies, due to their low variability across different cell lines and conditions (Gareth Williams, 
unpublished data). In summary, the probes were generated to this panel of genes for both 
the determination of transcript level in the CB1-Tango cells and as tools to validate disruption 






Optimisation of the Magpix Beads assay 
We wanted to quantitatively confirm the expression of the eCB gene transcripts in the CB1-
Tango cells using the multiplex system. We extracted RNA from CB1-Tango cells grown under 
normal culturing conditions in a T-75 flask. Preliminary experiments were carried out using 
the manufacturer’s recommended serial dilution of 50 – 500ng of total RNA from the CB1-
Tango cell line as described previously in methods. For each individual gene, the linear 
relationship between the RNA concentration and net MFI was calculated. A representative 
graph of DAGL is shown in Figure 5.2.3. The results show a good linear relationship when 
the net MFI lies within the dynamic detectable range of 10-20,000/30,000 MFI (3.5 log units). 
For some gene transcripts, particularly at lower concentrations, the net MFI lies outside the 
dynamic range which reduces the strength of the linear relationship (data not shown). Our 
highest net MFI reading from the eCB beads set was from 500ng of DAGL at 1780 ± 45.3 net 
MFI (Figure 5.2.3), which is within the dynamic detectable range but is rather low within the 
range. Also, signals that are about 3 standard deviations above background levels are 
typically considered a “real” signal from the noise and 5 of our genes were below this 
threshold even at 500ng (data not shown). This indicated that even the highest 
recommended RNA concentration would not give us enough signal to robustly detect the 
eCB gene transcripts from the CB1-Tango cells. 
For these reasons it was decided to increase the amount of RNA in the wells from 500ng to 
7500ng so that the net MFI signals lie more within the detectable range of the assay. The 
plot of the correlation of both RNA concentrations is shown in Figure 5.2.4. There is a strong 
positively linear relationship between the relative net MFIs of the genes from both RNA 
concentrations (Figure 5.2.4). The higher concentration of RNA also boosted the less 
expressed gene transcripts to give a better signal compared to background signal, and only 
two gene transcripts remained below the detection threshold. The relative expression and 
ranking of the eCB gene transcripts are maintained even at the higher concentration, which 
is also displayed in Figure 5.2.5. The higher concentration is therefore useful for detecting 
less highly expressed gene transcripts and is very consistent detecting the relative expression 









Figure 5.2.3. RNA concentration-intensity relationship of serial dilutions of CB1-Tango cell 
RNA 
CB1-Tango cells were grown until 90% confluent in T-75 flasks and RNA was extracted 
according to manufacturer’s instructions. The RNA was serially diluted to 50, 100, 200, 300, 
400 and 500ng in 20l. Nuclease free water was added in control wells instead of RNA 
samples. The RNA was then incubated with the probe sets designed to genes in the eCB 
signalling pathway and magnetic beads for at least 18 hours at 54oC shaking at 600rpm. The 
next day, the beads were washed and amplifying mixtures were added according to 
manufacturer’s instructions. The beads were read on the Magpix multiplex system (Luminex) 
and the Net MFI was calculated by removing background readings from the sample readings. 
Graph shows a single representative assay of DAGL points represent means and bars 













Figure 5.2.4. Comparison of signal amplification between 500ng RNA to 7500ng RNA 
CB1-Tango cells were grown until 90% confluent in T-75 flasks and RNA was extracted 
according to manufacturer’s instructions. In order to amplify the signal, RNA was diluted to 
7500ng in 20l (concentration of 375ng/l) and to 500ng in 20l (concentration of 25ng/l). 
Nuclease free water was added in control wells instead of RNA samples. The RNA was then 
incubated with the probe sets designed to genes in the eCB signalling pathway and magnetic 
beads for at least 18 hours at 54oC shaking at 600rpm. The next day, the beads were washed 
and amplifying mixtures were added according to manufacturer’s instructions. The beads 
were read on the Magpix multiplex system (Luminex) and the Net MFI was calculated by 
removing background readings from the sample readings. Graph shows plots of means of 5 
replicates of 7500ng against 500ng RNA of (A) all eCB components, (B) expanded view of box 














Relative expression of eCB components in the CB1-Tango cells 
Net MFIs obtained for each gene at 7500ng are plotted according to relative expression levels 
in Figure 5.2.5. The highest net MFI was again from DAGLtranscripts, giving a net MFI at 
14388.8 ± 456.4, which lies within the upper range of the dynamic detectable range, whilst 
the two lowest gene transcripts gave the measurements at just under 10 net MFI. The DAGL 
transcripts are both very highly expressed in CB1-Tango cells, DAGL transcripts were around 
4x higher than DAGL transcripts, and ~10x higher than NAPEPLD transcripts. These results 
are generally in keeping with the previous qPCR results from CB1-Tango cells carried out by 
other members of our lab, where endogenous DAGL transcripts were more highly detected 
than DAGL transcripts (thesis of Rachel Lane Markwick, 2015).  
The assay detected the transcripts for the major eCB degrading enzymes present in the cells, 
ABHD6 and MGLL. The ABHD6 transcript signal was around 2.5x higher than MGLL in the 
CB1-Tango cells. Low levels of FAAH transcripts were also detected and this can be viewed 
as perhaps supporting a low level of protein expression, as suggested by previous western 
blot analysis. As well as this, both MAGL and FAAH inhibitors are needed to reveal a low eCB 
tone in the cell line (thesis of Rachel Lane Markwick, 2015), indicating the expression of both 
enzymes in the cell line and some degree of crossover.  
CNR1 transcripts are also detected but it is unsure what proportion of the signal is from the 
cells’ own endogenous expression of the native CB1 or from the chimeric human CB1 from 
the assay system. It has been previously published in a few independent microarray studies 
that there is hardly any detectable native CNR1 transcripts found in U2OS cells (Kim et al., 
2007; Sadikovic et al., 2008; Abbas et al., 2010). It is therefore likely that the detected CNR1 
signal is reflective of the chimeric CB1 receptor only, however there still is relatively low 
CNR1 transcript levels in the CB1-Tango cells despite the gene being expressed under a 
strong cytomegalovirus promoter (Barrow et al., 2006). This might be due to the probe 
design targeting partially to the 3’-UTR of the CNR1 gene which would not be present in the 
pTangoCNR1 plasmid that the CB1-Tango cells are expressing, thus reducing some of the 
signal obtained. CNR2 transcripts are scarcely detectable in the assay when 15x concentrated 
RNA was used giving a net MFI reading of 8.1 ± 1.3. Nonetheless, the results do show that a 
relatively low level of transcript for the CB1 receptor is still sufficient for the cells to express 
functionally important levels of receptor as the cells are highly responsive to all of the 







Figure 5.2.5. Detection of key eCB signalling components in CB1-Tango cells using Magpix 
beads assay 
CB1-Tango cells were grown until 90% confluent in T-75 flasks and RNA was extracted 
according to manufacturer’s instructions. In order to amplify the signal, RNA was diluted to 
7500ng in 20l (concentration of 375ng/l). Nuclease free water was added in control wells 
instead of RNA samples. The RNA was then incubated with the probe sets designed to genes 
in the eCB signalling pathway and magnetic beads for at least 18 hours at 54oC shaking at 
600rpm. The next day, the beads were washed and amplifying mixtures were added 
according to manufacturer’s instructions. The beads were read on the Magpix multiplex 
system (Luminex) and the Net MFI was calculated by removing background readings from 
the sample readings. Graph shows means and bars represent SEMs of 5 replicates of each 
eCB component, insert shows expanded view of the 6 lowest detected eCB components 







Transcripts for the recently identified CaNAT PLA2G4E are essentially undetectable in the 
CB1-Tango cells (8.8 ± 3.8 net MFI). This low level of detection is out of the detectable 
dynamic range, even at very high concentrations of RNA at 7500ng. Interestingly, the 
transcripts for the structurally related (but functionally uncharacterised) PLA2G4B were 
readily detected.   
These results from the QuantiGene multiplex assay are further supported by “The Human 
Protein Atlas” (Thul et al., 2017). This is a project focused on profiling the human proteasome 
using antibody-based imaging and mRNA transcriptomics. Analysis of human tissues and 
several cell lines have been carried out and are publicly available online 
(https://www.proteinatlas.org/). In U2OS cells, expression of DAGL has been classified as 
high abundance; DAGL, NAPEPLD, ABHD6 and MGLL are classified as medium abundance; 
and PLA2G4B, PLA2G4E, FAAH, CNR1 and CNR2 are classified as low abundance which is 
generally in agreement with our results.  
We can conclude that the CB1-Tango cells in general express high level of transcripts for the 
synthesis enzymes for eCBs, moderate levels of the degrading enzymes and low levels of CB 
receptor gene transcripts and this is in keeping with the western blot analysis and qPCR 
results obtained previously in our lab and of publicly available mRNA data of U2OS cells from 
microarray and the Human Protein Atlas. However, they do not appear to express PLA2G4E 
transcripts or CB2 transcripts.  
 
Expression of eCB components in CB1-Tango cells compared to other cell lines 
and tissues 
Whilst we are able to detect RNA transcripts of key eCB genes from our CB1-Tango cells, we 
were unsure whether this was at physiologically relevant signalling levels. The U2OS host cell 
line (CB1-Tango cell background) is a cancer cell line and thus many genes may be up or 
downregulated abnormally to ensure survival of the cells. On top of this, the cells are 
overexpressing many non-native constructs and proteins for the Tango system – particularly 
of CB1, therefore it was prudent to evaluate the relative levels of transcripts of the eCB 
components with other human immortalised cell lines and human total RNA from relevant 
tissues.  
Total RNA from 3 human cancer cell lines in addition to CB1-Tango cells were extracted, and 





to the limited resource of human RNA from cerebellum and hippocampus, the RNA from all 
samples were used at 500ng in the assay. The RNA samples were incubated along with the 
magnetic beads and probe sets and the assay was carried out as described in Methods. The 
net MFI was calculated and then normalised to the GEO mean of the two housekeeping 
genes: HLCS and FOXJ2. The relative expression of the eCB genes to the housekeeping genes 
are graphed and the results are shown in Figure 5.2.6.  
The CNR1 transcript is expressed very highly in the cerebellum and hippocampus, as 
expected where it plays an important role in many synaptic functions (Kawamura et al., 
2006). CNR1 transcript expression is not reliably detected in the tested cancer cell lines (net 
MFI readings of <5) and is detected in the CB1-Tango cells (see above). Similarly, across all 
tested samples, CNR2 transcripts were not reliably detected (net MFI readings of <3).  
The DAGL transcript levels in our CB1-Tango cells are comparable to the levels found in the 
cerebellum and hippocampus where it is established as the major enzyme regulating eCB 
synthesis that functions in retrograde synaptic transmission (Tanimura et al., 2010). Out of 
all 4 tested cancer cell lines, CB1-Tango cells express the highest amount of DAGL 
transcripts. These results clearly point to DAGL being functional in the CB1-Tango cells.  
Remarkably, the DAGL transcript is expressed at considerably higher levels (4-8 fold) in 
Tango cells than the other cell lines and tissues, clearly pointing to an important function for 
this enzyme in these cells. NAPEPLD transcript levels are relatively similar in the CB1-Tango 
cells to other cancer cell lines, but the transcript is clearly more highly expressed in 
cerebellum and hippocampus, again where the eCB system is predominantly active in 
retrograde signalling in synapses (Egertova et al., 2008). These results would support all three 
enzymes being functional and potentially contributing to eCB signalling in Tango cells. 
Remarkably, PLA2G4E transcripts were not detected in any of the cancer cell lines (including 
the Tango cells – see above), but was found at relatively high levels in the skin. This 
observation clearly raises question as to whether this enzyme can be considered as the key 
CaNAT that generally regulates AEA synthesis. Interestingly, the structurally related PLA2G4B 
had robust expression of transcripts in most of the cell lines (the exception being MCF7 cells) 
and in all three tissues, with transcript levels in the skin again being relatively high. Thus if 
this enzyme also has CaNAT activity it might be better placed than PLA2G4E to play a general 





Finally, the levels of MGLL and ABHD6 transcripts in the Tango cells were as high (or higher) 
than those seen in the other cancer cell lines and only 2-3 times lower than levels seen in the 
cerebellum and/or hippocampus. The highest levels were seen in the hippocampus, the 
tissue that also had the highest levels of DAGL and NAPEPLD transcripts. Interestingly, 
although clearly detectable in Tango cells (see above), FAAH transcript levels were really very 
low in these cells relative to the levels seen in the MCF7 cell line and the three tissues. These 
results would be consistent with all three enzymes being involved in eCB turnover in Tango 












Figure 5.2.6. Comparison of eCB component expression in CB1-Tango cells and other cell 
lines 
RNA was extracted from immortalised cell lines: CB1-Tango, SHSH5Y, MCF7 and H460 lines 
and eluted in nuclease free water. Total RNA from cerebellum, hippocampus and skin were 
purchased and all RNA were diluted in nuclease free water to recommended amount of 
500ng in 20l (concentration of 25ng/l). Nuclease free water was added in control wells 
instead of RNA samples. The RNA was then incubated with the probe sets designed to genes 
in the eCB signalling pathway and magnetic beads for at least 18 hours at 54oC shaking at 
600rpm. The next day, the beads were washed and amplifying mixtures were added 
according to manufacturer’s instructions. The beads were read on the Magpix multiplex 
system (Luminex) and the relative expression was calculated by removing background 
readings from the sample readings and normalising to the GEO means of 2 housekeeping 
genes. Graph shows means and bars represent SEMs of 5 replicates of each normalised eCB 

























5.2.3 Results 3A. Summary & Conclusions 
In order to establish a reporter cell assay system tailored to answering some fundamentally 
important questions relating to eCB synthesis and signalling, we must first establish if the 
reporter cells express the enzymes that are necessary for the generation and degradation of 
the two well established eCBs, namely 2-AG and AEA. Probes were generated to a panel of 
eCB genes for use in the QuantiGene multiplex assay system for the purposes of profiling the 
transcriptome of CB1-Tango cells for the expression of eCB related enzyme transcripts, and 
for further downstream validation profiling of successful genetic KO of candidate enzymes.  
The QuantiGene assay system is a relatively simple and effective assay to profile the 
transcripts of a panel of genes in comparison to microarray which may introduce bias and 
false positives (Boelens et al., 2007) and is not as costly and time consuming as RNA 
sequencing (Wang et al., 2009). The customisable design of probes has the advantage of 
detecting catalytic regions of gene transcripts to reflect functional protein expression more 
closely, and this also allows the bead assay system to be used as a verification system for 
genetic deletion of catalytic regions of candidate genes using gene editing technique CRISPR. 
The results are generally easily scalable, particularly if some gene transcripts are on the 
threshold of detectability, whilst still retaining a good noise to background ratio. Finally the 
transcript levels detected corroborate well with already published data from publicly 
available databases. 
The bead assay confirmed previous conclusions reached by members of the lab that the CB1-
Tango cells express both DAGLs and MAGL at protein level, and that DAGL was expressed 
more highly than DAGL from qPCR results. There are low levels of transcripts for CNR1 and 
CNR2 in comparison to the high level of transcripts for DAGL, DAGL and NAPEPLD. This 
might suggest that the cells could be generating eCBs for signalling to other cells in an 
autocrine/paracrine system, or as highlighted before, it could be that the DAGLs and 
NAPEPLD have secondary roles in these cells. For example, the DAGL/MAGL pathway may 
also be responsible for the generation/maintenance of AA levels which can affect bone 
remodelling via the action of prostaglandins generated from AA (Kruger et al., 2010). 
NAPEPLD is not selective for its substrates (Ueda et al., 2013) and other NAEs produced by 
NAPEPLD can have a wide range of functions, including anti-inflammatory and anorexic 
effects (Rahman et al., 2014). Additionally, NAPEPLD-/- mice have also shown reductions in 2-
AG and 2-LG levels, suggesting biosynthesis and metabolic crosstalk between lipid species 





Generally, the CB1-Tango cells have similar transcript expression of the eCB components to 
other human cancer cell lines tested, however the most obvious difference is the 
substantially higher levels of DAGL and DAGL transcripts and comparable levels of 
NAPEPLD transcripts in the CB1-Tango cells, signifying that the U2OS cells are a good host 
line for the potential generation of eCBs. In comparison to relevant RNA from brain tissues 
where eCBs are known to be synthesised and functional in important roles, the CB1-Tango 
cells have comparable levels (or even higher levels in the case of DAGL) transcript levels of 
the eCB synthesising enzymes which would support all three enzymes potentially 
contributing to eCB signalling in the CB1-Tango cells.  
The recently identified CaNAT PLA2G4E was included in our panel of genes along with 
PLA2G4B which was also uncharacterised within the PLA2 family. Of the PLA2G4 family, 
PLA2G4A is the most well characterised as an enzyme involved in hydrolysis membrane 
phospholipids to release AA for the generation of eicosanoids to link oxidative events to 
inflammatory responses (Burke and Dennis, 2009; Niknami et al., 2009; Sun et al., 2010). 
Members of the PLA2G4 family are all cytosolic proteins, display calcium sensitivity (except 
PLA2G4C), and are likely to have similar function and activity to PLA2G4A which can also be 
activated by phosphorylation (Ghosh et al., 2006). PLA2G4D and PLA2G4F are also poorly 
characterised, but expression patterns showed abundancy in skin and reproductive organs 
but was not detected in RNA sequencing of various brain cells (Zhang et al., 2014).  
PLA2G4E was previously thought to be involved in recycling through an clathrin-independent 
endocytic route (Capestrano et al., 2014) and PLA2G4B does not currently have a defined 
function but has been linked to neuronal case studies including schizophrenia (Tao et al., 
2005) autism (Matsunami et al., 2014) and reading disability (Morris et al., 2004). 
Interestingly, tissues may also express a readthrough transcript of an upstream jumonji 
domain containing 7 (JMJD7) gene into the PLA2G4B gene, creating a conjoined JMJD7-
PLA2G4B transcript which may have implications in head and neck squamous cell carcinoma 
survival (Cheng et al., 2017).  
The Human Protein Atlas has documented very high expression of PLA2G4E transcripts in 
skin despite its unidentified function in the skin, which was reflected in our results obtained 
here. However, PLA2G4E transcripts were surprisingly below threshold in cancer cell lines 
and in human cerebellum and hippocampal RNA where NAPEPLD is known to be expressed 
and AEA is synthesised (Di Marzo et al., 1994; Egertova et al., 2008). PLA2G4E was suggested 





transcripts in human brain RNA raises the possibility that other enzymes responsible for the 
generation of NAPE may exist. PLA2G4B transcripts were readily detected in the human brain 
RNA most of the cancer cell lines including the CB1-Tango cells, and have previously been 
documented to be highly expressed in the cerebellum (Pickard et al., 1999), and from the 
Human Protein Atlas it is in abundance in skin and GI tract and is rather ubiquitous in the 
human body (Uhlen et al., 2015). 
The eCB degrading enzymes transcripts are also detected at moderate levels in the CB1-
Tango cells but are expressed much more highly in RNA extracted from cerebellum and 
hippocampus where eCB signalling activity is high and degradation of eCBs is a way of 
regulating retrograde signalling activity (Marrs et al., 2010; Savinainen et al., 2012; Tanimura 
et al., 2012), which might not be necessarily relevant in autocrine/paracrine signalling 
conditions. The eCB degrading enzymes are indeed functional in the CB1-Tango cells as 
pharmacological blockade of them with JZL195 results in an increased eCB tone that activates 
the CB1 receptor. The CB1-Tango cells therefore are a good cell line to study the regulation 
of eCB signalling in the context of autocrine/paracrine eCB signalling that is involved in 












5.3 Results 3B. Can we establish eCB assays? 
 
5.3.1 Results 3B. Introduction 
In the previous section it has been established that the CB1-Tango cells express the necessary 
machinery for the generation and degradation of the two major eCBs 2-AG and AEA. 
Expression levels of the synthesis enzymes DAGLs and NAPEPLD as well as the eCB 
hydrolysing enzymes are present at comparable levels to RNA extracted from areas of the 
brain where eCB signalling is predominant. Interestingly, the CB1-Tango cells actually express 
elevated levels of the DAGLs when compared to other possible host cell lines, which is 
favourable for evoking eCB signalling in the CB1-Tango cells.  
The CB1-Tango assay had been used in previous chapters to study exogenously applied CB1 
ligands, but seeing as they express the components for eCB signalling, it should be feasible 
to adapt the assay to study eCB signalling by stimulating the generation of eCBs with different 
assay conditions and stimuli. Currently, the methods used to monitor eCB signalling rely on 
electrophysiological responses such as DSI/DSE experiments or quantification of eCB levels 
following cell stimulation. Quantification of eCBs using mass spectrometry relies on an 
expensive laboratory set up and specialised equipment which tends to be low throughput 
(Balgoma et al., 2013). As well as this, it is unclear if the measurement of the eCBs from mass 
spectrometry studies reflect the presence of a signalling pool of eCB or a general metabolic 
pool which may contribute to a physiological eCB tone under resting conditions (Howlett et 
al., 2011); this is particularly relevant of AEA which has been suggested to be present in 
intracellular stores prior to signalling (Maccarrone et al., 2010). Our aim was therefore to 
adapt the CB1-Tango assay to more easily detect eCB-dependent CB1 activation which would 
furnish us with a simple cellular assay amenable from moderate to high throughput studies.  
The use of MAGL, FAAH and ABHD6 inhibitor JZL195 in the CB1-Tango assay highlighted the 
presence of at least a modest eCB tone, which is constitutively generated but not signalling 
at the CB1 receptor under normal conditions due to the gate keeping activity of the eCB 
hydrolysing enzymes. Importantly, the modest tone revealed by JZL195 is seen under 
conditions where there is no obvious eCB drive. The primary enzymes which can degrade 2-
AG and/or AEA are MAGL (Dinh et al., 2002; Makara et al., 2005) and FAAH (Giang and 
Cravatt, 1997; Cravatt et al., 2001) but these enzymes may have a degree of crossover 





acylethanolamines (Cravatt et al., 1996; Long et al., 2009a). ABHD6 and ABHD12 can also 
hydrolyse 2-AG but are responsible for only around 15% of 2-AG hydrolysis and ABHD12 is 
not currently recognised as a bona fide eCB component (Blankman et al., 2007; Savinainen 
et al., 2012). JZL195 has been shown to block MAGL, FAAH and ABHD6 but the study did not 
mention ABHD12 (Long et al., 2009a), nonetheless JZL195 can reveal a significant eCB tone 
by inhibiting eCB degradation; however it would be difficult to draw any conclusion as to the 
nature of the responsible eCBs.  
Several stimuli can evoke eCB signalling in neuronal cells, including elevated calcium levels 
(Di Marzo et al., 1994; Stella et al., 1997), activation of post synaptic GPCRs (Jung et al., 2007) 
and activation of PKA and PKC (Rosenberger et al., 2007; Vellani et al., 2008). Calcium 
elevation in neurons has long been shown to stimulate the release of the established eCBs 
2-AG and AEA (Di Marzo et al., 1994; Stella et al., 1997). In mouse neuroblastoma (N18TG2) 
cells, 2-AG was released into cell culture media following addition of the calcium ionophore 
ionomycin in a concentration dependent manner which is sensitive to the presence of EDTA 
(Bisogno et al., 1997). In the context of retrograde signalling, activation of post-synaptic 
glutamate receptors leads to increases in intracellular calcium and causes 2-AG synthesis via 
the activity of DAGL (reviewed in Kano, 2014).  
However, how elevated calcium levels can lead to 2-AG synthesis via DAGL remains unclear 
as the DAGLs do not show direct calcium sensitivity (Farooqui et al., 1984; Moriyama et al., 
1999). The current consensus is there are additional steps subsequent to an increase in 
calcium that are required for full eCB mobilisation. (Reisenberg et al., 2012; Kano, 2014; 
Ohno-Shosaku and Kano, 2014). It has been hypothesised that the activation of kinases may 
lead to the phosphorylation of DAGLs causing its activation and stimulating 2-AG synthesis 
(Reisenberg et al., 2012). Indeed, it has been reported that activation of PKA and PKC leads 
to the synthesis of 2-AG (Rosenberger et al., 2007; Vellani et al., 2008) and both PKA and PKC 
can be activated by an elevation in calcium (Steinberg, 2008; Dunn et al., 2009).  
The generation of AEA can also be stimulated by calcium and PKA and PKC. AEA is formed 
and released from cultured brain neurones in a calcium-dependent manner using ionomycin 
(Di Marzo et al., 1994) and the presence of extracellular calcium is necessary to generate AEA 
as release of intracellular calcium alone does not promote AEA synthesis (Placzek et al., 
2008). However, this is complicated by the fact that calcium has many direct as well as 
indirect effects in cells that include the release of other monoacylglycerols (Kondo et al., 





al., 2002), noladin ether (Hanus et al., 2001; Fezza et al., 2002) and others, although the full 
details on the synthesis of these lipids have yet to be elucidated. Therefore, it is likely that 
other levels of regulation exist to activate AEA synthesis. 
Activation of PKA and PKC in HEK-293 cells DRG neurones can also increase the levels of AEA 
which is unaffected by the presence of a calcium chelator, suggesting the presence of a 
calcium-insensitive synthesis pathway of AEA (van der Stelt and Di Marzo, 2005a; Vellani et 
al., 2008). The activity of CaNAT can be potentiated by PKA activation, leading to the 
increased synthesis of AEA, however CaNAT requires calcium for its activity and is not 
reported to be directly sensitive to PKA phosphorylation in the absence of calcium (Cadas et 
al., 1997). Thus, the target of PKA and PKC phosphorylation in the calcium-insensitive 
generation of AEA is currently unknown.  
As the CB1-Tango cells are a non-neuronal cell line, it is not clear how the synthesis of eCBs 
are stimulated and regulated, and whether the same type of stimulation that neuronal cells 
experience could also elicit eCB signalling in the CB1-Tango cells. As the U2OS cells are of a 
bone origin (Ponten and Saksela, 1967), it is likely that the high levels of calcium in cancellous 
bone matrix may have a role in the generation of eCBs. Indeed, 2-AG and AEA are both found 
in levels comparable to brain levels in cancellous bone tissue and are involved in bone 
maintenance (Bab et al., 2008; Tam et al., 2008; Maccarrone et al., 2015). The rapid 
generation of eCB signalling in synapses and the slower long-term generation of eCB in 
peripheral systems like in cancellous bone differs through environmental conditions as a way 
of regulating of eCB synthesis. We adapted the CB1-Tango assay to report on both rapid 
increases in calcium induced by ionomycin akin to neuronal signalling and through passive 
elevated extracellular calcium found in bone matrix to determine if eCB signalling can be 
stimulated in one cell line using different conditions.  
In this chapter I report on the use of three distinct stimuli to elicit a robust eCB response 
from the CB1-Tango cells. To establish which eCB pathway is dominant in the production of 
the eCB response, we utilised pharmacological tools to establish whether eCB signalling in 
the cells is likely to be DAGL dependent or due to the production of AEA or other possible 
eCBs. As there are currently no pharmacological tools to target AEA synthesis, it is not 
possible to pharmacologically isolate AEA synthesis from the overall eCB tone. Therefore, 
genetic intervention is considered to complement the pharmacological approach to test the 





5.3.2 Results 3B. Results 
The CB1-Tango assay is functional in a more physiological medium  
It has been highlighted that the cells’ own endogenous eCB production is active in the CB1-
Tango cells, but the assay requires the cells to be starved for 24 hours in the presence of 
serum free and calcium free Freestyle media, thus the background activity of eCB production 
is muted to reduce background noise. The assay was originally developed for the purposes 
of drug discovery of agonists and antagonists to the CB1 receptor so would not necessarily 
contain any factors needed for the synthesis of eCBs in the cells. The manufacturers do not 
fully disclose the contents of the media except confirming that it is calcium and serum free.  
Therefore, to fully assess whether we can stimulate robust eCB signalling in these CB1-Tango 
cells, preliminary tests in the lab determined that the cells were healthy and viable over a 48 
hour period when cultured in 0.5% FBS in McCoy’s assay media. This media was selected as 
its full contents are known and we found a good signal to noise ratio in the standard reporter 
cell assay. This media is modified to a reduced serum content of 0.5% from 10% to reduce 
metabolic processes in the cells and without antibiotics to reduce stress on the cells. As 
McCoy’s media contains around 1mM calcium, it allows for paradigms where the eCB system 
might be activated by the influx of extracellular calcium into the cells.  
To test that the CB1-Tango assay system is functional in the McCoy’s assay media, an ACEA 
concentration response curve in the presence of AM251 was carried out similarly to previous 
experiments. CB1-Tango cells were plated in 100l of McCoy’s assay media for 24 hours. A 
range of ACEA concentrations were added to the cells in the presence and absence of AM251 
for 4 hours before beta-lactamase substrate was added for 90 minutes and read on the 
Flexstation. A representative experiment is graphed in Figure 5.3.1. ACEA elicited a CB1 
dependent response at all tested concentrations (0.008 – 5M), with statistically significant 
levels detected at the low concentration of 0.008M. At 5M, the response reached 265.3% 
± 5.4% of control levels, which is of a similar magnitude to the maximal CB1 activation levels 
detected in Freestyle media (259.2% ± 2.5% of control). Despite not reaching a plateau at 
5M ACEA in our representative assay, it was used at that concentration for the remaining 
experiments as a positive control. AM251 on its own in this representative experiment was 
not statistically significantly different to the control in the absence of AM251 (p>0.05), 
indicating little if any basal eCB tone in McCoy’s assay medium despite the presence of 0.5% 





conclude that the assay can be performed in modified tissue culture media, and that the cells 
remain highly sensitive to ACEA. 
 
 
Figure 5.3.1. Tango assay responses to ACEA and AM251 are similar in McCoy’s media 
supplemented with 0.5% FBS 
CB1-Tango cells were seeded 30,000 cells per well in McCoy’s media supplemented with 
0.5% FBS for 24 hours in clear bottom black plates. CB1 response was established by adding 
ACEA (5M top concentration, 1:5 serial dilutions) in the absence and presence of AM251 
used in molar excess (10M). Drug compounds were left for 4 hours before green and blue 
fluorescence detection of -lactamase reporter gene was measured using a FRET-enabled 
substrate. Fluorescence ratios between green and blue channels were calculated and values 
were normalised to control well conditions (defined as 100) as % of control. Graph shows 
means and bars represent SEMs of 8 replicates from a single representative assay. Statistical 
significance of ACEA responses and ACEA responses in the presence of AM251 compared to 
the control in the absence of ACEA were established with One Way ANOVA. 





Detection of eCB tone with JZL195 in Freestyle and 0.5% FBS McCoy’s assay 
medium 
The McCoy’s assay medium is a more physiological medium for the CB1-Tango assay and the 
effects of ACEA and AM251 similarly elicit CB1 responses as in Freestyle media. There is no 
significant eCB tone in this assay media as treatment with AM251 has no significant effect 
on its own (Figure 5.3.1). This is comparable to Freestyle media where responses in cells to 
the presence of AM251 are not statistically different to control responses across several 
experiments (Figure 5.3.2). Likewise, in McCoy’s assay media, there was no statistically 
significant difference between control and AM251 treated cells across experiments as shown 
in Figure 5.3.2, suggesting no significant eCB tone in both media.  
The addition of JZL195 in previous experiments in Freestyle media revealed the presence of 
an eCB tone. When pooled across experiments, AM251 reduces the response in Freestyle 
media to around 15% below control levels in the presence of JZL195 (86.3% ± 2.40% of 
control, Figure 5.3.3). This eCB tone is also revealed in McCoy’s media, in the presence of 
JZL195 a significant eCB tone is revealed by AM251 across independent experiments (Figure 
5.3.3). The eCB tone in McCoy’s media is of a similar magnitude to that in Freestyle media 
(81.8% ± 2.03% of control), signifying the cells in 0.5% FBS McCoy’s media are capable of 
generating similarly low levels of eCBs in comparison to Freestyle media conditions, but 









Figure 5.3.2. CB1-Tango cells lack basal eCB tone in Freestyle and McCoy’s media in control 
conditions 
30,000 CB1-Tango cells were plated in Freestyle media or McCoy’s medium supplemented 
with 0.5% FBS and maintained for 24 hours. Half the cells were treated for a total of 4 hours 
with AM251 (10M) diluted in the same medium. CB1 activation was then measured by the 
-lactamase assay, as described previously and the fluorescence ratio between green and 
blue channels was calculated. Data was normalised to the control wells without the presence 
of any drugs (set to 100) as % of control. The graph presented shows means and bars 
represent SEMs of pooled independent experiments (number of experiments indicated on 
the graph) with 8 replicates in each experiment. Significance between control and AM251 
was calculated using Student’s T-test. 






Figure 5.3.3. Basal eCB tone in McCoy’s and Freestyle media is revealed in the presence of 
JZL195 
30,000 CB1-Tango cells were plated in Freestyle media or McCoy’s medium supplemented 
with 0.5% FBS and maintained for 24 hours. Cells were treated for a total of 4 hours in the 
presence or absence of AM251 (FAC 10M) with 100nM JZL195 present in all wells. CB1 
activation was then measured by the -lactamase assay, as described previously. Data was 
normalised to control wells with JZL195 present (set to 100) as % of control. The graph 
presented represents the mean and bars represent the SEMs of 8 pooled independent 
experiments, 8 replicates in each individual experiment. Significance between groups was 
calculated using Student’s T-test, as indicated below. 






Calcium ionophore ionomycin elicits an eCB response that is partially DAGL 
dependent 
Calcium has been documented to be able to stimulate release of both 2-AG and AEA, and 
calcium ionophore ionomycin has been used previously to elicit the synthesis of these eCBs 
(Di Marzo et al., 1994; Bisogno et al., 1997). The presence of calcium in McCoy’s assay media 
allows us to be able to increase the concentration of intracellular calcium with ionomycin, 
similarly to physiological conditions i.e. in neuronal cells. We therefore tested the CB1-Tango 
cells in McCoy’s media with ionomycin, to see if we could elicit an eCB-dependent CB1 
response. 
The CB1-Tango cells were plated in McCoy’s assay medium and treated with a range of 
concentrations of ionomycin (FAC 0.5 – 4M) in the presence or absence of AM251 for 4 
hours as described in methods. A clear concentration-dependent increase in CB1 response 
was measured at all concentrations, reaching statistically significance at 2M ionomycin. The 
responses are largely blocked by 10M AM251 at an ionomycin concentration of up to 2M. 
However, at the highest concentrations of ionomycin (4M), AM251 does not fully 
antagonise the response to baseline levels and there is still a significant response detected, 
perhaps indicating a non-specific component within the response (Figure 5.3.4).  
When pooled from a number of independent experiments, the CB1 response obtained at 
4M ionomycin (242.7% ± 14.0% of control) is comparable to the maximal ACEA response in 
these cells (254.7% ± 12.0% of control) (Figure 5.3.5), indicating that ionomycin can elicit 
robust CB1 activation via eCB signalling. AM251 substantially (~75%) but not completely 
blocked the ionomycin response at 4M (135.0% ± 6.5% of control), this is likely due to a 
non-specific component at the high concentration of ionomycin as it is not mediated through 
CB1 activation. Thus, for further experiments, to mitigate against the presence of the non-
specific component, ionomycin was generally used at 2M which gives a clearer window of 








Figure 5.3.4. Ionomycin treatment activates CB1 on CB1-Tango cells  
30,000 CB1-Tango cells were plated in clear bottom black plates and maintained in 0.5% FBS 
McCoy’s medium for 24 hours. Ionomycin was diluted in the same medium (FAC 4M top 
concentration, diluted 1:2) and cells were treated with the indicated concentrations of 
ionomycin in the presence or absence of AM251 (FAC 10M) for 4 hours. CB1 activation was 
then measured by the -lactamase assay as described in the methods. Results were 
normalised to the control wells (set to 100) as % of control. Graph shows means and bars 
represent SEMs of pooled independent experiments (n indicated on graph) with 8 replicates 
in each individual experiment. Statistical significance of ionomycin responses in the absence 
of AM251 compared to its control, and ionomycin responses in the presence of AM251 
compared to AM251 only control were established with One Way ANOVA, as indicated 
below. 









Figure 5.3.5. Ionomycin-induced CB1 activation is comparable to full activation of CB1 by 
ACEA 
30,000 CB1-Tango cells were plated in 0.5% FBS McCoy’s medium on clear bottom black 
plates for 24 hours. Cells were treated with either ACEA (FAC 5M) or ionomycin (FAC 4M) 
in the presence or absence of AM251 (FAC 10M) for 4 hours. CB1 activation was then 
measured by the -lactamase assay as described in the methods. Results were normalised 
to the control CB1 response (set as 100) and expressed % of control. Graph shows means 
and bars represent SEMs of pooled independent experiments (n indicated on the graph, 8 
replicates in each individual experiment). Significance between the two agonists, and 
significance between agonist and AM251 was established using the Two Way ANOVA, as 
indicated below. 






The above experiments indicate that ionomycin can elicit eCB signalling from the CB1-Tango 
cells, however the response is likely to be limited by MAGL, FAAH and ABHD6. To test this, 
the ionomycin concentration response was repeated in the presence of JZL195.  
To this end, the CB1-Tango cells were plated in McCoy’s assay medium and treated with a 
range of concentrations of ionomycin (FAC 0.25 – 4M) in the presence or absence of AM251 
for 4 hours as described in methods. 100nM JZL195 was included in all the wells and graphed 
in Figure 5.3.6. On its own AM251 in the presence of JZL195 inhibited the control response 
significantly to 81.6% ± 2.6% of control, as expected and in line with the results from Figure 
5.3.3. A clear concentration-dependent increase in CB1 response was measured at all 
concentrations of ionomycin, reaching statistical significance at 1M ionomycin and is 
maximally active at 2M (247.7% ± 20.6% of control). The responses are largely (~90%) 
blocked by 10M AM251. Previous results from the lab have shown that inhibition of MAGL 
and FAAH separately do not potentiate the ionomycin induced response (thesis of Rachel 
Lane Markwick, 2015), therefore the ionomycin response can be potentiated by the 
inhibition of MAGL, FAAH and ABHD6 together, indicative of eCB signalling.  
As the levels of both 2-AG and AEA are likely to be stimulated by elevated levels of calcium 
in the cells, it was of interest to determine which pathway may be responsible for the 
response. At this time, no AEA pathway inhibitors are available and the complexity of the 
AEA pathway hinders the use of pharmacological tools to dissect the pathway. We therefore 
considered the pharmacological blockade of the DAGL pathway with DAGL inhibitors which 
were used previously. THL inhibits DAGL but can also inhibit a wide range of lipases 
(Borgstrom, 1988), we therefore in addition tested two more specific DAGL inhibitors KT109 
and KT172 which reportedly have high selectivity for the DAGLs (Hsu et al., 2012). The 
compounds were used at concentrations which are likely to fully block both DAGL and 
DAGL. Using these two specific DAGL inhibitors should confirm if part of the ionomycin 
induced CB1 response is DAGL dependent.  
CB1-Tango cells were plated in McCoy’s 0.5% FCS media and starved for 24 hours before 
treating with 20M THL, 2M KT109 and 2M KT172 in the presence and absence of 2M 
ionomycin (Figure 5.3.7A). These inhibitors alone did not significantly affect base level 
signalling in the absence of ionomycin, reconfirming the effectiveness of the McCoy’s assay 
medium in starving the cells. 2M ionomycin elicited a response that is comparable to 
previous results in Figure 5.3.4 and in the presence of DAGL inhibitors, there was no 





This result was unexpected as the DAGLs are highly expressed in the CB1-Tango cells and it 




Figure 5.3.6. Ionomycin induced CB1-Tango response is potentiated by JZL195 
30,000 CB1-Tango cells were seeded and maintained in 0.5% FBS McCoy’s assay media for 
24 hours. The cells were treated with varying concentrations of ionomycin (4M top 
concentration, 1:2 dilution) in the presence and absence of AM251 (FAC 10M), 100nM 
JZL195 was included to prevent eCB hydrolysis. CB1 activation was then measured by the -
lactamase assay as described in the methods. Ratios were normalised to the control wells 
with JZL195 present (set to 100) as % of control. Graph shows means and bars represent 
SEMs of pooled independent experiments (n indicated on the graph) with 8 replicates in each 
individual experiment. Significance over the control was established using One-way ANOVA, 
as indicated below. 





We next wanted to test if the DAGL activity is required for the small basal eCB tone that is 
revealed when JZL195 is present. To this end we tested the effect of the KT compounds and 
THL on the cells in the presence of JZL195. In the presence of JZL195, but absence of 
ionomycin (Figure 5.3.8A) a slight but significant inhibition of the basal tone by THL (84.61% 
± 4.61% of control) was seen. Whilst KT172 has a small significance relative to control and 
KT109 does not, the effect of the two are not significantly different from each other. The KT 
compounds had at best a 5% inhibition, which suggests that if DAGL is contributing to the 
JZL195 tone it does so in a very minor manner; the significant effect of THL (~15% inhibition) 
is similar to the effect seen with AM251 and might be explained by the fact that it can inhibit 
several serine hydrolases, or it might be a non-specific effect.  
Interestingly in the presence JZL195, the ionomycin response is substantially potentiated 
(from 177.4% ± 12.1% in control to 258.8% ± 12.6% with JZL195) and in this circumstance 
KT109, KT172 and THL all inhibited the 2M ionomycin response similarly by around 50% of 
the full response, indicating that around half of the full ionomycin response is mediated by 
the DAGLs but this was not revealed previously due to the rapid activity of the eCB 
degradation enzymes (Figure 5.3.8B). Therefore, in the presence of JZL195, the ionomycin 























Figure 5.3.7. Ionomycin induced CB1-Tango response remains in the presence of DAGL 
inhibitors in CB1-Tango cells 
Tango assay plate was set up with 30,000 CB1-Tango cells maintained in 0.5% FBS McCoy’s 
assay media for 24 hours. The cells were treated with DAGL inhibitors KT109 (FAC 2M), 
KT172 (FAC 2M) or THL (FAC 20M) in the (A) absence or (B) presence of ionomycin (FAC 
2M) for 4 hours. CB1 activation was then measured by the -lactamase assay as described 
in the methods. Results were normalised to control response (set as 100) as % of control. 
Graphs show mean and bars represent SEMs across pooled independent experiments (n 
indicated on graph) with 8 replicates in each individual experiment. Significance across 
groups was calculated using One Way ANOVA, as indicated below. 






















Figure 5.3.8. JZL195 reveals DAGL dependent component in ionomycin-induced CB1-Tango 
response in CB1-Tango cells 
30,000 CB1-Tango cells were plated into 96 well assay plate and maintained in McCoy’s 
medium containing 0.5% FBS for 24 hours. The cells were then treated with DAGL inhibitors 
KT109 (FAC 500nM), KT172 (FAC 500nM) or THL (FAC 10M) in the (A) absence or (B) 
presence of ionomycin (FAC 2M) for 4 hours. FAC 100nM JZL195 was included in the wells. 
CB1 activation was then measured by the -lactamase assay as described in the methods. 
Results were normalised to control wells with JZL195 present (set as 100) as % of control. 
Graphs show mean and bars represent SEMs of pooled independent experiments with 8 
replicates in each individual experiment. Significance was established against control or 
ionomycin control using One Way ANOVA, as indicated below. 
















Increased calcium levels in Freestyle media generates a substantial eCB tone  
The physiological level of extracellular calcium is in the low mM range, and a high amount of 
extracellular calcium in cancellous bone may have a role in the maintenance of an eCB tone 
for bone growth and remodelling (Bab et al., 2008; Tam et al., 2008). The Freestyle media 
recommended for the standard CB1-Tango cell assay is serum and calcium free, we reasoned 
that the simple addition of calcium into the cell media for the duration of the assay might 
stimulate a significant basal eCB tone.  
Currently, overnight starvation in Freestyle media followed by a 4 hour drug treatment with 
JZL195 reveals an eCB tone that is around 15% of the control which suggests a relatively low 
basal turnover of the eCBs. The recommended 4 hour window for the activation of the CB1 
receptor is sufficient for drug discovery efforts which aim to act on the CB1 receptor directly, 
but the generation of eCBs for signalling at the CB1 receptor is likely to be much slower and 
exceed the 4 hour assay window, particularly if the cells have been starved beforehand to 
reduce eCB generation to a minimum. We adapted the assay by removing the overnight 
starvation period and adopted a 24 hour (rather than a 4 hour) assay period to determine if 
this would result in a more substantial eCB tone.  
First it was important to ensure the CB1-Tango assay is properly functional in this novel 
Freestyle condition using the CB1 agonist ACEA. The CB1-Tango cells were cultured and 
plated in Freestyle media as described in methods, however drug treatments were added 
immediately after the cells were plated. 100nM JZL195 was included in all wells and 
experiments to prevent the degradation of any eCBs synthesised during the assay period. 
AM251 (FAC 2.5M) was included as a very important control in all experiments to block all 
signalling at the CB1 level and thereby reveal a key basal control value. In the following set 
of experiments all results were expressed as a % of this basal control value (set to 100). The 
plate was then incubated for 24 hours in 37oC; after which the -lactamase substrate was 
added for 90 minutes and responses were measured in the Flexstation. 
The cells were also treated with a maximally active concentration of ACEA (FAC 5M) in the 
presence or absence of AM251 (FAC 2.5M). A very substantial ACEA response was apparent 
under the new assay condition (477.1% ± 27.7% of the basal AM251 control) (Figure 5.3.9). 
This ACEA response is much more robust after 24 hour drug treatment in comparison to 4 
hour treatments. AM251 was also able to largely block the ACEA response back to close to 
baseline value (142.8% ± 10.9% of AM251 control) but a small amount of CB1 activation was 





Next, the effect of the addition of calcium into Freestyle media for the duration of the 24 
hour incubation period on this eCB tone was tested. Across separate experiments, the CB1-
Tango cells were plated in Freestyle media supplemented with 100nM JZL195 with or 
without 2mM CaCl2 and with and without AM251 (FAC 2.5M). After 24hrs the substrate was 
added to determine the level of CB1 activation, with the data normalised to the basal AM251 
control value and is shown in Figure 5.3.10. Even in the absence of added calcium, the 
presence of AM251 revealed a substantial eCB tone that was 199.8% ± 20.0% of basal 
control. This was substantially larger than the equivalent tone seen in the 4 hour assay that 
followed a starvation period (116.6% ± 3.37% of the AM251 basal control (Figure 3 data 
normalised to the basal AM251 control)). The presence of 2mM calcium enhanced the eCB 
tone significantly by around 50% compared to the same conditions in the absence of calcium 
(Figure 5.3.10). This enhancement of the eCB tone suggests that the addition of extracellular 
calcium can affect the production of eCBs, likely through the increased basal activity of the 
eCB synthesising enzymes. For this reason, the following experiments include the addition of 







Figure 5.3.9. ACEA still elicits a robust CB1 dependent response in No Starve Freestyle 
conditions 
CB1-Tango cells were plated in 96 well plates at a density of 30,000 per well in Freestyle 
media supplemented with FAC 100nM JZL195. Immediately after plating, the cells were 
treated with ACEA (FAC 5M) in the presence and absence of AM251 (FAC 2.5M) diluted in 
the same medium and incubated for 24 hours. Control wells contained media only and no 
AM251. CB1 activation was then measured by the -lactamase assay as per manufacturer’s 
protocol. The data collected were normalised to wells containing AM251 only (set at 100) as 
% of AM251 control. The graph presented represents the mean and bars represent the SEM 
of n = 3 independent experiments, 8 replicates in each individual experiment. Significance 
was established using Student’s T-test, as indicated below.  
 






Figure 5.3.10. Reducing starvation time in Freestyle media and overnight treatment with 
JZL195 and calcium enhances eCB tone 
CB1-Tango cells were plated in 96 well plates at a density of 30,000 per well in Freestyle 
media supplemented with FAC 100nM JZL195 in the absence or presence of 2mM CaCl2. Cells 
were treated with AM251 (2.5M) diluted in the same medium as a control immediately 
after plating and incubated for 24 hours. Control wells contained media only and no AM251. 
CB1 activation was then measured by the -lactamase assay as per manufacturer’s protocol. 
The data collected were normalised to wells containing AM251 (set at 100) as % of AM251 
control. The graph presented represents the mean and bars represent the SEM of pooled 
independent experiments (n indicated on graph), 8 replicates in each individual experiment. 
Significance was established using Student’s T-test, as indicated below.  
 










PKA activation by forskolin generates an eCB dependent response 
Likely targets of calcium elevation in both rapid and long term eCB signalling are kinases 
which can regulate activity of other enzymes by phosphorylation. Based on the hypothesis 
that the DAGLs and the CaNAT are likely to be the targets of activation by PKA and/or PKC, 
we reasoned that direct activation of PKA and PKC in the CB1-Tango cells would activate eCB 
signalling which would be measurable in the CB1-Tango cells.  
Forskolin (FSK) has been reported to activate adenylyl cyclase which increases intracellular 
levels of cAMP leading to the activation of PKA (Seamon and Daly, 1986). CB1-Tango cells 
were plated in Freestyle media supplemented with 2mM calcium and 100nM JZL195 as 
described previously. Immediately after plating, the cells were treated with FSK at the final 
assay concentration of 10M, in the presence and absence of AM251 (FAC 2.5M). The 
responses were normalised to the basal control value (Figure 5.3.11). FSK elicited a robust 
CB1 response (656.8% ± 40.1% of AM251 control) which was essentially fully inhibited by the 
presence of AM251 (138.6% ± 3.9% of AM251 control), indicating CB1-dependent signalling. 
The FSK response is of a similar magnitude to a maximally active concentration of ACEA 
tested in the same assay conditions (612.8% ± 30.6% of AM251 control, data not shown).  
PKC activation by PMA generates an eCB dependent response 
Similarly to PKA, PKC has also been suggested to be able to activate the synthesis of 2-AG 
and AEA (Vellani et al., 2008). Based on publicly available databases from mass spectrometry 
studies DAGLs contain proposed PKC phosphorylation sites that are located in/around the 
regulatory loop (Reisenberg et al., 2012). AEA levels can also be enhanced by PKC activation 
in both HEK-293 cells and sensory neurons but by what mechanism this occurs has not been 
investigated (van der Stelt and Di Marzo, 2005a). Phorbol 12-myristate 13-acetate (PMA), is 
a potent tumour promoter and an activator of PKC due to its structural similarity to DAG 
(Castagna et al., 1982). Like FSK, we hypothesised that PMA could induce eCB signalling in 
the CB1-Tango cells by activation of PKC that may activate DAGLs and/or CaNAT.  
Cells were plated as above in Freestyle media (with 2mM calcium and JZL195) with PMA then 
added for 24 hours (FAC 25nM) in the presence and absence of AM251 with the results 
summarised in (Figure 5.3.12). PMA was able to elicit a CB1 dependent response reaching a 
mean of 383.2% ± 7.7% of AM251 control; while this is a considerable response, it is much 
lower than the maximal activity shown by ACEA and FSK. The PMA response was mostly 
blocked by AM251 but did show a small residual component, which could not be inhibited 






Figure 5.3.11. PKA activation stimulates an eCB response in the CB1-Tango cells 
CB1-Tango cells were plated in 96 well plates at a density of 30,000 per well in Freestyle 
media supplemented with FAC 100nM JZL195 in the presence of 2mM CaCl2. Immediately 
after plating, the cells were treated with FSK (FAC 10M) in the presence and absence of 
AM251 (FAC 2.5M) diluted in the same medium and incubated for 24 hours. CB1 activation 
was then measured by the -lactamase assay as per manufacturer’s protocol. The data 
collected were normalised to wells containing AM251 (set at 100) as % of AM251 control. 
The graph presented represents the mean and bars represent the SEM of 3 independent 
experiments, 8 replicates in each individual experiment. Significance was established using 
Student’s T-test, as indicated below.  
 






Figure 5.3.12. PKC activation stimulates an eCB response in the CB1-Tango cells 
CB1-Tango cells were plated in 96 well plates at a density of 30,000 per well in Freestyle 
media supplemented with FAC 100nM JZL195 in the presence of 2mM CaCl2. Immediately 
after plating, the cells were treated with PMA (FAC 25nM) in the presence and absence of 
AM251 (FAC 2.5M) diluted in the same medium and incubated for 24 hours. CB1 activation 
was then measured by the -lactamase assay as per manufacturer’s protocol. The data 
collected were normalised to wells containing AM251 (set at 100) as % of AM251 control. 
The graph represents the mean and bars represent the SEM of 4 independent experiments, 
8 replicates in each individual experiment. Significance was established using Student’s T-
test, as indicated below.  
 





5.3.3 Results 3B. Summary & Conclusions 
The aim of this section was to determine if the CB1-Tango assay can be adapted with 
different assay conditions and stimuli to maximise the eCB response from the CB1-Tango 
cells. Various conditions have been tested in our lab previously and have successfully evoked 
eCB signalling in many of the conditions, for example various media and growth 
supplements, starvation times and assay times (unpublished observations). Here I have 
reported the adaptation of the CB1-Tango assay in two ways to generate eCB signalling: (1) 
in a modified 0.5% FBS McCoy’s assay medium which allows for rapid intracellular increases 
of calcium in the cells by ionomycin, and (2) in Freestyle media supplemented with 2mM 
calcium and JZL195 with no starvation period and a 24 hour drug treatment to promote 
accumulation of eCBs over the drug treatment period. These two paradigms allow the use of 
pharmacological tools to evoke eCB signalling in conditions akin to neuronal signalling and in 
bone matrix. 
In McCoy’s assay media, no eCB tone is present in control conditions, indicating the assay 
media is sufficient to reduce basal activity of the cells. A small eCB tone can be revealed by 
JZL195 in McCoy’s media, similarly to standard Freestyle media, indicating a low turnover of 
eCBs is present. A more enhanced eCB tone can be generated in No starve Freestyle media 
in an overnight assay where the breakdown of eCBs are prevented. The addition of 
extracellular calcium into No Starve Freestyle media alone was sufficient to significantly 
enhance the basal production of the eCBs, suggesting that extracellular calcium in cancellous 
bone (and indeed other tissues) may indeed affect basal eCB generation (Idris and Ralston, 
2012). 
The presence of physiologically relevant levels of calcium in McCoy’s assay media allowed us 
to utilise ionomycin as a rapid elevator of intracellular calcium for the activation of eCB 
synthesis. Ionomycin increases calcium flux across the plasma membrane but also depletes 
intracellular calcium stores for a rapid increase in intracellular calcium (Kao et al., 1990). This 
rapid increase in calcium caused a concentration-dependent CB1 response that could be 
inhibited by AM251 and was enhanced by JZL195. It is noteworthy that when used at 4M 
in the absence of JZL195, a component of the ionomycin response was not inhibited by 10M 
AM251. This might reflect a non-specific activation of the pathway, perhaps by calcium 
activated proteases releasing the signalling moiety from the CB1 receptor. However, it might 





fully block an eCB response. Unfortunately, this could not simply be tested by increasing 
AM251 concentration as a precipitate was formed in the media at higher concentrations.  
The use of DAGL inhibitors showed surprisingly that the ionomycin response is independent 
of DAGL activity, despite the prominent levels of DAGL transcripts detected in the cells. Only 
in the presence of JZL195 is the response revealed to be only partially DAGL mediated by 
various DAGL inhibitors. Similar results have been obtained previously by other members of 
the lab using THL and another reported DAGL inhibitor OMDM-188 (an analogue of THL) 
(Ortar et al., 2008). Both THL and OMDM-188 inhibited a 2M ionomycin response in the 
presence of JZL195 by ~50% (thesis of Rachel Lane Markwick, 2015), consistent with the 
results of independent experiments reported here. The remaining response is likely to be 
attributed to other eCBs produced and suggests the activity of ABHD6 and MAGL are likely 
to limit 2-AG signalling.  
The mechanism for the elevation of calcium evoking eCB signalling is unclear; it is likely that 
calcium can stimulate the production of NAPE and subsequently AEA by activation of CaNAT 
directly (Cadas et al., 1997), but for the generation of 2-AG there are likely to be additional 
steps following on from calcium elevation (Reisenberg et al., 2012; Kano, 2014). A study has 
shown calcium can modulate DAGL activity via calcium/calmodulin-dependent protein 
kinase IIa (CAMKIIa) activity (Shonesy et al., 2013). Activated CAMKIIa has been shown in 
vitro to interact with the C-terminal tail of DAGL, can phosphorylate two serine residues 
and reduce DAGL activity by ~40%. Genetic deletion of CAMKIIa in mice models increased 
DAGL activity in striatal glutamatergic synapses leading to increased short term retrograde 
signalling. This suggests that calcium influx can modulate activity of CAMKIIa and 
subsequently DAGL to modulate retrograde synaptic signalling (Shonesy et al., 2013). 
However, the generation of eCB signalling in the CB1-Tango cell line is not likely to be 
mediated through a CAMKIIa dependent mechanism as the influx of calcium in our cell line 
increases the generation of eCBs for signalling rather than reducing the generation of 2-AG 
by inhibiting DAGL activity. The C-terminal tail of DAGL is dispensable for the catalytic 
activity of DAGL (Pedicord et al., 2011), thus the interaction of CAMKIIa and the DAGL tail 
is more likely to modulate activity in post synaptic densities with the aid of other anchoring 
proteins for DAGL recycling (Zhou et al., 2016). As well as this, a key difference between 
DAGL and DAGL is the absence of a long C-terminal tail in DAGL (Reisenberg et al., 2012) 





et al., 2013). This points to the involvement of other calcium-activated moieties in the CB1-
Tango cells for the generation of eCB signalling.  
As the DAGLs do not seem to have direct calcium sensitivity (Farooqui et al., 1984; Moriyama 
et al., 1999; Rosenberger et al., 2007), it has been hypothesised that the DAGLs are regulated 
by phosphorylation, similarly to the structurally-related hormone sensitive lipase (HSL) 
(Lampidonis et al., 2011). Using phosphorylation databases which curate experimentally 
observed phospho-sites identified from published sources, a predicted phosphorylation map 
of the DAGLs were generated (Reisenberg et al., 2012; thesis of Rachel Lane Markwick, 2015). 
Of all the predicted phosphorylation sites, sites which were detected independently more 
than 3 times and were detected in more than one database were included. Using these 
parameters, one site was present on the DAGL regulatory loop, along with several sites on 
the C-terminal tail. The site on the regulatory loop was predicted to be phosphorylated by 
PKC or cdc2. The tail of DAGL seems to be heavily phosphorylated by kinases other than 
CAMKIIa and is likely to play a role in the subtle modulation of DAGL activity and expression; 
in fact DAGL recycling seems to be dependent on PKC activity (Zhou et al., 2016). DAGL 
was also subject to the same analysis and only one site was present which was predicted to 
be phosphorylated by a range of kinases including PKA, PKC and cdc2 (thesis of Rachel Lane 
Markwick, 2015).  
Indeed, aside from calcium, activation of PKA and PKC can also reliably stimulate eCB 
signalling in the CB1-Tango cells in different media conditions. FSK had been used previously 
in the CB1-Tango assay in McCoy’s assay medium for 4 hours (thesis of Rachel Lane 
Markwick, 2015). The results showed that 10M FSK could induce a modest response when 
applied alone (~110% of control) which was potentiated by the presence of JZL195 (~115% 
of control). These responses could be fully inhibited by AM251, indicating CB1-dependency. 
The FSK responses were much more robust when the cells were incubated in the drugs for 
18 hours overnight than for 4 hours (FSK alone = ~137% and FSK + JZL195 = ~196%). 
PMA was also used in McCoy’s assay medium in a 4 hour assay system (thesis of Rachel Lane 
Markwick, 2015). In the absence of JZL195, 25nM PMA had little effect in the CB1-Tango 
assay; a small response was measured (~110% of control) but was not inhibited by AM251, 
indicative of a non-specific effect and could not be taken as an eCB response. In the presence 
of 100nM JZL195, PMA gave a slightly more substantial response (~145% of control) and this 
was fully inhibited by AM251. In overnight assays, the PMA response was much more robust 





CB1 responses evoked by PKA and PKC are much more enhanced and stable in Freestyle 
media in the presence of calcium and JZL195 with no cell starvation time. This might partially 
be due to the increased calcium concentration in the media which enhances basal eCB tone. 
Whilst PKA activation by FSK gives a full eCB response, PKC activation by PMA gave only about 
50% of full CB1 activation. Whilst the responses were originally thought to be DAGL 
dependent, in other similar paradigms tested by members of the lab, THL inhibited about 
half of the FSK response in Freestyle media plus JZL195, but OMDM-188 and KT compounds 
did not significantly inhibit the FSK response (unpublished observations, Emma Williams). 
This result was surprising; THL is likely to have non-specific effects however the lack of 
inhibition by other DAGL inhibitors would suggest the response is indeed largely DAGL 
independent. This may in part be due to low substrate (DAG) availability in Freestyle media 
thus limiting DAGL activity and driving other synthesis pathways, or PKA and PKC activation 
could stimulate the release of more than one eCB. 
It is not clear whether AEA synthesis is regulated by phosphorylation. It is possible that 
activation of PKA and PKC can generate AEA through the activity of CaNAT. CaNAT is the most 
likely candidate to be modulated by phosphorylation as NAPE generation was reported to be 
enhanced by FSK, despite FSK not directly activating CaNAT (Cadas et al., 1996). FSK has been 
shown to be able to generate AEA in the presence of a calcium chelator (Vellani et al., 2008) 
which might point to the involvement of iNAT, but it is unknown whether iNAT is regulated 
by phosphorylation (Jin et al., 2007; Jin et al., 2009). The hydrolysis of NAPE to AEA by 
NAPEPLD is currently considered to be constitutively active and the presence of multiple 
pathways of AEA synthesis is likely to occlude any regulatory step, but it is not ruled out that 
NAPEPLD may be regulated or modulated by phosphorylation. As well as this, the NAPEPLD-
independent generation of AEA relies on multiple enzymes, often consisting of more than 
two reaction steps and the enzymes are likely to have other functional roles; thus, it difficult 
to discern the phosphorylation sensitive enzymes and if they will generate AEA for eCB 
signalling following phosphorylation.  
However, during the development of the assay system, the activity of the DAGL inhibitors 
were tested on the CB1-Tango cells in the No Starve Freestyle conditions to elucidate what 
portion of eCB signalling is attributable to DAGL and other eCBs. Preliminary results tested 
THL, OMDM-188, KT109 and KT172 on the CB1-Tango cells in the presence of a maximally 
active concentration of ACEA. As ACEA maximally activates the CB1 receptor pool directly, 





viability. In most experimental paradigms, the ACEA response was generally not inhibited by 
the DAGL inhibitors. However, in the presence of the 4 DAGL inhibitors in the No Starve 
Freestyle conditions, the ACEA response had a reduction of between 20 – 50% of the full 
ACEA response (results not shown). Some of the DAGL inhibitors also display non-specific 
activity on the AM251 control of the cells, perhaps through a non-specific effect affecting 
the viability of the cells and expression of CB1 receptors. The reason for this effect is 
unknown; the DAGL inhibitors can inhibit other enzymes (Hoover et al., 2008; Ortar et al., 
2008; Hsu et al., 2012) and perhaps the long incubation period with DAGL inhibitors affects 
the overall metabolic activity of the cells. For this reason, the DAGL inhibitors were not used 
to determine the DAGL proportion of eCB signalling in the No Starve Freestyle conditions and 
genetic intervention would be required to perturb the expression of the DAGLs.  
As pharmacological blockade of eCB synthesis is limited in the new No Starve Freestyle 
paradigm and there are currently no pharmacological tools to separate the multiple 
pathways for anandamide synthesis, genetic disruption of key eCB synthesis enzymes would 
be required to further characterise the eCB responses to ionomycin, FSK and PMA, and more 
specifically to determine the absolute requirement for all of the known eCB synthetic 










Chapter 6. Results 4 – Dissection of eCB 




The CB1-Tango cells in the previous chapter have demonstrated inducible eCB signalling in 
two different assay conditions in response to calcium, PKA and PKC activation. Both 2-AG 
and AEA have been shown to be synthesised “on demand” by these stimuli by the proposed 
activation of the respective synthesis enzymes which will be briefly described here. The 
synthesis enzymes that can be activated by these stimuli are likely to be regulated in this 
manner in vivo and thus are the focus of this chapter.  
 
6.1.1 Activation and regulation of the production of 2-AG 
The signalling pathway for 2-AG begins with the generation of DAG by a PLC following cellular 
stimulation in the first step, and subsequent hydrolysis of DAG by DAGL at the sn-1 position 
leading to the release of 2-AG for signalling in the second step (Figure 6.1.1). 2-AG signalling 
is then terminated by the activity of MAGL/ABHD6 to AA and glycerol. As mentioned 
previously, several studies have reported increases in 2-AG signalling in response to a range 
of stimuli (Williams et al., 2003; Di Marzo, 2008a). These increases in 2-AG signalling can 
partially be explained by increased substrate availability due to the associated increase in 
activity of PLCβ/γ, however PLC-independent 2-AG release (CaER) also exists (Hashimotodani 
et al., 2005; Tanimura et al., 2010). This would suggest that the regulation step of 2-AG 
synthesis may not lie in the generation of DAG but rather at the level of 2-AG synthesis by 
the DAGLs. 
Studies of DAGL KO mice have shown that DAGL and DAGL are responsible for the 
production of virtually all 2-AG levels in the brain and other tissues, for example loss of 
DAGL has a dominant impact on brain and loss of DAGL has a dominant impact in the liver 
(Gao et al., 2010; Tanimura et al., 2010). Importantly from these studies, stimulus-induced 
increases in 2-AG are absent in all of the three forms of eCB-mediated retrograde signalling 





signalling (Tanimura et al., 2010). DAGL and DAGL both exhibit distinct contributions to 
the cellular levels of 2-AG and AA, for instance DAGL is primary responsible for CB1 
signalling at the neuronal synapse whilst recent studies have indicated DAGL as a key 
enzyme within the lipid network for the generation of proinflammatory molecules for 
immune responses within macrophages and microglia (Hsu et al., 2012). Importantly, the 
DAGL KO studies also showed the levels of AA to be substantially reduced alongside 2-AG 
reductions (Gao et al., 2010); AA had been thought to be generated largely through the 
activity of PLA2 (Balsinde et al., 2002), however this highlights that the DAGL/MAGL pathway 
may have a bigger role for the generation/regulation of AA levels (Figure 6.1.1). These studies 
highlight the importance of the DAGLs as major regulators of eCB signalling, 2-AG synthesis 
and the AA pool; this would suggest that a level of regulation is needed, however it is unclear 
how the DAGLs are regulated.   
The increased release of 2-AG following calcium elevation suggests that calcium is involved 
the regulation of the production of 2-AG. The DAGLs however, which catalyse the generation 
of 2-AG, do not appear to be directly sensitive to calcium (Farooqui et al., 1984; Moriyama 
et al., 1999). A simple model of explanation would be that increases in calcium levels can 
stimulate 2-AG generation via the DAGL pathway by indirect mechanisms that might involve 
an increased synthesis of substrate via PLC activation and/or the activation of DAGLs via a 
kinase network (Reisenberg et al., 2012). 
In the above context, the DAGLs are structurally similar to HSL which contains a module that 
is regulated through phosphorylation (Lampidonis et al., 2011). The DAGLs have a 
structurally related 50-60 amino acid insert in the catalytic domain, likely to be a regulatory 
loop positioned to restrict access of the substrate to the catalytic site. Various 
phosphorylation sites have been identified within this regulatory loop, suggesting 
conformational changes of the regulatory loop by phosphorylation to be a rate-limiting 
mechanism (Reisenberg et al., 2012). Indeed, DAGL from bovine brain microsomes can be 
directly activated by a cAMP-dependent protein kinase (Rosenberger et al., 2007), and 
activation of PKA and PKC can both increase 2-AG synthesis (Vellani et al., 2008). Both PKA 
and PKC can also be activated by calcium (Steinberg, 2008; Dunn et al., 2009). Our working 
hypothesis therefore is that the DAGLs are regulated by phosphorylation by calcium 
activated kinases with phosphorylation of the regulatory loop resulting in a structural change 
that facilitates substrate access to the catalytic domain, thus the regulation step of 2-AG 






Figure 6.1.1. Simplified schematic of the main biosynthesis and hydrolysis pathways of 
eCBs 2-AG and AEA 
The generation of 2-AG begins with a PLC hydrolysing sn-2-arachidonoyl PIP2 to release DAG 
(Step 1). DAG is then cleaved by sn-1-specific DAGLs (DAGLα and DAGLβ) to release 2-AG 
(Step 2). Finally, MAGL hydrolyses most of the 2-AG in the brain, and ABHD6 also catalyses 
residual 2-AG at the post synaptic compartment (Step 3).  
AEA synthesis starts with the formation of arachidonoyl-containing NAPE using PE and PC 
catalysed by a CaNAT (Step 1). Multiple synthetic pathways of AEA release from NAPE are 
postulated (Step 2). The consensus pathway posits that NAPE is hydrolysed in one step to 
release AEA by NAPEPLD, with secondary pathways containing the action of several enzymes 
including sPLA2 and lysoPLD which can also release AEA from NAPEPLD – explained in more 
detail in Introduction. Finally, FAAH hydrolyses AEA to AA and ethanolamine (Step 3). 
The hypothesised regulatory steps in 2-AG and AEA synthesis are highlighted in a red box. 






6.1.2 Role of NAPEPLD in AEA synthesis 
Whereas we now have a clearer understanding of 2-AG synthesis, the pathways that regulate 
the synthesis of AEA appear to be much more complex. The “model” view of AEA synthesis 
begins with generation of NAPE from PC and PE through a CaNAT enzyme that had until 
recently remained elusive (Ogura et al., 2016). The precursor NAPE is then hydrolysed by 
NAPEPLD in the second step to release AEA (Di Marzo et al., 1994; Liu et al., 2008). Finally, 
AEA is hydrolysed by FAAH to release AA and ethanolamine (Figure 6.1.1).  
However, some studies from NAPEPLD KO mice have shown that AEA levels were reduced 
slightly but not completely depleted in the brain (Leung et al., 2006; Tsuboi et al., 2011; 
Leishman et al., 2016). This highlights the presence of other biochemical pathways 
synthesising AEA from NAPE which are not necessarily NAPEPLD dependent, depicted in 
Figure 6.1.1 (Liu et al., 2006; Simon and Cravatt, 2006). Activation of PKA and PKC with FSK 
and PMA can also increase the levels of AEA in DRG neurones which is unaffected by the 
presence of a calcium chelator (Vellani et al., 2008). NAPEPLD also does not distinguish 
among other NAPEs containing different N-acyl substituents which are present even in 
unstimulated neurones (Ueda et al., 2013), while NAPE containing N-arachidonoyl, the 
precursor to AEA, is low in resting conditions but rapidly increases when neurones are 
exposed to stimuli that elevate intracellular calcium (Di Marzo et al., 1994; Cadas et al., 1996; 
Cadas et al., 1997). The redundancy of NAPEPLD for AEA synthesis and the presence of 
calcium-dependent and -independent pathways indicate that the regulatory step in the 
pathway of AEA synthesis does not lie with NAPEPLD but rather with the generation of N-
arachidonoyl containing NAPE.  
6.1.3 Identity of the putative CaNAT 
The regulatory step of AEA synthesis is likely to be through the generation of the precursor 
NAPE from membrane phospholipids. The enzyme responsible for this generation of NAPE 
was crudely purified and showed sensitivity to calcium in eCB enriched areas such as the 
brain and testes (Natarajan et al., 1983; Schmid et al., 1990; Cadas et al., 1997). The activity 
of the CaNAT can also be enhanced by cAMP elevating agents such as FSK but as addition of 
FSK does not directly generate NAPE itself, the target of cAMP leading to enhancement of 
NAPE production remains unclear (Cadas et al., 1996). A calcium-insensitive NAT (iNAT) 
enzyme had been identified as part of the HRASLS family of genes and was related to the N-





did not match the enzymological or expression profile of the CaNAT which had been 
extensively profiled (Ueda et al., 2010).  
The CaNAT was only recently proposed to be the poorly characterised serine hydrolase 
PLA2G4E, part of the PLA2 family of genes (Ogura et al., 2016). Of the PLA2G4 family, 
PLA2G4E and related enzyme PLA2G4B are both poorly characterised in terms of function. 
PLA2G4E exhibited calcium-dependent activity and could generate the NAPE precursor to 
AEA, along with other N-acylPE to NAE derivatives in mouse brain homogenate and in 
transfected mammalian cells. RT-PCR revealed expression of PLA2G4E in mouse brain and 
testis which generally matched areas of CaNAT activity but is also detected predominantly in 
heart, skeletal muscle, and thyroid (Ohto et al., 2005). The human orthologue of PLA2G4E 
has recently been functionally characterised in COS7 cells and also exhibit calcium-sensitive 
NAPE generation (Hussain et al., 2018).  
NAPEPLD expression is present in almost all organs but is predominantly higher in brain, 
kidney and testis in mice (Okamoto et al., 2004), which does not corroborate exactly with 
PLA2G4E expression. Comparison of RNA-Seq data from purified sub-populations of cells 
from mouse cerebral cortex show high transcript expression of PLA2G4E in neurones only, 
whilst NAPEPLD transcripts are more ubiquitous but are highly detected in myelinating 
oligodendrocytes and endothelial cells (Zhang et al., 2014). AEA can be produced in 
astrocytes for example (Walter et al., 2002) but the lack of PLA2G4E transcripts detected in 
astrocytes (Zhang et al., 2014) raises the possibility that other functionally related enzymes 
to PLA2G4E may also generate NAPE and contribute to AEA synthesis in cells and tissues 
where PLA2G4E appears to be absent. PLA2G4B is currently poorly characterised in terms of 
function but show high expression in cerebellum, heart, pancreas and liver in mice (Ghosh et 
al., 2006); has homology (~45-50%) and similar calcium sensitivity to PLA2G4E; and data from 
RNA-seq show the presence of PLA2G4B is also rather ubiquitous in mouse cerebral cortex 
but is more highly detected in astrocytes, neurons and oligodendrocyte precursor cells 
(Zhang et al., 2014) which is more in line with NAPEPLD expression and regions of AEA 
production.  
At this time, PLA2G4E expression in human tissues and proof-of-principle testing of PLA2G4E 
as the CaNAT responsible for the generation of NAPE for AEA signalling has not been 
established. In this section, the expression of PLA2G4E in our CB1-Tango cells will be 
questioned, as will whether PLA2G4E, and its related enzyme PLA2G4B, have a role in AEA 






From the above studies we can be sure that the DAGLs play an essential role in eCB signalling 
via the synthesis of 2-AG, but the role that NAPEPLD and PLA2G4E play in AEA synthesis 
remains unclear. The adaptation of the CB1-Tango assay to measure eCB signalling in the 
previous chapter revealed different stimuli and physiologically emulated conditions are able 
to elicit robust eCB dependent CB1 activation on par with that seen with a maximally active 
concentration of a synthetic CB1 agonist. However, the use of various DAGL inhibitors 
revealed that DAGLs are at best only partially responsible for eCB signalling, raising the 
prospect that other eCBs are primarily responsible for eCB signalling in the CB1-Tango cells, 
with the second most characterised eCB, AEA, being the most likely candidate. There are 
some reasonable pharmacological tools to inhibit 2-AG synthesis, but none to inhibit AEA 
synthesis due to the presence of multiple synthesis pathways and no inhibitors have been 
generated yet for the novel CaNAT (Hoover et al., 2008; Liu et al., 2008). As well as this, long-
term use of DAGL inhibitors in certain conditions causes non-specific inhibition of other 
enzymes. We therefore wanted to complement the pharmacological studies with genetic KO 
studies to determine the contributions of the DAGLs, NAPEPLD, PLA2G4E and candidate 
CaNAT enzyme PLA2G4B to eCB in the CB1-Tango cells. The aims of this chapter are to: 
- Utilise gene editing tool CRISPR to systematically KO individual known components 
for 2-AG and AEA synthesis: DAGLs, NAPEPLD and PLA2G4B 






6.2 Results 4A. To what extent is DAGL activity 
required for 2-AG synthesis and eCB signalling in 
this model? 
 
6.2.1 Results 4A. Introduction 
The first eCB synthesising enzymes to be targeted by CRISPR are the DAGLs as they have been 
shown previously to be major 2-AG synthesising enzymes in vivo (Gao et al., 2010; Tanimura 
et al., 2010) and the disruption of both DAGLs in animal KO studies have shown both enzymes 
are responsible for ~90% of 2-AG synthesis in the brain (Yoshino et al., 2011). The disruption 
of the DAGLs would eliminate the contribution of 2-AG to the eCB tone and provide a good 
basis for the study of the AEA pathways. DAGL and DAGL transcripts are detected at higher 
levels than NAPEPLD transcripts in the CB1-Tango cells despite only contributing to around 
half of the eCB tone and the relative contribution of the individual DAGLs to the generation 
of 2-AG in the cells are unknown. Thus, to determine which of the separate DAGLs are 
involved in the generation of 2-AG, DAGL and DAGL will be targeted separately to 
generate two KO lines. Furthermore, to ensure that the 2-AG pathway does not contribute 
to the eCB tone and for the purposes of elucidating how DAGL-independent eCB signalling is 
regulated in the CB1-Tango cells, a cell line with disruptions to both DAGLs will be generated 
using genetic tools.  
 
Recent advances in gene editing techniques have allowed for precise DNA cleavage in a site-
specific manner leading to many advances in the modelling of genetic causes of diseases and 
is a valuable tool for the manipulation of endogenous genes. Commonly used techniques 
include Zinc Finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases 
(TALENs) and RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) and CRISPR Associated (Cas) nuclease system. ZFNs and TALENs are DNA binding 
proteins that can be modified in their DNA binding domains to be able to bind to any desired 
portion of DNA (Durai et al., 2005; Gaj et al., 2013). ZNFs and TALENS are combined with a 
DNA cleavage domain (FokI) which dimerises to induce double strand breaks at the site of 
interest (Bitinaite et al., 1998). Although ZFN and TALENs have proven to be successful for 
gene editing, the requirement for two ZNFs or TALENs to be generated in near proximity for 





consuming and costly. CRISPR-Cas9 is an RNA-guided nuclease system, where the 
straightforward design of a guide RNA sequence can target the nuclease to any desired 
portion of DNA, thus making for a much faster, more efficient and cost-effective genome 
editing technique.  
 
CRISPR-Cas system is a bacterial and archaeal adaptive immune system that uses RNA-guided 
nucleases to cleave foreign genetic elements such as viral DNA (Barrangou et al., 2007; 
Deveau et al., 2010). Different types of CRISPR systems have been identified across a range 
of bacterial and archaeal hosts (Makarova et al., 2011; Koonin et al., 2017) but the most 
characterised system is Type II CRISPR from Streptococcus pyogenes (Garneau et al., 2010; 
Deltcheva et al., 2011; Jinek et al., 2012). In brief, stretches of sequences with homology to 
foreign DNA incorporated into bacterial DNA are separated by short palindromic repeat 
sequences in a CRISPR array (crRNA). The array is transcribed and processed into individual 
crRNAs by RNase III and special trans-activating crRNA (tracrRNA) with homology to the short 
palindromic repeats. Cas9 enzymes are recruited and form Cas9:crRNA complexes with 
individual cRNAs. These complexes target foreign genomic DNA sequences which are 
complementary to the crRNA and induce a double strand break. In Type II CRISPR systems, 
the target sequence must contain a Protospacer Adjacent Motif (PAM) directly downstream 
of where the crRNA would bind (5'-NGG).  
 
The Type II CRISPR system was adapted for precise genome editing in mammalian systems 
(Jinek et al., 2013; Mali et al., 2013; Ran et al., 2013). The system utilises Streptococcus 
pyogenes endonuclease Cas9 which has been codon-corrected for mammalian expression, 
and the crRNA and tracrRNA are fused together to create a chimeric, single-guide RNA 
(sgRNA) which is linked to the Cas9 nuclease (Figure 6.2.1). A 20-nucleotide guide RNA 
(gRNA) sequence within the sgRNA can be designed to a genomic target site preceding a PAM 
site to cleave the double-stranded DNA at that site. Upon causing a double stranded break, 
two possible mechanisms for DNA repair are triggered: Non-Homologous End Joining (NHEJ) 
and Homology Direct Repair (HDR) leading to mutations within genomic DNA (Jinek et al., 
2012; Jinek et al., 2013).  
 
Intrinsically within mammalian cells, NHEJ is the default pathway of repair when there is an 
absence of a homology repair template. In this circumstance, repair machinery within the 





overhangs allow. When there are no compatible overhangs, the error-prone pathway 
introduces additional nucleotides or removes nucleotides at the breakage site which causes 
insertion/deletion mutations (indel mutations). Indel mutations often lead to premature 
stop codons and truncated proteins (Moore and Haber, 1996; Pardo et al., 2009). HDR on the 
other hand allows for precise genomic editing when a repair template is introduced to the 
cell with homology arms flanking the CRISPR site (Pardo et al., 2009). For the purposes of 
genetic KO of candidate genes, we have utilised NHEJ as the preferred method to introduce 
frameshift mutations in the catalytic regions of the genes as homology directed repair 





Figure 6.2.1. Schematic overview of CRISPR/Cas9 causing double stranded breaks in gene 
editing 
Cas9 endonuclease (yellow) is guided by sgRNA to the correct cleavage site which is directly 
upstream a 5’-NGG PAM sequence and induces a double strand break in the genomic DNA. 
Double strand breaks can be repaired in one of two ways: NHEJ and HDR. NHEJ utilises the 
endogenous repair mechanism in the cell to rejoin the two strands which can be error prone 
and introduce random indel mutations at the site, which in the coding frame could lead to 
frameshift mutations or premature stop codons. HDR uses a homology repair template in 
the form of a plasmid or single stranded oligonucleotides introduced into the cell to allow 







It has been established in previous chapters that endogenous DAGL and DAGL transcripts 
are detected in CB1-Tango cells at relatively high levels but that their enzymatic products are 
not likely to be solely responsible for eCB signalling in the CB1-Tango cell line. To try to strip 
back the eCB tone detected in the CB1-Tango cells, we aimed to systematically eliminate key 
enzymes that are likely to contribute to eCB synthesis. We first targeted the DAGLs 
separately with CRISPR to determine the relative contributions of the DAGLs to 2-AG 
generation in the CB1-Tango cells, and then disrupted both genes to generate a cell line that 
would allow us to study DAGL-independent eCB pathways. Three cell lines were generated: 
a DAGL knock out cell line, a DAGL knock out cell line and a dual DAGL knock out cell line. 
I will describe the generation of a DAGL knock out line and the characterisation of the dual 
DAGL KO line which was generated in tandem by other members of the lab (thesis of 
Rachel Lane Markwick, 2015). The eCB levels of the three KO cell lines were measured to 
determine the contribution of each of these enzymes to 2-AG synthesis in the CB1-Tango 
cells and finally the DAGL KO line was tested in the CB1-Tango assay to determine if eCB 












6.2.2 Results 4A. Results 
Design of gRNAs to the catalytic regions of DAGL 
To introduce the CRISPR/Cas9 system to the CB1-Tango cells, we used the pSpCas9(BB)-2A-
Puro (PX459) backbone plasmid which was deposited on Addgene by the Feng Zhang lab (Ran 
et al., 2013). This plasmid contains all the necessary components for the expression of Cas9 
gene (4272 bp) with nuclear localization signal for eukaryotic expression, U6 promoter and 
allows insertion of the desired gRNAs using a restriction enzyme digest and ligation step 
(Figure 2.2.1). The plasmid also contains puromycin antibiotic resistance which allows for 
selection of successfully transfected cells.  
The catalytic region of the candidate genes were targeted as frameshift mutations in the 
region would disrupt the catalytic activity of the enzymes even if various splice variants of 
the enzymes are made. The genomic sequences for the genes were obtained from Ensembl 
Genome Browser (ensembl.org). The catalytic triad crucial for DAGL activity consists of a 
serine residue in exon 11, aspartic acid residue in exon 12 and a histamine residue in exon 
15. As the deletion of serine renders the enzyme catalytically dead (Bisogno et al., 2003) and 
is the most upstream of the three catalytic residues, we chose to design gRNAs in exon 11, 
10 and 9 in hopes of a frameshift mutation that would affect serine and also further 
downstream catalytic residues.  
To generate the gRNAs, the genetic sequence of DAGL catalytic domain was uploaded onto 
publicly available software to generate CRISPR guides. 20 nucleotide long sequences were 
selected using software available on ZiFiT (http://zifit.partners.org/ZiFiT/) (Sander et al., 
2010) and cross-referenced with nucleotides generated from ATUM CRISPR design tool 
(https://www.atum.bio/eCommerce/cas9/input). We chose 9 different gRNAs to target exon 
9, 10 and 11 of DAGL (Table 2.1.2 and Figure 6.2.2). The gRNA and complementary 
oligonucleotides were ordered as single strands with additional modifications: a starting 5’–
G nucleotide as transcription initiation has requirement of a ‘G’ base for the human U6 
promoter (Cong et al., 2013), and with BbsI restriction enzyme overhangs for annealing and 









Figure 6.2.2. gRNA sequences selected for Cas9 recognition of DAGLβ catalytic domain 
 
Schematic representation of the human DAGLβ sequence, indicating exons (numbered) 
which harbour the catalytic domain (blue). There are many predicted splice variants of 
DAGLβ with this diagram representing the longest predicted transcript (and exons that cross 
most predicted variants). Sequences for gRNAs begin with G (bold) for U6 promotor 





Cloning and validation of constructs and generation of DAGL KO line 
The vectors were constructed to contain the custom gRNA oligonucleotides into the PX459 
backbone vector. In brief, the backbone vector was digested by the restriction enzyme BbsI, 
dephosphorylated and purified after separation on an agarose gel. The complementary pair 
of oligonucleotides were annealed together and phosphorylated, and then ligated to the 
purified backbone. Once the 9 complete vectors were constructed, the vectors were 
individually transfected into separate pools of CB1-Tango cells for transient expression of 





It is important that the gRNA has been ligated into the vector in the correct place and 
orientation, and thus produce active Cas9 to cleave genomic DNA and introduce indel 
mutations. To test the efficiency of each gRNA we designed, the Surveyor Nuclease assay 
(Qiu et al., 2004) was used to detect mismatched base pairs that have been caused by indel 
mutations within the alleles of DAGL gene. In brief, hybridising PCR amplicons containing 
indel mutations with wild-type PCR amplicons that do not contain the CRISPR indels causes 
a mismatch in base pairs which Surveyor nuclease detects and cleaves apart, resulting in 
smaller sized fragments (Figure 6.2.3). This can easily be visualised by gel electrophoresis, 
indicating whether CRISPR treatment has been successful. 
The genomic DNA for the pool of transfected cells were extracted and PCR amplification of 
the CRISPR site was carried out using primers flanking each exon (Table 2.1.2) and half of the 
reaction mix was visualised on 2% agarose gel (Figure 6.2.4A). PCR amplifications of the 
regions were very clean at the correct band size with the exception of exon 10 PCR product 
which seemed to have a higher molecular weight band above the expected band size. Since 
this was seen in both the untransfected and transfected cells, for the purposes of the 
Surveyor nuclease assay, it would not affect the formation of hetero-duplexes and cleavage 
of the mismatched nucleotides.  
The remaining PCR mix was boiled and reannealed to form mismatched hetero-duplexes 
then Surveyor nuclease enzyme was added to the mix for the cleavage of mismatched pairs. 
The remaining products were then run on 2% agarose gel (Figure 6.2.4B). Untransfected CB1-
Tango cells did not show any signs of mismatch cleavage which indicates that within the 
CRISPR region there are no endogenously mismatched pairs. Upon comparison of the PCR 
products of transfected cells with untransfected cells, certain vectors show additional 
smaller sized fragments under the large band size (indicated by asterisks in Figure 6.2.4B). 
This indicated that the vector could introduce indel mutations via NHEJ. For our further 














Figure 6.2.3. Schematic of Surveyor nuclease cleavage of mismatch heteroduplexes of DNA 
Extraction of genomic DNA and PCR amplification of the region of known indel formation by 
CRISPR (indicated in red) was carried out on a pool of transfected cells (DNA indicated by 
black lines) and untransfected cells (DNA indicated by blue lines) (step 1). PCR products were 
heated to separate the DNA strands and slowly cooled to promote annealing of 
heteroduplexes of mismatched DNA (step 2). Surveyor nuclease (indicated in green) then 
cleaves mismatched DNA strands into smaller fragments (step 3) which can be visualised by 























Figure 6.2.4. PCR amplification of DAGL catalytic domain exons from transfected CB1-
Tango cells (A) and Surveyor Nuclease digestion products of PCR products (B). 
CB1-Tango cells were seeded on 6 well dishes and transfected with CRISPR vectors 24 hours 
after. Genomic DNA from the pool of cells in each well was extracted using Puregene Core 
Kit B (Qiagen) after 24 hours of transient expression of the vector. PCR amplification of exon 
9 (284bp), exon 10 (246bp) and exon 11 (210bp) of DAGL catalytic domain was performed 
from extracted genomic DNA from transfected CB1-Tango cells and untransfected CB1-
Tango cells (Ctrl). Half the volume of PCR products were run on 2% agarose gel (A) and 
Surveyor enhancer S and Surveyor nuclease were added to the remaining PCR product 
mixture before incubating at 42oC for 1 hour and run on 2% agarose gel (B). Asterisks indicate 






RT-PCR and sequencing show genetically disrupted DAGL transcripts  
After transfection of parental CB1-Tango cells with vector CRISPR 9.2 and treatment for 24 
hours with the selection agent puromycin, cells were reseeded at very low density and cell 
colonies were left to grow for 3 weeks before being selected for cell expansion.  It was hoped 
that these would be clonal, but we could not exclude the possibility that a more careful 
cloning step would be required further down the line. Once sufficient numbers of cells had 
grown, RNA was extracted from each colony pool and converted to cDNA before PCR 
amplification of DAGL gene between exons 8 – 10 (Figure 6.2.5). 
Certain colony lines had observable differences from untransfected parental CB1-Tango cells 
(marked with an asterisk) and others had no observable differences, perhaps due to the 
introduction of very subtle mutations. The PCR for all the knock out cell lines and 
untransfected cells were carried out using the same primers simultaneously, therefore any 
observable differences are a result of the differences caused by CRISPR indel mutations.  
For further analysis, certain candidate knock out cell lines were picked based on their 
observable differences – F and C3, but we also selected lines with no observable differences 
– H and G2. The PCR product of RT-PCR of these cell lines were ligated into a TOPO-cloning 
expression vector and transformed into E. coli. 24 bacterial E. coli colonies were picked from 
each knock out line and sent for sequencing.  
Sequences of DAGL RT-PCR from selected knock out cell lines were analysed and compared 
to wild type DAGL sequence. Ideally, both alleles of DAGL in the cell lines would have 
undergone NHEJ and repaired in slightly different ways; with both alleles containing indel 
mutations leading to truncated protein. We therefore expected at least two transcripts 
arising from sequencing results of each knock out line. The results from the first round of 
















Figure 6.2.5. Reverse Transcription PCR amplification of DAGL CRISPR site of 
CRISPR knock out lines. 
RNA from selected CRISPR knock out lines and parental CB1-Tango cells (Ctrl) were extracted 
and converted to cDNA. PCR amplification of cDNA surrounding the CRISPR site was 
performed with primers spanning exons 8 to 10. The PCR products were run on 2% agarose 
gel and visualised. Knock out cell lines with observable differences from parental CB1-Tango 
cells have been highlighted with an asterisk and lines taken for further analysis are indicated 





CELL LINE MUTATION FREQUENCY 
COLONY F 1bp insertion (CRISPR site) 15/24 
 78bp deletion * (Exon 9) 3/24 
 299bp insertion (Retained intron 8-9) 1/24 
COLONY H 1bp insertion (CRISPR site) 23/24 
 1bp insertion (CRISPR site) & 1bp deletion * (upstream of 
CRISPR site) 
1/24 
COLONY G2 1bp insertion (CRISPR site) 23/24 
 Wild type sequence 1/24 
COLONY C3 1bp insertion (CRISPR site) 13/24 
 178bp insertion (CRISPR site) 6/24 
 1bp deletion (CRISPR site) 2/24 
Table 6.2.1. Sequencing results of DAGL catalytic domain exon 8-10 in selected CRISPR 
lines. 
PCR amplified cDNA between exons 8 to exon 10 of DAGL in CRISPR knock out lines F, H, G2 
and C3 were cloned into TOPO vector and sent for sequence analysis. The types of indel 
mutations and locations of these mutations were categorised and tallied as listed in the 
table. Asterisk indicates in-frame deletions. 
 
CELL LINE MUTATION FREQUENCY 
COLONY H 1bp insertion (CRISPR site) 14/21 
 1bp insertion & 128bp deletion (Exon 11) 3/21 
 1bp insertion & 41bp deletion (End of exon 14) 2/21 
 1bp insertion & 209bp deletion (Exons 10 & 11) 1/21 
 1bp insertion & 1bp deletion *† (Within exon 14) 1/21 
Table 6.2.2. Sequencing results of DAGL catalytic domain exon 8-15 in selected CRISPR 
lines. 
PCR amplified cDNA between exons 8 to exons 15 of DAGLin knock out cell line H were 
cloned into TOPO vector and sent for sequence analysis. The types of indel mutations were 
categorised and tallied as listed in the table. * indicate in frame mutations. † indicates the 






The promising result from Table 6.2.1 was knock out line H, which has only 2 different 
sequencing reads from the total of 24, other cell lines either had more than two reads or the 
presence of a wild type sequence. However, one of the transcripts from knock out line H had 
a 1bp insertion & 1bp deletion within the same read, which would put the sequence back in 
frame as a stop codon was not reached before the sequence shifted back in frame. We were 
unsure if this mutation affected the catalytic domain which was further downstream as 
sequencing was carried out between exon 8 – 10 which did not span the catalytic triad of 
DAGL. To ensure that the catalytic triad of DAGL is disrupted a longer PCR product for the 
second round of sequencing was carried out from exon 8 – 15, summarised in Table 6.2.2. 
Longer sequencing reads of knock out line H have shown that there were more than two 
types of transcript present, where the majority of deletions occur after exon 10 which 
includes deletion of the catalytic triad. In the second round of sequencing, the same 1bp 
insert that would cause an in-frame read was not detected and no wildtype sequence was 
detected. When converting the sequences of the transcripts to protein sequences, all 
detected KO line H transcripts gave disrupted protein sequences with a premature stop 
codon after the 1bp mutation at the CRISPR site. To see whether this translates to disrupted 
protein expression, western blot analysis was carried out in the 4 CRISPR treated cell lines.  
 
Western blot analysis shows disrupted DAGL protein in CRISPR treated cells 
To determine if mutations seen within the genome corresponded to subsequent knock down 
of DAGLprotein, membrane preparations and cell lysates of four DAGL knock out lines: F, 
H, G2 and C3 were analysed on a western blot as described in methods (Figure 6.2.6). The 
DAGL antibody was generated using an epitope corresponding to residues surrounding 
Leu505 in exon 13 of human DAGLβ protein. Wild type DAGL is around 73kD and expression 
is concentrated in the cell membrane, and thus produces a more prominent band in the 
membrane preparation compared with cell lysates (Figure 6.2.6A). DAGL expression in 
membrane preparations of the knock out lines is reduced to essentially undetectable levels, 
which is mirrored in the cell lysates blot (Figure 6.2.6B).  
Taking together the sequencing results with the western blotting results, we can conclude 
that CRISPR has clearly disrupted essentially all of the DAGL transcripts in the selected cell 
colonies, and perhaps more importantly we cannot detect the expression of DAGL protein 













Figure 6.2.6. Western blot analysis of DAGL expression in CRISPR DAGL knock out 
cell lines. 
Membrane preps and cell lysates were prepared of parental CB1-Tango cells (Ctrl) and 
DAGL knock out lines F, H, G2 and C3. 20g of protein was loaded and run on SDS-PAGE gel 
before transferring onto nitrocellulose membrane and probed for DAGL expression 
(~73kD). Bands were visualised using ECL analysis in membrane preparations (A) and whole 
















DAGL double knockout generation and characterisation 
In tandem with the generation of the DAGL KO line, the generation of a DAGL KO line 
was carried out by other members of the lab (thesis of Rachel Lane Markwick, 2015). DAGL 
was first targeted in the parental CB1-Tango cells with the same CRISPR methods using 
gRNAs designed to exon 14 where the catalytic residue serine is located. After expanding 
colonies of CRISPR transfected cells and sequencing of DAGL transcripts from selected 
colonies, the KO line that showed most disrupted transcripts of DAGL was taken forward as 
a DAGL KO line. Following from that, DAGL was then targeted in the DAGL KO line to 
generate a dual DAGL KO line. The same DAGL CRISPR vector and methods were used 
as the ones described above.  
Genomic sequencing of the CRIPSR site of both DAGL and DAGL was carried out in the 
DAGL KO cell line to decisively conclude the nature of the CRIPSR mutations (Figure 6.2.7). 
Only one mutation result of DAGL was picked up from genomic DNA sequencing which was 
a 2bp deletion, however through sequencing of over 100 transcripts using RT-PCR it has been 
concluded that mRNA of DAGL protein is produced with large deletions within the catalytic 
domain, effectively rendering the protein catalytically dead. Furthermore, there are no 
wildtype transcripts, suggesting a successful KO of both alleles of DAGL(thesis of Rachel 
Lane Markwick, 2015). DAGLhas successfully been shown to contain two different 
mutations, one per allele of the gene. One allele contains 4bp deletion and the other allele 
shows 1bp insertion. The mRNA of DAGL has also been shown to contain large deletions of 
exons of the catalytic domain. 
To confirm the knock out at the protein level, western blot analysis was carried out on the 
KO cell line probing for DAGL. We were not confident that the DAGL antibody was specific 
enough for western blot analysis of DAGL as previous experiments often detected non-
specific bands. Membrane preparations of parental CB1-Tango and DAGL KO cells were 
prepared as described in methods. DAGL protein was detected in CB1-Tango cells but not 
in DAGL KO cells, and -actin was also detected as a control. Based on the sequencing 
and western blot results, the DAGL and DAGL transcripts and DAGL protein are non-








Figure 6.2.7. Sequencing reactions show mutations in genomic DNA of DAGL and DAGL 
in DAGL KO line.  
PCR reactions of DAGL and DAGL flanking the exon of the CRISPR site (DAGL exon 14, 
DAGL exon 9) was carried out and run on 1% agarose gel. The resolved band was cut from 
the gel and purified using gel extraction kit according to manufacturer’s instructions. The 
purified PCR product was cloned into TOPO vectors and transformed into bacteria which 
were sent for Sanger sequencing. Results were aligned against expected amplification 
sequence (top row sequences) obtained from Ensembl on Clustal Omega. Mutations are 








Figure 6.2.8. Western blotting shows lack of expression of DAGL in DAGL KO cells 
Parental CB1-Tango cells and DAGL KO cells were grown on 10cm dishes until 90% 
confluent. Cells were then washed with cold PBS and were harvested and membranes were 
extracted from both cell lines, details in methods. Samples of membranes were then 
prepared with a total of 20g of protein in each sample and loaded onto a 7.5% SDS-PAGE 
gel. The gel was then transferred onto nitrocellulose membrane and blocked with 5% milk 
for 1 hour. Primary anti-DAGL antibody (Cell Signaling) was diluted in milk 1:2500 and 
incubated with the membrane for 1 hour before being washed. Secondary anti-rabbit 





washed. The blot was visualised on the Odyssey system (Licor) and then stripped and 
reprobed for actin. 
Measurement of 2-AG in the DAGL KO lines show DAGL is responsible for 2-AG 
synthesis in the CB1-Tango cells 
Having generated three DAGL KO lines, it was prudent to determine the effects this has on 
the production of 2-AG in the cells, the relative contribution of each DAGL to 2-AG production 
and to the overall lipid biome in the cells. Lipid levels of 2-AG, AEA and related lipids OEA and 
PEA were measured from pelleted samples of the parental CB1-Tango line and each DAGL 
KO cell line and normalised to pg per 106 cells.  
Levels of lipids were measured from 3-6 independent cell samples from each individual 
experiment and pooled across three independent experiments for the parental CB1-Tango 
cells and DAGL KO cells and two independent experiments for the other cell lines with 
the final level taken as the mean of all of the individual cultures. Levels might fluctuate 
depending on growth status and batches of cells as the cells could be a heterogenous 
population with different basal signalling levels. 
 
2-AG can readily be detected in parental CB1-Tango cells (890.69 ± 191.04 pg/106 cells) 
(Figure 6.2.9). Levels of 2-AG were significantly lower in the DAGL KO cells (194.19 ± 28.57 
pg/106 cells) and even lower in the dual DAGL KO (108.94 ± 13.20 pg/106 cells) which was 
about 10% of the level seen in parental cells. These results indicate that DAGL is central in 
the production of 2-AG in the CB1-Tango cells but that dual KO of both DAGLs produces the 
most pronounced effect on 2-AG. Interestingly in DAGL KO cells, 2-AG levels were 
significantly higher (1902.61 ± 244.32 pg/106 cells) than the level seen in parental cells. This 
might simply be a clonal artefact, but it does suggest that DAGL is the dominant enzyme 
controlling 2-AG levels. 
 
AEA levels were detected in parental CB1-Tango cells at a much lower levels than 2-AG (2.41 
± 0.53 pg/106 cells), and showed little change in individual DAGL or DAGL KO lines. 
However, AEA levels were significantly increased in the DAGLKO cells to 7.21 ± 0.96 
pg/106 cells. Again, this might be a clonal artefact, but the results clearly show that AEA 
synthesis does not depend on the DAGLs. Other AEA related lipids OEA and PEA were also 
measured and showed little changes between the cell lines, however OEA was significantly 














Figure 6.2.9. Measurements of 2-AG, AEA, OEA and PEA levels in DAGL KO cell lines  
Parental CB1-Tango cells and DAGL KO cell lines were grown in regular conditions until 90% 
confluent. Cells were then harvested and counted to ensure there were more than 6x106 
cells present per sample. Cells were then pelleted and immediately frozen in -80oC and then 
shipped on dry ice for their lipid levels to be measured by mass spectrometry. 2-AG, AEA, 
OEA and PEA levels were measured in each sample and normalised to pg per 106 cells. Graph 
shows means and bars represent SEMs across independent samples (n = 12 for parental CB1-
Tango cells; n = 9 for DAGL KO, DAGL KO and DAGL KO cells). Significance between 
groups was calculated using One Way ANOVA. 










Beads assay of DAGL KO cell line show higher NAPEPLD transcript expression 
The significantly higher AEA levels in DAGL KO cell line were of interest as it confirmed 
that the AEA pathway was active in the CB1-Tango cells; this might be a causative effect, 
however we cannot exclude the possibility that it simply reflects clonal variation. 
Nonetheless, we once again performed the transcript beads assay on the DAGL KO cells 
to determine if NAPEPLD levels were also higher and/or FAAH levels lower in this cell line as 
one of these might explain the higher levels of AEA.  
 
Our probe sets for DAGL and DAGL were not directed to the sites targeted for mutagenesis 
and as such can still detect mutated transcripts; thus, any changes in expression of these 
transcripts are not important as the transcripts do not encode functional enzymes.   
 
Whilst most other components showed non-significant changes in transcript expression 
levels, the NAPEPLD transcript was significantly higher in the DAGL KO line (1.022 ± 0.014 
relative expression) (Figure 6.2.10). This is around a 5x increase in this clone over the level 
seen in the parental cell population (0.192 ± 0.003 relative expression). Thus, it is tempting 
to speculate that the increased expression of NAPEPLD transcripts might cause an increase 
in enzyme level and account for the increase in AEA levels, however this has not been directly 
tested. The transcript levels of FAAH in the DAGL KO cells were around similar levels as 
those detected in the parental CB1-Tango cells, which is not likely to account for the increase 
in AEA levels produced in the DAGL KO cells. 
 
Also of interest are the transcript levels of MGLL, ABHD6 and PLA2G4B. MGLL levels were 
around 1.7x (Parental = 0.023 ± 0.002 relative expression; DAGL KO = 0.041 ± 0.001 
relative expression) higher in expression and ABHD6 levels were around 3x higher (Parental 
= 0.071 ± 0.003 relative expression; DAGL KO = 0.205 ± 0.007 relative expression), both 
statistically significant. PLA2G4B transcript levels were also slightly, but not significantly, 
higher in the DAGL KO clone (Parental = 0.313 ± 0.008 relative expression; DAGL KO 
= 0.423 ± 0.006 relative expression). Again, these changes might reflect an adaptive response 
to the loss of the DAGLs, however they might simply reflect clonal variation. The most key 
point is the DAGL KO cell line clearly retains transcripts for the enzymes that serve as 
















Figure 6.2.10. Beads assay results show DAGL KO cells have higher expression of 
NAPEPLD, PLA2G4B, MGLL and ABHD6 
Parental CB1-Tango cells and DAGL KO RNA was extracted from cells and diluted to 
375g/l in 20l for a total RNA amount of 7500ng per well. RNA was incubated with 
magnetics beads and probes overnight as described in methods. Amplification steps were 
carried out the next day as instructed by the manufacturer and the plate was read on the 
Magpix system. Data was analysed by subtracting the background readings from the sample 
readings and normalising to the expression of two housekeeping genes. Graph shows means 
and bars represent SEMs of 5 replicates of from one single experiment. Significance between 
groups was calculated using Student’s T-test. 




















eCB signalling is still present in the DAGLKO cell line in McCoy’s assay media 
The DAGL KO cells were tested in the CB1-Tango assay to see if the KO of the DAGLs 
affected eCB signalling. First, the responsiveness of the cells in the assay was tested using 
ACEA in 0.5% FBS McCoy’s assay media. Parental CB1-Tango and DAGLKO cells were 
plated overnight in McCoy’s assay media and treated with ACEA in the presence and absence 
of AM251 in the standard 4 hour assay (Figure 6.2.11). The DAGL KO cells are still 
responsive to the maximal ACEA concentration (226.7 ± 12.6% of control) to similar levels 
reached by parental CB1-Tango cells (245.6 ± 15.4% of control) and this response can be fully 
antagonised by AM251 to baseline levels suggesting no negative effects of CRISPR on the CB1 
reporter assay itself.  
Next, we looked to see if the basal eCB tone can still be generated in the DAGL KO clone. 
The parental CB1-Tango and DAGL KO cells were treated with JZL195 for 4 hours. An eCB 
tone is still clearly revealed by AM251 under these conditions in the DAGL KO cells (150.6 
± 4.0% of AM251 control) and was actually higher in comparison to that seen in parental cells 
(129.5% ± 4.8% of AM251 control) (Figure 6.2.12). In non-JZL195 conditions, there was no 
significant eCB tone in parental CB1-Tango cells and or the DAGL KO cells (Parental = 98.6 
± 3.2% of AM251 control; DAGL KO = 107.5 ± 2.3% of AM251 control) (data not shown), 
confirming that the eCB tone in both cell lines is consequential to the presence of JZL195. 
Thus we can conclude that the DAGLs are not responsible for this tone and this is in keeping 
with the earlier pharmacological results. The apparent increase in the tone in the DAGL 
knockout line might be consequential to loss of these enzymes, but it might simply reflect 
clonal variability. 
In response to a 4 hour treatment with ionomycin in the presence of JZL195, a CB1 response 
was still readily detected in the DAGL KO cells (186.9 ± 10.4% of AM251 control) and this 
was of a similar magnitude to the response seen in the parental CB1-Tango cells (200.1 ± 
31.0% on AM251 control) (Figure 6.2.13). Responses in both cell lines are substantially, but 
again not fully inhibited by AM251. The residual response in both cases might reflect the 
competitive nature of AM251 that might have failed to fully block an eCB response or as 
discussed previously, the ionomycin response might also have a non-specific component. 
The level of the ionomycin response has not reduced to halfway, as predicted previously with 
the use of DAGL inhibitors, and is on a comparable level to parental CB1-Tango cells, this is 







Figure 6.2.11. The ACEA response is present in the DAGL KO cells and comparable to 
parental CB1-Tango cells 
30,000 cells per well were seeded in McCoy’s plating media in 96 well black plates and 
incubated overnight in 37oC. Cells were treated for 4 hours with 5M ACEA in the presence 
and absence of AM251 (2.5M). Assay substrate was combined according to manufacturer’s 
instructions and added to the cells for 90 minutes before being read on the Flexstation. Data 
was normalised to control wells (set as 100) as % of control. Graph shows means and bars 
represent SEMs of n = 6 independent experiments, 8 technical replicates in each experiment. 
Significance between groups was calculated using Student’s T-test. 








Figure 6.2.12. The eCB tone in DAGL KO cells is elevated compared to parental CB1-
Tango cells 
30,000 cells per well were seeded in McCoy’s plating media in 96 well black plates and 
incubated overnight in 37oC. Cells were treated for 4 hours with 100nM JZL195 in the 
presence and absence of AM251 (FAC 2.5M). Assay substrate was combined according to 
manufacturer’s instructions and added to the cells for 90 minutes before being read on the 
Flexstation. To best visualise the eCB tone present shown by JZL195, the data was normalised 
to the wells containing AM251 (set as 100) as % of AM251. Graph shows means and bars 
represent SEMs of n = 6 independent experiments, 8 technical replicates in each experiment. 
Significance between groups was calculated using Student’s T-test. 












Figure 6.2.13. Ionomycin response in DAGL KO cells and parental CB1-Tango cells are 
similar 
CB1-Tango cells and DAGL KO cells were plated into 96 well black plates in 100l of 
McCoy’s plating media and incubated overnight. Cells were then treated with ionomycin 
(2M) in the presence and absence of AM251 (2.5M) for 4 hours. 100nM JZL195 was 
included in all the wells. Substrate was added for 90 minutes at room temperature and read 
on the Flexstation. Data collected were normalised to wells containing AM251 (set as 100) 
as % of AM251 control. Graph shows means and bars represent SEMs of n = 4 for parental 
CB1-Tango and n = 5 for DAGL KO, 8 technical replicates in each experiment. Significance 
between groups was calculated using Student’s T-test. 
 







FSK and PMA can still elicit eCB signalling in DAGL KO cells in No Starve 
Freestyle media 
Next, we tested the DAGL KO cells in Freestyle media supplemented with 2mM calcium 
and 100nM JZL195. Again, the ACEA response was first tested to see if the cells still respond 
in a comparable manner to parental CB1-Tango cells. The cells were plated and ACEA and 
AM251 were added immediately afterwards for 24 hours (Figure 6.2.14). Both parental CB1-
Tango cells and DAGL KO cells were able to generate a substantial ACEA response in this 
assay condition (parental CB1-Tango = 612.8 ± 30.6; DAGL KO = 688.1 ± 55.5% of AM251 
control). There is no statistically significant difference between the maximal ACEA responses 
between parental CB1-Tango cells and the DAGL KO cells indicating the expression of 
similar levels of CB1 receptors. AM251 was also able to largely block the ACEA response in 
both cell lines.  
To test the presence of the eCB tone in the DAGL KO cells in this paradigm, both parental 
CB1-Tango cells and DAGL KO cells were plated in the same way in No Starve Freestyle 
media conditions in the presence of 2mM calcium and 100nM JZL195. AM251 was included 
as the control and data was normalised to the wells containing AM251 only (set to 100%) 
(Figure 6.2.15). The results show the presence of a significant eCB tone in DAGL KO cells 
(356.0 ± 14.4% of AM251 control), which is actually higher in comparison to parental CB1-
Tango cells (246.2 ± 12.0% of AM251 control), much like in the McCoy’s assay media.  Thus, 
in agreement with the pharmacological results this substantial eCB tone does not depend on 
DAGL function. Possible reasons for the enhanced response in the DAGL knockout cells will 
be discussed later. 
Following from this, the effects of FSK and PMA were tested to see if the cells still have kinase 
driven eCB signalling. The cells were treated with 10M FSK for 24 hours in the No Starve 
Freestyle conditions in the presence and absence of AM251 (Figure 6.2.16). A robust 
response was detected in both cell lines which was essentially inhibited by AM251 indicating 
CB1-dependency (parental CB1-Tango = 656.8 ± 40.1%; DAGL KO = 522.3 ± 26.5% of 
AM251 control). The FSK response in DAGL KO cells was slightly lower when compared 
to the parental CB1-Tango cells and is not as robust as the ACEA response.  However, the 
main observation is that there is a very substantial FSK response in the knockout cells 
confirming previous pharmacological results that suggested this is not DAGL dependent. 
Lastly, the cells were treated with 25nM PMA in the presence and absence of AM251 in the 





response in both cell lines which was mostly blocked by AM251 but did show a component 
which could not be blocked by AM251 in both cell lines. In the DAGL KO cells the PMA 
response reached 277.8 ± 21.5% of control, which is very robust but significantly lower when 
compared to the parental CB1-Tango cells response (383.2 ± 7.7% of AM251 control). This 
comparatively reduced response might be attributable to the KO of the DAGLs, but it might 
simply reflect clonal variability. However, the important observation is that a robust and 
substantial PMA response can be elicited in the absence of the DAGLs, and again this is 








Figure 6.2.14. ACEA responses is comparable between the two cell lines in Freestyle no 
starve conditions 
30,000 of parental CB1-Tango and DAGL KO cells were plated in 100l of Freestyle media 
with 2mM Ca2+ and 100nM JZL195. 5M (FAC) ACEA in the presence and absence of 2.5M 
(FAC) AM251 was added to the cells shortly after plating and left for 24 hours in the 
incubator. Substrate was added to the cells the next day for 90 minutes and read on the 
Flexstation. Data collected was normalised to wells containing AM251 only (set to 100) as % 
of AM251 control. Graph shows means and bars represent SEMs of n = 3 independent 
experiments, 8 technical replicates in each experiment. Significance between groups was 
calculated using Student’s T-test. 
 







Figure 6.2.15. The eCB tone is enhanced in DAGL KO cells compared to parental CB1-
Tango in reduced starve conditions 
CB1-Tango cells and DAGL KO cells were plated into 96 well black plates in 100l of 
Freestyle media supplemented with 2mM Ca2+ and 100nM JZL195. Cells were treated with 
AM251 (2.5M) diluted in the plating medium immediately after plating the cells and 
incubated for 24 hours. Substrate was added for 90 minutes at room temperature and read 
on the Flexstation. To best display the eCB tone produced in this condition, data collected 
were normalised to wells containing AM251 (set as 100) as % of AM251 control. Graph shows 
means and bars represent SEMs of n = 9 for parental CB1-Tango and n = 16 for DAGL KO, 
8 technical replicates in each experiment. Significance between groups was calculated using 
Student’s T-test. 
 













Figure 6.2.16. FSK induced response is reduced in DAGL KO cells 
30,000 of parental CB1-Tango and DAGL KO cells were plated in 100l of Freestyle media 
supplemented with 2mM Ca2+ and 100nM JZL195. FAC 10M FSK in the presence and 
absence of FAC 2.5M AM251 was added to the cells shortly after plating and left for 24 
hours in the incubator. Substrate was added to the cells the next day for 90 minutes and read 
on the Flexstation. Data collected was normalised to wells containing AM251 only (set to 
100) as % of AM251 control. Graph shows means and bars represent SEMs of n = 3 
independent experiments for parental CB1-Tango and n = 7 for DAGL KO cells, 8 technical 
replicates in each experiment. Significance between groups was calculated using Student’s 
T-test. 
 








Figure 6.2.17. PMA induced response is reduced in DAGL KO cells 
30,000 of parental CB1-Tango and DAGL KO cells were plated in 100l of Freestyle media 
supplemented with 2mM Ca2+ and 100nM JZL195. FAC 25nM PMA in the presence and 
absence of 2.5M AM251 was added to the cells shortly after plating and left for 24 hours in 
the incubator. Substrate was added to the cells the next day for 90 minutes and read on the 
Flexstation. Data collected was normalised to wells containing AM251 only (set to 100) as % 
of AM251 control. Graph shows means and bars represent SEMs of n = 4 independent 
experiments for parental CB1-Tango and n = 5 for DAGL KO cells, 8 technical replicates in 
each experiment. Significance between groups was calculated using Student’s T-test. 
 










6.2.3 Results 4A. Summary & Conclusions 
To complement the pharmacological studies of eCB signalling in the CB1-Tango cell line, a 
genetic approach was taken to disrupt DAGL function which would give us a platform for 
studies of the non-DAGL dependent eCB pathway. CRISPR is a relatively new and powerful 
tool for genome editing which uses gRNA to guide Cas9 nuclease to target sequences which 
has been utilised to target DAGL and DAGL. As gRNA can be readily replaced within CRISPR 
vectors, compared to ZNFs and TALENs, CRISPR is a relatively faster and simpler method of 
genome editing. Viable CRISPR vectors were created targeted to the catalytic domain of 
DAGL and validated by the Surveyor nuclease confirming that our guide sequences can 
create indel mutations within the genomic DNA. 
Following treatment with the CRISPR constructs and the selection of resistant colonies, RT-
PCR revealed different PCR band sizes of the catalytic domain, indicative of modified mRNA 
of DAGL. It is worth noting that the control PCR product is a clear single band. As the RT-
PCR spans exon 8 to exon 10, this suggests that there are no naturally spliced variant of 
DAGL which skips exon 9 as if this were the case a smaller PCR product (lacking exon 9) 
would also have been detected. Substantial differences in transcript size were only seen in 
some colonies, but not others, indicating that CRISPR has induced major as well as more 
subtle changes in gene structure. This suggests that in those cell lines with a shift in the RT-
PCR, it is likely that the mRNA transcripts contain aberrant splicing of exon 9 due to CRISPR 
interference. This leads to the appearance of a smaller weighted band that has a consistent 
size across cell lines.  
From the sequencing results in Table 6.2.1, it would appear that two knock out cell lines (F 
and C3) are not likely to be clonal as more than two transcripts were picked up. However, 
the nature of the mutations in the detected transcripts are intronic and exonic features that 
tend to occur across different knock out cell lines. Commonly, large deletions and insertions 
are present – 78bp, 128bp and 209bp deletions correspond to complete bypass of exons 9, 
11 and both 10 & 11 respectively; whilst the 299bp insert correspond to retained intron 
sequences located between exons 8 – 9. These exonic and intronic deletions and insertions 
are detected at relatively low frequencies indicating the instability of these transcripts, 
particularly as the host cell line is originally a cancer cell line which may have aberrant splicing 
due to differentially expressed genes (Fackenthal and Godley, 2008; Eswaran et al., 2013). 





caused by CRISPR but it could also be possible that the selected colonies were originally not 
clonal and derived from two or more cell types. 
Smaller insertions and deletions tend to occur within the exon sequence which is more likely 
to be a genuine disruption of the genomic DNA compared to the indel mutations found 
between exons. Surprisingly the mutation at the CRISPR site was commonly seen across the 
other cell lines. The same 1bp insertion, located at the CRISPR site may possibly occur 
because of HDR from a similar template or from one allele using the second allele as a 
template (Canver et al., 2014). It is of note to point out that the 1bp deletion seen in the first 
sequencing result from KO line H (Table 6.2.1) was not picked up in the second round of 
sequencing, but a different 1bp deletion in exon 14 was found (Table 6.2.2). It is uncertain 
whether this is due to the mutations being present in low frequency within the population 
or if it is due to sequencing errors.  
It is possible to target genes using CRISPR with a slightly altered strategy of using two double 
strand breaks to induce a large deletion of the intervening segment (Canver et al., 2014). This 
method may prove more reliable as only 2/3 of indel mutations would give rise to a 
frameshift mutation, as shown in Table 6.2.1 – certain clones can produce in frame 
mutations, and alternative splicing may compensate for the gene disruption. This method 
would rely on major disruptions on the genome, which may impact on other genes within 
the cell such as DAGL due to its homology with DAGL that could potentially impact on the 
viability of the cell. To mitigate against this, gRNAs would have to be designed to unique 
stretches of DNA to prevent off target effects. Nonetheless, western blot analysis shows a 
very a substantial reduction in the expression of wild type DAGL from cell membranes and 
lysate. 
The DAGL KO line was also generated using the same strategy as the DAGL KO line 
(thesis of Rachel Lane Markwick, 2015). From the sequencing results, DAGL and DAGL are 
both mutated in ways that if protein product is expressed it would not be enzymatically 
active as the catalytic domain is functionally compromised. Western blot analysis of DAGL 
was carried out as the antibody can consistently detect DAGL, however the DAGL antibody 
proved to be unreliable and often detects non-specific bands, thus DAGL protein function 
was not determined until lipid measurements were carried out from the parental CB1-Tango 






Lipid measurements revealed the large depletion of 2-AG from the DAGL KO line which was 
only slightly lower in the dual DAGL KO line. This confirms the KO of DAGL, and also 
suggests that DAGL is the key enzyme contributing to 2-AG synthesis in the cell line. This is 
surprising as DAGL transcripts were detected much more highly in the CB1-Tango cells but 
do not seem to be contributing much to 2-AG synthesis. This was observed previously in 
studies with commercially available DAGL surrogate substrates (Pedicord et al., 2011), 
namely p-nitrophenyl butyrate (PNPB) and 6,8-difluoro-4-methylumbelliferyl octanoate 
(DiFMUO). The substrates were used on CB1-Tango cell lines stably overexpressing DAGLs 
with a V5 tag for use in a live cell assay (Singh et al., 2016). Overexpressed DAGL-V5 was far 
more (~5 fold) active than overexpressed DAGL-V5 in hydrolysing the surrogate substrates 
despite DAGL-V5 having higher expression levels in western blot analysis (thesis of Praveen 
K Singh, 2013). Thus, despite the very high homology between the DAGLs, and the fact that 
they catalyse the same physiological reaction, there are in fact clear differences between the 
catalytic properties of DAGLα and DAGLβ.  
 
From the lipid measurements of the DAGL KO line, 2-AG levels are significantly higher than 
those seen in parental cells. This is unexpected and the reasons for the significantly higher 
2-AG levels in DAGL KO cells are unknown. As the DAGL KO cells were generated 
separately from the DAGL and DAGL KO cells, it could be likely that due to clonal 
differences between the cell lines that the DAGL KO cell line was derived from a cell that 
had higher endogenous production of 2-AG. However, it is possible that this is a real adaption 
to the loss of DAGL, as mentioned above, DAGL might have different catalytic properties 
to DAGL. For example, the KO of DAGL could essentially increase the free levels of DAG 
which may be catalysed at a much faster rate by DAGL, thus causing an increase in the levels 
of 2-AG. It was outside of the scope of the thesis to investigate this possibility, and it is 
perhaps noteworthy that similar increase in 2-AG levels are not seen in any brain regions or 
peripheral organ tissues in DAGL knockout animals (Gao et al., 2010; Tanimura et al., 2010; 
Yoshino et al., 2011). Nonetheless, the results do point to DAGL as the major contributor 
to the generation of the basal pool of 2-AG in the CB1-Tango cells and DAGLmay have a 
minor contribution. But, as stated our measurements reflect only the basal pool and further 
studies would be required to determine the contribution of each enzyme to stimulus induced 






Whilst the majority of the 2-AG levels has been depleted in DAGL KO cells, a small 
detectable level of 2-AG is still present. This suggests that there may be other synthesis 
routes of 2-AG, for example through the actions of PLA1 and lysoPLC (Higgs and Glomset, 
1994). Recently, DDHD2 enzyme (previously regarded as a phospholipase A1) was purified 
from the soluble fraction of rat brain and exhibited sn-1 DAGL ability (Aso et al., 2016). This 
enzyme is ubiquitously expressed, with particularly high detection in the brain in astrocytes 
and neurons. When DDHD2 was overexpressed in CHO cells, 2-AG release from [14C] SAG 
increased in a time dependent manner (Araki et al., 2016; Aso et al., 2016). This enzyme may 
also contribute to the generation of 2-AG, however the importance of this enzyme in cells 
and tissues for the generation of 2-AG requires further study. The low levels of 2-AG may 
also indicate the presence of a DAGL-independent signalling pool of 2-AG which may be 
stored, however this would also mean that the large majority of 2-AG is synthesised on 
demand as the abolishment of DAGLs reduced the majority of 2-AG levels.  
 
Lipid measurements of AEA were unchanged in the individual KO lines, but were higher in 
the dual DAGL KO clonal cell line. This again might simply reflect clonal variation, but 
nonetheless could reflect an adaptive change. Previous studies in KO mice showed surprising 
reductions in brain levels of AEA in DAGL KO mice. Around 40-50% reduction of AEA was 
observed in whole brain (Gao et al., 2010; Ogasawara et al., 2016) with significant reductions 
in specific regions of the brain e.g. cortex, hippocampus and amygdala (Tanimura et al., 2010; 
Yoshino et al., 2011; Jenniches et al., 2016). This reduction in AEA levels was not seen in 
DAGL KO mice (Gao et al., 2010; Tanimura et al., 2010; Yoshino et al., 2011) and had no 
significant reduction in most brain regions in mice lacking both DAGLs (Yoshino et al., 2011). 
The crosstalk between DAGL and thus the level of 2-AG and AEA levels observed in KO 
animals were reproducible using pharmacological blockade of the DAGLs with specific DAGL 
inhibitors. Blockade of both DAGL and DAGL with selective inhibitors DH376 and DO34 
significantly decreased whole brain levels of 2-AG (>80%) and AEA (~40%), mimicking the 
effects seen from animal KO studies (Ogasawara et al., 2016; Wilkerson et al., 2017). It seems 
there is crosstalk between DAGL and thus 2-AG levels with AEA levels in a brain-region 
specific manner, although the underlying mechanism behind this is inconclusive but likely to 
be through indirect mechanisms such as maintenance of lipid pools or through the altered 
activity of cyclooxygenase which both 2-AG and AEA are substrates for (Gao et al., 2010; Di 






The increased levels of AEA from the DAGL KO line therefore does not corroborate the 
majority of the studies mentioned above. However, there are brain specific regions where 
the KO of DAGL did not affect AEA levels e.g. striatum (Tanimura et al., 2010; Jenniches et 
al., 2016). Therefore, the impact of DAGL KO on AEA levels may differ depending on the 
degree of crosstalk between the two pathways. Again, the higher levels of AEA could just be 
reflective of clonal variances between the cell lines as there is little evidence to support the 
increase of AEA in the absence/inhibition of the DAGLs. It might also be worth noting the 
DAGL KO clones have changed morphology and slower growth rate following the KO of 
DAGLs (unpublished observations). There are many reasons why this might be the case: 
perhaps the KO of DAGLs induced off-target effects which may affect cell morphology; the 
depletion of DAGLs, which may have other functions, affects cell survival; or the significantly 
increased levels of AEA may have a negative effect on the survival of the cells (Maccarrone 
et al., 2000a) – however the levels of AEA increase is relatively low so it is unclear if this is 
physiologically relevant and this increase is not seen in the CB1-Tango assay in the absence 
of JZL195.  
 
Related lipids OEA is a proposed ligand for PPARα, TRPV1 and GPR119 receptors (Romano et 
al., 2014) and PEA is also a ligand for PPARα receptor (Petrosino et al., 2010). PEA showed 
no significant changes, whilst OEA had a small significant increase, however this slight 
increase could be due to clonal differences from a heterogenous pool of cells.  
 
The increased AEA levels in the double DAGL knockout cell line is possibly associated with 
an increase in transcript levels of NAPEPLD, with no change in FAAH transcripts. This 
increased expression serves as evidence of active pathways that can generate AEA for 
signalling in the eCB cells in the absence of the DAGLs. This increase in the ability of the cells 
to make AEA could conceivably account for the increase in eCB tone seen in response to 
JZL195 treatment in the DAGL deficient cells relative to the parental cells, an interesting 
possibly that perhaps warrants further investigation. Irrespective of the cause, the higher 
basal levels of AEA in these cells will be advantageous in further studies into the AEA 
pathways to determine which enzymes contribute to AEA synthesis. From the results of the 
QuantiGene beads assay, PLA2G4B transcript levels are also slightly, although significantly 
higher in this clonal cell line. Interestingly, MGLL and ABHD6 transcript levels are also 
significantly higher by 2 fold but FAAH transcript levels are similar, it would be of interest to 





scope of the thesis. Nonetheless, the increased expression of MAGL and ABHD6 transcripts 
could function to maintain the levels of AA and other lipids in the absence of DAGL which 
contribute greatly to the generation of AA (Gao et al., 2010). The transcripts of the DAGLs 
were also measured in the beads assay but it is not possible to measure accurate transcript 
levels using the probe sets on our beads as the probes are targeted to many sites on the gene 
and are insensitive to indel mutations.  
 
The DAGL KO cells were tested in the assay paradigms that were described in Chapter 5. 
Results show the expression of CB1 receptors to be similar between the DAGL KO clone 
and the parental cells and importantly there was no obvious difference in responsiveness to 
ACEA in McCoy’s assay media. A robust JZL195-elicited eCB tone is still present in the 
DAGL KO cells, which agrees with previous pharmacological experiments with DAGL 
inhibitors KT107 and KT172 i.e. that the eCB tone produced in the presence of JZL195 is not 
DAGL dependent. This eCB tone is significantly increased despite the KO of the DAGLs which 
again might be due to clonal variability or a real adaptive change. If the increase in eCB is an 
adaptive change, one possible explanation is that it is reflective of the activation of the CB1 
receptor by other eCBs which may have different signalling dynamics to 2-AG. For example, 
measured AEA levels may be much lower than 2-AG but AEA has shown much more potent 
activity towards the CB1 receptor than 2-AG (Sugiura et al., 1995; Steffens et al., 2005). This 
is also evidenced in previous CB1-Tango assays where the EC50 of AEA is lower than that of 
2-AG. Another possibility is perhaps higher levels of eCBs are generated, for example the 
increased measured AEA levels in the DAGL KO cell line. Despite the increased levels of 
AEA, there is no eCB tone present in the absence of JZL195, suggesting that perhaps the 
activity of MAGL, FAAH and ABHD6 is sufficient in limiting the activity of the increased AEA 
and perhaps any other eCBs produced.  
Likewise, after treatment with ionomycin, there is still an inducible eCB signalling which is on 
comparable levels to parental CB1-Tango cells despite removing the DAGL dependent 
portion of the response. This increase in eCB tone and the maintenance of the ionomycin 
response in DAGL KO cells was surprising as it suggests that despite the substantial 
reduction of 2-AG present in these cells, there is either more eCB signalling or that the DAGL 
dependent portion can be compensated for. One possibility is the increase in basal AEA levels 
is reflective of overall increased AEA generation and signalling, or it could also be the action 
of other possible eCBs that may have either increased synthesis or different signalling 





Similarly, when tested in the No Starve Freestyle conditions, ACEA showed similar maximal 
responses and the eCB tone is also significantly increased in the DAGL KO cells. When 
testing FSK and PMA responses, eCB signalling is slightly reduced in the DAGL KO cells 
compared to parental CB1-Tango cells but there are still large responses that are elicited. 
The reduction of the responses might reflect the contribution of 2-AG to the responses, or it 
might be due to clonal variability. It is unknown precisely how the activity of PKA and PKC 
directly induces eCB signalling. The activity of PKA and PKC may induce synthesis of other 
eCBs, for example PKC dependent signalling promoted AEA and other NAE synthesis in 
neuronal cultures (Cadas et al., 1996; Vellani et al., 2008). However, the remaining response 
is further evidence that activation of PKA and PKC can evoke eCB signalling that is largely not 
DAGL and 2-AG dependent.  
 
The above results clearly show that loss of the DAGLs has little, if any impact on eCB signalling 
in response to a wide range of stimuli. Given our sequencing results and the dramatic (~90%) 
reduction in 2-AG levels in the knockout cells, the conclusion that 2-AG is not responsible for 
a wide range of eCB signalling can be reached. This is further supported by the 
pharmacological evidence, for example KT109 and KT172 failed to inhibit the presence of the 
basal tone induced by JZL195 and in general had no impact on ionomycin, PKA or PKC 
responses. The one exception was a partial reduction in the enhanced ionomycin response 
seen in presence of JZL195. 
 
It remains possible that the DAGLs can drive eCB responses stimulated by other agents or 
pathways. PKA and PKC were hypothesised as the key kinases that can activate DAGL activity, 
but other kinases may also activate the DAGLs (Reisenberg et al., 2012). Platelets stimulated 
by thrombin showed accumulation of 2-AG (Prescott and Majerus, 1983) and other stimuli 
such as ethanol and glutamate have been found to increase 2-AG levels in primary cultures 
of cerebellar granular neurons (Basavarajappa et al., 2000). Endothelin-1 and ATP can also 
stimulate 2-AG production from astrocytes via endothelin A receptor and P2X7 receptors, 
although both stimuli require the presence of extracellular calcium (Walter and Stella, 2003; 
Walter et al., 2004). In the context of retrograde signalling, excitatory neurotransmitters such 
as glutamate, activate post synaptic receptors which drives eCB signalling via G-protein or 
calcium activation of PLC (Stella and Piomelli, 2001; Kano, 2014). As most of these stimuli 
function through receptors which require the extracellular presence of calcium, those stimuli 





It is also possible that DAGL function in these cells is unrelated to eCB signalling. The presence 
of high transcript levels of the DAGLs appears paradoxal to the minor impact of these 
enzymes on eCB signalling, however the DAGLs can also generate other related lipid species 
which may have other signalling roles (Bisogno et al., 2003). This additional role would seem 
logical as a DAGL homologue is expressed in species such as Drosophila melanogaster which 
do not synthesise AA nor contain CB receptors (Elphick and Egertova, 2001; McPartland et 
al., 2001; Tortoriello et al., 2013), suggesting that the DAGLs can generate other MAGs for 
non-CB purposes. As well as this, the measured levels of 2-AG were magnitudes larger than 
AEA levels in the CB1-Tango cells, which was not unexpected as 2-AG is the most abundant 
eCB in the developing and adult brain (Mechoulam et al., 1995; Sugiura et al., 1999). The 
DAGLs were responsible for the generation of ~90% of 2-AG, but the presence of DAGLs and 
much higher levels of 2-AG had little impact on eCB signalling in the CB1-Tango cells. The 
presence and continual activity of the eCB degrading enzymes MAGL, ABHD6 and perhaps 
FAAH limits the signalling activity of the eCBs, but these could also have secondary roles, for 
instance in liberating the AA from the 2-AG produced by the DAGLs. Indeed, genetic and 
pharmacological studies of DAGL showed the levels of AA to be substantially reduced 
alongside 2-AG (Gao et al., 2010; Tanimura et al., 2010; Ogasawara et al., 2016). When 
viewed this way, the hydrolysis of 2-AG by MAGL/ABHD6 would have the direct function of 
generating AA as opposed to terminating the action of 2-AG for eCB signalling. The 
generation of AA could serve as precursors for eicosanoids such as PGE2 (Kozak et al., 2002) 
which are involved in various pathological processes such as inflammation in macrophages 
and microglia (Harizi et al., 2008). This function is supported by the presence of DAGL 
expression exclusively in microglia in the brain (Zhang et al., 2014) and has shown active 
involvement in inflammatory responses (Hsu et al., 2012). This highlights the DAGL/MAGL 
pathway may have a role in the CB1-Tango cells for the generation/regulation of AA levels, 
however it was beyond the scope of this thesis to determine contribution of DAGLs to the 
AA pool.  
 
The DAGL knockout cell lines do have enhanced AEA levels and this is the next obvious 
candidate to be responsible for the robust eCB signalling that remains in the cells.   They also 
express relatively high levels of NAPEPLD, an enzyme largely attributed to the synthesis of 
this eCB. However, this is a contentious point as some (but not all) animal KO studies of 
NAPEPLD have shown that NAPEPLD is dispensable in the synthesis of AEA (Leung et al., 





compensatory pathways could have emerged due to global deletion of NAPEPLD to maintain 
physiological levels of AEA. In addition, recent studies have identified other enzymes that 
might play pivotal roles in the synthesis of this eCB. Having generated a cell line that lacks 
the DAGLs and has lost ~90% of its basal levels of 2-AG, yet retains robust eCB responses to 
a variety of stimuli, we have perhaps inadvertently generated a very important model for 
identifying the pathways responsible for DAGL independent eCB signalling. In the next 
section of the thesis we will test the importance of NAPEPLD for AEA synthesis and eCB 







6.3 Results 4B. Evaluating the role of NAPEPLD in 
AEA synthesis 
 
6.3.1 Results 4B. Introduction 
 
Pharmacological inhibition and genetic knock out of the DAGLs has revealed that eCB 
signalling can still be robustly generated in a DAGL independent manner in the CB1-Tango 
cells. It is not known through which eCB this signalling occurs through, but it is speculated to 
be the second most characterised eCB: AEA. From the lipid measurements of the CRISPR 
treated cells, basal 2-AG levels were almost completely abolished upon the genetic KO of the 
DAGLs, highlighting the necessary involvement of the DAGLs in the generation of 2-AG, 
however basal levels of AEA were significantly higher than in parental CB1-Tango cells. FAAH 
transcript levels in the DAGL KO cells were of similar levels to the parental CB1-Tango 
cells, however NAPEPLD transcripts are significantly higher suggesting that this might 
account for the this increase in AEA. AEA is also a good candidate to be the eCB that can be 
evoked in the CB1-Tango assay as it can be synthesised in response to various 
pharmacological stimulations (Di Marzo et al., 1994; Vellani et al., 2008; Ueda et al., 2013), 
but it is not currently known through which synthesis pathway(s) this occurs through.  
AEA has been shown to be a key biological signalling molecule in both the CNS (Elphick and 
Egertova, 2001; Maccarrone et al., 2014; Di Marzo et al., 2015; Curran et al., 2016) and in the 
periphery (Berdyshev et al., 1997; Bab et al., 2008; Maccarrone et al., 2015). Due to the 
ubiquitous presence of AEA in the human body (and other organisms (Elphick, 2012)), focus 
has been placed on the emerging importance of the AEA as a signalling molecule, as it is a 
ligand for many receptors aside from CB1 and CB2, for example TRPV1, GPR55, GPR119 and 
PPARs (Brown and Robin Hiley, 2009; Godlewski et al., 2009; O'Sullivan and Kendall, 2010; 
Sousa-Valente et al., 2014). It has also therefore been of interest to elucidate through which 
mechanisms AEA is synthesised and potentially regulated.  
NAPEPLD was identified as the enzyme in generating AEA from the precursor NAPE and is 
highly conserved in sequence from mice to humans (Okamoto et al., 2004). It belongs to the 
metallohydrolase family, shows calcium sensitivity (Ueda et al., 2001) and the requirement 





(Magotti et al., 2015). NAPEPLD is also expressed in many organs in mice, with high 
expression in the brain and testes where AEA levels are relatively high, placing NAPEPLD as 
a principle candidate enzyme in AEA generation (Okamoto et al., 2004). However, from 
various animal KO studies of NAPEPLD, it has been shown that the lack of NAPEPLD enzyme 
can have little if any impact on AEA levels suggesting that it is not important, or that its loss 
can be compensated for by alternative routes producing AEA (Leung et al., 2006; Tsuboi et 
al., 2011; Leishman et al., 2016; Inoue et al., 2017). Most of these studies measured 
endogenous levels of AEA from the whole brain or large brain regions where compensation 
mechanisms can occur from different subpopulations of cells, and global deletion of an 
enzyme that may contribute to the generation of a widely distributed signalling molecule 
could cause the emergence of alternative pathways that may not normally be active and so 
should be interpreted with some caution. Based on this, we focused on the extent NAPEPLD 
is required for eCB signalling in a cell based system where the involvement from secondary 
pathways might be restricted.  
NAPEPLD transcripts were readily detected in the CB1-Tango cells and were significantly 
higher in the DAGL KO line, which may be connected to the high AEA levels measured in 
the DAGL KO line. CRISPR strategy was utilised once again to genetically target the 
NAPEPLD gene from the DAGL KO cells to generate a cell line with three disrupted genes 
to determine if eCB signalling in the CB1-Tango cells is impacted by the genetic deletion of 
three major eCB synthesis enzymes. However as mentioned previously, the currently 
adopted CRISPR technique described by Ran et al. (2013) and used to disrupt the DAGL genes 
causes relatively subtle changes in the genome thus characterisation of the effects of CRISPR 
proves relatively inefficient. Therefore, for NAPEPLD a slightly different approach was 
adopted as described by Canver et al. (2014). Instead of transfecting pools of cells with 
individual CRISPR vectors and relying on the action of one gRNA, two or more gRNAs are used 
simultaneously to generate two double strand breaks for the deletion of a defined segment 
of a gene (Figure 6.3.1) and in this case of NAPEPLD, the region targeted was required for 
catalytic activity. This method would allow for clearly identifiable successful KO of genes 
using PCR primers flanking the deletion site, and allows for deletion of whole catalytic regions 
which may otherwise escape nonsense mediated decay via alternatively spliced variants of 
the genes. It is also possible to use QuantiGene Multiplex probes designed to the region 






In this chapter, the generation of a NAPEPLD KO cell line from the DAGL KO cell line using 
CRISPR will be described. The characterisation of the cell line determined the successful KO 
of NAPEPLD and the effects of triple gene KO on the measured eCB levels of the cells. The 
cell line will then be tested in the CB1-Tango assay using previously established paradigms 
that can generate eCB signalling to determine the necessity of NAPEPLD not only for the 
synthesis of the basal levels of AEA in the cells, but also for the cells ability to generate a 
robust eCB response to the various stimuli described previously.  
 
 
Figure 6.3.1. Schematic of genomic deletion using two or more CRISPR gRNA targets on a 
single gene 
The two gRNA sites are shown located within two different exons of a gene. The gRNA 
sequences (green and grey) are shown on the top strand located immediately upstream of a 
subsequent PAM sequence (purple). The red line indicates the predicted Cas9 cleavage site 
between nucleotide positions 17 and 18 on the gRNA. The blue arrows indicate the position 
of PCR primers for deletion band amplification.  





6.3.2 Results 4B. Results 
Design of gRNAs to NAPEPLD catalytic domain and generation of CRISPR vectors 
The NAPEPLD gene consists of 6 exons (Figure 6.3.2) coding for 393 amino acid length 
protein. Previous animal KO models genetically deleted exon 3 of NAPEPLD where the 
catalytic HXHXDH motif is situated (Okamoto et al., 2004). It was logical to therefore also aim 
for disruption of exon 3 with CRISPR. This region is 647bp long with the motif positioned in 
the centre of the exon, gRNAs were designed around the catalytic motif using public gRNA 
generation websites as described previously (Figure 6.3.2 and Table 2.1.2). For further 
analysis later using the QuantiGene multiplex assay system, it was also ensured that the 
Multiplex probes are designed to target the region of the transcript encoded by the stretch 
of DNA targeted for deletion. 
Previous CRISPR experiments aimed to generate indel mutations which would cause 
frameshift mutations leading to disrupted protein, however with this method it was difficult 
to characterise the nature of the mutations as they are usually subtle. Instead, 4 gRNAs were 
selected based on their location prior to and after the HXHXDH motif (Figure 6.3.3) so that 
upon introduction of two double strand breaks, the two flanking regions would repair and 
the internal segment would be deleted (Canver et al., 2014). The largest deletion between 
the two furthest gRNAs is predicted to be around 243bp.  
The gRNAs were inserted into the CRISPR backbone vector as previously described and four 
CRISPR vectors were generated. The vectors were then transfected into plated DAGL KO 
cells as described in Methods. Pools of cells were transfected with one gRNA vector or all 
four gRNA vectors together. After transfection and puromycin selection, the remaining cells 
were seeded at low density to facilitate the growth of individual cells into discrete colonies 






Figure 6.3.2. Selection of gRNA sequences selected for Cas9 recognition of NAPEPLD 
catalytic domain 
Schematic representation of the human NAPEPLD sequence, indicating the exon 1 and 6 
UTRs (yellow) and the catalytic domain (blue) in exon 3. Target sequences were designed 
flanking the catalytic HXHXDH motif necessary for NAPEPLD catalytic action (Daiyasu et al., 




















Figure 6.3.3. Targets of exon 3 of NAPEPLD DNA sequence 
DNA sequence of exon 3 is displayed above and the corresponding amino acid sequence is 
displayed in purple below the DNA sequence. The HXHXDH sequence important for catalytic 
activity of NAPEPLD is highlighted in green and underlined. Guide RNA sequences are 
highlighted in blue above the sequence and underlined, the 5’-NGG PAM sequence is in red 














Characterisation of NAPEPLD knockout cell lines 
After the colonies had grown to sufficient numbers, RNA was extracted from the cells and 
converted to cDNA before PCR amplification of the CRISPR site with primers designed to exon 
2 and exon 4 (Figure 6.3.4). The parental DAGL KO cell line had a relatively clean band at 
around the predicted size of 856bp. Colonies which were transfected with single vectors (4B1 
– 4B6 and others not shown) showed minor changes in RT-PCR which might be indicative of 
subtle mutations. Colonies which were transfected with all four CRISPR vectors at once (A41 
– A47) showed much more variable transcripts and larger shifts in the RT-PCR band which 
are indicative of larger mutations. The A43 and A47 cell lines showed large transcript 
disruptions and produced clean RT-PCR bands at around 600bp mark which would be the 
expected size if the large targeted region has been disrupted. These two cell lines are likely 
to have disrupted transcripts in both alleles, although it is not for certain. For further analysis, 
these lines were selected and renamed NAPEPLD KO1 and NAPEPLD KO2 respectively. 
Next, genomic sequencing of the cells were carried out. Genomic DNA was extracted from 
the cells and PCR was carried out with primers located in the introns flanking exon 3. The 
PCR product was purified and sent for Sanger sequencing. The sequencing results were clean 
with only one result obtained, suggesting that both alleles of NAPEPLD could have been 
cleaved and mutated in the same way although further analysis would need to be carried out 
to confirm this. The alignment of the sequences in Figure 6.3.5 shows subtle indel mutations 
present at some of the CRISPR sites, and large deletions beginning and terminating at CRISPR 
sites flanking the catalytic motif. Analysis of these sequences show that a stop codon has 
been introduced prior to the catalytic motif (Figure 6.3.6); this indicates the transcripts no 




































































































































































































































































































































































































































































































Figure 6.3.5. Genomic DNA sequencing of PCR products reveal large deletions of NAPEPLD 
between CRISPR sites 
NAPEPLD CRISPR treated cells NAPEPLD KO1 and KO2 and DAGL KO cells were grown in 
T75 flasks until confluent and genomic DNA was extracted from the pelleted cells. PCR was 
carried out with primers flanking exon 3 as listed in methods. The PCR product was then run 
on 1% agarose gel and purified from the gel. The purified PCR product and primers were sent 
for Sanger sequencing, results were aligned in Clustal Omega. Letters in red show indel 










Figure 6.3.6. NAPEPLD KO1 and KO2 protein sequences encounter early stop codons shortly 
after CRISPR site 
DNA sequencing results were translated into protein sequences and aligned with wild type 
NAPEPLD protein sequence. The stars within the sequence indicated stop codons; the stop 
codons highlighted in red and underlined are the first stop codons encountered in the 





QuantiGene multiplex assay of NAPEPLD KO cell lines confirm undetectable 
NAPEPLD transcripts 
RT-PCR and genome sequencing has shown major disruptions in the NAPEPLD gene. For 
further evidence of the disruption of both alleles of NAPEPLD in KO1 and KO2 lines the 
transcriptomes of the cell lines were subject to analysis in the QuantiGene multiplex assay 
as described in methods (Figure 6.3.7). 
NAPEPLD KO1 and NAPEPLD KO2 clones showed complete abolition of detectable NAPEPLD 
transcripts to below the detectable threshold (KO1 = 4.0 ± 0.3 net MFI; KO2 = 5.1 ± 0.9 net 
MFI). This confirms that both alleles of NAPEPLD are mutated with a substantial deletion of 





Expression of CNR2 and PLA2G4E transcripts showed non-significant differences in detected 
levels when comparing the parental CB1-Tango and DAGL KO cells to the NAPEPLD KO 
cells. The transcripts levels of CNR1 in the NAPEPLD KO cell lines were not significantly 
different to the levels detected in both the CB1-Tango and the DAGL KO cells, however 
the levels of CNR1 transcripts in NAPEPLD KO1 tend to be lower which nears statistical 
significance when compared to parental CB1-Tango and the DAGL KO cell lines and has a 
small significance (p<0.05) when compared to the NAPEPLD KO2 cell line. 
The levels of DAGL and DAGL transcripts were not included for reasons mentioned 
previously; in brief the more subtle indel mutations introduced into those genes generates 
transcripts that can still be detected by our DAGL probes.  
Interestingly, relative expression of PLA2G4B transcript levels in KO1 and KO2 were 0.51 ± 
0.01 and 0.57 ± 0.01 respectively which are both significantly higher, albeit by a relatively 
small amount, than the relative levels in DAGL KO cells (0.42 ± 0.01 relative expression). 
FAAH transcripts levels were also detected in both KO1 and KO2 cells (0.017 ± 0.002 relative 
expression and 0.031 ± 0.001 relative expression respectively) which were relatively higher 
than the levels in the DAGL KO cells (0.011 ± 0.0004 relative expression). Meanwhile, the 
levels of MGLL are significantly lower in both NAPEPLD KO lines (0.017 ± 0.001 relative 
expression and 0.017 ± 0.0008 relative expression KO1 and KO2 respectively) and ABHD6 
showed a slight significant reduction in NAPEPLD KO2 cells. However, generally speaking 
most of these changes are relatively minor (e.g. see PLAG42B result) and importantly variable 
levels of the transcripts can also be seen between the NAPEPLD KO1 and KO2 lines (e.g. see 
the FAAH result) and in the case of MGLL the transcript level in the triple KO is similar to the 
level found in the parental cells. These observations point to simple clonal differences across 














Figure 6.3.7. Results from beads assay show CRISPR has knocked out the catalytic region 
of NAPEPLD 
CRISPR-treated NAPEPLD KO1 and KO2 cells and DAGL KO cells were grown in T75 flasks 
until confluent and RNA was extracted from the pelleted cells according to manufacturer’s 
instructions. RNA was diluted to a concentration of 375ng/l and 20l was added to wells in 
a 96 well plate, leading to total RNA in each well to be 7500ng. RNA samples and nuclease 
free water control samples were then incubated with magnetic beads and probes overnight. 
The beads were then washed and amplified and read on the Magpix system as in the 
methods section. The background readings from control wells were subtracted from the 
sample wells and the data was normalised to the expression of two housekeeping genes. 
Graph shows  means and bars represent SEMs of 5 replicates from one single experiment. 
Significance between groups was calculated using One Way ANOVA. 


















Lipid measurements show insignificant change in AEA levels in NAPEPLD KO 
lines 
Following confirmation of undetectable NAPEPLD transcripts from both cell lines thus 
confirming successful KO of NAPEPLD in two independent cell lines, the lipid levels of 2-AG, 
AEA, OEA and PEA were measured from 3 pelleted samples of the NAPEPLD KO cell lines 
across two independent experiments (Figure 6.3.8).  
Low levels of 2-AG were detected in both cell lines (KO1 = 110.8 ± 10.3 and KO2 = 123.8 ± 
25.0 pg/106 cells) which are consistent with the 2-AG levels from DAGL KO cells these 
lines were generated from. AEA levels are still readily detectable in the two NAPEPLD KO cell 
lines (KO1 = 4.74 ± 0.14 and KO2 = 5.82 ± 0.47 pg/106 cells), and show no significant 
difference to the levels in DAGL KO cells (7.21 ± 0.96 pg/106 cells) but remain significantly 
higher than the levels found in parental CB1-Tango cells (2.41 ± 0.53 pg/106 cells).  
Other related lipids OEA and PEA were also measured. Levels of OEA were detected in both 
KO lines (KO1 = 131.3 ± 7.2 and KO2 = 113.0 ± 19.7 pg/106 cells) and this was not significantly 
different to the levels detected in parental CB1-Tango (118.6 ± 8.9 pg/106 cells) or DAGL 
KO cells (175.5 ± 26.4 pg/106 cells). In both cell lines however, levels of PEA were significantly 
lower (KO1 = 38.8 ± 2.6 and KO2 = 39.2 ± 3.3 pg/106 cells) when compared to parental (94.1 
± 4.5 pg/106 cells) and DAGL KO lines (102.6 ± 19.6 pg/106 cells).  
The results of AEA levels from the cell lines may again be down to clonal variation giving rise 
to significantly higher levels in comparison to the parental CB1-Tango line, or could be 
reflective of functional changes in the cell, however the key results suggest that despite the 
genetic deletion of NAPEPLD, AEA can still be generated in the triple KO cell lines. 
Nonetheless, it is also interesting that PEA levels were reduced by a similar extent in both 















Figure 6.3.8. Lipid measurements of triple KO cells NAPEPLD KO 1 and NAPEPLD KO 2  
All cell lines were grown in regular conditions until 90% confluent. Cells were then harvested 
and counted to ensure there were more than 6x106 cells present per sample. Cells were then 
pelleted and frozen in -80oC and then shipped on dry ice for their lipid levels to be measured 
by mass spectrometry. 2-AG, AEA, OEA and PEA levels were measured in each sample and 
normalised to pg per 106 cells. Graph shows means and bars represent SEMs of n = 12 for 
parental CB1-Tango cells; n = 9 for DAGL KO cells; n = 3 for NAPEPLD KO cells. Significance 
between DAGL KO cells and NAPEPLD KO cells was calculated using One Way ANOVA. 














eCB signalling is still present in NAPEPLD KO lines in McCoy’s assay media 
The NAPEPLD KO cell lines were then tested in comparison to the DAGL KO cells in the 
CB1-Tango assays to determine if there were any changes in eCB signalling as a result of the 
absence of NAPEPLD which could possibly be involved in a stimulus induced increase in the 
signalling pool of AEA, or perhaps involved in the synthesis of other eCBs. The cells were first 
tested in 0.5% FBS McCoy’s assay media with ACEA in a standard 4 hour assay. The NAPEPLD 
KO cells and DAGL KO cells were treated with 5M ACEA in the presence and absence of 
2.5M AM251 (Figure 6.3.9). The DAGL KO were responsive to ACEA similarly to 
previously obtained levels (227.6 ± 2.8% of control). NAPEPLD KO2 cells are still responsive 
to ACEA in the same way as the DAGL KO cells (225.3 ± 13.2% of control). The NAPEPLD 
KO1 cells are also still responsive to ACEA but showed a significantly lower response when 
compared to the other two cell lines (179.7 ± 4.2% of control). This suggests that the multiple 
rounds of mutagenesis and selection might have created a cell line that has become 
compromised in the CB1 reporter aspect of the assay and this needs to be borne in mind in 
the following sections. 
Next the cells were subject to treatment with JZL195 to determine if an eCB tone is still 
present in the absence of the three key synthesising enzymes. The cells were treated with 
100nM JZL195 in the presence or absence of 2.5M AM251 for 4 hours (Figure 6.3.10). An 
eCB tone was present in DAGL KO cell line at similar levels to those obtained previously 
(142.7 ± 4.1% of AM251 control). The NAPEPLD KO1 cell line still produced a significant eCB 
tone, although this was slightly but significantly lower than that detected in the DAGL KO 
line (123.8 ± 4.2% of AM251 control). However, the NAPEPLD KO2 also produced a 
substantial eCB tone (148.1 ± 6.6% of AM251 control) which was not significantly different 
to the tone in its parental DAGL KO line.  
Finally, the cells were treated with ionomycin to see if eCB signalling can still be induced by 
the influx of calcium (Figure 6.3.11). The DAGL KO line produced an ionomycin response 
that was of an expected magnitude (186.1 ± 13.7% of AM251 control) which also contained 
a portion of response that could not be blocked by AM251 (140.2 ± 2.5% of AM251 control), 
similar to previously obtained results. The NAPEPLD KO cell lines also produced measurable 
CB1 dependent responses with the KO2 line again behaving like the parental double 
DAGL KO line and the KO1 line again showing a significant but muted response (KO1 = 
156.0 ± 6.0% of control; KO2 = 198.1 ± 13.9% of control), but had variable sizes of the non-





normalised to the wells containing ionomycin and AM251 to normalise the data to display 
only the CB1-dependent portion of the ionomycin response (Figure 6.3.11B). In this case, 
there were no statistically significant differences between all three cell lines in response to 
ionomycin (DAGL KO = 132.4 ± 7.3% of control; KO1 = 124.4 ± 4.5% of control; KO2 = 
124.7 ± 8.9% of control). Thus, all three cell lines were responsive to 2M ionomycin, and 




Figure 6.3.9. ACEA response is present in NAPEPLD KO cells  
Cells were grown until 90% confluent and plated in black 96 well plates and incubated for 24 
hours. The next day cells were treated with 5M ACEA in the presence or absence of 2.5M 
AM251 for 4 hours. Substrate was mixed according to manufacturer’s instructions and added 
to the cells for 90 minutes. The plate was then read on the Flexstation. Data was normalised 
to wells containing AM251 (set as 100%). Graph shows means and bars represent SEMs of 3 
independent experiments, 8 replicates in each individual experiment. Significance between 
groups was calculated using One Way ANOVA.  







Figure 6.3.10. NAPEPLD KO cells still exhibit eCB tone in the presence of JZL195 
30,000 cells were plated in black 96 well plates in 0.5% FBS McCoy’s media for 24 hours. The 
cells were treated the next morning with 100nM JZL195 in the presence and absence of 
2.5M AM251 for 4 hours. The substrate was then mixed according to manufacturer’s 
instructions and added to the wells for 90 minutes. Fluorescent substrate was then read on 
the Flexstation and the fluorescence ratio calculated. Data was normalised to the wells 
containing AM251 (set as 100%). Graph shows means and bars represent SEMs of 6 
independent experiments, 8 replicates in each individual experiment. Significance between 
groups was calculated using One Way ANOVA.  


















Figure 6.3.11. Ionomycin induced response is present in NAPEPLD KO cells 
Cells were grown until 90% confluent and plated in black 96 well plates and incubated for 24 
hours. The next day cells were treated with 2M ionomycin in the presence or absence of 
2.5M AM251 for 4 hours. 100nM JZL195 was included in all wells. Substrate was mixed 
according to manufacturer’s instructions and added to the cells for 90 minutes. The plate 
was then read on the Flexstation. Data was normalised to wells containing AM251 (set as 
100%) (A); or the data was normalised to wells containing ionomycin in the presence of 
AM251 to give the % of ionomycin response (B). Graph shows means and bars represent 
SEMs of 3 independent experiments, 8 replicates in each individual experiment. Significance 
between groups was calculated using One Way ANOVA.  















FSK and PMA can still elicit eCB signalling in NAPEPLD KO cells in No Starve 
Freestyle media 
Subsequently, the cells were tested in the 24 hour No Starve Freestyle assay conditions to 
again determine the effect the absence of functional NAPEPLD has on the eCB tone in these 
conditions and on the FSK and PMA responses. To begin with, the cells were treated with 
ACEA in the presence and absence of AM251 to determine if CRISPR treatment has affected 
the expression of the CB1 receptors or the assay system (Figure 6.3.12). The ACEA responses 
elicited in DAGL KO cells, as expected, are robust reaching 650.5 ± 71.5% of AM251 
control. NAPEPLD KO lines are still responsive to ACEA; NAPEPLD KO2 elicited a response 
reaching 621.2 ± 69.9% of AM251 control which was not statistically different to the 
response elicited by DAGL KO cells. NAPEPLD KO1 also show responsiveness to ACEA, 
however the response is again significantly lower than responses evoked by the other two 
cell lines (421.7 ± 98.6% of AM251 control). Thus it is clear that the NAPEPLD KO1 line is 
compromised in its sensitivity to CB1 signalling, possibly due to a lower expression of the CB1 
receptor. The ACEA responses from all 3 cell lines were largely inhibited by AM251 to near 
control levels.  
The eCB tone was also examined in the NAPEPLD KO cells in this paradigm; the cells were 
plated in No Starve Freestyle conditions as described in methods in the presence and 
absence of 2.5M AM251 (Figure 6.3.13). A substantial eCB tone was detected in DAGL 
KO cells (373.7 ± 24.2% of AM251 control) which is still significantly higher than the tone 
detected previously in parental CB1-Tango cells. The NAPEPLD KO2 line showed a very robust 
response (310.1 ± 13.7% of AM251 control) which was not significantly different from the 
response of its parental line. Again, the NAPEPLD KO1 cell line showed a substantial and 
significant response (220.3 ± 24.0% of AM251 control) which, like the ACEA response, was 
muted when compared to the parental line response. Thus it is clear that NAPEPLD is not 
required for the generation of the eCB in this paradigm.  
To test whether activation of kinases continues to elicit eCB signalling in the NAPEPLD KO cell 
lines, the cell lines were treated with 10M FSK in the presence and absence of AM251 
(Figure 6.3.14). A robust FSK induced response was measured from the DAGL KO cells 
(519.0 ± 48.1% of AM251 control) which is on a comparable level to those obtained 
previously. The NAPEPLD KO2 line gave a robust response to FSK treatment (475.3 ± 14.0% 
of AM251 control) which was not significantly different to the response of the parental 





AM251 control) however again similarly to the ACEA response, this was muted when 
compared to the parental DAGL KO line response most likely due to reduced sensitivity 
of this line to CB1 signalling. 
Finally, the cells were treated with 25nM PMA in the presence and absence of AM251 in the 
No Starve Freestyle conditions for 24 hours to if eCB signalling can still be elicited by PKC in 
the NAPEPLD KO lines (Figure 6.3.15). PMA elicited a response reaching 289.3 ± 21.4% of 
AM251 control in the DAGL KO cells which was mostly blocked by AM251 but did show a 
component that could not be inhibited by AM251, which is in line with previously obtained 
results. Interestingly, PMA also elicited responses in the NAPEPLD KO cell lines (KO1 = 375.2 
± 76.8%; KO2 = 532.3 ± 15.8% of AM251 control) which lean towards the presence of higher 
responses in comparison to the DAGL KO line. However, these PMA responses also had 
higher portions of responses that could not be inhibited by AM251 and therefore may not 
necessarily be signalling through the CB1 receptor (Figure 6.3.15A). Considering this, the data 
was instead normalised to PMA in the presence of AM251 to give a clearer indication of the 
CB1 dependent response (Figure 6.3.15B). When presented this way, the PMA responses 
from all three cell lines are not significantly different, although the response from NAPEPLD 
KO2 is of a higher magnitude and nears statistical significance. PMA, along with FSK, still 
elicits eCB signalling in the NAPEPLD KO cell lines in a very similar manner to the DAGL 









Figure 6.3.12. The NAPEPLD KO cells are still responsive to ACEA in No Starve Freestyle 
conditions 
Cells were grown until 90% confluent and plated in black 96 well plates in Freestyle media 
supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, cells were 
treated with 5M ACEA in the presence and absence of 2.5M AM251 for 24 hours. 
Substrate was mixed according to manufacturer’s instructions and added to the cells for 90 
minutes. The plate was then read on the Flexstation. Data was normalised to wells containing 
AM251 only (set as 100%). Graph shows means and bars represent SEMs of 4 independent 
experiments, 8 replicates in each individual experiment. Significance between groups was 
calculated using One Way ANOVA.  








Figure 6.3.13. eCB tone is present in NAPEPLD KO cells in No Starve Freestyle conditions 
Cells were grown until 90% confluent and plated in black 96 well plates in Freestyle media 
supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, cells were 
treated with control media or 2.5M AM251 for 24 hours. Substrate was mixed according to 
manufacturer’s instructions and added to the cells for 90 minutes. The plate was then read 
on the Flexstation. Data was normalised to wells containing AM251 (set as 100%). Graph 
shows means and bars represent SEMs of 4 independent experiments, 8 replicates in each 
individual experiment. Significance between groups was calculated using One Way ANOVA.  








Figure 6.3.14. FSK still elicits a response in NAPEPLD KO cells in No Starve Freestyle 
conditions 
Cells were grown until 90% confluent and plated in black 96 well plates in Freestyle media 
supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, cells were 
treated with 10M FSK in the presence and absence of 2.5M AM251 for 24 hours. Substrate 
was mixed according to manufacturer’s instructions and added to the cells for 90 minutes. 
The plate was then read on the Flexstation. Data was normalised to wells containing AM251 
only (set as 100%). Graph shows means and bars represent SEMs of 4 independent 
experiments, 8 replicates in each individual experiment. Significance between groups was 
calculated using One Way ANOVA.  














Figure 6.3.15. PMA induced response is unchanged in NAPEPLD KO cells in No Starve 
Freestyle conditions 
Cells were grown until 90% confluent and plated in black 96 well plates in Freestyle media 
supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, cells were 
treated with 25nM PMA in the presence and absence of 2.5M AM251 for 24 hours. Data 
was normalised to wells containing AM251 (set as 100%) (A); or the data was normalised to 
wells containing PMA in the presence of AM251 to give the % of PMA response (B). Graph 
shows means and bars represent SEMs of 4 independent experiments, 8 replicates in each 
individual experiment. Significance between groups was calculated using One Way ANOVA.  
















6.3.3 Results 4B. Summary & conclusions  
Genetic KO of the DAGLs in the CB1-Tango cells revealed significant reduction of 2-AG levels 
confirming the necessity of the DAGLs in the generation of 2-AG. However, despite the 
substantial reduction of 2-AG levels, there was little change in JZL195, calcium, PKA and PKC 
stimulated eCB signalling. AEA is the other well characterised eCB and NAPEPLD remains the 
best characterised enzyme in the pathway that is generally taken to be responsible for the 
synthesis of this eCB, and for this reason we have directly tested the requirement for this 
enzyme for both the synthesis of AEA and stimulus induced eCB signalling in the host cell 
line. 
A CRISPR strategy that uses single gRNAs to introduce small mutations into the genome 
proved successful for the generation of cell lines that lacked functional DAGL and DAGL 
gene products. A different CRISPR approach was taken in the generation of NAPEPLD KO 
lines. As opposed to relying on individual gRNAs in separate pools of cells which had 
commonly been the technique used (Ran et al., 2013), a new method of combining several 
CRISPR vectors in one transfection to cause two double strand breaks and thus cause a repair 
with substantial missing portions of DNA sequence was adopted (Canver et al., 2014). Cell 
lines generated this way can be predicted to make transcripts will relatively large well 
defined deletions that would very easily be confirmed by RT-PCR in comparison to subtle 
mutations that are generated by individual vectors. Genome sequencing could also then be 
used to confirm the removal of the intermediate DNA flanked by the two CRISPR sites, which 
in the case of NAPEPLD involves removal of the catalytic motif. Thus, if translated from the 
compromised transcripts, the truncated protein would be catalytically dead.  
Further confirmation of NAPEPLD knockout came from isolating mRNA from two NAPEPLD 
KO lines for analysis using the QuantiGene multiplex assay. The NAPEPLD probe sets were 
designed to bind to the region of the transcript corresponding to the catalytic domain that 
would be missing if the CRISPR strategy was successful. Indeed, the results from the assay 
showed no detectable levels of NAPEPLD transcripts in both cell lines, indicating the 
complete knockout of NAPEPLD activity. Unfortunately, a reliable NAPEPLD antibody is 
unavailable so western blot analysis of NAPEPLD protein expression in the cells was 
inconclusive. However, from the results of genomic sequencing and transcriptome analysis, 






The QuantiGene multiplex assay also revealed other changes in the transcript levels within 
the two NAPEPLD KO cell lines. The PLA2G4E transcript levels remained below detectable 
threshold and the CNR2 transcript levels remained largely unchanged in all of the cell lines. 
Transcript levels of CNR1 in the NAPEPLD KO1 line was significantly lower in comparison to 
the NAPEPLD KO2 line and tended to be lower in comparison to the parental CB1-Tango and 
DAGL KO lines but did not reach statistical significance. This could have been a result of 
clonal variances, however from the results of the CB1-Tango assay, the responses to ACEA, 
JZL195 and FSK from the NAPEPLD KO1 line were significantly lower from both media 
conditions and across several independent experiments. The magnitude of the lowered 
responses were similar between the ACEA response and JZL195 and/or FSK responses; 
responses in McCoy's media were ~15-20% lower whilst the responses in No Starve Freestyle 
media were consistently ~40% lower in comparison the DAGL KO line. In particular, the 
sustained and consistent muted response to maximally active concentration of ACEA in both 
media conditions would indicate that there could have been some CRISPR-related side 
effects on the receptor reporter system, e.g. CRISPR introducing off-target mutations leading 
to the reduced expression of CB1 receptors, which would be in keeping with the lower levels 
of CNR1 transcripts. The ACEA response is therefore necessary to ensure the cells maintain 
similar levels of CB1 activation as a compromised assay system could preclude any changes 
in eCB signalling and ideally any cell lines generated and taken forward in the project will 
maintain similar levels of CB1 activation by ACEA. This highlights the importance of selecting 
and profiling multiple cell clones due to clonal variances and potential CRISPR side effects 
which could affect responsiveness in the CB1-Tango assay.  
Other changes seen in the transcript levels are from the eCB hydrolysing enzymes. First, in 
comparison to the parental CB1-Tango cell line, the DAGL KO cell line had higher 
measured levels of AEA and NAPEPLD transcripts despite unchanged transcript levels of 
FAAH. As well as this, the two NAPEPLD KO lines show the same genetic mutation in 
NAPEPLD, but have widely different transcript levels of FAAH. This casts doubt on a causal 
relationship between NAPEPLD and FAAH transcripts and the differences in the FAAH 
transcript levels between the three KO cell lines are more likely to be caused by clonal 
variation rather than due to a functional change in AEA synthesis/degradation. Furthermore, 
transcript levels of MGLL were significantly higher in the DAGL KO cell line, however when 
measured from the NAPEPLD KO lines, the levels of MGLL transcripts were comparable to 
the original levels from the parental CB1-Tango cell line. This raises doubt whether the higher 





absence of functional DAGL enzyme as the NAPEPLD KO cells also do not express functional 
DAGL but the transcript levels of MGLL are similar to those from parental CB1-Tango cells. 
Finally, transcript levels of ABHD6 remained largely around the same levels between the 
DAGL KO cell line and the NAPEPLD KO lines which are also significantly higher than levels 
from the parental CB1-Tango cells. Despite this sustained high level of ABHD6 transcripts, 
the levels of 2-AG remained unchanged between the three KO cell lines, thus it is unlikely 
that transcript changes detected from these cell lines truly relate to any functional changes 
in eCB synthesis and are more likely to be due to clonal variation.  
As mentioned above, there was negligible difference in the levels of 2-AG and AEA between 
the three KO cell lines despite the additional absence of NAPEPLD. AEA levels from NAPEPLD 
KO cells are still relatively higher than those measured from the parental CB1-Tango cells, 
and slight differences observed between the KO lines are likely due to clonal differences. This 
sustained AEA level could be attributed to the activity of a FAAH backwards reaction 
combining free AA with ethanolamine (Arreaza et al., 1997; Mukhopadhyay et al., 2011), 
however high levels of AA and ethanolamine are required to tip the equilibrium of the 
reaction backwards to generate AEA from FAAH (Katayama et al., 1999). Whether this is 
relevant in our cell line is unknown, but as local concentrations of AA and ethanolamine may 
reach high enough concentrations, this pathway cannot be rigorously ruled out (Ueda et al., 
2000). However, seeing the readily detectable and stable levels of AEA between the three 
KO cell lines, it is more likely that the other documented synthesis pathways which are not 
NAPEPLD-dependent are contributing to the generation of AEA (Liu et al., 2008).  
Related lipid OEA also showed no differences in the NAPEPLD KO lines. Interestingly, the 
other related lipid PEA had significantly lower but not complete depletion in the NAPEPLD 
KO line. Again, this could be a result of clonal variances, but could also be indicative of the 
partial involvement of NAPEPLD in the generation of PEA, despite showing no changes 
between the parental CB1-Tango cells and the DAGL KO line with higher NAPEPLD 
transcript levels. From previous animal KO studies of NAPEPLD, the largest changes were 
seen in saturated and monounsaturated NAEs such as PEA and OEA (as opposed to AEA 
which is polyunsaturated), with reductions seen in both PEA and OEA but with more 
noticeable reductions in PEA levels (Leung et al., 2006; Tsuboi et al., 2011; Leishman et al., 
2016). This would suggest there are NAPEPLD-dependent and independent pathways to the 
generation of these NAEs and that there are overlapping but distinct substrate specificity 





to be involved in the generation of AEA (Liu et al., 2008). If the change in PEA levels was 
reflective of a functional change in the NAPEPLD KO cell line, this would fit with the studies 
of NAPEPLD KO mice and the observation that NAPEPLD is non-selective for the lipid side 
chain of the substrate (Ueda et al., 2013). It is also possible that NAPEPLD can generate other 
lipids that might function as an eCB, however due to the scope of the work and the 
availability of equipment and methods available to us, only the levels of the mentioned lipids 
were measured from the cell lines. 
When tested in the CB1-Tango assays, NAPEPLD KO2 line generally responded in the same 
manner as the DAGL KO line in the CB1-Tango assays. Treatment with ACEA revealed 
similar maximal activation levels to the DAGL KO line, a substantial basal eCB tone is still 
present and evoked eCB signalling with ionomycin, FSK and PMA also generated eCB 
signalling on comparable levels. The lack of change in the responses and the basal levels of 
AEA despite the genetic KO of NAPEPLD would suggest that NAPEPLD does not have a pivotal 
role in the generation of eCBs such as AEA for eCB signalling in NAPEPLD KO2 cell line. The 
NAPEPLD KO1 line, as mentioned previously, showed muted responses to ACEA, JZL195 and 
FSK in both media conditions which was present across several experiments and conditions 
indicating disruption of some of the internal metabolic processes of the cell, thus affecting 
the responsiveness of the cell to agonists at the CB1 receptor. The absolute magnitude of 
the response is therefore not fundamental in this cell line due to the off-target effects, but a 
substantial eCB tone and eCB signalling can still be evoked and detected in the NAPEPLD KO1 
cell line despite the KO of NAPEPLD, supporting the generation of eCB signalling through 
DAGL and NAPEPLD-independent pathways.  
The minor role of NAPEPLD towards AEA synthesis is supported by previous studies in 
NAPEPLD KO mice models (Leung et al., 2006; Liu et al., 2008; Tsuboi et al., 2011; Leishman 
et al., 2016). Studies differ between different strains of mice used to generate the NAPEPLD 
KO lines, analytical methods and which lipids were measured, however the general 
consensus is whilst there are slight reductions in endogenous AEA and other saturated and 
mono-unsaturated NAE levels in the brain, the attenuation of NAPEPLD does not abolish AEA 
and NAE levels completely, thus independent mechanisms of AEA generation clearly exist 
(Liu et al., 2008; Simon and Cravatt, 2010; Tsuboi et al., 2011). These studies generally 
focused on measuring lipid levels in the brain, but NAE levels (including AEA) were also 
unaltered in peripheral tissues including the heart, kidney and jejunum (Inoue et al., 2017), 





cells in this study. However, NAPE levels did generally increase in the NAPEPLD KO animals 
(Tsuboi et al., 2011; Inoue et al., 2017), and NAPEPLD activity against exogenously applied 
NAPE was reduced in different tissue areas (Leung et al., 2006). This suggests that NAPEPLD 
does facilitate the hydrolysis of certain NAPE into NAEs (such as PEA) but other mechanisms 
also exist to generate and maintain levels of NAEs, particularly of AEA. Therefore, in the 
NAPEPLD KO cell lines generated in this study, NAPEPLD independent pathways must exist 
to generate the basal pool of AEA in these cells.  
The bulk of AEA synthesis may not be attributable to the action of NAPEPLD, but NAPEPLD is 
widely expressed and conserved (Okamoto et al., 2004) indicating possible secondary roles 
of this enzyme that is not eCB signalling. Aside from the generation of NAEs which are 
biologically active at different receptors, another possible role of NAPEPLD was reported 
(Guo et al., 2013). NAPEPLD was proposed to degrade potentially harmful aldehyde-modified 
phosphatidylethanolamines such as isolevuglandin-modified phosphatidylethanolamine 
(IsoLG-PE). Levels of IsoLG-PE are increased during oxidative stress in vivo and can induce a 
variety of pathological cellular responses (Hoppe et al., 1997; Davies et al., 2002; Fukuda et 
al., 2005), therefore NAPEPLD may be useful to relieve the pathological effects of oxidative 
stress. In fact, other NAEs generated by NAPEPLD have protective roles, for example PEA has 
been suggested to show anti-inflammatory, analgesic, and neuroprotective actions through 
activity at the PPAR receptor (Hansen, 2010; Petrosino et al., 2010). NAPEPLD might 
therefore be involved in a protective role against inflammation and oxidative stress by the 
degradation of harmful modified PE such as IsoLG-PE and the production of protective NEAs 
such as PEA, which may be physiologically relevant in areas of high oxidative stress such as 
the brain. Indeed, brain insults such as traumatic brain injury or ischemic conditions cause 
the increase in NAPE and NAE levels (Moesgaard et al., 1999; Hansen et al., 2001a; Berger et 
al., 2004) which can have protective effects (Esposito et al., 2014) and NAPEPLD could play a 
vital role. FAAH has also been implicated in the generation of potentially protective NAEs 
under ischaemic conditions in a backwards reaction (Lin et al., 2017) which could potentially 
function in tandem with the actions of NAPEPLD. Other lipids can also be generated by NAPE 
such as OEA which has also been proposed to bind to PPAR receptor and mediates feeding 
behaviour (Piomelli, 2013) and SEA also possesses anti-inflammatory and anorexic properties 
(Astarita and Piomelli, 2009). 
Since the generation of NAPEPLD KO mice revealed its slight contribution to AEA levels, other 





pathways have been suggested for the generation of AEA. First the combined actions of 
ABHD4 and GDE1 (Simon and Cravatt, 2006) which has shown expression in brain as well as 
other tissues in the body (Simon and Cravatt, 2008). These enzymes have also been detected 
at relatively high levels in the U2OS cells from data gathered from the Human Protein Atlas 
(Thul et al., 2017). However, this pathway is complicated by the result from double 
NAPEPLD/GDE1 KO mice showing no reduction in AEA levels (Simon and Cravatt, 2010), thus 
a lysoPLD activity has been attributed to the generation of AEA from the intermediate 
generated by ABHD4 (Sun et al., 2004). Secondly, the actions of an unidentified PLC and 
PTPN22 can also generate AEA (Liu et al., 2006). This mechanism is highly localised to 
macrophages in response to stimulation to lipopolysaccharide (LPS) and thus PTPN22 has 
very low level of detection in U2OS cells (Thul et al., 2017). It is more likely that the former 
pathway is present in the NAPEPLD KO cell lines generated, however there are limited 
pharmacological tools targeting these enzymes, the enzymes themselves may have more 
than one role, and some enzymes have not been fully characterised for CRISPR treatment. 
As well as this, it is not likely that the regulatory step of AEA synthesis lies in the hydrolysis 
step from NAPE to NAEs. Therefore, focus was placed on the calcium sensitive generation 
step of NAPE as the regulatory step of AEA synthesis.  
The calcium sensitive generation of NAPE is mediated through a CaNAT enzyme, which has 
recently been identified as PLA2G4E (Ogura et al., 2016). This enzyme also displays similar 
activity in the human isotope (Hussain et al., 2018) and can generate the precursor NAPE to 
AEA along with other N-AcylPEs. Although there are other proposed enzymes that can 
generate NAPE (i.e. iNAT and related PLAAT enzymes (Jin et al., 2007; Jin et al., 2009; Hussain 
et al., 2017)), these enzymes show very limited calcium sensitivity. Since we can evoke eCB 
signalling through calcium elevation in our cell lines, this suggests a calcium sensitive NAT is 
present in our CB1-Tango cell lines.  
From the results in this chapter, two NAPEPLD KO lines have been generated in which AEA 
levels are largely unchanged and eCB signalling can still be evoked in both lines to similar 
levels as DAGL KO line. Between the two cell lines generated, NAPEPLD KO1 shows 
reduced responsiveness to ACEA, reduced eCB tone and more rounded morphology 
(unpublished observations), which may be due to either clonal variances or from CRISPR-
mediated off-target effects causing metabolic changes on the cells. Because of this, for 
further downstream applications of CaNAT characterisation, the NAPEPLD KO2 line (later 





6.4 Results 4C. The role of PLA2G4B in eCB 
signalling  
 
6.4.1 Results 4C. Introduction  
The genetic deletion of the DAGLs and NAPEPLD from the CB1-Tango cells revealed that very 
robust eCB signalling can still be evoked by three different stimuli and that these enzymes 
are also dispensable in the generation of the a basal eCB tone. The genetic KO of the DAGLs 
reduced the basal levels of 2-AG by ~90%, identifying them as key enzymes for 2-AG 
synthesis, however the DAGLs and 2-AG had only a minor contribution to the measured eCB 
tone. Whilst the lipid(s) responsible for eCB signalling remain uncertain, the second most 
abundant eCB AEA obviously emerges as the prime candidate, although other unidentified 
eCBs could also be responsible. The most widely accepted synthesis pathway of AEA is 
through the hydrolysis of NAPE by NAPEPLD, however conclusions from various animal KO 
studies and through the results of the previous chapter, an eCB tone including but not limited 
to AEA, can still be robustly generated in the absence of NAPEPLD in addition to the DAGLs. 
Thus, other pathways of AEA generation must be present in the CB1-Tango cells. 
Since the generation of NAPEPLD KO mice revealed the minor contribution of NAPEPLD to 
the generation of AEA (Leung et al., 2006; Tsuboi et al., 2011; Leishman et al., 2016), other 
synthesis pathways have been suggested as the pathways for the generation of AEA in a 
NAPEPLD independent manner (Liu et al., 2006; Simon and Cravatt, 2006, 2008). The 
presence of more than one separate pathway complicates the study of AEA synthesis in the 
CB1-Tango cells as pharmacological tools are limited for these pathways, the enzymes may 
have more than one role in the cell and some of the enzymes in the pathway are not fully 
characterised for CRISPR treatment. As well as this, it is not likely that the regulatory step of 
AEA synthesis lies with the step from NAPE hydrolysis to AEA due to the redundancy of these 
pathways. It was therefore prudent to focus on the preceding step: NAPE synthesis from 
membrane lipids catalysed by an N-acyltransferase enzyme.  
In the 1980s, a single step N-acyltransferase enzymatic activity was described from dog heart 
and brain tissue that could transfer an acyl group (including arachidonoyl to generate the 
precursor for AEA) from PC to PE to generate N-AcylPE (Natarajan et al., 1983; Reddy et al., 
1983). This enzymatic activity had been extensively characterised since first described, but 





many years until its recent discovery. The key features of this enzyme are: (1) its dependence 
on calcium for activation, (2) its preference for the sn-1 position over the sn-2 position of the 
donor lipid and (3) to use phospholipids but not free fatty acid or acyl-CoA as a donor 
(Natarajan et al., 1981; Schmid et al., 1990; Cadas et al., 1996; Cadas et al., 1997). As well as 
this, areas of CaNAT activity were characterised in rat tissues. The highest activity was 
present in the brain, with lower but significant activity in testis and muscles, and low activity 
in other tissues. Within the brain, the highest activity was detected in brainstem, with 
intermediate activity in the cortex, striatum, hippocampus, medulla and cerebellum and low 
levels present in the thalamus, hypothalamus and olfactory bulb (Cadas et al., 1997).  
The dependence on calcium for activity would suggest the activation of CaNAT is a regulatory 
step of NAPE and consequently AEA synthesis. Low levels of arachidonoyl-containing NAPE 
and AEA are measured from brain homogenate but are markedly increased after stimulation 
with calcium (Cadas et al., 1996; Sugiura et al., 1996; Astarita et al., 2008). The activity of the 
CaNAT can also be enhanced by treatment with FSK indicating and involvement of cAMP in 
activity regulation, however the precise mechanism through which this occurs has not been 
elucidated (Cadas et al., 1996). The areas of CaNAT activity coincides with the pattern of 
NAPEPLD expression with prominent levels detected in the brain and testis, areas where AEA 
is known to be generated, but CaNAT activity is slightly more restricted than NAPEPLD 
expression (Cadas et al., 1997). Taking together the expression pattern of the CaNAT activity 
and its dependence on calcium for activation, this places the CaNAT as an interesting enzyme 
to examine as the potential regulatory step of AEA synthesis pathway and the key enzyme 
for the generation of AEA for eCB signalling.  
In the pursuit to identify the CaNAT enzyme, calcium-insensitive enzymes that have N-
acyltransferase activity were identified (i.e. iNAT and related PLAAT enzymes) however these 
enzymes did not match the enzymological or expression profile of the CaNAT which had been 
extensively profiled and the physiological role of these enzymes in the generation of AEA 
uncertain (Jin et al., 2007; Jin et al., 2009; Ueda et al., 2010; Hussain et al., 2017). The enzyme 
responsible for the CaNAT activity remained elusive for many years but was recently 
proposed to be the poorly characterised serine hydrolase PLA2G4E (Ogura et al., 2016).  
PLA2G4E was identified as the elusive CaNAT through activity-based protein profiling from 
mouse brain homogenate. Expression of PLA2G4E in HEK293T cells demonstrated N-
acyltransferase activity, could generate the NAPE precursor to AEA along with other N-acylPE 





(Ogura et al., 2016). Expression of PLA2G4E was revealed by RT-PCR to be present in mouse 
brain and testis which generally matched areas of CaNAT activity but is also detected 
predominantly in heart, skeletal muscle, and thyroid (Ohto et al., 2005). The human 
orthologue of PLA2G4E has recently been functionally characterised in COS7 cells and also 
shown to exhibit calcium-sensitive NAPE generation (Hussain et al., 2018). Finally, RNA-seq 
data of sub-populations of cells from mouse cerebral cortex show the highest transcript 
expression (albeit still relatively low) of PLA2G4E almost exclusively in neurones (Zhang et 
al., 2014).  
However, expression of PLA2G4E is restricted to subpopulations of cells within the brain 
despite the more ubiquitous expression of NAPEPLD transcripts in other subpopulations of 
cells such as myelinating oligodendrocytes and endothelial cells (Zhang et al., 2014). 
Ionomycin also stimulated AEA synthesis from astrocytes despite the lack of PLA2G4E 
transcripts in astrocytes (Walter et al., 2002). As well as this, previous results from the 
Quantigene multiplex assay system revealed a lack of PLA2G4E transcripts in the tested cell 
lines and total RNA from cerebellum and hippocampal brain regions. This raises the 
possibility that other functionally related enzymes may also generate NAPE and contribute 
to AEA synthesis in cells and tissues where PLA2G4E appears to be absent. Since PLA2G4E is 
unlikely to be the enzyme responsible for AEA synthesis in the CB1-Tango cells as the 
transcripts are not detected, we aimed to search for novel enzymes that could function as 
the CaNAT.  
To begin the search for novel candidate enzymes that could function as an additional CaNAT, 
focus was placed on the related family of genes to PLA2G4E which may have similar N-
acyltransferase function to PLA2G4E. PLA2G4E belongs to the PLA2G4 family (A-F) of which, 
aside from PLA2G4A, are poorly characterised (Ghosh et al., 2006). These members of the 
family are all cytosolic proteins but are membrane associated and display calcium sensitivity 
through the conserved C2 domain (except PLA2G4C) and share homology in the catalytic 
region (Table 6.4.1). The related enzymes may therefore exhibit similar activity to PLA2G4E 
and perhaps can also generate NAPE in regions where expression of PLA2G4E is not present. 
Of the poorly characterised enzymes, PLA2G4C shows no calcium sensitivity and expression 
patterns of PLA2G4D and PLA2G4F showed abundancy in skin and reproductive organs but 










PLA2G4A Human Ubiquitous C2 R200, S228, D549 
Mouse Ubiquitous C2 R200, S228, D548 
PLA2G4B Human Ubiquitous JMJC, C2 R538, S566, D846 
Mouse Not determined C2 R305, S333, D613 
PLA2G4C Human Ubiquitous CAAX R54, S82, D385 
Mouse Oocytes -  R55, S83, D417 
PLA2G4D Human  Psoriatic lesions, fetal skin, cervix C2 R333, S361, D647 
Mouse Placenta C2 R342, S370, D654 
PLA2G4E Human Skin, GI tract, ovaries  R8, S36, D324 
Mouse Heart, skeletal muscle, testis, 
thyroid 
C2 R392, S420, D708 
PLA2G4F Human  Skin, lung, muscles C2 R367, S395, D680 
Mouse Prostate, stomach, large intestine C2 R365, S393, D685 
Table 6.4.1. Properties of human and mouse PLA2G4 family 
Adapted from Ghosh et al. (2006). 
 
 
PLA2G4B on the other hand shows high expression in cerebellum, heart, pancreas and liver 
in mice (Ghosh et al., 2006) and is detected relatively ubiquitously in mouse cerebral cortex 
but is more highly detected in astrocytes, neurons and oligodendrocyte precursor cells 
(Zhang et al., 2014). From results in the previous chapters, expression of PLA2G4B is readily 
detected in total RNA from cerebellum and hippocampus and from the CB1-Tango cells in 
relatively comparable levels, which was maintained through CRISPR treatments and genetic 
KO of the eCB synthesising enzymes, placing it as a suitable candidate enzyme for CaNAT 
activity in the CB1-Tango cells. Since PLA2G4B is detected readily in the triple KO cell line 
generated in the last section, genetic disruption will be adopted in this chapter to elucidate 
what possible role PLA2G4B may have on eCB signalling.  
In this chapter, the expression of PLA2G4E in the CB1-Tango cells will be determined with 
RT-PCR and its role in AEA synthesis in our cell line will be discussed. The generation of 
PLA2G4B KO cell line from the triple KO cell line (NAPEPLD KO) will be described in this 
chapter. The characterisation of the cell line will determine the successful KO of PLA2G4B 
and the effects on the eCB levels of the cells will be measured. The cell line will then be tested 
in the CB1-Tango assay using previously established paradigms that can generate eCB 






6.4.2 Results 4C. Results 
PLA2G4E expression is not detected in CB1-Tango cells 
Previous results from the QuantiGene multiplex assay revealed no PLA2G4E transcripts were 
detected in the parental CB1-Tango cell line (Net MFI <10). Subsequent treatments with 
CRISPR also failed to induce any noticeable changes in transcript levels, despite changes in 
NAPEPLD transcript levels and AEA lipid levels. Based on this we can conclude that PLA2G4E 
is not expressed in the CB1-Tango cell line and that it cannot play a role in AEA synthesis. 
However, given the importance of this point we performed additional studies to confirm the 
result. 
To confirm the results from the QuantiGene multiplex assay, RT-PCR was carried out from 
the parental CB1-Tango cell line and the DAGL KO cell line. In the original publication by 
Ogura et al. (2016), total RNA from various organs of C57BL/6J mice was used to detect 
expression of PLA2G4E, therefore as a control C57BL/6J mouse brain RNA was included in 
the RT-PCR reaction. The primers used for mouse PLA2G4E were also the same as previously 
described by Ogura et al. (2016) and the primers were codon matched for the human variant 
of PLA2G4E (Table 2.1.2). GAPDH was also included as a control and the primers used were 
also codon matched. 
RT-PCR results show detectable levels of PLA2G4E in mouse brain at around the expected 
size of 403bp (Figure 6.4.1). However, a corresponding band from the CB1-Tango cells at 
around 400bp is not present. The RT-PCR for GAPDH, which was carried out at the same time, 
was successful in both mouse brain RNA and RNA from the CB1-Tango cell lines indicating a 
successful reaction. This result supports the QuantiGene multiplex assay results of a lack of 








Figure 6.4.1. RT-PCR of PLA2G4E and GADPH in CB1-Tango and DAGLKO cells 
CB1-Tango and DAGL KO cells were grown in T75 flasks until 90% confluent, pelleted and 
RNA was extracted according to manufacturer’s instructions. Mouse brain RNA was 
extracted from brain of a C57BL/6J WT mouse, aged embryonic day 17.5 using TRIzol RNA 
extraction kit. RNA was then converted to cDNA and mixed with primers to PLA2G4E and 
GAPDH and PCR mix and the PCR programme was run as previously described by (Ogura et 
al., 2016). The PCR was then run on 1% agarose gel (expected band sizes: PLA2G4E Ms – 







Design of PLA2G4B gRNA and generation of CRISPR vectors 
As PLA2G4E transcript expression is not present in the CB1-Tango cell lines, CRISPR treatment 
of the PLA2G4E gene would be imprudent and could further disrupt expression of other 
genes or overall cell viability. Therefore, focus was placed on the related yet uncharacterised 
enzyme PLA2G4B, transcripts of which can be readily detected in the cells and have shown 
slight increases in transcript levels between CB1-Tango KO lines, although this may be a 
clonal variance.  
The PLA2G4B gene consists of 21 exons, with the catalytic triad residues arginine and serine 
located in exon 13 and aspartic acid located in exon 19 (Figure 6.4.2). Aside from the catalytic 
residues, another arginine residue in exon 19 is also required for structural integrity of the 
catalytic site (Pickard et al., 1999; Song et al., 1999), as highlighted in green in Figure 6.4.2. 
Thus, the gRNAs were designed to exon 13 and exon 19 to encompass the catalytic triad to 
completely eradicate catalytic activity of the cells (Figure 6.4.3).  
The gRNAs were inserted in the vector backbone as described previously in 2.2 Methods and 
four separate CRISPR vectors were generated. Pools of cells were transfected with all four 
CRISPR vectors at once and positively selected with puromycin. The selected cells were then 
seeded at low density to facilitate isolation of individual cells, left to grow into discrete 
colonies for picking and expansion for further analysis as previously described.  
 
 
Figure 6.4.2. Selection of gRNA sequences selected for Cas9 recognition of PLA2G4B 
catalytic domain 
Schematic representation of the human PLA2G4B sequence, indicating the UTRs (yellow) and 
the catalytic domains (blue). Target sequences were designed to exon 13 and exon 19 to 
target the catalytic triad residues. Sequences for gRNAs begin with G (bold) for U6 promotor 














Figure 6.4.3. Targets of exon 13 and exon 19 of PLA2G4B DNA sequence 
DNA sequence of PLA2G4B exon 13 (A) and exon 19 (B) is displayed above and the 
corresponding amino acid sequence is displayed in purple below the DNA sequence. The 
sequences important for catalytic activity of PLA2G4B is highlighted in green and underlined. 
Guide RNA sequences are highlighted in blue above and below the sequence and underlined, 








Characterisation of PLA2G4B KO cell lines show disrupted transcripts 
After the cell colonies were grown to sufficient numbers, genomic DNA was extracted from 
according to manufacturer’s instructions. PCR amplification of the catalytic site was carried 
out with primers located in the introns flanking exon 13 and 19 (Table 2.1.2) to PCR across 
the CRISPR sites. The PCR reaction was then run on 1% agarose gel to visualise the bands 
(Figure 6.4.4). 
The NAPEPLD KO parental control line had a prominent band at around 3kbp which is around 
the expected size of the intact fragment. A few of the tested cell colonies failed to produce 
a band and others showed more subtle mutations. With the largest deletion of the middle 
fragment of DNA, the expected band size was predicted to be around 500bp. Three colonies 
contained a relatively clean band around the predicted size; clone 1, 6 and 8 were therefore 





Figure 6.4.4. PCR of PLA2G4B CRISPR treated cells show disruptions in the genomic DNA 
NAPEPLD KO cell line, which the PLA2G4B CRISPR treated cells were derived from, and 
PLA2G4B CRISPR treated cells were grown from individual colonies to 90% confluent T75 
flasks and then pelleted and DNA was extracted according to manufacturer’s instructions. 
PCR was run with primers located in introns before exon 13 and after exon 19 of PLA2G4B. 
The PCR was then run on 1% agarose gel (expected band sizes: PLA2G4B WT – 2704bp; with 
the widest expected mutations – around 472bp). Red asterisks indicate cell lines taken 






The bands from the PCR with genomic DNA was extracted from the gel, purified and then 
sent for Sanger sequencing. The results for PLA2G4B KO1 and KO2 were clear with only one 
reading per line, but results for KO3 showed disruption at the first CRISPR gRNA which leads 
to the detection of two separate sequences (Figure 6.4.5). The presence of two sequences 
would indicate the presence of two differentially repaired alleles, although it would be 
difficult to determine the separate sequences after the CRISPR site. The sequences from all 
three KO lines are aligned against the complete PLA2G4B exon 13 sequence in Figure 6.4.6A 
and KO1 and KO2 were aligned to the exon 19 sequence in Figure 6.4.6B.  
The mutations from the cell lines begin and end at CRISPR targeted areas with minor indel 
mutations found at the CRISPR sites. The sequence contained within the CRISPR sites are 
absent in KO1 and KO2 sequences. Translation of the DNA sequences obtained confirm the 
absence of the catalytic residues of PLA2G4B, despite not reaching a stop codon within the 
sequence (Figure 6.4.7). Whilst the sequence from KO3 could be aligned to the beginning of 
exon 13, it was not possible to align KO3 after the CRISPR treated site, therefore it was not 



































































































































































Figure 6.4.6. Sequencing results of PLA2G4B PCR product reveal large deletions between 
CRISPR sites 
PLA2G4B CRISPR treated cells KO1, KO2 and KO3 were grown in T75 flasks until confluent 
and genomic DNA was extracted from the pelleted cells. PCR was carried out with primers 
flanking exon 13 and 19 as listed in methods. The PCR product was then run on 1% agarose 
gel and purified from the gel. The purified PCR product and primers were sent for Sanger 
sequencing. The results for PLA2G4B KO1, KO2 and KO3 were aligned in Clustal Omega 
against WT PLA2G4B sequence (AmpSeq). Results show the beginning of alignment (A) and 



















Figure 6.4.7. Protein sequences of PLA2G4B KO1 and KO2 cells exclude catalytically 
important motifs 
The sequencing results of exons from PLA2G4B KO1 and KO2 cells were translated and 
aligned with the amino acid sequence of WT PLA2G4B (AmpSeq). Motifs which are important 







QuantiGene multiplex assay of PLA2G4B KO cell lines confirm genuine PLA2G4B 
KO lines 
For further evidence of the genetic disruption of PLA2G4B in these three cell lines and to 
determine the effects of PLA2G4B KO on other transcripts of the key components in eCB 
signalling, the transcriptome of the three cell lines and NAPEPLD KO line were subjected to 
the QuantiGene multiplex assay (Figure 6.4.8).  
Transcript levels of other key components remained largely unchanged across all the cell 
lines, CNR1 transcripts in PLA2G4B KO3 are detected at slightly lower levels but this was not 
statistically significant. There were some statistically significant but relatively minor 
fluctuations in transcript levels of the eCB degrading enzymes MGLL, FAAH and ABHD6 across 
the cell lines. The relative levels obtained in NAPEPLD KO line were 0.017 ± 0.001 for MGLL, 
0.031 ± 0.001 for FAAH and 0.177 ± 0.004 for ABHD6. PLA2G4B KO2 showed slightly higher 
levels of MGLL (0.028 ± 0.002) and ABHD6 (0.303 ± 0.004) but decreases in level in FAAH 
(0.023 ± 0.001). PLA2G4B KO3 had the most similar levels of the eCB degrading enzymes to 
those obtained from the NAPEPLD KO line (0.018 ± 0.003 for MGLL, 0.038 ± 0.002 for FAAH 
and 0.237 ± 0.011 for ABHD6).  
PLA2G4B transcripts from the NAPEPLD KO line are readily detectable at relatively elevated 
levels (0.57 ± 0.02 relative expression; 3667.0 ± 124.0 net MFI). The detected transcript levels 
are significantly reduced in the PLA2G4B KO1 cell line (0.41 ± 0.01 relative expression; 1507.4 
± 47.9 net MFI), but are not completely depleted as expected. Instead, moderate levels of 
PLA2G4B transcripts are still detected, indicating that the catalytic domain of PLA2G4B is not 
fully eliminated in this cell line and thus is not a complete knockout. For this reason, the cell 
line PLA2G4B KO1 is not taken further in the project.  
The results from PLA2G4B KO2 show more substantial loss of PLA2G4B transcripts (0.019 ± 
0.001 relative expression; 84.8 ± 5.9 net MFI) but this is still within the dynamic detectable 
range. PLA2G4B KO3 shows complete depletion of PLA2G4B transcripts to below the 
dynamic detectable range (0.002 ± 0.0005 relative expression; 7.0 ± 1.8 net MFI), indicating 
that PLA2G4B is likely to be completely eradicated in this cell line despite inconclusive 
sequencing results. As these two cell lines show substantial KO of PLA2G4B transcripts, they 












Figure 6.4.8. Results from the QuantiGene beads assay show PLA2G4B transcripts lack the 
catalytic domain 
NAPEPLD KO cells and PLA2G4B CRISPR treated cells KO1, KO2 and KO3 were grown in T75 
flasks until confluent and RNA was extracted from the pelleted cells according to 
manufacturer’s instructions. RNA was diluted to a concentration of 375ng/l and 20l was 
added to wells in a 96 well plate, leading to total RNA in each well to be 7500ng. RNA samples 
and nuclease free water control samples were then incubated with magnetic beads and 
probes overnight. The beads were then washed and amplified and read on the Magpix 
system as in the methods section. The background readings from control wells were 
subtracted from the sample wells and the data was normalised to the expression of two 
housekeeping genes. Graph shows to means and bars represent SEMs of 5 replicates of 
normalised PLA2G4B results from one single experiment. Significance between groups was 
calculated using One Way ANOVA. 


















Lipid measurements show insignificant change in AEA levels in PLA2G4B KO 
lines 
After confirmation of successful PLA2G4B KO from the two cell lines: KO2 and KO3, the levels 
of 2-AG, AEA, OEA and PEA were measured from three independent pelleted samples from 
each of the PLA2G4B KO cell lines (Figure 6.4.9).  
The levels of 2-AG detected in the PLA2G4B KO cell lines remain at a low level (KO2 = 85.69 
± 1.39 pg/106 cells, KO3 = 120.95 ± 5.32 pg/106 cells) which was not significantly different to 
the levels mesured from the parental NAPEPLD KO line (123.82 ± 25.06 pg/106 cells). The 
levels of 2-AG from these lines remain at around 10% of the original levels of 2-AG measured 
from the parental CB1-Tango cell line.  
Measured levels of AEA was not significantly different between the NAPEPLD KO (5.82 ± 0.47 
pg/106 cells) and the PLA2G4B KO cell lines (KO2 = 5.38 ± 0.74 pg/106 cells, KO3 = 6.44 ± 0.68 
pg/106 cells). As well as this, levels of PEA and OEA were also not significantly different 















Figure 6.4.9. Lipid measurements of PLA2G4B KO2 and KO3 compared to NAPEPLD KO cells 
Cell lines were grown in regular conditions until 90% confluent. Cells were then harvested 
and counted to ensure there were more than 6x106 cells present per sample. Cells were then 
pelleted and frozen in -80oC and then shipped on dry ice for their lipid levels to be measured 
by mass spectrometry. 2-AG, AEA, OEA and PEA levels were measured in each sample and 
normalised to pg per 106 cells. Graph shows means and bars represent SEMs of n = 3. 
Significance between NAPEPLD KO and PLA2G4B KO2 and KO3 was calculated using One Way 
ANOVA. 











eCB signalling is still present in PLA2G4B KO lines in McCoy’s assay media 
There were no significant changes to the measured lipid levels of 2-AG, AEA, OEA and PEA, 
however the KO of the PLA2G4B enzyme could potentially impact on stimulus induced 
changes in AEA or other potential eCBs which could be produced, thus the PLA2G4B KO cells 
were tested in the CB1-Tango assay alongside the NAPEPLD KO line for comparison. First the 
cells were subject to treatment with 5M ACEA in the absence and presence of 2.5M 
AM251 in a standard 4 hour assay in 0.5% FBS McCoy’s assay media as described in Methods. 
The NAPEPLD KO cell line evoked a robust ACEA response (248.7 ± 10.1 % of control) which 
was of comparable magnitudes to results previously obtained with its parental line (Figure 
6.4.10). The PLA2G4B KO lines showed slightly lower responses to ACEA (KO2 = 193.2 ± 10.2 
% of control, KO3 = 213.6 ± 8.3% of control), however the response from the PLA2G4B KO3 
line was not significantly different to the NAPEPLD KO line and the parental CB1-Tango cells 
(Table 6.4.2). The responses from the two PLA2G4B lines are not significantly different to 
each other despite the KO2 line having a significantly lower response, which could be a result 
of clonal variances between the cells. Both cell lines are still responsive to ACEA which can 
be inhibited by AM251 to the same level near the baseline.  
Next, the cells were treated with JZL195 to determine if there are any changes to the basal 
generation of eCB in the absence of the PLA2G4B enzyme. The cells were treated with 100nM 
JZL195 in the absence or presence of 2.5M AM251 (Figure 6.4.11). The NAPEPLD KO line 
generated a substantial eCB tone (134.0 ± 4.0% of AM251 control) which was in line with 
previous results. The PLA2G4B KO2 line produced an eCB tone at 119.9 ± 2.5% of AM251 
control and the PLA2G4B KO3 line gave a response at 143.4 ± 7.1 % of AM251 control. Both 
responses from the PLA2G4B KO lines were not significantly different to the NAPEPLD KO 
line and are still relatively higher than the eCB tone observed from parental CB1-Tango cells 
(Table 6.4.2). The eCB tones have remained largely unchanged and slight differences may be 
due to clonal variances.  
Finally, responses to ionomycin were tested in the PLA2G4B KO lines to determine if eCB 
signalling can still be evoked from the cells due to rapid calcium influx. The cells were treated 
with 2M ionomycin in the absence or presence of 2.5M AM251 in the presence of 100nM 
JZL195 (Figure 6.4.12). The NAPEPLD KO line gave a response reaching 207.5 ± 23.7% of 
AM251 control, the PLA2G4B KO2 line response was 179.6 ± 21.2% of AM251 control and 
the PLA2G4B KO3 line response was 202.7 ± 23.1% of AM251 control. These responses were 





(Table 6.4.2). AM251 blocked the response partially for all the cell lines (NAPEPLD KO = 134.2 
± 9.0; KO2 = 147.0 ± 17.4; KO3 = 146.6 ± 13.8% of AM251 control) which may indicate a non-
specific effect or simply that the concentration of AM251 used was not sufficient to inhibit 
the response completely. Nonetheless, the eCB response to the influx of calcium was still 
present in the PLA2G4B KO lines and there were no significant differences in the magnitudes 




Figure 6.4.10. PLA2G4B KO cells can still respond to ACEA 
30,000 cells were plated in black 96 well plates in 0.5% FBS McCoy’s media for 24 hours. The 
cells were treated the next morning with 5M ACEA in the presence and absence of 2.5M 
AM251 for 4 hours. Data was normalised to the control wells (set as 100) as % of control. 
Graph shows means and bars represent SEMs of 4 independent experiments, 6 replicates in 
each individual experiment. Significance between groups was calculated using One Way 
ANOVA.  







Figure 6.4.11. PLA2G4B KO2 and KO3 cells exhibit eCB tone in the presence of JZL195 
30,000 cells were plated in black 96 well plates in 0.5% FBS McCoy’s media for 24 hours. The 
cells were treated the next morning with 100nM JZL195 in the presence and absence of 
2.5M AM251 for 4 hours. Data was normalised to the wells containing AM251 (set as 100) 
as % of AM251 control. Graph shows means and bars represent SEMs of 4 independent 
experiments, 6 replicates in each individual experiment. Significance between groups was 
calculated using One Way ANOVA.  







Figure 6.4.12. Ionomycin treatment continue to evoke responses in PLA2G4B KO cell lines 
30,000 cells were plated in black 96 well plates in 0.5% FBS McCoy’s media for 24 hours. The 
cells were treated the next morning with 2M ionomycin in the presence and absence of 
2.5M AM251 for 4 hours. 100nM JZL195 was included in all wells. Data was normalised to 
the wells with AM251 (set as 100) as % of AM251 control. Graph shows means and bars 
represent SEMs of 4 independent experiments, 6 replicates in each individual experiment. 
Significance between groups was calculated using One Way ANOVA.  








FSK and PMA can still elicit eCB signalling in PLA2G4B KO cells in No Starve 
Freestyle media 
Next, we tested the PLA2G4B KO cells in Freestyle media supplemented with 2mM calcium 
and 100nM JZL195 and stimulating eCB signalling with calcium, FSK and PMA in a 24 hour 
assay. Again, the ACEA response was first tested to see if the cells still respond to CB1 
activation in this paradigm. The cells were plated in the No Starve Freestyle media conditions 
and treated with 5M ACEA in the absence and presence of 2.5M AM251 as described in 
Methods (Figure 6.4.13). The NAPEPLD KO cell line responded to ACEA to comparable levels 
measured previously (689.5 ± 82.5% of AM251 control). The PLA2G4B KO lines also 
responded robustly to ACEA to levels which were surprisingly higher than those in the 
NAPEPLD KO line (KO2 = 1051.6 ± 111.9; KO3 = 890.8 ± 63.0% of AM251 control) and higher 
than the parental CB1-Tango cells (Table 6.4.2), however this may be due to clonal 
differences. The ACEA responses in all three cell lines were all largely inhibited by AM251 to 
near control levels.  
The eCB response produced in this paradigm was also examined from all three cell lines in 
this paradigm. The cells were plated as previously described and treated in the absence or 
presence of 2.5M AM251 to inhibit basal eCB activity (Figure 6.4.14). Substantial eCB tones 
were detected for all three cell lines (NAPEPLD KO = 331.8 ± 31.7%; PLA2G4B KO2 = 439.7 ± 
62.2 and KO3 = 429.9 ± 55.4% of AM251 control) which still reflect relatively higher levels of 
eCB than previously detected in the parental CB1-Tango cells (Table 6.4.2). The magnitudes 
of the responses are not significantly different to each other, however the PLA2G4B KO lines 
tend toward higher levels of eCB signalling, which is in keeping with the higher response to 
ACEA. 
The effect of kinase driven eCB signalling was also tested in the PLA2G4B KO cell lines. Firstly, 
the cells were treated with 10M FSK in the absence or presence of 2.5M AM251 in the No 
Starve Freestyle conditions (Figure 6.4.15). The response to FSK was 511.0 ± 65.8% of AM251 
control in the NAPEPLD KO line, which was of comparable levels to previously obtained 
results. FSK was still able to elicit responses in the PLA2G4B KO lines; the responses were 
substantially higher (KO2 = 856.0 ± 61.5; KO3 = 810.7 ± 8.7% of AM251 control) even in 
comparison to the parental CB1-Tango cells (Table 6.4.2), which as mentioned previously, 
could be a result of functional changes within the cells or are artefacts of clonal differences. 
All FSK responses were inhibited by AM251 to near basal control levels, indicating a CB1 





Secondly, the cell lines were treated with 25nM PMA in the absence or presence of AM251 
in the No Starve Freestyle conditions for 24 hours to establish if eCB signalling can still be 
evoked with PKC activation (Figure 6.4.16). PMA elicited robust responses in the NAPEPLD 
KO cell line (534.0 ± 75.6% of AM251) which had a nonspecific component when AM251 is 
present (209.8 ± 26.9% of AM251) and this is in keeping with the results obtained in the 
previous chapter. The responses from the PLA2G4B KO lines were not significantly different 
to those obtained in the NAPEPLD KO line (KO2 = 649.8 ± 32.1%; KO3 = 594.4 ± 40.9% of 
AM251 control) and also contain a relatively similar sized nonspecific component (KO2 = 
229.9 ± 22.3%; 193.4 ± 12.9% of AM251 control). The responses to PMA from all three cell 
lines are at higher levels than detected from the parental CB1-Tango cells (Table 6.4.2). Thus 
kinase activation by PMA and FSK, still elicits eCB signalling in the PLA2G4B KO cell lines in a 








Figure 6.4.13. PLA2G4B KO cells respond to ACEA in No Starve Freestyle conditions 
Cells were plated on black 96 well plates at a density of 30,000 cells per well in Freestyle 
media supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, the cells 
were treated with 5M ACEA in the presence and absence of 2.5M AM251. Data was 
normalised to wells containing AM251 only (set to 100%). Graph shows means and bars 
represent SEMs of 4 independent experiments, 6 replicates in each individual experiment. 
Significance between groups was calculated using One Way ANOVA.  









Figure 6.4.14. An eCB tone is still present in PLA2G4B KO cells in No Starve Freestyle 
conditions 
Cells were plated on black 96 well plates at a density of 30,000 cells per well in Freestyle 
media supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, the cells 
were treated with control media or 2.5M AM251 for 24 hours. Data was normalised to wells 
containing AM251 only (set to 100%). Graph shows means and bars represent SEMs of 4 
independent experiments, 6 replicates in each individual experiment. Significance between 
groups was calculated using One Way ANOVA.  








Figure 6.4.15. FSK continues to evoke eCB signalling in PLA2G4B KO cells 
Cells were plated on black 96 well plates at a density of 30,000 cells per well in Freestyle 
media supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, the cells 
were treated with 10M FSK in the presence or absence of 2.5M AM251 for 24 hours. Data 
was normalised to wells containing AM251 only (set to 100%). Graph shows means and bars 
represent SEMs of 4 independent experiments, 6 replicates in each individual experiment. 
Significance between groups was calculated using One Way ANOVA.  









Figure 6.4.16. PMA evoked responses were unchanged in PLA2G4B KO cells 
Cells were plated on black 96 well plates at a density of 30,000 cells per well in Freestyle 
media supplemented with 2mM Ca2+ and 100nM JZL195. Immediately after plating, the cells 
were treated with 25nM PMA in the presence or absence of 2.5M AM251 for 24 hours. 
Data was normalised to wells containing AM251 only (set to 100%). Graph shows means and 
bars represent SEMs of 4 independent experiments, 6 replicates in each individual 
experiment. Significance between groups was calculated using One Way ANOVA.  











































































































6.4.3 Results 4C. Summary & Conclusions 
The transcript levels of the recently identified CaNAT PLA2G4E measured by the QuantiGene 
Multiplex assay was below the dynamic detectable range in the CB1-Tango cells suggesting 
a lack of PLA2G4E expression in the CB1-Tango cells. This was reconfirmed in this chapter 
with RT-PCR reaction from the CB1-Tango cell lines of PLA2G4E transcripts, the lack of a 
corresponding PCR band from the CB1-Tango and the DAGL KO cells indicates that 
PLA2G4E transcripts are not present in the cells. As well as this, PLA2G4E transcripts could 
not be detected from RNA from other human cell lines and brain regions tested (net MFI 
<10) but was robustly detected in skin RNA using the QuantiGene multiplex assay system. In 
support of these results, data from the Human Protein Atlas database documented low 
PLA2G4E transcript levels in U2OS cells and other cancer cell lines, as well as low expression 
in brain regions (Thul et al., 2017), casting doubt on the involvement of PLA2G4E in AEA 
synthesis in these cells and brain regions.  
PLA2G4E was previously detected in both neonatal and adult mouse brain with RT-PCR 
(Ogura et al., 2016) and was confirmed by the RT-PCR results of embryonic mice brain 
obtained in this chapter, but could not be found from human cell lines or RNA from two 
human brain regions with prominent AEA synthesis (Felder et al., 1996) which raises the 
possibility that whilst PLA2G4E could function as a CaNAT regulating AEA synthesis in the 
mouse brain, this function may not be conserved in humans. In addition, high levels of 
transcripts were detected using RNA-seq almost exclusively from neurones in the mouse 
brain samples (Zhang et al., 2014) and yet it is possible for other cells to generate AEA such 
as mouse astrocytes (Walter et al., 2002) where PLA2G4E expression is not present. 
Together, the above points to other as yet to be identified CaNATs being present in humans 
and in cells that do not express PLA2G4E which are most likely responsible for the generation 
of the NAPE precursor for AEA synthesis. It follows that a major effort needs to be placed on 
identifying other enzymes that could have a similar N-acyltransferase activity as PLA2G4E 
with more widespread expression in humans. This led us to focus on the very closely related 
enzyme PLA2G4B as another possible CaNAT.  
Results from the QuantiGene multiplex assay has shown readily detectable levels of PLA2G4B 
transcripts in the CB1-Tango cells on comparable levels to those found in cerebellum and 
hippocampus, and is relatively higher in skin RNA. As well as this, levels of PLA2G4B had 
maintained a relatively steady state across the KO cell lines generated in the study, although 





to clonal variances. Previous characterisation efforts of PLA2G4B revealed associations to 
neuronal functions including schizophrenia (Tao et al., 2005), autism (Matsunami et al., 2014) 
and reading disability (Morris et al., 2004). Interestingly, human PLA2G4B contains a JMJC 
domain from a read-through of the upstream JMJD7 gene creating a conjoined JMJD7-
PLA2G4B transcript which may have implications in head and neck squamous cell carcinoma 
survival (Cheng et al., 2017). JMJC domains are predicted to be metalloenzymes and may 
have a role in gene transcription or chromatin stability (Clissold and Ponting, 2001). The 
removal of the JMJC domain has been shown to enhance the activity of PLA2G4B however 
(Pickard et al., 1999), it could possibly function as a regulator of PLA2G4B activity although 
the exact role of the domain is unknown. This gene was therefore of interest as a candidate 
enzyme for the identification of a novel CaNAT. 
In order to elucidate if PLA2G4B is involved in eCB signalling in the CB1-Tango cell lines, 
CRISPR probes were generated to the PLA2G4B gene in the catalytic region (Pickard et al., 
1999) and the PLA2G4B KO lines were generated with previously described methods. Three 
cell lines showed disrupted transcripts in the RT-PCR and sequence thus were taken forward 
to characterisation in the QuantiGene multiplex assay system. The results from the beads 
assay highlighted that PLA2G4B KO1 may not have complete disruption of the PLA2G4B gene 
despite the RT-PCR and sequencing results not detecting any other longer transcript 
variations. It could be possible that RT-PCR preferentially amplified the shorter mutated 
transcript, and alongside gel extraction and purification of only the prominent band from the 
agarose gel would omit any other longer fragments. Thus, the verification of genetic 
disruptions of CRISPR-treated gene transcripts using the QuantiGene multiplex assay is vital 
in the generation of KO lines. The other two PLA2G4B KO clones (KO2 and KO3) show low 
detection of PLA2G4B transcripts and is indicative of successfully mutated PLA2G4B 
transcripts, thus only these two lines were taken forward further analysis. 
Other gene transcripts of the eCB components generally maintained their levels between the 
KO cell lines, with only clonal variances in the eCB hydrolysing enzymes. Interestingly, despite 
the partial KO of PLA2G4B in KO1 (as mentioned above), in comparison to PLA2G4B KO2 
which had a more substantial depletion of transcripts, their changes in the eCB hydrolysing 
enzymes were almost identical. This is more evidence that minor changes are reflective of 
clonal variation between lines and that the KO of PLA2G4B is not likely to affect the 
expression levels of other enzymes measured in the beads assay panel. The difference in the 





in comparison to magnitudes seen before, thus significance between these levels are not 
truly reflective of an adaptive change in function. Nonetheless, the relative expression levels 
of the eCB hydrolysing enzymes are within a relatively narrow range across cell lines 
regardless of the presence of functional PLA2G4B.  
The lipid levels from the PLA2G4B KO cells were virtually unchanged between cell lines for 
all measured lipids. These unchanged levels also serve as confirmation that the fluctuations 
in eCB hydrolysing enzymes are not due to a functional change in the cells as they do not 
have altered activity levels, but rather are only a consequence of clonal variation or batch 
differences. It is not known whether PLA2G4B may generate other potential eCBs that could 
signal at the CB1 receptor, but in terms of the two major eCBs and the two related lipids 
moieties we measured, PLA2G4B is not involved in the generation of these lipid species.  
As it could be possible that PLA2G4B may be involved in the generation of other lipid moieties 
that could affect eCB signalling either directly or indirectly, the cell lines were tested in the 
CB1-Tango assay. Despite PLA2G4B KO2 and KO3 showing slightly muted responses in the 4 
hour McCoy’s assay paradigm, robust responses are present in the 24 hour No Starve 
Freestyle assay conditions which were on comparably higher levels than the NAPEPLD KO 
line. Upon comparison of the absolute values of the responses from the PLA2G4B KO3 line 
which has four separate enzymes genetically deleted, and the parental CB1-Tango cell line, 
the differences between the responses are of a small magnitude and in fact most responses 
are higher in the PLA2G4B KO3 line (Table 6.4.2). This really confirms the presence of a robust 
eCB tone that can be generated in the absence of the DAGLs, NAPEPLD and a candidate 
enzyme PLA2G4B from the CB1-Tango cells.  
As PLA2G4E and PLA2G4B are both unlikely to be involved in eCB signalling and the 
generation of AEA in the CB1-Tango cells, the presence of a robust eCB tone that can be 
enhanced by the presence of calcium is indicative of the presence of a novel unidentified 
CaNAT. As mentioned before, in the pursuit to identify the elusive CaNAT, other N-
acyltransferase enzymes were discovered through a bioinformatics search of related 
enzymes to the N-acyltransferase LRAT (Jin et al., 2007; Ueda et al., 2010). LRAT catalyses 
the transfer of the sn-1 acyl group from PC to vitamin A leading to the formation of retinyl 
ester which is used in visual processes (Rando, 2002). This acyltransferase activity is 
functionally similar to the activity of the CaNAT and thus a bioinformatics approach was 
taken to identify any homologous enzymes related to LRAT. Members of the HRAS-like 





5) showed homology to LRAT and are a family of class II tumour suppressors (Jahng et al., 
2003; Golczak et al., 2012). HRASLS5 (also known as PLAAT-5) was extensively studied and 
displayed similar N-acyltransferase activity to form NAPE from PC and PE (Jin et al., 2007; Jin 
et al., 2009). However, HRASLS5 was most highly expressed in the testis of rat, mouse and 
human with lower levels in the brain, showed little calcium activity and was not selective of 
the sn-1 position for the donor acyl group, which does not exactly correlate with the 
described enzymatic activity of the CaNAT, and thus was identified as a calcium-insensitive 
N-acyltransferase (iNAT) (Jin et al., 2009). Other related members of the family also show 
varying degrees of N-acyltransferase and PLA1/A2 activity, but all show little calcium 
sensitivity for activity, and are not activated by FSK or PMA (Shinohara et al., 2011; Uyama 
et al., 2012; Hussain et al., 2017).  
Whilst the physiological contribution of the PLAAT family of enzymes towards AEA synthesis 
has not been fully elucidated, overexpression PLAATs in COS7 cells led to the accumulation 
of N-AcylPE and NAE in the absence of any stimuli, indicating that they may contribute to 
basal turnover of N-AcylPEs (Uyama et al., 2012). As well as this, suppression of endogenous 
PLAAT1 and PLAAT2 expression from mouse ATDC5 chondrogenic cells and HeLa cells with 
siRNA partly (~20-50%) reduced N-AcylPE levels (Uyama et al., 2012; Uyama et al., 2013), 
suggesting some involvement in the generation of NAPE. Moderate expression of only 
PLAAT1 is detected in the CB1-Tango cells (Thul et al., 2017) but is calcium insensitive 
(Hussain et al., 2016), thus it is possible that certain members of this family of enzymes are 
active in the CB1-Tango cells and may generate a continual turnover of N-AcylPEs in 
unstimulated conditions. However, calcium and activation of kinases can elicit eCB signalling 
from the CB1-Tango cells and thus that is likely to involve the activity of a CaNAT which has 
been shown to be calcium sensitive and its activity can be modulated by kinases (Cadas et 
al., 1996; Cadas et al., 1997). Nonetheless, through extensive characterisation by the efforts 
of the Ueda group (Jin et al., 2009; Ueda et al., 2010; Hussain et al., 2017; Uyama et al., 2017), 
the PLAAT family are independent to the activities CaNAT and thus are not candidate 
enzymes for the CaNAT in the CB1-Tango cells.  
To summarise, PLA2G4E is unlikely to be the enzyme responsible for the generation of NAPE 
for AEA synthesis as transcript levels of PLA2G4E are undetected in the CB1-Tango cells which 
can generate detectable levels of AEA. In search for novel candidate enzymes that could 
generate NAPE, focus was first placed on enzymes with homology to PLA2G4E that are poorly 





to the previously described CaNAT. PLA2G4B was therefore the first candidate enzyme to be 
genetically deleted from the cell line lacking the major eCB synthesis enzymes DAGLs and 
NAPEPLD to determine its involvement in eCB signalling. The KO of PLA2G4B with CRISPR 
showed no changes in the levels of AEA and other lipid moieties, and had little effect on eCB 
signalling in the CB1-Tango cells. The CB1-Tango cells can still elicit robust eCB signalling in 
the absence of the major eCB synthesis enzymes but serve as valuable tools for further study 









Chapter 7. Discussion  
 
7.1 Therapeutic potential of the eCBs and CB ligands 
 
The field of eCB signalling has grown extensively since the isolation of 9-THC, the major 
psychoactive component of Cannabis sativa around 50 years ago (Gaoni and Mechoulam, 
1964). In the most recent decades, major advances have been made in the field particularly 
the identification and cloning of the receptors for 9-THC: CB1 and CB2 (Matsuda et al., 1990; 
Munro et al., 1993) and the identification of the two major endogenous ligands: 2-AG and 
AEA (Devane et al., 1992; Mechoulam et al., 1995). Since the initial stages of eCB research, 
many discoveries have linked this signalling pathway with a wide range of physiological CNS 
processes such as neuronal migration, retrograde synaptic signalling and adult neurogenesis 
(Goncalves et al., 2008; Oudin et al., 2011a; Kano, 2014) and various disease states (Fowler 
et al., 2010; Paloczi et al., 2017; Bajwa et al., 2018). The involvement of the eCB system in 
many processes led to increased interest in targeting the eCB system for therapeutics, 
however targeting the eCB system has proven difficult, perhaps precisely because of the 
widespread presence of the eCB system. For example, the anti-obesity drug SR141716A, a 
CB1 antagonist commercially known as Rimonabant (Christensen et al., 2007; Costa, 2007), 
was withdrawn from the market following severe side effects such as anxiety and suicide 
ideation (Moreira and Crippa, 2009), demonstrating the severity of undesired effects 
associated with targeting the CB1 receptors in the CNS. However, the therapeutic potential 
of the eCB system is still generating a great deal of interest as more is understood about the 
metabolic pathways of the eCB ligands, particularly of the synthesis enzymes for two 
reasons: 1) they can generate other family of molecules which have the potential to 
modulate the activation of the CB receptors and 2) elucidation of the key enzymes involved 
in eCB synthesis would provide novel targets for drug discovery efforts, with the idea of 
designing specific drugs to minimise unwanted effects. 
The cloning and characterisation of DAGLα and DAGLβ highlighted the ability of the DAGLs 
to generate the major eCB 2-AG, plus other 2-acylglycerols such as 2-LG, 2-PG and 2-OG 
(Bisogno et al., 2003), however the physiological role of these 2-acylglycerols are often 
overlooked. 2-OG has been proposed to be novel endogenous ligand for GPR119 receptors 





2-LG and 2-PG have been proposed to be entourage molecules for 2-AG (Ben-Shabat et al., 
1998) but have also shown antagonistic activity against 2-AG (Murataeva et al., 2016).  
It has been shown through the work in this thesis that 2-LG is a novel partial agonist at the 
CB1 receptor and is capable of signalling on its own and can modulate both 2-AG and AEA 
signalling with little entourage ability. 2-LG is present in mammalian brain at around 10x 
lower concentration than 2-AG whilst AEA is around 200x lower than 2-AG (Richardson et al., 
2007; Williams et al., 2007), suggesting 2-LG may be at high enough concentrations to exert 
physiological effects. Whilst concentrations of 2-LG may not be high enough to act as an 
agonist to the CB1 receptor, it could potentially modulate signalling of 2-AG and/or AEA in 
distinct areas of the brain such as the hypothalamus where the concentration of 2-LG is 
higher (Richardson et al., 2007). Levels of 2-LG is around 12x higher than 2-AG in the spleen 
in a ratio that was reported to be ideal for maximum potentiation of 2-AG (Ben-Shabat et al., 
1998; Gallily et al., 2000) and thus may be physiologically relevant to the biological activity 
of 2-LG. It might also be possible that 2-LG is a ligand for CB2 or an unidentified receptor, 
much like the case of AEA which was considered a partial agonist of the CB1 receptor but a 
full agonist of TRPV1 (Smart et al., 2000; Sugiura et al., 2000) but further clarifications of the 
role of 2-LG in the brain will need to be explored. Nonetheless, the partial agonist activity of 
2-LG raises the exciting prospect of the presence of other eCBs/CB ligands that can exert 
different potencies against the CB receptors to modulate eCB signalling which could perhaps 
reduce the severity of drug treatments.  
Hp was also proposed to be an endogenous ligand of the CB1 receptor with antagonistic 
activity against the CB1 (Heimann et al., 2007) but more recent contentious studies reported 
Hp does not exhibit activity towards the CB1 receptor (Hama and Sagen, 2011a; Straiker et 
al., 2015; Dvoracsko et al., 2016). In support of the more recent publications, Hp did not show 
any antagonistic effect, nor any modulation against different CB1 ligands in the CB1-Tango 
assay. Independent sources of both rat and human Hp also failed to show any significant 
antagonistic effect against the human CB1 receptor. Furthermore, aside from the original 
studies (Heimann et al., 2007; Gomes et al., 2009), evidence that Hp directly binds to CB1 
has not been confirmed.  
Additionally, Hp was suggested to be produced endogenously from cleavage of the 1 chain 
of haemoglobin (Rioli et al., 2003). However, later studies failed to detect any levels of 
endogenous Hp in brain and concluded Hp is in fact an artefact of hot acid extraction and 





2013). As Hp is not an endogenous ligand and only RVD-Hp is suggested to be endogenously 
produced (Bauer et al., 2012), the therapeutic potential of Hp is restricted as there are no 
endogenous enzymes that can be the target for drug discovery. Not much is currently known 
about the degradation of the 1 chain of haemoglobin and the metabolic pathways of RVD-
Hp. Therefore, it is difficult to develop drugs to target the potential enzymes involved in the 
production of RVD-Hp for any therapeutic benefit until conclusive evidence of the synthesis 
of RVD-Hp is found.  
One major issue is Hp is currently sold as a selective CB1 antagonist when Hp does not show 
any CB1 activity. The use of Hp as a CB1 antagonist for studies therefore has posed a problem 
in literature where mistaken conclusions might have been drawn, adding to the growing 
problem of reproducibility in the biological scientific field (Baker, 2016). Studies of Hp were 
carried out in animal models with animal preparations of Hp, which exhibited different 
pharmacological effects in vivo (Lippton et al., 2006; Petrovszki et al., 2012; Leone et al., 
2017). Despite Hp not acting through the CB receptors, it does still have some desirable 
pharmacological effects, including attenuation of pain (Dale et al., 2005b; Toniolo et al., 
2014), which may still be of therapeutic benefit. It is therefore vital that further study and 
clarification of the biological effects of Hp should be taken to prevent further mistaken 
conclusions to be drawn, and to elucidate the real mechanism of action of Hp for the 
potential generation of therapeutic drugs following full elucidation of the mechanism of 
action.  
 
7.2 The CB1-Tango cells as a model system to 
investigate eCB signalling 
 
Originally developed for drug screening and discovery efforts, the CB1-Tango assay was 
utilised in this work to study eCB signalling. The effects of exogenously applied CB1 ligands 
such as agonists ACEA, 2-AG and AEA gave measurable activation of the CB1 receptor and 
antagonist AM251 prevented the activation of the CB1 receptor, as expected. The activities 
of exogenously applied 2-LG and Hp on the CB1 receptor were clarified using the cell-based 
assay system, however for the study of eCB signalling, the endogenous production of eCBs 





eCB signalling through electrophysiological responses such as DSI/DSE experiments or 
quantification of eCB levels following cell stimulation (Balgoma et al., 2013). However, for 
the study of eCB signalling in the absence of stimuli-dependent release of eCBs such as in 
peripheral organs, it is not possible to measure eCB through DSI/DSE studies and mass 
spectrometry studies are usually low throughput. It is also unclear if the measurement of the 
eCBs from mass spectrometry studies reflect the presence of a signalling pool of eCB or a 
general metabolic pool which may contribute to a physiological eCB tone under resting 
conditions (Howlett et al., 2011). We therefore adapted the CB1-Tango assay as a model cell 
line to study eCB signalling as the CB1-Tango cells express the machinery necessary for the 
generation and degradation of the two major eCBs.  
The CB1-Tango cells revealed an eCB tone in a 4 hour treatment with JZL195 which is much 
more pronounced following 24 hour drug treatment with JZL195, suggesting there is a 
constant low turnover of eCBs which is not signalling at the CB1 receptor. It is likely that this 
eCB tone generated is limited by the activity of MAGL and/or FAAH as a “gatekeeper” to 
prevent the activation of CB1 receptor. This gatekeeping activity is seen in developing axons 
where MAGL expression is excluded from the growth cone but is restricted further back along 
the axon to limit 2-AG signalling from seeping from the localised area around the growth 
cone (Keimpema et al., 2013). The stimulation of the CB1-Tango cells with known stimuli that 
enhances eCB signalling such as calcium influx, PKA and PKC activators (Di Marzo et al., 1994; 
Bisogno et al., 1997; Vellani et al., 2008) in different media conditions led to detectable and 
reliable CB1 activation which could be antagonised by AM251 and enhanced by JZL195, 
attributable to eCB signalling. 
There are many advantages of the CB1-Tango assay to study eCB signalling. The main 
advantage is it is a live cell assay which measures the direct activation of the CB1 receptor 
rather than a binding assays such as binding of the substrate to CB1 or [35S]GTPS binding, 
which may be influenced by the expression of other receptors. The CB1-Tango assay is also 
in a convenient 96-well assay format which does not require isolation of tissues and primary 
cells from animals thus reducing the cost and timescale of experiments. Lastly, the results 
are sensitive as it was able to detect responses to a minor eCB tone and partial agonist 2-LG, 
are less likely to be subject to false positives and reproducibility issues (Barnea et al., 2008). 
High transcript levels of the eCB synthesising enzymes DAGLs and NAPEPLD were detected 
in the CB1-Tango cells, particularly of DAGL by the QuantiGene multiplex assay. Unlike 





sequencing which is costly, time consuming and may introduce bias and false positives 
(Boelens et al., 2007; Wang et al., 2009), the QuantiGene multiplex assay amplifies the signal 
and not the gene transcripts. This removes bias amplification, is relatively faster to conduct 
and can be customisable in terms of the number of genes to detect and the targeted region 
(Flagella et al., 2006). The design of the probes to the catalytic regions of genes allowed the 
beads assay system to be used as a reliable verification system for genetic manipulation using 
CRISPR. Characterisation of CRISPR treated genes is difficult with subtle mutations using 
single gRNAs, so multiple gRNAs were used to delete sections of genes (Canver et al., 2014). 
However, with RT-PCR characterisation of deleted regions that may have repaired 
unpredictably, biased amplification of the template cDNA could occur (Acinas et al., 2005) 
leading to false positives KO results as seen with the results from PLA2G4B KO1.  
Gene expression in the cells can be manipulated with CRISPR technique and verified with the 
QuantiGene multiplex beads assay for high throughput screening of potential enzymes 
involved in eCB signalling. Thus, the CB1-Tango assay and various KO cell lines are valuable 
research tools which can be used to study the aspects of CB1 receptor activation by 
exogenously applied ligands and evoked eCB signalling in different conditions.  
 
7.3 Differential synthesis of 2-AG by the DAGLs 
 
The genetic deletion of DAGL and DAGL (Gao et al., 2010; Tanimura et al., 2010) have 
shown that these enzymes are key regulators of many physiological processes in the body 
mediated by eCB signalling. Individually, these enzymes are responsible for generating 90% 
reduction all the 2-AG in the brain (DAGLα) and liver (DAGLβ) (Gao et al., 2010). Importantly, 
stimulus-driven 2-AG release in the brain is absent from DAGL KO animals (Tanimura et al., 
2010). Various stimuli have been reported to stimulate the release of 2-AG from neurons, 
including ionomycin, glutamate, NMDA, and ethanol (Bisogno et al., 1997; Stella et al., 1997; 
Basavarajappa et al., 2000). Ionomycin, ATP and endothelin-1 can stimulate 2-AG release 
from astrocytes (Walter and Stella, 2003; Walter et al., 2004).  
In the CB1-Tango cells, ionomycin could induce CB1-activation which could be enhanced by 
JZL195 and antagonised by AM251, indicative of eCB signalling. However, this response was 





2-AG signalling in response to calcium stimulation under normal conditions. However, the 2-
AG produced might not be for CB1 signalling but perhaps the secondary role of the 
generation of AA by DAGL/MAGL pathway. As the CB1-Tango cells are a non-neuronal cell 
line (Ponten and Saksela, 1967), calcium influx might not induce a rapid release of 2-AG for 
eCB signalling in the same manner as neurons, possibly due to the specific localisation of the 
DAGLs and thus 2-AG in neurons (Bisogno et al., 2003).  
In previous studies conducted by other members of our lab, it was established that the level 
of DAGL expression is not the rate-limiting step for eCB signalling and does not contribute to 
a larger eCB tone as no changes were observed following overexpression of DAGL or DAGL 
in the CB1-Tango cells (thesis of Rachel Lane Markwick, 2015). Results shown here from 
DAGL KO cells is in keeping with the conclusion, deletion of the DAGLs resulted in the 
drastic decrease of basal 2-AG, however this decrease in 2-AG did not reflect any eCB 
signalling changes. It is possible that despite the basal levels of 2-AG is affected, stimulus-
induced release of 2-AG is still present, however this is not likely as in vivo studies has shown 
stimulus-driven 2-AG release in the brain is absent from DAGL KO animals (Tanimura et al., 
2010) and the majority of 2-AG in the CB1-Tango cells is generated by DAGL rather than 
DAGL.  
An interesting observation from DAGL KO cell lines was that DAGL is largely responsible for 
the majority of the basal 2-AG synthesis in an osteosarcoma cell background despite 
expressing much higher transcript levels of DAGL. This is further evidence suggesting that 
the DAGLs might have different enzyme kinetics between them, and this has been observed 
previously in studies with surrogate substrates whereby DAGL showed much more 
hydrolysis activity than DAGL within the same time frame (thesis of Praveen Singh, 2013; 
thesis of Rachel Lane Markwick, 2015; Singh et al., 2016). This finding provides potential for 
specific therapeutic intervention of one DAGL over the other by developing more selective 
drugs or drugs which may be metabolised differently by the individual DAGLs.  
The eCB system is involved in many physiological processes and in numerous 
pathophysiological states such as neurodegeneration, cancer, gastrointestinal and metabolic 
diseases, the eCB tone is dysregulated which may be of potential therapeutic interest (Toczek 
and Malinowska, 2018), which may be subject to therapeutic intervention. Obesity and type 
2 diabetes are associated with altered gut microbiome, low-grade inflammation and 
increased eCB tone (Muccioli et al., 2010), with more evidence emerging suggesting a link 





Muccioli et al., 2010; Olefsky and Glass, 2010; Geurts et al., 2011). The increased eCB tone 
and connection to low-grade inflammation could be mediated by the kinetically slower 
activity of DAGL rather than DAGLas it has been shown that DAGL mediates 
inflammatory responses in macrophages and microglia (Hsu et al., 2012; Viader et al., 2016). 
Furthermore, recent studies have shown correlations between neuroinflammation and the 
gut microbiome (Matcovitch-Natan et al., 2016; Sundman et al., 2017). This suggests another 
possible connection between inflammation and the eCB system in the gut, raising interest in 
therapeutics targeting the widespread role of DAGL in inflammation.  
As discussed, the generation of the DAGL KO cell line provided evidence for the 
differential contribution of DAGL and DAGL to 2-AG generation in the CB1-Tango cells. 
Despite the large changes in basal 2-AG levels, eCB signalling was still present and could be 
stimulated by calcium, PKA and PKC. This eCB tone is likely to be comprised of AEA as AEA 
levels are measurable from the cells. The genetic deletion of the DAGLs have provided a 
valuable cell line for the study of AEA synthesis pathways.  
 
7.4 Physiological role of NAPEPLD  
 
In contrast to 2-AG and the DAGLs, the identification (Okamoto et al., 2004) and genetic 
deletion (Leung et al., 2006; Tsuboi et al., 2011; Leishman et al., 2016) of the proposed AEA 
synthesising enzyme NAPEPLD did not highlight its necessity in the synthesis of AEA and thus 
secondary pathways were suggested. However, no significant reduction in AEA was seen in 
the brains of animals lacking the main enzymes thought to be responsible for AEA synthesis: 
NAPEPLD, GDE1 or both (Leung et al., 2006; Simon and Cravatt, 2010). Thus, the 
identification of a selective enzyme for AEA production from NAPE has remained elusive.  
AEA levels and NAPEPLD transcripts were detected in the CB1-Tango cells, so it was 
speculated that NAPEPLD might contribute to the generation of AEA in the cells. Genetic KO 
of NAPEPLD revealed very little change in AEA levels, but did show effect on PEA levels which 
was generally seen in KO animal studies (Leung et al., 2006; Tsuboi et al., 2011; Leishman et 
al., 2016). As well as this, little effect was seen in the CB1-Tango assay, with an eCB tone and 
stimulus-induced eCB signalling intact in the absence of the DAGLs and NAPEPLD. Thus, 





Other pathways are likely to mediate the hydrolysis of NAPE into AEA in the CB1-Tango cells 
that is independent to NAPEPLD, however these pathways usually contain more than one 
step and not all the enzymes are fully characterised. The generation of AEA in rat neuron 
homogenate was observed to occur in one hydrolysis step (Di Marzo et al., 1994), whilst this 
was attributed to NAPEPLD, it remains possible that it could be mediated by a different 
enzyme in vivo.  
The bulk of AEA synthesis may not be attributable to the action of NAPEPLD, but NAPEPLD is 
widely expressed and conserved (Okamoto et al., 2004) indicating possible secondary roles 
of NAPEPLD, perhaps in neuroprotection. It was suggested that NAPEPLD may have a role in 
the breakdown of harmful IsoLG-PE (Guo et al., 2013) alongside generating the 
neuroprotective NAEs. However, this neuroprotective role of NAPEPLD would require further 
research as the breakdown of IsoLG-PE is relatively specific in terms of substrate and it would 
be appealing to determine if NAPEPLD can breakdown other harmful molecules.  
The physiological role of NAPEPLD remains to be elucidated. Whilst NAPEPLD KO revealed its 
involvement in the generation of saturated and mono-unsaturated NAEs in this and other 
studies (Leung et al., 2006; Tsuboi et al., 2011; Leishman et al., 2016), these NAEs are still 
detectable and thus generated by other non-NAPEPLD mechanisms. The emergence of a 
novel NAPEPLD inhibitor (Castellani et al., 2017) may be of interest to study short term/local 
inhibition of NAPEPLD activity and if it may affect AEA or other NAE synthesis as global KO of 
NAPEPLD could cause compensatory pathways to emerge. However, further testing with this 
inhibitor was beyond the scope of this thesis.  
 
7.5 Identification of the CaNAT 
 
As AEA levels can be detected and other reported synthesis pathways for AEA could still be 
active in the CB1-Tango cells, AEA is likely to be the main eCB contributing to the eCB tone, 
but it is possible that the eCB tone could be comprised of a novel eCB. As some enzymes 
facilitating NAPE cleavage to AEA are not fully characterised and are not specific to AEA 
synthesis (e.g. PLCs, lysoPLD, lysoPLC), it is more feasible that the regulation of AEA synthesis 
occurs in the generation of NAPE by CaNAT as the presence of a calcium and phosphorylation 





Through the results of RT-PCR and the QuantiGene multiplex assay in this work, it was 
determined that PLA2G4E – the enzyme reported to function as CaNAT (Ogura et al., 2016), 
is not expressed in the CB1-Tango cells and thus does not contribute to AEA synthesis and 
eCB signalling in the cells. This was unexpected as the cells lacking the DAGLs and NAPEPLD 
still clearly show calcium-sensitive eCB signalling and AEA levels can still be detected. As well 
as this, some expression profiles of PLA2G4E does not correlate with the expression patterns 
of NAPEPLD and the partially purified CaNAT (Cadas et al., 1997; Okamoto et al., 2004), and 
PLA2G4E is not present in some cells that can produce AEA such as astrocytes (Walter et al., 
2002; Zhang et al., 2014). The activity of PLA2G4E as a CaNAT in vivo has not been elucidated, 
but previous studies have suggested it may regulate recycling in endosomes (Capestrano et 
al., 2014). Whether the association of PLA2G4E with endosomes may contribute to the 
accumulation of AEA in liposomes (Oddi et al., 2008) is also unknown. Nonetheless, it was 
hypothesised that another enzyme is likely to function as the CaNAT in the CB1-Tango cells 
and perhaps in vivo.  
PLA2G4B was studied in this work as it is closely related to PLA2G4E, has a poorly 
characterised function and its expression profile is more in line with the expression of 
NAPEPLD and the description of CaNAT (Song et al., 1999; Ghosh et al., 2006). However, AEA 
levels and eCB signalling in PLA2G4B KO cells were unchanged, signifying PLA2G4B is not 
likely to be involved in eCB signalling. The current role of PLA2G4B is unknown, however 
some studies have associated PLA2G4B with neuronal functions (Morris et al., 2004; Tao et 
al., 2005; Matsunami et al., 2014) where it could perhaps interact with the eCB system in 
vivo. It had been highlighted that PLAAT enzymes do not fit the profile of the CaNAT (Jin et 
al., 2009; Ueda et al., 2013) but the possibility that these enzymes may be modulated by 
other calcium-sensitive signalling molecules in the CB1-Tango cells exist. 
In summary, DAGL, DAGL, NAPEPLD and PLA2G4B were identified as the potential 
regulatory enzymes of eCB synthesis and have been targeted with CRISPR (Figure 7.5.1). The 
resulting KO of the DAGLs, NAPEPLD and PLA2G4B in the PLA2G4B KO3 cell line revealed that 
eCB signalling is still present at comparable levels to the parental cell line which can be 
evoked by calcium and activation of PKA and PKC. The identity of the CaNAT that is 
hypothesised to be regulatory step and main generator of AEA is still elusive in our CB1-
Tango cells and the remaining 10% of 2-AG levels may be generated by a novel DAGL related 
enzyme. The generation of a KO line in the absence of the DAGLs and NAPEPLD therefore 






Figure 7.5.1. Summary of the CRISPR KO of key synthesis enzymes involved in eCB 
signalling in PLA2G4B KO cells. 
Genes targeted with CRISPR are denoted with red crosses. KO of both DAGLs caused large 
reductions in 2-AG levels (~90%), the remaining 2-AG levels detected in the cells may be due 
to the contribution of DDHD2 in 2-AG synthesis. Slightly higher levels of AEA were detected 
following the KO of the DAGLs. This AEA level was unaffected by the genetic deletion of 
NAPEPLD. Secondary synthesis pathways could contribute to the maintained AEA levels 
which includes ABHD4, GDE1 and PTPN22 enzymes. Proposed CaNAT enzyme PLA2G4E was 
not detected in the cell line and genetic deletion of proposed CaNAT enzyme PLA2G4B did 
not alter AEA levels. Endocannabinoid signalling in PLA2G4B KO cells remained largely 
unchanged in comparison to parental CB1-Tango cells and can be stimulated by calcium and 
activation of PKA and PKC.  






7.6 Future Directions 
 
The identification of PLA2G4E as a CaNAT was elucidated through ABPP (Ogura et al., 2016) 
but a bioinformatics search could also narrow down possible candidate enzymes for CaNAT 
based on gene expression from publicly available databases. The primary criteria for the 
candidate enzyme would be a similar transcript expression profile to CaNAT such as high 
expression in the brain and testes with low levels in other organs. Computational models of 
the functions of genes are annotated with gene ontology terms which gives clues about 
function of uncharacterised enzymes. Genes that have been annotated with closely related 
terms such as acyltransferase activity or acyl modelling would be high priority, with lower 
priority for more general terms such as phospholipid binding or calcium sensing. 
Furthermore, characterised enzymes will have extensively studied functions, another 
criterion for the candidates would therefore be a poorly characterised function. Finally, the 
enzymes should be expressed in the CB1-Tango cells.  
Following the compilation of a list of candidate enzymes, these candidates would then be 
genetically knocked out of the PLA2G4B KO line with CRISPR and characterised with the 
QuantiGene multiplex assay before subject to drug treatment in the CB1-Tango assay to 
evaluate the contribution of the candidate genes to AEA synthesis and eCB signalling in an 
effort to identify the CaNAT in the CB1-Tango cells. Further characterisation of the enzymes 
involved in the AEA synthesis pathways (e.g. PLAAT, iNAT, ABHD4/GDE1 and PTPN22) and in 
the DAGL synthesis pathway (e.g. DDHD2 (Araki et al., 2016)) (Figure 7.5.1) could also be 
subject to CRISPR KO and analysis in the CB1-Tango assay.  
The generation of a CB1-Tango cell line with no eCB signalling would serve as a good parent 
line for the reconstitution of any enzymes that could generate eCB signalling and could allow 
the study of 2-AG and AEA synthesis separately. Mutagenesis studies on the DAGLs or the 
enzymes from the AEA pathway could highlight regulatory residues on these enzymes 
involved in the regulation of eCB synthesis once reconstituted back into the parental line. 
The reconstitution of enzymes of 2-AG or AEA synthesis separately into each parental cell 
line would also be powerful tools for drug discovery efforts, in particular for a full 







Abbas T, Shibata E, Park J, Jha S, Karnani N, Dutta A (2010) CRL4(Cdt2) Regulates Cell 
Proliferation and Histone Gene Expression by Targeting PR-Set7/Set8 for 
Degradation. Mol Cell 40:9-21. 
Abzhanov A, Kaufman TC (2000) Crustacean (malacostracan) Hox genes and the evolution of 
the arthropod trunk. Development 127:2239-2249. 
Acinas SG, Sarma-Rupavtarm R, Klepac-Ceraj V, Polz MF (2005) PCR-induced sequence 
artifacts and bias: insights from comparison of two 16S rRNA clone libraries 
constructed from the same sample. Appl Environ Microbiol 71:8966-8969. 
Agarwal N et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 
cannabinoid receptors in nociceptors. Nat Neurosci 10:870-879. 
Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzman 
M, Galve-Roperh I (2005) The endocannabinoid system drives neural progenitor 
proliferation. Faseb J 19:1704-1706. 
Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, 
Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, 
Swaney S, Van Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and 
characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. 
Chem Biol 16:411-420. 
Alger BE (2002) Retrograde signaling in the regulation of synaptic transmission: focus on 
endocannabinoids. Prog Neurobiol 68:247-286. 
Altman J (1969) Autoradiographic and histological studies of postnatal neurogenesis. IV. Cell 
proliferation and migration in the anterior forebrain, with special reference to 
persisting neurogenesis in the olfactory bulb. J Comp Neurol 137:433-457. 
Altman J, Das GD (1965) Autoradiographic and histological evidence of postnatal 
hippocampal neurogenesis in rats. J Comp Neurol 124:319-335. 
Alvarez-Buylla A, Garcia-Verdugo JM (2002) Neurogenesis in adult subventricular zone. J 
Neurosci 22:629-634. 
Andersson H, D'Antona AM, Kendall DA, Von Heijne G, Chin CN (2003) Membrane assembly 
of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol Pharmacol 
64:570-577. 
Araki M, Ohshima N, Aso C, Konishi A, Obinata H, Tatei K, Izumi T (2016) Enzymatic 
characterization of recombinant rat DDHD2: a soluble diacylglycerol lipase. J 
Biochem 160:269-279. 
Ariuens EJ, Simonis AM (1964) A Molecular Basis for Drug Action. The Interaction of One or 
More Drugs with Different Receptors. J Pharm Pharmacol 16:289-312. 
Arreaza G, Devane WA, Omeir RL, Sajnani G, Kunz J, Cravatt BF, Deutsch DG (1997) The cloned 
rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes 
its formation via the condensation of arachidonic acid and ethanolamine. Neurosci 
Lett 234:59-62. 
Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O (2002) Neuronal replacement from 
endogenous precursors in the adult brain after stroke. Nat Med 8:963-970. 
Aso C, Araki M, Ohshima N, Tatei K, Hirano T, Obinata H, Kishi M, Kishimoto K, Konishi A, 
Goto F, Sugimoto H, Izumi T (2016) Protein purification and cloning of diacylglycerol 
lipase from rat brain. J Biochem 159:585-597. 
Astarita G, Piomelli D (2009) Lipidomic analysis of endocannabinoid metabolism in biological 
samples. J Chromatogr B Analyt Technol Biomed Life Sci 877:2755-2767. 
Astarita G, Ahmed F, Piomelli D (2008) Identification of biosynthetic precursors for the 





Atwood BK, Straiker A, Mackie K (2012) CB(2) cannabinoid receptors inhibit synaptic 
transmission when expressed in cultured autaptic neurons. Neuropharmacology 
63:514-523. 
Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008) Endocannabinoids and the regulation of 
bone metabolism. J Neuroendocrinol 20 Suppl 1:69-74. 
Bajwa NM, Kesavan C, Mohan S (2018) Long-term Consequences of Traumatic Brain Injury in 
Bone Metabolism. Front Neurol 9:115. 
Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. 
Lancet Neurol 2:291-298. 
Baker D, Pryce G, Davies WL, Hiley CR (2006) In silico patent searching reveals a new 
cannabinoid receptor. Trends Pharmacol Sci 27:1-4. 
Baker M (2016) 1,500 scientists lift the lid on reproducibility. Nature 533:452-454. 
Balgoma D, Checa A, Sar DG, Snowden S, Wheelock CE (2013) Quantitative metabolic 
profiling of lipid mediators. Mol Nutr Food Res 57:1359-1377. 
Balsinde J, Winstead MV, Dennis EA (2002) Phospholipase A(2) regulation of arachidonic acid 
mobilization. FEBS Lett 531:2-6. 
Barnea G, Strapps W, Herrada G, Berman Y, Ong J, Kloss B, Axel R, Lee KJ (2008) The genetic 
design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A 
105:64-69. 
Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath 
P (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 
315:1709-1712. 
Barrow KM, Perez-Campo FM, Ward CM (2006) Use of the cytomegalovirus promoter for 
transient and stable transgene expression in mouse embryonic stem cells. Methods 
Mol Biol 329:283-294. 
Basavarajappa BS, Saito M, Cooper TB, Hungund BL (2000) Stimulation of cannabinoid 
receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by 
specific neuromodulators in cerebellar granule neurons. Biochim Biophys Acta 
1535:78-86. 
Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J 
(2012) Identification and quantification of a new family of peptide endocannabinoids 
(Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem 
287:36944-36967. 
Begbie J, Doherty P, Graham A (2004) Cannabinoid receptor, CB1, expression follows 
neuronal differentiation in the early chick embryo. J Anat 205:213-218. 
Begley CG, Ellis LM (2012) Drug development: Raise standards for preclinical cancer research. 
Nature 483:531-533. 
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di 
Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid 
glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J 
Pharmacol 353:23-31. 
Benard G et al. (2012) Mitochondrial CB(1) receptors regulate neuronal energy metabolism. 
Nat Neurosci 15:558-564. 
Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V (1997) Influence of fatty 
acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate 
release by mononuclear cells. Eur J Pharmacol 330:231-240. 
Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH (2004) Massive 
accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral 
ischemia? J Neurochem 88:1159-1167. 
Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano 





Harkany T (2007) Hardwiring the brain: endocannabinoids shape neuronal 
connectivity. Science 316:1212-1216. 
Berrendero F, Garcia-Gil L, Hernandez ML, Romero J, Cebeira M, de Miguel R, Ramos JA, 
Fernandez-Ruiz JJ (1998) Localization of mRNA expression and activation of signal 
transduction mechanisms for cannabinoid receptor in rat brain during fetal 
development. Development 125:3179-3188. 
Birdsall NJ (2010) Class A GPCR heterodimers: evidence from binding studies. Trends 
Pharmacol Sci 31:499-508. 
Bisogno T, Sepe N, De Petrocellis L, Di Marzo V (1997) Biosynthesis of 2-arachidonoyl-
glycerol, a novel cannabimimetic eicosanoid, in mouse neuroblastoma cells. Adv Exp 
Med Biol 433:201-204. 
Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, 
Martin B, Razdan R, Di Marzo V (2006) Development of the first potent and specific 
inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-212. 
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello 
A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P (2003) Cloning 
of the first sn1-DAG lipases points to the spatial and temporal regulation of 
endocannabinoid signaling in the brain. J Cell Biol 163:463-468. 
Bitinaite J, Wah DA, Aggarwal AK, Schildkraut I (1998) FokI dimerization is required for DNA 
cleavage. Proc Natl Acad Sci U S A 95:10570-10575. 
Blais PA, Cote J, Morin J, Larouche A, Gendron G, Fortier A, Regoli D, Neugebauer W, Gobeil 
F, Jr. (2005) Hypotensive effects of hemopressin and bradykinin in rabbits, rats and 
mice. A comparative study. Peptides 26:1317-1322. 
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that 
hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347-1356. 
Boelens MC, te Meerman GJ, Gibcus JH, Blokzijl T, Boezen HM, Timens W, Postma DS, Groen 
HJ, van den Berg A (2007) Microarray amplification bias: loss of 30% differentially 
expressed genes due to long probe - poly(A)-tail distances. BMC Genomics 8:277. 
Bomar MG, Galande AK (2013) Modulation of the cannabinoid receptors by hemopressin 
peptides. Life Sci 92:520-524. 
Bomar MG, Samuelsson SJ, Kibler P, Kodukula K, Galande AK (2012) Hemopressin forms self-
assembled fibrillar nanostructures under physiologically relevant conditions. 
Biomacromolecules 13:579-583. 
Borgstrom B (1988) Mode of action of tetrahydrolipstatin: a derivative of the naturally 
occurring lipase inhibitor lipstatin. Biochim Biophys Acta 962:308-316. 
Bosier B, Muccioli GG, Hermans E, Lambert DM (2010) Functionally selective cannabinoid 
receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 
80:1-12. 
Bouquet C, Nothias F (2007) Molecular mechanisms of axonal growth. Adv Exp Med Biol 
621:1-16. 
Brittis PA, Silver J, Walsh FS, Doherty P (1996) Fibroblast Growth Factor Receptor Function Is 
Required for the Orderly Projection of Ganglion Cell Axons in the Developing 
Mammalian Retina. Mol Cell Neurosci 8:120-128. 
Brose N, Betz A, Wegmeyer H (2004) Divergent and convergent signaling by the diacylglycerol 
second messenger pathway in mammals. Curr Opin Neurobiol 14:328-340. 
Brown AJ, Robin Hiley C (2009) Is GPR55 an anandamide receptor? Vitam Horm 81:111-137. 
Brusco A, Tagliaferro P, Saez T, Onaivi ES (2008) Postsynaptic localization of CB2 cannabinoid 
receptors in the rat hippocampus. Synapse 62:944-949. 
Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A (2000) 
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid 





Burke JE, Dennis EA (2009) Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 23:49-59. 
Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI (1997) 
Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J 
Pharmacol 336:295-298. 
Burstein S (2005) PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 
77:1674-1684. 
Cadas H, di Tomaso E, Piomelli D (1997) Occurrence and biosynthesis of endogenous 
cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J 
Neurosci 17:1226-1242. 
Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D (1996) Biosynthesis of an endogenous 
cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 
16:3934-3942. 
Calvey TN, Williams NE (2008) Principles and practice of pharmacology for anaesthetists, 5th 
Edition. Malden, Mass.: Blackwell Pub. 
Canver MC, Bauer DE, Dass A, Yien YY, Chung J, Masuda T, Maeda T, Paw BH, Orkin SH (2014) 
Characterization of genomic deletion efficiency mediated by clustered regularly 
interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. 
J Biol Chem 289:21312-21324. 
Capasso A, Milano W, Cauli O (2018) Changes in the Peripheral Endocannabinoid System as 
a Risk Factor for the Development of Eating Disorders. Endocr Metab Immune Disord 
Drug Targets. 
Capestrano M, Mariggio S, Perinetti G, Egorova AV, Iacobacci S, Santoro M, Di Pentima A, 
Iurisci C, Egorov MV, Di Tullio G, Buccione R, Luini A, Polishchuk RS (2014) Cytosolic 
phospholipase A(2)epsilon drives recycling through the clathrin-independent 
endocytic route. J Cell Sci 127:977-993. 
Carta M, Lanore F, Rebola N, Szabo Z, Da Silva SV, Lourenco J, Verraes A, Nadler A, Schultz C, 
Blanchet C, Mulle C (2014) Membrane lipids tune synaptic transmission by direct 
modulation of presynaptic potassium channels. Neuron 81:787-799. 
Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y (1982) Direct activation of 
calcium-activated, phospholipid-dependent protein kinase by tumor-promoting 
phorbol esters. J Biol Chem 257:7847-7851. 
Castellani B, Diamanti E, Pizzirani D, Tardia P, Maccesi M, Realini N, Magotti P, Garau G, 
Bakkum T, Rivara S, Mor M, Piomelli D (2017) Synthesis and characterization of the 
first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). 
Chem Commun (Camb) 53:12814-12817. 
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and 
synaptic function. Neuron 76:70-81. 
Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M (2007) The endocannabinoid system 
in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 
28:180-187. 
Chau LY, Tai HH (1981) Release of arachidonate from diglyceride in human platelets requires 
the sequential action of a diglyceride lipase and a monoglyceride lipase. Biochem 
Biophys Res Commun 100:1688-1695. 
Cheng Y, Wang Y, Li J, Chang I, Wang CY (2017) A novel read-through transcript JMJD7-
PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and 
survival. Oncotarget 8:1972-1982. 
Choi SH, Arai AL, Mou Y, Kang B, Yen CC, Hallenbeck J, Silva AC (2018) Neuroprotective Effects 






Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the 
weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-
1713. 
Citri A, Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. 
Neuropsychopharmacology 33:18-41. 
Clissold PM, Ponting CP (2001) JmjC: cupin metalloenzyme-like domains in jumonji, hairless 
and phospholipase A2beta. Trends Biochem Sci 26:7-9. 
Collingridge GL, Peineau S, Howland JG, Wang YT (2010) Long-term depression in the CNS. 
Nat Rev Neurosci 11:459-473. 
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and 
weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-117. 
Compagnucci C, Di Siena S, Bustamante MB, Di Giacomo D, Di Tommaso M, Maccarrone M, 
Grimaldi P, Sette C (2013) Type-1 (CB1) cannabinoid receptor promotes neuronal 
differentiation and maturation of neural stem cells. PLoS One 8:e54271. 
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang 
F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819-
823. 
Costa B (2007) Rimonabant: more than an anti-obesity drug? Br J Pharmacol 150:535-537. 
Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular 
characterization of an enzyme that degrades neuromodulatory fatty-acid amides. 
Nature 384:83-87. 
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) 
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in 
mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98:9371-9376. 
Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH (2016) Keep off the 
grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17:293-306. 
Daiyasu H, Osaka K, Ishino Y, Toh H (2001) Expansion of the zinc metallo-hydrolase family of 
the beta-lactamase fold. FEBS Lett 503:1-6. 
Dale CS, Pagano Rde L, Rioli V (2005a) Hemopressin: a novel bioactive peptide derived from 
the alpha1-chain of hemoglobin. Mem Inst Oswaldo Cruz 100 Suppl 1:105-106. 
Dale CS, Pagano Rde L, Rioli V, Hyslop S, Giorgi R, Ferro ES (2005b) Antinociceptive action of 
hemopressin in experimental hyperalgesia. Peptides 26:431-436. 
Davies SS, Amarnath V, Montine KS, Bernoud-Hubac N, Boutaud O, Montine TJ, Roberts LJ, 
2nd (2002) Effects of reactive gamma-ketoaldehydes formed by the isoprostane 
pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome 
function. Faseb J 16:715-717. 
Davis MP (2014) Cannabinoids in pain management: CB1, CB2 and non-classic receptor 
ligands. Expert Opin Investig Drugs 23:1123-1140. 
De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V (1999) Finding of the 
endocannabinoid signalling system in Hydra, a very primitive organism: possible role 
in the feeding response. Neuroscience 92:377-387. 
Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, 
Charpentier E (2011) CRISPR RNA maturation by trans-encoded small RNA and host 
factor RNase III. Nature 471:602-607. 
Devane WA, Axelrod J (1994) Enzymatic synthesis of anandamide, an endogenous ligand for 
the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci U S A 91:6698-
6701. 
Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and 





Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum 
A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that 
binds to the cannabinoid receptor. Science 258:1946-1949. 
Deveau H, Garneau JE, Moineau S (2010) CRISPR/Cas system and its role in phage-bacteria 
interactions. Annu Rev Microbiol 64:475-493. 
Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-
Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley 
B, Friedman D (2014) Cannabidiol: pharmacology and potential therapeutic role in 
epilepsy and other neuropsychiatric disorders. Epilepsia 55:791-802. 
Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178. 
Di Marzo V (1998) 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic 
properties: biochemistry and possible physiopathological relevance. Biochim 
Biophys Acta 1392:153-175. 
Di Marzo V (2008a) Endocannabinoids: synthesis and degradation. Rev Physiol Biochem 
Pharmacol 160:1-24. 
Di Marzo V (2008b) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev 
Drug Discov 7:438-455. 
Di Marzo V (2011) Endocannabinoid signaling in the brain: biosynthetic mechanisms in the 
limelight. Nat Neurosci 14:9-15. 
Di Marzo V (2018) New approaches and challenges to targeting the endocannabinoid system. 
Nat Rev Drug Discov 17:623-639. 
Di Marzo V, Petrosino S (2007) Endocannabinoids and the regulation of their levels in health 
and disease. Curr Opin Lipidol 18:129-140. 
Di Marzo V, Stella N, Zimmer A (2015) Endocannabinoid signalling and the deteriorating 
brain. Nat Rev Neurosci 16:30-42. 
Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) 
Formation and inactivation of endogenous cannabinoid anandamide in central 
neurons. Nature 372:686-691. 
Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) 
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl 
Acad Sci U S A 99:10819-10824. 
Dodd GT, Mancini G, Lutz B, Luckman SM (2010) The peptide hemopressin acts through CB1 
cannabinoid receptors to reduce food intake in rats and mice. J Neurosci 30:7369-
7376. 
Dodd GT, Worth AA, Hodkinson DJ, Srivastava RK, Lutz B, Williams SR, Luckman SM (2013) 
Central functional response to the novel peptide cannabinoid, hemopressin. 
Neuropharmacology 71:27-36. 
Duff G, Argaw A, Cecyre B, Cherif H, Tea N, Zabouri N, Casanova C, Ptito M, Bouchard JF 
(2013) Cannabinoid receptor CB2 modulates axon guidance. PLoS One 8:e70849. 
Dunn TA, Storm DR, Feller MB (2009) Calcium-dependent increases in protein kinase-A 
activity in mouse retinal ganglion cells are mediated by multiple adenylate cyclases. 
PLoS One 4:e7877. 
Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S (2005) Zinc finger 
nucleases: custom-designed molecular scissors for genome engineering of plant and 
mammalian cells. Nucleic Acids Res 33:5978-5990. 
Dvoracsko S, Tomboly C, Berkecz R, Keresztes A (2016) Investigation of receptor binding and 
functional characteristics of hemopressin(1-7). Neuropeptides 58:15-22. 
Eccles JC, McIntyre AK (1951) Plasticity of Mammalian Monosynaptic Reflexes. Nature 
167:466. 
Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using 





Egertova M, Simon GM, Cravatt BF, Elphick MR (2008) Localization of N-acyl 
phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: 
A new perspective on N-acylethanolamines as neural signaling molecules. J Comp 
Neurol 506:604-615. 
El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, van den Brink W, 
Huizink AC (2009) Intrauterine cannabis exposure affects fetal growth trajectories: 
the Generation R Study. J Am Acad Child Adolesc Psychiatry 48:1173-1181. 
Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, 
Schneider-Stock R, Nitsch R, Ullrich O (2006) The endocannabinoid anandamide 
protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. 
Neuron 49:67-79. 
Elphick MR (2012) The evolution and comparative neurobiology of endocannabinoid 
signalling. Philos Trans R Soc Lond B Biol Sci 367:3201-3215. 
Elphick MR, Egertova M (2001) The neurobiology and evolution of cannabinoid signalling. 
Philos Trans R Soc Lond B Biol Sci 356:381-408. 
ElSohly MA, Slade D (2005) Chemical constituents of marijuana: The complex mixture of 
natural cannabinoids. Life Sci 78:539-548. 
Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH 
(1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317. 
Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, Frisen J (2014) 
Neurogenesis in the striatum of the adult human brain. Cell 156:1072-1083. 
Esposito E, Cordaro M, Cuzzocrea S (2014) Roles of fatty acid ethanolamides (FAE) in 
traumatic and ischemic brain injury. Pharmacol Res 86:26-31. 
Eswaran J, Horvath A, Godbole S, Reddy SD, Mudvari P, Ohshiro K, Cyanam D, Nair S, Fuqua 
SA, Polyak K, Florea LD, Kumar R (2013) RNA sequencing of cancer reveals novel 
splicing alterations. Sci Rep 3:1689. 
Fackenthal JD, Godley LA (2008) Aberrant RNA splicing and its functional consequences in 
cancer cells. Dis Model Mech 1:37-42. 
Farooqui AA, Taylor WA, Horrocks LA (1984) Separation of bovine brain mono- and 
diacylglycerol lipases by heparin sepharose affinity chromatography. Biochem 
Biophys Res Commun 122:1241-1246. 
Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, 
Riggin RM, Koppel GA, Paul SM, Becker GW (1996) Isolation and measurement of the 
endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral 
tissues of human and rat. FEBS Lett 393:231-235. 
Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V (2002) Noladin ether, 
a putative novel endocannabinoid: inactivation mechanisms and a sensitive method 
for its quantification in rat tissues. FEBS Lett 513:294-298. 
Fezza F, Bari M, Florio R, Talamonti E, Feole M, Maccarrone M (2014) Endocannabinoids, 
related compounds and their metabolic routes. Molecules 19:17078-17106. 
Fine PG, Rosenfeld MJ (2013) The endocannabinoid system, cannabinoids, and pain. 
Rambam Maimonides Med J 4:e0022. 
Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, Pastor L, Ma Y, Yang W, Crawford KL, 
McMaster GK, Witney F, Luo Y (2006) A multiplex branched DNA assay for parallel 
quantitative gene expression profiling. Anal Biochem 352:50-60. 
Fogaca MV, Sonego AB, Rioli V, Gozzo FC, Dale CS, Ferro ES, Guimaraes FS (2015) Anxiogenic-
like effects induced by hemopressin in rats. Pharmacol Biochem Behav 129:7-13. 
Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A (2010) Modulation of the endocannabinoid 
system: neuroprotection or neurotoxicity? Exp Neurol 224:37-47. 
Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke 





and body weight through activation of the nuclear receptor PPAR-alpha. Nature 
425:90-93. 
Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, Guijarro A, Lodola A, Armirotti 
A, Garau G, Bandiera T, Reggiani A, Mor M, Cavalli A, Piomelli D (2011) A catalytically 
silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci 15:64-
69. 
Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J, Amarnath V, Anderson 
ME, Boyden PA, Viswanathan PC, Roberts LJ, 2nd, Balser JR (2005) Oxidative 
mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium 
channels. Circ Res 97:1262-1269. 
Gaj T, Gersbach CA, Barbas CF, 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for 
genome engineering. Trends Biotechnol 31:397-405. 
Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, 
Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid 
receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 
232:54-61. 
Gallily R, Breuer A, Mechoulam R (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, 
inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. 
Eur J Pharmacol 406:R5-7. 
Gantz SC, Bean BP (2017) Cell-Autonomous Excitation of Midbrain Dopamine Neurons by 
Endocannabinoid-Dependent Lipid Signaling. Neuron 93:1375-1387 e1372. 
Gao Y et al. (2010) Loss of retrograde endocannabinoid signaling and reduced adult 
neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30:2017-2024. 
Gaoni Y, Mechoulam R (1964) Isolation, Structure, and Partial Synthesis of an Active 
Constituent of Hashish. J Am Chem Soc 86:1646-+. 
Garneau JE, Dupuis ME, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath 
P, Magadan AH, Moineau S (2010) The CRISPR/Cas bacterial immune system cleaves 
bacteriophage and plasmid DNA. Nature 468:67-71. 
Gelman JS, Dasgupta S, Berezniuk I, Fricker LD (2013) Analysis of peptides secreted from 
cultured mouse brain tissue. Biochim Biophys Acta 1834:2408-2417. 
Gerard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular cloning of a human 
cannabinoid receptor which is also expressed in testis. Biochem J 279 ( Pt 1):129-
134. 
Geurts L, Lazarevic V, Derrien M, Everard A, Van Roye M, Knauf C, Valet P, Girard M, Muccioli 
GG, Francois P, de Vos WM, Schrenzel J, Delzenne NM, Cani PD (2011) Altered gut 
microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant 
mice: impact on apelin regulation in adipose tissue. Front Microbiol 2:149. 
Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR, Fowler CJ (2004) 
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 
2-arachidonoylglycerol. Br J Pharmacol 143:774-784. 
Ghosh M, Tucker DE, Burchett SA, Leslie CC (2006) Properties of the Group IV phospholipase 
A2 family. Prog Lipid Res 45:487-510. 
Giang DK, Cravatt BF (1997) Molecular characterization of human and mouse fatty acid 
amide hydrolases. Proc Natl Acad Sci U S A 94:2238-2242. 
Godlewski G, Offertaler L, Wagner JA, Kunos G (2009) Receptors for acylethanolamides-
GPR55 and GPR119. Prostaglandins Other Lipid Mediat 89:105-111. 
Goings GE, Sahni V, Szele FG (2004) Migration patterns of subventricular zone cells in adult 
mice change after cerebral cortex injury. Brain Res 996:213-226. 
Golczak M, Kiser PD, Sears AE, Lodowski DT, Blaner WS, Palczewski K (2012) Structural basis 






Gomes I, Dale CS, Casten K, Geigner MA, Gozzo FC, Ferro ES, Heimann AS, Devi LA (2010) 
Hemoglobin-derived peptides as novel type of bioactive signaling molecules. Aaps J 
12:658-669. 
Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, 
Scarlata S, Fricker LD, Devi LA (2009) Novel endogenous peptide agonists of 
cannabinoid receptors. Faseb J 23:3020-3029. 
Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, Zentar MP, 
Pollard S, Yanez-Munoz RJ, Williams G, Walsh FS, Pangalos MN, Doherty P (2008) A 
diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone 
neurogenesis in an age-dependent manner. Mol Cell Neurosci 38:526-536. 
Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid 
CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10-23. 
Guo L, Gragg SD, Chen Z, Zhang Y, Amarnath V, Davies SS (2013) Isolevuglandin-modified 
phosphatidylethanolamine is metabolized by NAPE-hydrolyzing phospholipase D. J 
Lipid Res 54:3151-3157. 
Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, Devi LA (2007) 
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 
282:5116-5124. 
Hama A, Sagen J (2011a) Activation of spinal and supraspinal cannabinoid-1 receptors leads 
to antinociception in a rat model of neuropathic spinal cord injury pain. Brain Res 
1412:44-54. 
Hama A, Sagen J (2011b) Centrally mediated antinociceptive effects of cannabinoid receptor 
ligands in rat models of nociception. Pharmacol Biochem Behav 100:340-346. 
Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, Bornheim LM (1995) 
Anandamide hydroxylation by brain lipoxygenase:metabolite structures and 
potencies at the cannabinoid receptor. Biochim Biophys Acta 1259:173-179. 
Han ZL, Fang Q, Wang ZL, Li XH, Li N, Chang XM, Pan JX, Tang HZ, Wang R (2014) 
Antinociceptive effects of central administration of the endogenous cannabinoid 
receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(alpha)], an N-
terminally extended hemopressin peptide. J Pharmacol Exp Ther 348:316-323. 
Hansen HH, Ikonomidou C, Bittigau P, Hansen SH, Hansen HS (2001a) Accumulation of the 
anandamide precursor and other N-acylethanolamine phospholipids in infant rat 
models of in vivo necrotic and apoptotic neuronal death. J Neurochem 76:39-46. 
Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou 
C, Schmid HH, Fernandez-Ruiz JJ, Hansen HS (2001b) Anandamide, but not 2-
arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 
78:1415-1427. 
Hansen HS (2010) Palmitoylethanolamide and other anandamide congeners. Proposed role 
in the diseased brain. Exp Neurol 224:48-55. 
Hansen HS, Moesgaard B, Hansen HH, Petersen G (2000) N-Acylethanolamines and precursor 
phospholipids - relation to cell injury. Chem Phys Lipids 108:135-150. 
Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, Andersen UB, Holst JJ, 
Hansen HS (2011) 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in 
humans. J Clin Endocrinol Metab 96:E1409-1417. 
Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 
receptor. Proc Natl Acad Sci U S A 98:3662-3665. 
Harbison RD, Mantilla-Plata B (1972) Prenatal toxicity, maternal distribution and placental 
transfer of tetrahydrocannabinol. J Pharmacol Exp Ther 180:446-453. 






Harizi H, Corcuff JB, Gualde N (2008) Arachidonic-acid-derived eicosanoids: roles in biology 
and immunopathology. Trends Mol Med 14:461-469. 
Harkany T, Mackie K, Doherty P (2008) Wiring and firing neuronal networks: 
endocannabinoids take center stage. Curr Opin Neurobiol 18:338-345. 
Hashimotodani Y, Ohno-Shosaku T, Kano M (2007) Presynaptic monoacylglycerol lipase 
activity determines basal endocannabinoid tone and terminates retrograde 
endocannabinoid signaling in the hippocampus. J Neurosci 27:1211-1219. 
Hashimotodani Y, Ohno-Shosaku T, Tsubokawa H, Ogata H, Emoto K, Maejima T, Araishi K, 
Shin HS, Kano M (2005) Phospholipase Cbeta serves as a coincidence detector 
through its Ca2+ dependency for triggering retrograde endocannabinoid signal. 
Neuron 45:257-268. 
Heifets BD, Castillo PE (2009) Endocannabinoid signaling and long-term synaptic plasticity. 
Annu Rev Physiol 71:283-306. 
Heifets BD, Chevaleyre V, Castillo PE (2008) Interneuron activity controls endocannabinoid-
mediated presynaptic plasticity through calcineurin. Proc Natl Acad Sci U S A 
105:10250-10255. 
Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, Luchessi AD, Castro LM, 
Giorgi R, Rioli V, Ferro ES, Devi LA (2007) Hemopressin is an inverse agonist of CB1 
cannabinoid receptors. Proc Natl Acad Sci U S A 104:20588-20593. 
Heng L, Beverley JA, Steiner H, Tseng KY (2011) Differential developmental trajectories for 
CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical 
areas. Synapse 65:278-286. 
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) 
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932-1936. 
Higgs HN, Glomset JA (1994) Identification of a phosphatidic acid-preferring phospholipase 
A1 from bovine brain and testis. Proc Natl Acad Sci U S A 91:9574-9578. 
Hillard CJ, Jarrahian A (2000) The movement of N-arachidonoylethanolamine (anandamide) 
across cellular membranes. Chem Phys Lipids 108:123-134. 
Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee 
RG, Campbell WB (1999) Synthesis and characterization of potent and selective 
agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology and 
Experimental Therapeutics 289:1427-1433. 
Hohmann AG, Herkenham M (1999) Localization of central cannabinoid CB1 receptor 
messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label 
in situ hybridization study. Neuroscience 90:923-931. 
Hollister LE (1974) Structure-activity relationships in man of cannabis constituents, and 
homologs and metabolites of delta9-tetrahydrocannabinol. Pharmacology 11:3-11. 
Holtmaat A, Svoboda K (2009) Experience-dependent structural synaptic plasticity in the 
mammalian brain. Nat Rev Neurosci 10:647-658. 
Hoover HS, Blankman JL, Niessen S, Cravatt BF (2008) Selectivity of inhibitors of 
endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg 
Med Chem Lett 18:5838-5841. 
Hoppe G, Subbanagounder G, O'Neil J, Salomon RG, Hoff HF (1997) Macrophage recognition 
of LDL modified by levuglandin E2, an oxidation product of arachidonic acid. Biochim 
Biophys Acta 1344:1-5. 
Howlett AC (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69:619-
631. 
Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate 





Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG (2011) 
Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J 
Pharmacol 163:1329-1343. 
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, 
Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of 
Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-
202. 
Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF (2012) DAGLbeta inhibition 
perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem 
Biol 8:999-1007. 
Hu SS, Bradshaw HB, Benton VM, Chen JS, Huang SM, Minassi A, Bisogno T, Masuda K, Tan 
B, Roskoski R, Jr., Cravatt BF, Di Marzo V, Walker JM (2009) The biosynthesis of N-
arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via 
conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty 
Acids 81:291-301. 
Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros 
TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (2002) An 
endogenous capsaicin-like substance with high potency at recombinant and native 
vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99:8400-8405. 
Hurd YL, Wang X, Anderson V, Beck O, Minkoff H, Dow-Edwards D (2005) Marijuana impairs 
growth in mid-gestation fetuses. Neurotoxicol Teratol 27:221-229. 
Hussain Z, Uyama T, Tsuboi K, Ueda N (2017) Mammalian enzymes responsible for the 
biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1862:1546-1561. 
Hussain Z, Uyama T, Kawai K, Rahman IA, Tsuboi K, Araki N, Ueda N (2016) Comparative 
analyses of isoforms of the calcium-independent phosphatidylethanolamine N-
acyltransferase PLAAT-1 in humans and mice. J Lipid Res 57:2051-2060. 
Hussain Z, Uyama T, Kawai K, Binte Mustafiz SS, Tsuboi K, Araki N, Ueda N (2018) 
Phosphatidylserine-stimulated production of N-acyl-phosphatidylethanolamines by 
Ca(2+)-dependent N-acyltransferase. Biochim Biophys Acta 1863:493-502. 
Iannotti FA, Di Marzo V, Petrosino S (2016) Endocannabinoids and endocannabinoid-related 
mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res 
62:107-128. 
Idris AI, Ralston SH (2012) Role of cannabinoids in the regulation of bone remodeling. Front 
Endocrinol (Lausanne) 3:136. 
Idris AI, Sophocleous A, Landao-Bassonga E, van't Hof RJ, Ralston SH (2008) Regulation of 
bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 
cannabinoid receptor. Endocrinology 149:5619-5626. 
Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005) Regulation of 
bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 
11:774-779. 
Ihunwo AO, Tembo LH, Dzamalala C (2016) The dynamics of adult neurogenesis in human 
hippocampus. Neural Regen Res 11:1869-1883. 
Imperatore R, Morello G, Luongo L, Taschler U, Romano R, De Gregorio D, Belardo C, Maione 
S, Di Marzo V, Cristino L (2015) Genetic deletion of monoacylglycerol lipase leads to 
impaired cannabinoid receptor CB(1)R signaling and anxiety-like behavior. J 
Neurochem 135:799-813. 
Inoue M, Tsuboi K, Okamoto Y, Hidaka M, Uyama T, Tsutsumi T, Tanaka T, Ueda N, Tokumura 
A (2017) Peripheral tissue levels and molecular species compositions of N-acyl-
phosphatidylethanolamine and its metabolites in mice lacking N-acyl-





Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G (1996) Inhibition of exocytotic 
noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral 
sympathetic nerves. Br J Pharmacol 118:2023-2028. 
Jahng WJ, Xue L, Rando RR (2003) Lecithin retinol acyltransferase is a founder member of a 
novel family of enzymes. Biochemistry 42:12805-12812. 
Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley 
NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced mesenteric 
vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl 
Acad Sci U S A 96:14136-14141. 
Jenniches I, Ternes S, Albayram O, Otte DM, Bach K, Bindila L, Michel K, Lutz B, Bilkei-Gorzo 
A, Zimmer A (2016) Anxiety, Stress, and Fear Response in Mice With Reduced 
Endocannabinoid Levels. Biol Psychiatry 79:858-868. 
Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, 
Alexander SP, Kendall DA, Barrett DA, Chapman V (2008) Inhibition of fatty acid 
amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related 
molecules and produces analgesia via peroxisome proliferator-activated receptor-
alpha in a model of inflammatory pain. Neuropharmacology 55:85-93. 
Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote 
embryonic and adult hippocampus neurogenesis and produce anxiolytic- and 
antidepressant-like effects. J Clin Invest 115:3104-3116. 
Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, Childs J, Greenberg DA (2004) 
Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol 
Pharmacol 66:204-208. 
Jin XH, Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2007) Discovery and 
characterization of a Ca2+-independent phosphatidylethanolamine N-
acyltransferase generating the anandamide precursor and its congeners. J Biol Chem 
282:3614-3623. 
Jin XH, Uyama T, Wang J, Okamoto Y, Tonai T, Ueda N (2009) cDNA cloning and 
characterization of human and mouse Ca(2+)-independent 
phosphatidylethanolamine N-acyltransferases. Biochim Biophys Acta 1791:32-38. 
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable 
dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 
337:816-821. 
Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J (2013) RNA-programmed genome editing in 
human cells. Elife 2:e00471. 
Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D (2007) A key role for 
diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent 
endocannabinoid mobilization. Mol Pharmacol 72:612-621. 
Kaczocha M, Glaser ST, Deutsch DG (2009) Identification of intracellular carriers for the 
endocannabinoid anandamide. Proc Natl Acad Sci U S A 106:6375-6380. 
Kano M (2014) Control of synaptic function by endocannabinoid-mediated retrograde 
signaling. Proc Jpn Acad Ser B Phys Biol Sci 90:235-250. 
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) 
Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-
380. 
Kao JP, Alderton JM, Tsien RY, Steinhardt RA (1990) Active involvement of Ca2+ in mitotic 
progression of Swiss 3T3 fibroblasts. J Cell Biol 111:183-196. 
Katayama K, Ueda N, Katoh I, Yamamoto S (1999) Equilibrium in the hydrolysis and synthesis 
of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim 





Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF (2006) 
Molecular composition of the endocannabinoid system at glutamatergic synapses. J 
Neurosci 26:5628-5637. 
Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano 
M (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at 
excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26:2991-
3001. 
Keimpema E, Tortoriello G, Alpar A, Capsoni S, Arisi I, Calvigioni D, Hu SS, Cattaneo A, Doherty 
P, Mackie K, Harkany T (2013) Nerve growth factor scales endocannabinoid signaling 
by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. 
Proc Natl Acad Sci U S A 110:1935-1940. 
Kim D, Thayer SA (2001) Cannabinoids inhibit the formation of new synapses between 
hippocampal neurons in culture. J Neurosci 21:RC146. 
Kim HS, Kim MS, Hancock AL, Harper JCP, Park JY, Poy G, Perantoni AO, Cam M, Malik K, Lee 
SB (2007) Identification of novel Wilms' tumor suppressor gene target genes 
implicated in kidney development. Journal of Biological Chemistry 282:16278-16287. 
Kim SR, Lee DY, Chung ES, Oh UT, Kim SU, Jin BK (2005) Transient receptor potential vanilloid 
subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and 
in vitro. J Neurosci 25:662-671. 
Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, Horvat V, Volk B, Kempermann 
G (2010) Murine features of neurogenesis in the human hippocampus across the 
lifespan from 0 to 100 years. PLoS One 5:e8809. 
Kondo S, Kondo H, Nakane S, Kodaka T, Tokumura A, Waku K, Sugiura T (1998) 2-
Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification 
as one of the major species of monoacylglycerols in various rat tissues, and evidence 
for its generation through CA2+-dependent and -independent mechanisms. FEBS 
Lett 429:152-156. 
Koonin EV, Makarova KS, Zhang F (2017) Diversity, classification and evolution of CRISPR-Cas 
systems. Curr Opin Microbiol 37:67-78. 
Kouchi Z (2015) Physiological Role of Endocannabinoid Hydrolyzing Enzymes in Brain 
Development and Neurodegeneration. Biochemistry & Physiology: Open Access 04. 
Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Jakobsson PJ, Marnett LJ 
(2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and 
anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and 
ethanolamides. J Biol Chem 277:44877-44885. 
Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by 
endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-
727. 
Kruger MC, Coetzee M, Haag M, Weiler H (2010) Long-chain polyunsaturated fatty acids: 
selected mechanisms of action on bone. Prog Lipid Res 49:438-449. 
Kumar RN, Chambers WA, Pertwee RG (2001) Pharmacological actions and therapeutic uses 
of cannabis and cannabinoids. Anaesthesia 56:1059-1068. 
Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A (2009) Should peripheral 
CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends 
Pharmacol Sci 30:1-7. 
Lampidonis AD, Rogdakis E, Voutsinas GE, Stravopodis DJ (2011) The resurgence of Hormone-
Sensitive Lipase (HSL) in mammalian lipolysis. Gene 477:1-11. 
Lan RX, Liu Q, Fan PS, Lin SY, Fernando SR, McCallion D, Pertwee R, Makriyannis A (1999) 
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor 





Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, 
Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness 
to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout 
mice. Science 283:401-404. 
Leishman E, Mackie K, Luquet S, Bradshaw HB (2016) Lipidomics profile of a NAPE-PLD KO 
mouse provides evidence of a broader role of this enzyme in lipid metabolism in the 
brain. Biochim Biophys Acta 1861:491-500. 
Leone S, Recinella L, Chiavaroli A, Martinotti S, Ferrante C, Mollica A, Macedonio G, 
Stefanucci A, Dvoracsko S, Tomboly C, De Petrocellis L, Vacca M, Brunetti L, Orlando 
G (2017) Emotional disorders induced by Hemopressin and RVD-hemopressin(alpha) 
administration in rats. Pharmacol Rep 69:1247-1253. 
Leung D, Saghatelian A, Simon GM, Cravatt BF (2006) Inactivation of N-acyl 
phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the 
biosynthesis of endocannabinoids. Biochemistry 45:4720-4726. 
Leung HT, Tseng-Crank J, Kim E, Mahapatra C, Shino S, Zhou Y, An L, Doerge RW, Pak WL 
(2008) DAG lipase activity is necessary for TRP channel regulation in Drosophila 
photoreceptors. Neuron 58:884-896. 
Li HL (1974) Archeological and Historical Account of Cannabis in China. Econ Bot 28:437-448. 
Li XH, Lin ML, Wang ZL, Wang P, Tang HH, Lin YY, Li N, Fang Q, Wang R (2016) Central 
administrations of hemopressin and related peptides inhibit gastrointestinal motility 
in mice. Neurogastroenterol Motil 28:891-899. 
Li Y, Kim J (2015) Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse 
hippocampus. Neuroscience 311:253-267. 
Li Y, Kim J (2016) Deletion of CB2 cannabinoid receptors reduces synaptic transmission and 
long-term potentiation in the mouse hippocampus. Hippocampus 26:275-281. 
Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004a) Mice lacking fatty acid amide 
hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 
109:319-327. 
Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF (2004b) 
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence 
for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 
311:441-448. 
Liedhegner ES, Vogt CD, Sem DS, Cunningham CW, Hillard CJ (2014) Sterol carrier protein-2: 
binding protein for endocannabinoids. Mol Neurobiol 50:149-158. 
Ligresti A, Cascio MG, Di Marzo V (2005) Endocannabinoid metabolic pathways and enzymes. 
Curr Drug Targets CNS Neurol Disord 4:615-623. 
Lin L, Metherel AH, Jones PJ, Bazinet RP (2017) Fatty acid amide hydrolase (FAAH) regulates 
hypercapnia/ischemia-induced increases in n-acylethanolamines in mouse brain. J 
Neurochem 142:662-671. 
Lippton H, Lin B, Gumusel B, Witriol N, Wasserman A, Knight M (2006) Hemopressin, a 
hemoglobin fragment, dilates the rat systemic vascular bed through release of nitric 
oxide. Peptides 27:2284-2288. 
Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang 
BX, Kim HY, Kunos G (2006) A biosynthetic pathway for anandamide. Proc Natl Acad 
Sci U S A 103:13345-13350. 
Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, 
Mahadevan A, Razdan RK, Kunos G (2008) Multiple pathways involved in the 
biosynthesis of anandamide. Neuropharmacology 54:1-7. 
Locher RJ, Lunnemann T, Garbe A, Schaser K, Schmidt-Bleek K, Duda G, Tsitsilonis S (2015) 





of bone formation and stability in a combined murine trauma model. J Musculoskelet 
Neuronal Interact 15:309-315. 
Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, 
Lichtman AH, Wiley JL, Cravatt BF (2009a) Dual blockade of FAAH and MAGL 
identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc 
Natl Acad Sci U S A 106:20270-20275. 
Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley 
DE, Parsons LH, Lichtman AH, Cravatt BF (2009b) Selective blockade of 2-
arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem 
Biol 5:37-44. 
Ma L, Jia J, Niu W, Jiang T, Zhai Q, Yang L, Bai F, Wang Q, Xiong L (2015) Mitochondrial CB1 
receptor is involved in ACEA-induced protective effects on neurons and 
mitochondrial functions. Sci Rep 5:12440. 
Maccarrone M (2017) Metabolism of the Endocannabinoid Anandamide: Open Questions 
after 25 Years. Front Mol Neurosci 10:166. 
Maccarrone M, Dainese E, Oddi S (2010) Intracellular trafficking of anandamide: new 
concepts for signaling. Trends Biochem Sci 35:601-608. 
Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A (2000a) Anandamide induces 
apoptosis in human cells via vanilloid receptors. Evidence for a protective role of 
cannabinoid receptors. J Biol Chem 275:31938-31945. 
Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T (2014) Programming of neural 
cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev 
Neurosci 15:786-801. 
Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro A (2000b) 
Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J 
Biol Chem 275:13484-13492. 
Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam 
R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the 
periphery: 50 years after THC. Trends Pharmacol Sci 36:277-296. 
Mackie K, Devane WA, Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits 
calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 
44:498-503. 
Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M (2001) Presynaptic inhibition caused by 
retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 
31:463-475. 
Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G (2015) Structure 
of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation 
of fatty acid ethanolamide biosynthesis by bile acids. Structure 23:598-604. 
Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, 
Rivara S, Freund TF, Piomelli D (2005) Selective inhibition of 2-AG hydrolysis 
enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8:1139-1141. 
Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, Moineau S, Mojica 
FJ, Wolf YI, Yakunin AF, van der Oost J, Koonin EV (2011) Evolution and classification 
of the CRISPR-Cas systems. Nat Rev Microbiol 9:467-477. 
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-
guided human genome engineering via Cas9. Science 339:823-826. 
Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and 
implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-
137. 
Marchalant Y, Brothers HM, Wenk GL (2009) Cannabinoid agonist WIN-55,212-2 partially 





Markwick RLL (2015) Regulation of DAG Lipase Activity – Implications for ‘On-Demand’ 
Endocannabinoid Signalling. In: Wolfson Centre for Age-Related Diseases, p 338. 
London: King's College London. 
Marrs WR et al. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy 
of 2-AG at cannabinoid receptors. Nat Neurosci 13:951-957. 
Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal 
subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225. 
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, 
Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous 
cannabinoid system controls extinction of aversive memories. Nature 418:530-534. 
Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, 
Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, 
Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and 
on-demand defense against excitotoxicity. Science 302:84-88. 
Martin GG, Landrock D, Dangott LJ, McIntosh AL, Kier AB, Schroeder F (2018) Human Liver 
Fatty Acid Binding Protein-1 T94A Variant, Nonalcohol Fatty Liver Disease, and 
Hepatic Endocannabinoid System. Lipids 53:27-40. 
Matcovitch-Natan O et al. (2016) Microglia development follows a stepwise program to 
regulate brain homeostasis. Science 353:aad8670. 
Matias I, Di Marzo V (2007) Endocannabinoids and the control of energy balance. Trends 
Endocrinol Metab 18:27-37. 
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a Cannabinoid 
Receptor and Functional Expression of the Cloned Cdna. Nature 346:561-564. 
Matsunami N et al. (2014) Identification of rare DNA sequence variants in high-risk autism 
families and their prevalence in a large case/control population. Mol Autism 5:5. 
McCarron RM, Shohami E, Panikashvili D, Chen Y, Golech S, Strasser A, Mechoulam R, Spatz 
M (2003) Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl 
glycerol (2-AG). Acta Neurochir Suppl 86:271-275. 
McHugh D, Page J, Dunn E, Bradshaw HB (2012) Delta(9) -Tetrahydrocannabinol and N-
arachidonyl glycine are full agonists at GPR18 receptors and induce migration in 
human endometrial HEC-1B cells. Br J Pharmacol 165:2414-2424. 
McPartland J, Di Marzo V, De Petrocellis L, Mercer A, Glass M (2001) Cannabinoid receptors 
are absent in insects. J Comp Neurol 436:423-429. 
McPartland JM (2004) Phylogenomic and chemotaxonomic analysis of the endocannabinoid 
system. Brain Res Brain Res Rev 45:18-29. 
McPartland JM, Agraval J, Gleeson D, Heasman K, Glass M (2006) Cannabinoid receptors in 
invertebrates. J Evol Biol 19:366-373. 
Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1-18. 
Mechoulam R, Lander N, University A, Zahalka J (1990) Synthesis of the individual, 
pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. 
Tetrahedron: Asymmetry 1:315-318. 
Mechoulam R, Benshabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog 
S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) 
Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds 
to Cannabinoid Receptors. Biochem Pharmacol 50:83-90. 
Melamed E, Robinson D, Halperin N, Wallach N, Keren O, Groswasser Z (2002) Brain injury-
related heterotopic bone formation: treatment strategy and results. Am J Phys Med 
Rehabil 81:670-674. 
Merida I, Avila-Flores A, Merino E (2008) Diacylglycerol kinases: at the hub of cell signalling. 
Biochem J 409:1-18. 





Mikuriya TH (1969) Marijuana in medicine: past, present and future. Calif Med 110:34-40. 
Moesgaard B, Jaroszewski JW, Hansen HS (1999) Accumulation of N-acyl-ethanolamine 
phospholipids in rat brains during post-decapitative ischemia: a 31p NMR study. J 
Lipid Res 40:515-521. 
Molina-Holgado F, Rubio-Araiz A, Garcia-Ovejero D, Williams RJ, Moore JD, Arevalo-Martin 
A, Gomez-Torres O, Molina-Holgado E (2007) CB2 cannabinoid receptors promote 
mouse neural stem cell proliferation. Eur J Neurosci 25:629-634. 
Moore JK, Haber JE (1996) Cell cycle and genetic requirements of two pathways of 
nonhomologous end-joining repair of double-strand breaks in Saccharomyces 
cerevisiae. Mol Cell Biol 16:2164-2173. 
Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S, 
Piomelli D (2004) Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters 
as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity 
relationships, and molecular modeling studies. J Med Chem 47:4998-5008. 
Morales M, Backman C (2002) Coexistence of serotonin 3 (5-HT3) and CB1 cannabinoid 
receptors in interneurons of hippocampus and dentate gyrus. Hippocampus 12:756-
764. 
Morales P, Reggio PH (2017) An Update on Non-CB1, Non-CB2 Cannabinoid Related G-
Protein-Coupled Receptors. Cannabis Cannabinoid Res 2:265-273. 
Moreira FA, Crippa JA (2009) The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 
31:145-153. 
Morgan NH, Stanford IM, Woodhall GL (2009) Functional CB2 type cannabinoid receptors at 
CNS synapses. Neuropharmacology 57:356-368. 
Moriyama T, Urade R, Kito M (1999) Purification and characterization of diacylglycerol lipase 
from human platelets. J Biochem 125:1077-1085. 
Morris DW, Ivanov D, Robinson L, Williams N, Stevenson J, Owen MJ, Williams J, O'Donovan 
MC (2004) Association analysis of two candidate phospholipase genes that map to 
the chromosome 15q15.1-15.3 region associated with reading disability. Am J Med 
Genet B Neuropsychiatr Genet 129B:97-103. 
Movahed P, Jonsson BA, Birnir B, Wingstrand JA, Jorgensen TD, Ermund A, Sterner O, 
Zygmunt PM, Hogestatt ED (2005) Endogenous unsaturated C18 N-
acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 280:38496-
38504. 
Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD (2010) 
The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 
6:392. 
Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, Harvey-White J, Mordi I, Cravatt 
BF, Lotersztajn S, Gao B, Yuan Q, Schuebel K, Goldman D, Kunos G (2011) 
Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via 
cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S 
A 108:6323-6328. 
Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, 
Marsicano G, Di Marzo V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzman M, Lu HC, 
Galve-Roperh I, Harkany T (2008) Endocannabinoid signaling controls pyramidal cell 
specification and long-range axon patterning. Proc Natl Acad Sci U S A 105:8760-
8765. 
Munro S, Thomas KL, Abushaar M (1993) Molecular Characterization of a Peripheral 
Receptor for Cannabinoids. Nature 365:61-65. 
Murataeva N, Dhopeshwarkar A, Yin D, Mitjavila J, Bradshaw H, Straiker A, Mackie K (2016) 
Where's my entourage? The curious case of 2-oleoylglycerol, 2-linolenoylglycerol, 





Natarajan V, Schmid PC, Schmid HH (1986) N-acylethanolamine phospholipid metabolism in 
normal and ischemic rat brain. Biochim Biophys Acta 878:32-41. 
Natarajan V, Reddy PV, Schmid PC, Schmid HH (1981) On the biosynthesis and metabolism 
of N-acylethanolamine phospholipids in infarcted dog heart. Biochim Biophys Acta 
664:445-448. 
Natarajan V, Schmid PC, Reddy PV, Zuzarte-Augustin ML, Schmid HH (1983) Biosynthesis of 
N-acylethanolamine phospholipids by dog brain preparations. J Neurochem 
41:1303-1312. 
Niknami M, Patel M, Witting PK, Dong Q (2009) Molecules in focus: cytosolic phospholipase 
A2-alpha. Int J Biochem Cell Biol 41:994-997. 
Nomura DK, Hudak CS, Ward AM, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman 
AH, Casida JE (2008) Monoacylglycerol lipase regulates 2-arachidonoylglycerol 
action and arachidonic acid levels. Bioorg Med Chem Lett 18:5875-5878. 
Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn 
YK, Lichtman AH, Conti B, Cravatt BF (2011) Endocannabinoid hydrolysis generates 
brain prostaglandins that promote neuroinflammation. Science 334:809-813. 
O'Shaughnessy WB (1843) On the Preparations of the Indian Hemp, or gunjah: Cannabis 
Indica Their Effects on the Animal System in Health, and their Utility in the Treatment 
of Tetanus and other Convulsive Diseases. Provincial Medical Journal and Retrospect 
of the Medical Sciences 5:343-347. 
O'Sullivan SE, Kendall DA (2010) Cannabinoid activation of peroxisome proliferator-activated 
receptors: potential for modulation of inflammatory disease. Immunobiology 
215:611-616. 
Oddi S, Fezza F, Pasquariello N, De Simone C, Rapino C, Dainese E, Finazzi-Agro A, Maccarrone 
M (2008) Evidence for the intracellular accumulation of anandamide in adiposomes. 
Cell Mol Life Sci 65:840-850. 
Oddi S, Fezza F, Pasquariello N, D'Agostino A, Catanzaro G, De Simone C, Rapino C, Finazzi-
Agro A, Maccarrone M (2009) Molecular identification of albumin and Hsp70 as 
cytosolic anandamide-binding proteins. Chem Biol 16:624-632. 
Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, 
Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral cannabinoid receptor, 
CB2, regulates bone mass. Proc Natl Acad Sci U S A 103:696-701. 
Ogasawara D, Deng H, Viader A, Baggelaar MP, Breman A, den Dulk H, van den Nieuwendijk 
AM, Soethoudt M, van der Wel T, Zhou J, Overkleeft HS, Sanchez-Alavez M, Mori S, 
Nguyen W, Conti B, Liu X, Chen Y, Liu QS, Cravatt BF, van der Stelt M (2016) Rapid 
and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase 
inhibition. Proc Natl Acad Sci U S A 113:26-33. 
Ogura Y, Parsons WH, Kamat SS, Cravatt BF (2016) A calcium-dependent acyltransferase that 
produces N-acyl phosphatidylethanolamines. Nat Chem Biol 12:669-+. 
Ohno-Shosaku T, Kano M (2014) Endocannabinoid-mediated retrograde modulation of 
synaptic transmission. Curr Opin Neurobiol 29:1-8. 
Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde 
signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 
29:729-738. 
Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M (2012) Endocannabinoids and 
retrograde modulation of synaptic transmission. Neuroscientist 18:119-132. 
Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M (2002) 
Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced 





Ohto T, Uozumi N, Hirabayashi T, Shimizu T (2005) Identification of novel cytosolic 
phospholipase A(2)s, murine cPLA(2){delta}, {epsilon}, and {zeta}, which form a gene 
cluster with cPLA(2){beta}. J Biol Chem 280:24576-24583. 
Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T 
(2003) Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not 
detected in the brains of various mammalian species. J Neurochem 85:1374-1381. 
Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a 
phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298-
5305. 
Okazaki T, Sagawa N, Okita JR, Bleasdale JE, MacDonald PC, Johnston JM (1981) 
Diacylglycerol metabolism and arachidonic acid release in human fetal membranes 
and decidua vera. J Biol Chem 256:7316-7321. 
Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev 
Physiol 72:219-246. 
Oliver D, Lien CC, Soom M, Baukrowitz T, Jonas P, Fakler B (2004) Functional conversion 
between A-type and delayed rectifier K+ channels by membrane lipids. Science 
304:265-270. 
Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V (2008) Tetrahydrolipstatin 
analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J 
Med Chem 51:6970-6979. 
Oudin MJ, Hobbs C, Doherty P (2011a) DAGL-dependent endocannabinoid signalling: roles in 
axonal pathfinding, synaptic plasticity and adult neurogenesis. Eur J Neurosci 
34:1634-1646. 
Oudin MJ, Gajendra S, Williams G, Hobbs C, Lalli G, Doherty P (2011b) Endocannabinoids 
regulate the migration of subventricular zone-derived neuroblasts in the postnatal 
brain. J Neurosci 31:4000-4011. 
Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, 
Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006) 
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use 
in the discovery of small-molecule hypophagic agents. Cell Metab 3:167-175. 
Oz M (2006) Receptor-independent actions of cannabinoids on cell membranes: focus on 
endocannabinoids. Pharmacol Ther 111:114-144. 
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the 
endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 
27:73-100. 
Palazuelos J, Ortega Z, Diaz-Alonso J, Guzman M, Galve-Roperh I (2012) CB2 cannabinoid 
receptors promote neural progenitor cell proliferation via mTORC1 signaling. J Biol 
Chem 287:1198-1209. 
Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I (2006) Non-
psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. 
Faseb J 20:2405-2407. 
Paloczi J, Varga ZV, Hasko G, Pacher P (2017) Neuroprotection in Oxidative Stress-Related 
Neurodegenerative Diseases: Role of Endocannabinoid System Modulation. Antioxid 
Redox Signal. 
Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, Liu QS (2009) Blockade of 2-
arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-
nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate 
(JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 
331:591-597. 
Pan JX, Wang ZL, Li N, Han ZL, Li XH, Tang HH, Wang P, Zheng T, Fang Q, Wang R (2014) 





hemopressin, VD-hemopressin(alpha) and WIN55,212-2 at the supraspinal level in 
mice. Neurosci Lett 578:187-191. 
Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E 
(2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. 
Nature 413:527-531. 
Pardo B, Gomez-Gonzalez B, Aguilera A (2009) DNA repair in mammalian cells: DNA double-
strand break repair: how to fix a broken relationship. Cell Mol Life Sci 66:1039-1056. 
Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA (2002) Increased severity of stroke 
in CB1 cannabinoid receptor knock-out mice. J Neurosci 22:9771-9775. 
Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, 
Macias M, Goya P, de Fonseca FR (2008) Central versus peripheral antagonism of 
cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral 
cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20 Suppl 1:116-
123. 
Pedicord DL, Flynn MJ, Fanslau C, Miranda M, Hunihan L, Robertson BJ, Pearce BC, Yu XC, 
Westphal RS, Blat Y (2011) Molecular characterization and identification of surrogate 
substrates for diacylglycerol lipase alpha. Biochem Biophys Res Commun 411:809-
814. 
Pernia-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, Watanabe M, Filitz J, 
Koppert W, Schuttler J, Ji G, Neugebauer V, Marsicano G, Lutz B, Vanegas H, Zeilhofer 
HU (2009) Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced 
heterosynaptic pain sensitization. Science 325:760-764. 
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 
74:129-180. 
Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol:1-51. 
Pertwee RG (2015) Endocannabinoids and Their Pharmacological Actions. Handb Exp 
Pharmacol 231:1-37. 
Petrosino S, Iuvone T, Di Marzo V (2010) N-palmitoyl-ethanolamine: Biochemistry and new 
therapeutic opportunities. Biochimie 92:724-727. 
Petrovszki Z, Kovacs G, Tomboly C, Benedek G, Horvath G (2012) The effects of peptide and 
lipid endocannabinoids on arthritic pain at the spinal level. Anesth Analg 114:1346-
1352. 
Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, Pacher P, Gertsch J (2017) Pepcan-12 
(RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively 
secreted by adrenals and in liver upon tissue damage. Sci Rep 7:9560. 
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a 
cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in 
overweight or obese patients: RIO-North America: a randomized controlled trial. 
Jama 295:761-775. 
Pickard RT, Strifler BA, Kramer RM, Sharp JD (1999) Molecular cloning of two new human 
paralogs of 85-kDa cytosolic phospholipase A2. J Biol Chem 274:8823-8831. 
Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-
884. 
Piomelli D (2013) A fatty gut feeling. Trends Endocrinol Metab 24:332-341. 
Placzek EA, Okamoto Y, Ueda N, Barker EL (2008) Mechanisms for recycling and biosynthesis 
of endogenous cannabinoids anandamide and 2-arachidonylglycerol. J Neurochem 
107:987-1000. 
Ponten J, Saksela E (1967) Two established in vitro cell lines from human mesenchymal 
tumours. International journal of cancer 2:434-447. 
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, 





endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J 
Pharmacol Exp Ther 301:1020-1024. 
Powell DR, Gay JP, Wilganowski N, Doree D, Savelieva KV, Lanthorn TH, Read R, Vogel P, 
Hansen GM, Brommage R, Ding ZM, Desai U, Zambrowicz B (2015) Diacylglycerol 
Lipase alpha Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes 
Similar to Those of Cannabinoid Receptor 1 Knockout Mice. Front Endocrinol 
(Lausanne) 6:86. 
Prenderville JA, Kelly AM, Downer EJ (2015) The role of cannabinoids in adult neurogenesis. 
Br J Pharmacol 172:3950-3963. 
Prescott SM, Majerus PW (1983) Characterization of 1,2-diacylglycerol hydrolysis in human 
platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol 
Chem 258:764-769. 
Psychoyos D, Vinod KY, Cao J, Xie S, Hyson RL, Wlodarczyk B, He W, Cooper TB, Hungund BL, 
Finnell RH (2012) Cannabinoid receptor 1 signaling in embryo neurodevelopment. 
Birth Defects Res B Dev Reprod Toxicol 95:137-150. 
Qiu P, Shandilya H, D'Alessio JM, O'Connor K, Durocher J, Gerard GF (2004) Mutation 
detection using Surveyor (TM) nuclease. Biotechniques 36:702-+. 
Rahman IA, Tsuboi K, Uyama T, Ueda N (2014) New players in the fatty acyl ethanolamide 
metabolism. Pharmacological research 86:1-10. 
Rahmani MR, Shamsizadeh A, Moghadam-Ahmadi A, Kaeidi A, Allahtavakoli M (2018) 
Monoacylglycerol lipase inhibitor, JZL-184, confers neuroprotection in the mice 
middle cerebral artery occlusion model of stroke. Life Sci 198:143-148. 
Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention 
of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by 
blockade of microglial activation. J Neurosci 25:1904-1913. 
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using 
the CRISPR-Cas9 system. Nat Protoc 8:2281-2308. 
Randall AS, Liu CH, Chu B, Zhang Q, Dongre SA, Juusola M, Franze K, Wakelam MJ, Hardie RC 
(2015) Speed and sensitivity of phototransduction in Drosophila depend on degree 
of saturation of membrane phospholipids. J Neurosci 35:2731-2746. 
Rando RR (2002) Membrane-bound lecithin-retinol acyltransferase. Biochem Biophys Res 
Commun 292:1243-1250. 
Reddy PV, Natarajan V, Schmid PC, Schmid HH (1983) N-Acylation of dog heart ethanolamine 
phospholipids by transacylase activity. Biochim Biophys Acta 750:472-480. 
Regehr WG, Carey MR, Best AR (2009) Activity-dependent regulation of synapses by 
retrograde messengers. Neuron 63:154-170. 
Regier JC, Shultz JW, Zwick A, Hussey A, Ball B, Wetzer R, Martin JW, Cunningham CW (2010) 
Arthropod relationships revealed by phylogenomic analysis of nuclear protein-
coding sequences. Nature 463:1079-1083. 
Reisenberg M, Singh PK, Williams G, Doherty P (2012) The diacylglycerol lipases: structure, 
regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc 
Lond B Biol Sci 367:3264-3275. 
Remelli M, Ceciliato C, Guerrini R, Kolkowska P, Krzywoszynska K, Salvadori S, Valensin D, 
Watly J, Kozlowski H (2016) DOES hemopressin bind metal ions in vivo? Dalton Trans 
45:18267-18280. 
Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA (2007) Quantitative profiling of 
endocannabinoids and related compounds in rat brain using liquid chromatography-
tandem electrospray ionization mass spectrometry. Anal Biochem 360:216-226. 
Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani 
J, Neliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of 





Rioli V, Gozzo FC, Heimann AS, Linardi A, Krieger JE, Shida CS, Almeida PC, Hyslop S, Eberlin 
MN, Ferro ES (2003) Novel natural peptide substrates for endopeptidase 24.15, 
neurolysin, and angiotensin-converting enzyme. J Biol Chem 278:8547-8555. 
Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE (2006) Interleukin-2 
suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-
activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol 
Pharmacol 70:101-111. 
Romanko MJ, Rola R, Fike JR, Szele FG, Dizon ML, Felling RJ, Brazel CY, Levison SW (2004) 
Roles of the mammalian subventricular zone in cell replacement after brain injury. 
Prog Neurobiol 74:77-99. 
Romano A, Coccurello R, Giacovazzo G, Bedse G, Moles A, Gaetani S (2014) 
Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid 
antagonists for the control of appetite. Biomed Res Int 2014:203425. 
Rosenberger TA, Farooqui AA, Horrocks LA (2007) Bovine brain diacylglycerol lipase: 
substrate specificity and activation by cyclic AMP-dependent protein kinase. Lipids 
42:187-195. 
Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ, Scott 
RH (2001) Actions of cannabinoid receptor ligands on rat cultured sensory neurones: 
implications for antinociception. Neuropharmacology 40:221-232. 
Rouzer CA, Marnett LJ (2011) Endocannabinoid oxygenation by cyclooxygenases, 
lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and 
endocannabinoid signaling pathways. Chem Rev 111:5899-5921. 
Rozenfeld R, Devi LA (2008) Regulation of CB1 cannabinoid receptor trafficking by the 
adaptor protein AP-3. Faseb J 22:2311-2322. 
Rubio-Araiz A, Arevalo-Martin A, Gomez-Torres O, Navarro-Galve B, Garcia-Ovejero D, 
Suetterlin P, Sanchez-Heras E, Molina-Holgado E, Molina-Holgado F (2008) The 
endocannabinoid system modulates a transient TNF pathway that induces neural 
stem cell proliferation. Mol Cell Neurosci 38:374-380. 
Russo EB, Jiang HE, Li X, Sutton A, Carboni A, del Bianco F, Mandolino G, Potter DJ, Zhao YX, 
Bera S, Zhang YB, Lu EG, Ferguson DK, Hueber F, Zhao LC, Liu CJ, Wang YF, Li CS (2008) 
Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 
59:4171-4182. 
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, 
Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid 
receptor. Br J Pharmacol 152:1092-1101. 
Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, Squire JA (2008) In Vitro 
Analysis of Integrated Global High-Resolution DNA Methylation Profiling with 
Genomic Imbalance and Gene Expression in Osteosarcoma. PLoS One 3. 
Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA (2007) Cannabinoid CB1 
receptor inverse agonists and neutral antagonists: effects on food intake, food-
reinforced behavior and food aversions. Physiol Behav 91:383-388. 
Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, 
McDermott MW, Parsa AT, Manuel-Garcia Verdugo J, Berger MS, Alvarez-Buylla A 
(2004) Unique astrocyte ribbon in adult human brain contains neural stem cells but 
lacks chain migration. Nature 427:740-744. 
Sanai N, Nguyen T, Ihrie RA, Mirzadeh Z, Tsai HH, Wong M, Gupta N, Berger MS, Huang E, 
Garcia-Verdugo JM, Rowitch DH, Alvarez-Buylla A (2011) Corridors of migrating 
neurons in the human brain and their decline during infancy. Nature 478:382-386. 
Sander JD, Maeder ML, Reyon D, Voytas DF, Joung JK, Dobbs D (2010) ZiFiT (Zinc Finger 





Sarne Y, Keren O (2004) Are cannabinoid drugs neurotoxic or neuroprotective? Med 
Hypotheses 63:187-192. 
Sarne Y, Mechoulam R (2005) Cannabinoids: between neuroprotection and neurotoxicity. 
Curr Drug Targets CNS Neurol Disord 4:677-684. 
Savinainen JR, Saario SM, Laitinen JT (2012) The serine hydrolases MAGL, ABHD6 and 
ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid 
receptors. Acta Physiol (Oxf) 204:267-276. 
Scherer T, Buettner C (2009) The dysregulation of the endocannabinoid system in diabesity-
a tricky problem. J Mol Med (Berl) 87:663-668. 
Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic 
cannabinoid receptors. Trends Pharmacol Sci 22:565-572. 
Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, 
Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu QS, Lichtman AH, 
Cravatt BF (2010) Chronic monoacylglycerol lipase blockade causes functional 
antagonism of the endocannabinoid system. Nat Neurosci 13:1113-1119. 
Schmid HH (2000) Pathways and mechanisms of N-acylethanolamine biosynthesis: can 
anandamide be generated selectively? Chem Phys Lipids 108:71-87. 
Schmid HH, Berdyshev EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and 
other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent 
Fatty Acids 66:363-376. 
Schmid HH, Schmid PC, Natarajan V (1990) N-acylated glycerophospholipids and their 
derivatives. Prog Lipid Res 29:1-43. 
Scrima M, Di Marino S, Grimaldi M, Mastrogiacomo A, Novellino E, Bifulco M, D'Ursi AM 
(2010) Binding of the hemopressin peptide to the cannabinoid CB1 receptor: 
structural insights. Biochemistry 49:10449-10457. 
Seamon KB, Daly JW (1986) Forskolin: its biological and chemical properties. Adv Cyclic 
Nucleotide Protein Phosphorylation Res 20:1-150. 
Segula D (2014) Complications of obesity in adults: a short review of the literature. Malawi 
Med J 26:20-24. 
Shen LR, Lai CQ, Feng X, Parnell LD, Wan JB, Wang JD, Li D, Ordovas JM, Kang JX (2010) 
Drosophila lacks C20 and C22 PUFAs. J Lipid Res 51:2985-2992. 
Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit 
glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322-
4334. 
Shinohara N, Uyama T, Jin XH, Tsuboi K, Tonai T, Houchi H, Ueda N (2011) Enzymological 
analysis of the tumor suppressor A-C1 reveals a novel group of phospholipid-
metabolizing enzymes. J Lipid Res 52:1927-1935. 
Shonesy BC, Bluett RJ, Ramikie TS, Baldi R, Hermanson DJ, Kingsley PJ, Marnett LJ, Winder 
DG, Colbran RJ, Patel S (2014) Genetic disruption of 2-arachidonoylglycerol synthesis 
reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Rep 
9:1644-1653. 
Shonesy BC, Wang X, Rose KL, Ramikie TS, Cavener VS, Rentz T, Baucum AJ, 2nd, Jalan-
Sakrikar N, Mackie K, Winder DG, Patel S, Colbran RJ (2013) CaMKII regulates 
diacylglycerol lipase-alpha and striatal endocannabinoid signaling. Nat Neurosci 
16:456-463. 
Sierra S, Luquin N, Navarro-Otano J (2017) The endocannabinoid system in cardiovascular 
function: novel insights and clinical implications. Clin Auton Res. 
Simon GM, Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through 
glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this 





Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase 
GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse 
brain. J Biol Chem 283:9341-9349. 
Simon GM, Cravatt BF (2010) Characterization of mice lacking candidate N-acyl ethanolamine 
biosynthetic enzymes provides evidence for multiple pathways that contribute to 
endocannabinoid production in vivo. Mol Biosyst 6:1411-1418. 
Singh PK (2013) Investigating the role of phosphorylation in the regulation of Diacylglycerol 
Lipase α/β activity. In: Wolfson Centre for Age-Related Diseases, p 284. London: 
King's College London. 
Singh PK, Markwick R, Howell FV, Williams G, Doherty P (2016) A novel live cell assay to 
measure diacylglycerol lipase alpha activity. Biosci Rep 36. 
Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis 
JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid 
receptor (hVR1). Br J Pharmacol 129:227-230. 
Smith DR, Stanley CM, Foss T, Boles RG, McKernan K (2017) Rare genetic variants in the 
endocannabinoid system genes CNR1 and DAGLA are associated with neurological 
phenotypes in humans. PLoS One 12:e0187926. 
Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The 
pharmacological activity of anandamide, a putative endogenous cannabinoid, in 
mice. J Pharmacol Exp Ther 270:219-227. 
Snider NT, Walker VJ, Hollenberg PF (2010) Oxidation of the endogenous cannabinoid 
arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological 
and pharmacological implications. Pharmacol Rev 62:136-154. 
Song B, Kibler PD, Endsley AN, Nayak SK, Galande AK, Jambunathan K (2015) Site-specific 
Substitutions Eliminate Aggregation Properties of Hemopressin. Chem Biol Drug Des 
86:1433-1437. 
Song CZ, Chang XJ, Bean KM, Proia MS, Knopf JL, Kriz RW (1999) Molecular characterization 
of cytosolic phospholipase A(2)-beta. Journal of Biological Chemistry 274:17063-
17067. 
Song ZH, Zhong M (2000) CB1 cannabinoid receptor-mediated cell migration. J Pharmacol 
Exp Ther 294:204-209. 
Sophocleous A, Marino S, Kabir D, Ralston SH, Idris AI (2017a) Combined deficiency of the 
Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast 
inhibition. Aging Cell 16:1051-1061. 
Sophocleous A, Robertson R, Ferreira NB, McKenzie J, Fraser WD, Ralston SH (2017b) Heavy 
Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of 
Fractures. Am J Med 130:214-221. 
Sousa-Valente J, Varga A, Ananthan K, Khajuria A, Nagy I (2014) Anandamide in primary 
sensory neurons: too much of a good thing? Eur J Neurosci 39:409-418. 
Spano MS, Ellgren M, Wang X, Hurd YL (2007) Prenatal cannabis exposure increases heroin 
seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol 
Psychiatry 61:554-563. 
Stefano GB, Liu Y, Goligorsky MS (1996) Cannabinoid receptors are coupled to nitric oxide 
release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem 
271:19238-19242. 
Steffens M, Zentner J, Honegger J, Feuerstein TJ (2005) Binding affinity and agonist activity 
of putative endogenous cannabinoids at the human neocortical CB1 receptor. 
Biochem Pharmacol 69:169-178. 






Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in 
cortical neurons. Eur J Pharmacol 425:189-196. 
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates 
long-term potentiation. Nature 388:773-778. 
Straiker A, Mitjavila J, Yin D, Gibson A, Mackie K (2015) Aiming for allosterism: Evaluation of 
allosteric modulators of CB1 in a neuronal model. Pharmacological research 99:370-
376. 
Sugiura T, Kobayashi Y, Oka S, Waku K (2002) Biosynthesis and degradation of anandamide 
and 2-arachidonoylglycerol and their possible physiological significance. 
Prostaglandins Leukot Essent Fatty Acids 66:173-192. 
Sugiura T, Kishimoto S, Oka S, Gokoh M (2006) Biochemistry, pharmacology and physiology 
of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid 
Res 45:405-446. 
Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-
Arachidonoylgylcerol - a Possible Endogenous Cannabinoid Receptor-Ligand in Brain. 
Biochem Biophys Res Commun 215:89-97. 
Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamashita A, Ishima Y, Waku K 
(1996) Transacylase-mediated and phosphodiesterase-mediated synthesis of N-
arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain 
microsomes. Comparison with synthesis from free arachidonic acid and 
ethanolamine. Eur J Biochem 240:53-62. 
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, 
Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-
palmitoylethanolamine or anandamide is the physiological ligand for the 
cannabinoid CB2 receptor. Comparison of the agonistic activities of various 
cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605-612. 
Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, 
Baba N, Ishima Y (1999) Evidence that the cannabinoid CB1 receptor is a 2-
arachidonoylglycerol receptor. Structure-activity relationship of 2-
arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 
274:2794-2801. 
Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipases A2 and 
inflammatory responses in the central nervous system. Neuromolecular Med 
12:133-148. 
Sun YX, Tsuboi K, Okamoto Y, Tonai T, Murakami M, Kudo I, Ueda N (2004) Biosynthesis of 
anandamide and N-palmitoylethanolamine by sequential actions of phospholipase 
A2 and lysophospholipase D. Biochem J 380:749-756. 
Sundholm-Peters NL, Yang HK, Goings GE, Walker AS, Szele FG (2005) Subventricular zone 
neuroblasts emigrate toward cortical lesions. J Neuropathol Exp Neurol 64:1089-
1100. 
Sundman MH, Chen NK, Subbian V, Chou YH (2017) The bidirectional gut-brain-microbiota 
axis as a potential nexus between traumatic brain injury, inflammation, and disease. 
Brain Behav Immun 66:31-44. 
Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central 
pain in multiple sclerosis? Randomised double blind placebo controlled crossover 
trial. Bmj 329:253. 
Swartz KJ (2008) Sensing voltage across lipid membranes. Nature 456:891-897. 
Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, Kuo MS, Bokvist K, Barrett 
DG, Efanov AM (2012) Regulation of GPR119 receptor activity with 





Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K (1998) Inhibition of GABAergic 
inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. 
Neuroscience 85:395-403. 
Szlavicz E, Perera PS, Tomboly C, Helyes Z, Zador F, Benyhe S, Borsodi A, Bojnik E (2015) 
Further Characterization of Hemopressin Peptide Fragments in the Opioid and 
Cannabinoid Systems. Anesth Analg 121:1488-1494. 
Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty 
G (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 
111:305-317. 
Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, Zimmer A, Mackie K, Mechoulam R, 
Shohami E, Bab I (2006) Involvement of neuronal cannabinoid receptor CB1 in 
regulation of bone mass and bone remodeling. Mol Pharmacol 70:786-792. 
Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap N, 
Shteyer A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami E, Bab 
I (2008) The cannabinoid CB1 receptor regulates bone formation by modulating 
adrenergic signaling. Faseb J 22:285-294. 
Tanimura A, Uchigashima M, Yamazaki M, Uesaka N, Mikuni T, Abe M, Hashimoto K, 
Watanabe M, Sakimura K, Kano M (2012) Synapse type-independent degradation of 
the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. 
Proc Natl Acad Sci U S A 109:12195-12200. 
Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, Kita Y, 
Hashimoto K, Shimizu T, Watanabe M, Sakimura K, Kano M (2010) The 
endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha 
mediates retrograde suppression of synaptic transmission. Neuron 65:320-327. 
Tao R, Yu Y, Zhang X, Guo Y, Shi J, Zhang X, Xie L, Liu S, Ju G, Xu Q, Shen Y, Wei J (2005) 
Cytosolic PLA2 genes possibly contribute to the etiology of schizophrenia. Am J Med 
Genet B Neuropsychiatr Genet 137B:56-58. 
Taschler U, Radner FP, Heier C, Schreiber R, Schweiger M, Schoiswohl G, Preiss-Landl K, 
Jaeger D, Reiter B, Koefeler HC, Wojciechowski J, Theussl C, Penninger JM, Lass A, 
Haemmerle G, Zechner R, Zimmermann R (2011) Monoglyceride lipase deficiency in 
mice impairs lipolysis and attenuates diet-induced insulin resistance. J Biol Chem 
286:17467-17477. 
Terrazzino S, Berto F, Dalle Carbonare M, Fabris M, Guiotto A, Bernardini D, Leon A (2004) 
Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver 
stearoyl-coenzyme A desaturase-1 mRNA expression. Faseb J 18:1580-1582. 
Thul PJ et al. (2017) A subcellular map of the human proteome. Science 356. 
Toczek M, Malinowska B (2018) Enhanced endocannabinoid tone as a potential target of 
pharmacotherapy. Life Sci. 
Toniolo EF, Maique ET, Ferreira WA, Jr., Heimann AS, Ferro ES, Ramos-Ortolaza DL, Miller L, 
Devi LA, Dale CS (2014) Hemopressin, an inverse agonist of cannabinoid receptors, 
inhibits neuropathic pain in rats. Peptides 56:125-131. 
Tortoriello G, Rhodes BP, Takacs SM, Stuart JM, Basnet A, Raboune S, Widlanski TS, Doherty 
P, Harkany T, Bradshaw HB (2013) Targeted lipidomics in Drosophila melanogaster 
identifies novel 2-monoacylglycerols and N-acyl amides. PLoS One 8:e67865. 
Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, Wang J, Deutsch DG, Burns 
MP, Ulloa NM, Tokumura A, Ueda N (2011) Enzymatic formation of N-
acylethanolamines from N-acylethanolamine plasmalogen through N-
acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -





Turcotte C, Chouinard F, Lefebvre JS, Flamand N (2015) Regulation of inflammation by 
cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-
ethanolamide, and their metabolites. J Leukoc Biol. 
Ueda H, Kobayashi T, Kishimoto M, Tsutsumi T, Okuyama H (1993) A possible pathway of 
phosphoinositide metabolism through EDTA-insensitive phospholipase A1 followed 
by lysophosphoinositide-specific phospholipase C in rat brain. J Neurochem 61:1874-
1881. 
Ueda N, Liu Q, Yamanaka K (2001) Marked activation of the N-
acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations. 
Biochim Biophys Acta 1532:121-127. 
Ueda N, Tsuboi K, Uyama T (2010) Enzymological studies on the biosynthesis of N-
acylethanolamines. Biochim Biophys Acta 1801:1274-1285. 
Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-
acylethanolamines: canonical and alternative pathways. Febs J 280:1874-1894. 
Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG (2000) The fatty acid amide hydrolase 
(FAAH). Chem Phys Lipids 108:107-121. 
Ueda N, Tsuboi K, Uyama T, Ohnishi T (2011) Biosynthesis and degradation of the 
endocannabinoid 2-arachidonoylglycerol. Biofactors 37:1-7. 
Uhlen M et al. (2015) Proteomics. Tissue-based map of the human proteome. Science 
347:1260419. 
Urquhart P, Nicolaou A, Woodward DF (2015) Endocannabinoids and their oxygenation by 
cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta 
1851:366-376. 
Uyama T, Tsuboi K, Ueda N (2017) An involvement of phospholipase A/acyltransferase family 
proteins in peroxisome regulation and plasmalogen metabolism. FEBS Lett 
591:2745-2760. 
Uyama T, Ikematsu N, Inoue M, Shinohara N, Jin XH, Tsuboi K, Tonai T, Tokumura A, Ueda N 
(2012) Generation of N-acylphosphatidylethanolamine by members of the 
phospholipase A/acyltransferase (PLA/AT) family. J Biol Chem 287:31905-31919. 
Uyama T, Inoue M, Okamoto Y, Shinohara N, Tai T, Tsuboi K, Inoue T, Tokumura A, Ueda N 
(2013) Involvement of phospholipase A/acyltransferase-1 in N-
acylphosphatidylethanolamine generation. Biochim Biophys Acta 1831:1690-1701. 
Vadodaria KC, Jessberger S (2014) Functional neurogenesis in the adult hippocampus: then 
and now. Front Neurosci 8:55. 
Valverde O, Torrens M (2012) CB1 receptor-deficient mice as a model for depression. 
Neuroscience 204:193-206. 
van der Lee MM, Blomenrohr M, van der Doelen AA, Wat JW, Smits N, Hanson BJ, van Koppen 
CJ, Zaman GJ (2009) Pharmacological characterization of receptor redistribution and 
beta-arrestin recruitment assays for the cannabinoid receptor 1. J Biomol Screen 
14:811-823. 
van der Stelt M, Di Marzo V (2005a) Anandamide as an intracellular messenger regulating 
ion channel activity. Prostaglandins Other Lipid Mediat 77:111-122. 
van der Stelt M, Di Marzo V (2005b) Cannabinoid receptors and their role in neuroprotection. 
Neuromolecular Med 7:37-50. 
van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agro 
A, Vliegenthart JF, Maccarrone M (2002) Oxygenated metabolites of anandamide 
and 2-arachidonoylglycerol: conformational analysis and interaction with 
cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J 





van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, 
Vliegenthart JF, Di Marzo V, Nicolay K (2001) Exogenous anandamide protects rat 
brain against acute neuronal injury in vivo. J Neurosci 21:8765-8771. 
Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis 
A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA 
(2005) Identification and functional characterization of brainstem cannabinoid CB2 
receptors. Science 310:329-332. 
Varma N, Carlson GC, Ledent C, Alger BE (2001) Metabotropic glutamate receptors drive the 
endocannabinoid system in hippocampus. J Neurosci 21:RC188. 
Vellani V, Petrosino S, De Petrocellis L, Valenti M, Prandini M, Magherini PC, McNaughton 
PA, Di Marzo V (2008) Functional lipidomics. Calcium-independent activation of 
endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein 
kinases C and A and thrombin. Neuropharmacology 55:1274-1279. 
Viader A, Ogasawara D, Joslyn CM, Sanchez-Alavez M, Mori S, Nguyen W, Conti B, Cravatt BF 
(2016) A chemical proteomic atlas of brain serine hydrolases identifies cell type-
specific pathways regulating neuroinflammation. Elife 5:e12345. 
Walsh FS, Doherty P (1997) Neural cell adhesion molecules of the immunoglobulin 
superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol 13:425-456. 
Walter L, Stella N (2003) Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in 
astrocytes. Glia 44:85-90. 
Walter L, Dinh T, Stella N (2004) ATP induces a rapid and pronounced increase in 2-
arachidonoylglycerol production by astrocytes, a response limited by 
monoacylglycerol lipase. J Neurosci 24:8068-8074. 
Walter L, Franklin A, Witting A, Moller T, Stella N (2002) Astrocytes in culture produce 
anandamide and other acylethanolamides. J Biol Chem 277:20869-20876. 
Wang J, Ueda N (2009) Biology of endocannabinoid synthesis system. Prostaglandins Other 
Lipid Mediat 89:112-119. 
Wang X, Dow-Edwards D, Keller E, Hurd YL (2003) Preferential limbic expression of the 
cannabinoid receptor mRNA in the human fetal brain. Neuroscience 118:681-694. 
Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat 
Rev Genet 10:57-63. 
Watson S, Chambers D, Hobbs C, Doherty P, Graham A (2008) The endocannabinoid 
receptor, CB1, is required for normal axonal growth and fasciculation. Mol Cell 
Neurosci 38:89-97. 
Watson SJ, Benson JA, Jr., Joy JE (2000) Marijuana and medicine: assessing the science base: 
a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 57:547-
552. 
Wilkerson JL, Donvito G, Grim TW, Abdullah RA, Ogasawara D, Cravatt BF, Lichtman AH 
(2017) Investigation of Diacylglycerol Lipase Alpha Inhibition in the Mouse 
Lipopolysaccharide Inflammatory Pain Model. J Pharmacol Exp Ther 363:394-401. 
Williams EJ, Walsh FS, Doherty P (1994a) The production of arachidonic acid can account for 
calcium channel activation in the second messenger pathway underlying neurite 
outgrowth stimulated by NCAM, N-cadherin, and L1. J Neurochem 62:1231-1234. 
Williams EJ, Walsh FS, Doherty P (2003) The FGF receptor uses the endocannabinoid signaling 
system to couple to an axonal growth response. J Cell Biol 160:481-486. 
Williams EJ, Furness J, Walsh FS, Doherty P (1994b) Characterisation of the second 
messenger pathway underlying neurite outgrowth stimulated by FGF. Development 
120:1685-1693. 
Williams EJ, Furness J, Walsh FS, Doherty P (1994c) Activation of the FGF receptor underlies 





Williams J, Wood J, Pandarinathan L, Karanian DA, Bahr BA, Vouros P, Makriyannis A (2007) 
Quantitative method for the profiling of the endocannabinoid metabolome by LC-
atmospheric pressure chemical ionization-MS. Anal Chem 79:5582-5593. 
Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at 
hippocampal synapses. Nature 410:588-592. 
Wu CS, Zhu J, Wager-Miller J, Wang S, O'Leary D, Monory K, Lutz B, Mackie K, Lu HC (2010) 
Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for 
appropriate development of corticothalamic and thalamocortical projections. Eur J 
Neurosci 32:693-706. 
Xapelli S, Agasse F, Grade S, Bernardino L, Ribeiro FF, Schitine CS, Heimann AS, Ferro ES, 
Sebastiao AM, De Melo Reis RA, Malva JO (2014) Modulation of subventricular zone 
oligodendrogenesis: a role for hemopressin? Front Cell Neurosci 8:59. 
Xapelli S, Agasse F, Sarda-Arroyo L, Bernardino L, Santos T, Ribeiro FF, Valero J, Braganca J, 
Schitine C, de Melo Reis RA, Sebastiao AM, Malva JO (2013) Activation of type 1 
cannabinoid receptor (CB1R) promotes neurogenesis in murine subventricular zone 
cell cultures. PLoS One 8:e63529. 
Yamaguchi S, Mase T, Takeuchi K (1991) Cloning and structure of the mono- and 
diacylglycerol lipase-encoding gene from Penicillium camembertii U-150. Gene 
103:61-67. 
Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, Watanabe M (2006) 
Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close 
proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, 
and presynaptic cannabinoid CB1 receptor. J Neurosci 26:4740-4751. 
Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, Blat Y, Westphal RS, 
Zaczek R, Lewis DA, Gonzalez-Burgos G (2011) Postsynaptic diacylglycerol lipase 
mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal 
cortex. J Physiol 589:4857-4884. 
Yu H, Watt H, Mohan S (2014) The negative impact of traumatic brain injury (TBI) on bone in 
a mouse model. Brain Inj 28:244-251. 
Yuan D, Wu Z, Wang Y (2016) Evolution of the diacylglycerol lipases. Prog Lipid Res 64:85-97. 
Zarate J, Churruca I, Echevarria E, Casis L, Lopez de Jesus M, Saenz del Burgo L, Salles J (2008) 
Immunohistochemical localization of CB1 cannabinoid receptors in frontal cortex 
and related limbic areas in obese Zucker rats: effects of chronic fluoxetine treatment. 
Brain Res 1236:57-72. 
Zhang L, Kolaj M, Renaud LP (2015) Intracellular postsynaptic cannabinoid receptors link 
thyrotropin-releasing hormone receptors to TRPC-like channels in thalamic 
paraventricular nucleus neurons. Neuroscience 311:81-91. 
Zhang L, Kolaj M, Renaud LP (2016a) Endocannabinoid 2-AG and intracellular cannabinoid 
receptors modulate a low-threshold calcium spike-induced slow depolarizing 
afterpotential in rat thalamic paraventricular nucleus neurons. Neuroscience 
322:308-319. 
Zhang R, Xie X (2012) Tools for GPCR drug discovery. Acta Pharmacol Sin 33:372-384. 
Zhang RS, He Z, Jin WD, Wang R (2016b) Effects of the cannabinoid 1 receptor peptide ligands 
hemopressin, (m)RVD-hemopressin(alpha) and (m)VD-hemopressin(alpha) on 
memory in novel object and object location recognition tasks in normal young and 
Abeta1-42-treated mice. Neurobiol Learn Mem 134 Pt B:264-274. 
Zhang Y, Chen KN, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, 
Caneda C, Ruderisch N, Deng SY, Liddelow SA, Zhang CL, Daneman R, Maniatis T, 
Barres BA, Wu JQ (2014) An RNA-Sequencing Transcriptome and Splicing Database 






Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult 
neurogenesis. Cell 132:645-660. 
Zhou Y, Falenta K, Lalli G (2014) Endocannabinoid signalling in neuronal migration. Int J 
Biochem Cell Biol 47:104-108. 
Zhou Y, Howell FV, Glebov OO, Albrecht D, Williams G, Doherty P (2016) Regulated 
endosomal trafficking of Diacylglycerol lipase alpha (DAGLalpha) generates distinct 
cellular pools; implications for endocannabinoid signaling. Mol Cell Neurosci 76:76-
86. 
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, 
hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl 
Acad Sci U S A 96:5780-5785. 
Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, 
Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator 
action of anandamide. Nature 400:452-457. 
 
